pyrazines has been researched along with Kahler Disease in 1790 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 710 (39.66) | 29.6817 |
| 2010's | 1066 (59.55) | 24.3611 |
| 2020's | 14 (0.78) | 2.80 |
| Authors | Studies |
|---|---|
| Garrido, D; Riva, E | 1 |
| Choi, Y; Heo, SK; Jo, JC; Koh, S; Lee, YJ; Min, YJ; Noh, EK; Seo, HJ | 1 |
| Sak, K | 1 |
| Callander, NS; Hematti, P; Mark, C; Miyamoto, S; Warrick, J | 1 |
| Cui, Y; Ding, H; Gao, Y; Huang, J; Lin, Z; Liu, T; Luo, H; Niu, T; Qu, Y; Wang, F; Xu, J; Yang, Y; Yang, Z; Ye, L; Zhai, X; Zhang, L; Zheng, Y | 1 |
| Devasia, AJ; Lancman, G; Stewart, AK | 1 |
| Anderson, LD; Banerjee, R; Cowan, AJ; Kaur, G; McCaughan, G; Mehra, N; Rajkumar, SV; Wang, B | 1 |
| Bolomsky, A; Branstrom, A; Breid, H; Caers, J; Duray, E; Hübl, W; Lejeune, M; Ludwig, H; Muller, J; Pfeiffer, C; Stangelberger, K; Vrancken, L; Weetall, M; Willheim, M; Zojer, N | 1 |
| Goldberg, AL; Sha, Z | 1 |
| Backes, BJ; Hosoi, H; Ishibashi, T; Kinoshita, A; Kishimoto, S; Kobata, H; Mishima, H; Morita, S; Papa, FR; Sonoki, T; Tamura, S; Yamashita, Y; Yoshiura, KI | 1 |
| Feng, YF; Li, G; Sun, YQ; Wei, XF; Yang, WH; Zhang, QK | 1 |
| Chiba, T; Iseki, T; Isshiki, Y; Iwama, A; Koide, S; Lennox, W; Mimura, N; Mitsukawa, S; Miyota, M; Muto, T; Nagai, Y; Nakajima-Takagi, Y; Nakaseko, C; Ohwada, C; Oshima, M; Oshima-Hasegawa, N; Rizk, M; Rizq, O; Sakaida, E; Saraya, A; Sheedy, J; Takeda, Y; Takeuchi, M; Tsukamoto, S; Weetall, M; Yokote, K | 1 |
| Gul, E; Gyger, M; Jazubowiak, A; Kaufman, J; Khan, S; Lau, A; Le, LW; LeBlanc, R; Li, Z; Paul, H; Trudel, S; White, D | 1 |
| Cheon, J; Choi, Y; Heo, SK; Jo, JC; Ju, LJ; Kim, DK; Kim, JY; Koh, S; Lee, YJ; Min, YJ; Noh, EK; Seo, HJ; Sung, JY; Yu, HM | 1 |
| Ma, J; Shao, ZH; Wang, YH; Zhang, LL | 1 |
| Chen, JF; Li, YX; Meng, XY; Xiao, LF; Zeng, ZH; Zhang, R | 1 |
| Wang, CY; Wang, L; Wang, XF; Wang, YF; Xia, B; Xu, YJ; Yang, HL; Yu, Y; Zhang, YZ; Zhao, HF | 1 |
| Azab, AK; Azab, F; Buggio, M; de la Puente, P; Fiala, M; Muz, B; Pachter, JA; Padval, MV; Vij, R; Weaver, DT | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Lin, B; Wang, Y | 1 |
| Adam, Z; Cermáková, Z; Hájek, R; Král, Z; Krejčí, M; Mayer, J; Navrátil, M; Pospíšilová, Y; Pour, L; Sandecká, V; Stork, M; Zahradová, L | 1 |
| Casneuf, T; Frank, RC; Hall, B; Jagannath, S; Kranenburg, B; Krishnan, A; Lentzsch, S; Manges, RF; Orlowski, RZ; Qin, X; Somlo, G; Sonneveld, P; Thomas, SK; van de Velde, H; Voorhees, PM; Wijermans, PW; Xie, H; Zweegman, S | 1 |
| Gillet, JP; Gottesman, MM; Varma, S | 1 |
| Davies, FE; Fryer, RA; Graham, TJ; Morgan, GJ; Robinson, SP; Smith, EM; Walker-Samuel, S | 1 |
| Rajkumar, SV | 5 |
| Chen, J; Lin, J; Zeng, Z | 1 |
| Bergsagel, PL; Chesi, M | 1 |
| Dumontet, C; Plesa, A; Tagoug, I | 1 |
| Downey, SL; Eastman, A; Goddard, AL; Kisselev, AF; Lucas, MM; Screen, M; Shabaneh, TB | 1 |
| Han, J; Jeong, SH; Kim, HK; Kim, N; Ko, KS; Lee, SR; Rhee, BD; Song, IS | 1 |
| Hatano, Y; Iida, S; Ito, M; Iwamoto, K; Kitabayashi, A; Kume, M; Nara, M; Sawada, K; Tagawa, H; Takahashi, N; Teshima, K; Watanabe, A | 1 |
| Doi, T; Fujimi, A; Hashimoto, A; Ishikawa, K; Kanisawa, Y; Matsuno, T; Minami, S; Okuda, T; Uemura, N | 1 |
| Eriksson, E; Sävendahl, L; Zaman, F | 1 |
| Lacy, MQ | 1 |
| Chen, W; Gao, W; Geng, C; Li, Y; Wang, C; Zhang, L | 1 |
| Lu, H; Sheng, Z; Yu, J; Zou, Y | 1 |
| Abe, M; Fujii, S | 1 |
| Goel, S; Lue, J; Mazumder, A | 1 |
| Hájek, R; Kryukov, F; Kubiczková, L; Matějíková, J; Sedlaříková, L; Sevčíková, S | 1 |
| Catley, L; Connor, T; McGee, SL; Mottram, B; Sanchez, WY; Vuckovic, S; Whitehead, JP; Wilkinson, A | 1 |
| Álvarez-Fernández, S; Burrows, FJ; Esparís-Ogando, A; Ocio, EM; Ortiz-Ruiz, MJ; Pandiella, A; Parrott, T; San Miguel, J; Zaknoen, S | 1 |
| Baughn, LB; Deshpande, R; Dolloff, NG; Janz, S; Linden, MA; Mansoor, A; Myers, CL; Sarver, A; Stessman, HA; Sunderland, JJ; Van Ness, BG; Walsh, SA; Xia, T; Zhan, F | 1 |
| Brown, CO; Fitzgerald, MP; Goel, A; Salem, K; Schibler, J; Singh, N; Zhan, F | 1 |
| Alsina, M; Anasetti, C; Baz, R; Jim, HS; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Pidala, J; Shain, K; Sullivan, D | 1 |
| Minvielle, S; Moreau, P | 1 |
| Chen, J; Li, S; Que, W | 1 |
| Abe, A; Che, XF; Gotoh, A; Inazu, M; Kawaguchi, T; Komatsu, S; Miyazawa, K; Moriya, S; Tomoda, A | 1 |
| Conticello, C; Di Raimondo, F; Romano, A | 1 |
| Arnulf, B; Attal, M; Benajiba, L; Caillot, D; Caulier, A; Chaleteix, C; Chrétien, ML; Facon, T; Fermand, JP; Fouquet, G; Garciaz, S; Garderet, L; Hebraud, B; Leleu, X; Loiseau, HA; Moreau, P; Pegourie, B; Regny, C; Roussel, M; Royer, B; Stoppa, AM; Szalat, R; Touzeau, C | 1 |
| Dorr, RT; Escalante, AM; Karolak, MR; Landowski, TH; Lynch, RM; McGrath, RT | 1 |
| Ando, K; Hotta, T; Iida, S; Ishii, M; Matsue, K; Matsumoto, M; Mukai, HY; Ogawa, Y; Ogura, M; Ohashi, K; Sakai, A; Suzuki, K; Terui, Y; Tobinai, K | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L | 1 |
| Anderson, K; Clynes, M; Delmore, J; Jakubikova, J; Klippel, S; Meiller, J; Mitsiades, CS; O'Connor, R; O'Gorman, P; Ooi, MG; Richardson, P | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Bhutani, D; Deol, A; Lum, L; Ratanatharathorn, V; Tageja, N; Uberti, J; Valent, J; Zonder, J | 1 |
| Cao, ZG; Liu, M; Zhou, HW | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Kim, JA; Kwak, JY; Lee, BH; Min, CK; Shin, SH; Yhim, HY | 1 |
| Abildgaard, N; Ahlberg, L; Andersen, NF; Blimark, C; Carlson, K; Dahl, IM; Forsberg, K; Gedde-Dahl, T; Gimsing, P; Gregersen, H; Gruber, A; Guldbrandsen, N; Haukås, E; Hjertner, O; Kvam, AK; Laane, E; Lenhoff, S; Lindås, R; Mellqvist, UH; Nahi, H; Remes, K; Steingrimsdottir, H; Turesson, I; Waage, A; Westin, J | 1 |
| Ramachandran, PV | 1 |
| Banerjee, SK; Das, BC; Das, S; Evans, T; Kambhampati, S; Karki, R; Schinke, C; Thapa, P; Van Veldhuizen, P; Verma, A; Weiss, LM | 1 |
| Mahindra, A; Saini, N | 1 |
| Brandi, G; Dika, E; Maibach, H; Patrizi, A; Tacchetti, P; Venturi, M | 1 |
| Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N | 1 |
| Coglitore, M; Li, CG; Rotolo, U; Schillaci, O; Servillo, F; Tralongo, A; Zagarrigo, C | 1 |
| Ahluwalia, R; Carson, KR; Cox, DP; Fiala, MA; Jaenicke, M; Moliske, CC; Stockerl-Goldstein, KE; Tomasson, MH; Trinkaus, KM; Vij, R; Wang, TF; Wildes, TM | 1 |
| Arakaki, H; Uchihara, JN | 1 |
| An, G; Deng, SH; Feng, XY; Hao, M; Li, F; Qiu, LG; Sui, WW; Wang, YF; Xu, Y | 1 |
| Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Jin, LN; Lan, HF; Lu, J; Yuan, ZG; Zeng, TM; Zhang, CY; Zhou, F; Zhou, LL | 1 |
| Gu, JL; Li, J; Liu, JR; Wang, HH; Xu, DR; Yan, MS; Zheng, D; Zou, WY | 1 |
| Chettab, K; Dumontet, C; Herveau, S; Huber, AL; Jordheim, LP; Manié, S; Matera, EL; Tagoug, I | 1 |
| Aoki, K; Arima, H; Imai, H; Ishikawa, T; Kato, A; Matsushita, A; Mori, M; Nagano, S; Ono, Y; Tabata, S; Takahashi, T; Takiuchi, Y; Yanagita, S | 1 |
| Cerrato, C; Palumbo, A | 2 |
| Alma, E; Cox, MC; Di Napoli, A; Naso, V; Pelliccia, S; Rebecchini, C | 1 |
| Arai, R; Fujimoto, K; Isozumi, Y; Koyama, T | 1 |
| Lin, YJ; Liu, XJ; Shang, BY; Zhen, YS; Zhen, YZ | 1 |
| Dimopoulos, MA; Kastritis, E; Terpos, E | 1 |
| Brissot, E; Gaugler, B; Mohty, M; Savani, BN | 1 |
| Cao, B; Du, X; Mao, X; Zhang, Z; Zhao, C; Zhao, Y | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Kido, S; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, K | 1 |
| Jongen, JL; Rampen, AJ; Scheltens-de Boer, M; Sonneveld, P; van den Bent, MJ; van Heuvel, I | 1 |
| Allietta, N; Angermund, R; Beksac, M; Benboubker, L; Broer, E; Couturier, C; Dimopoulos, MA; Facon, T; Mazier, MA; Roddie, H | 1 |
| Bernasconi, P; Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pochintesta, L; Pompa, A | 1 |
| Ihara, K; Inomata, H; Kato, J; Kikuchi, S; Koyama, R; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Ono, K; Tanaka, S; Yamada, H; Yamauchi, N; Yano, T | 1 |
| Baughn, LB; Janz, S; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F | 1 |
| Gumulec, J; Hájek, R; Plonková, H | 1 |
| Awan, F; Chaudhary, L; Craig, M; Cumpston, A; Hamadani, M; Leadmon, S; Tse, W; Watkins, K | 1 |
| Caballero, D; Caballero-Velázquez, T; Castilla-Llorente, C; Encinas, C; Heras, I; López-Corral, L; Martino, R; Pérez-Simón, JA; Rosiñol, L; Sampol, A; San Miguel, J; Serrano, D | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Boccadoro, M; Cavallo, F; Corradini, P; Crippa, C; Ferrari, S; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Magarotto, V; Montefusco, V; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Pescosta, N; Petrucci, MT; Pezzatti, S; Pietrantuono, G | 1 |
| Carrie, D; Despas, F; Dumonteil, N; Galinier, M; Honton, B; Montastruc, JL; Pathak, A; Roussel, M; Rouvellat, C | 1 |
| Azzarà, A; Carulli, G; Ciabatti, E; Ciancia, EM; Ferreri, MI; Grassi, S; Marini, A; Ottaviano, V; Petrini, M; Rocco, M | 1 |
| Horiike, S; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Bignon, E; Facon, T; Fermand, JP; Fitoussi, O; Fourrier-Réglat, A; Grelaud, A; Jové, J; Lassalle, R; Marit, G; Moore, N; Noize, P; Robinson, P; Rouyer, M; Thomaré, P | 1 |
| Alsina, M; Baz, R; Dalton, WS; Djulbegovic, B; Ho, VQ; Miladinovic, B; Nishihori, T; Ochoa-Bayona, JL; Patel, A; Shain, KH; Sullivan, DM | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN | 1 |
| Wan, J | 1 |
| Chng, WJ; Durie, BG; Eom, HS; Goh, YT; Kim, JS; Kim, K; Lee, JH; Ong, KH; Tan, D; Teoh, G | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Acharya, C; Anderson, KC; Cagnetta, A; Calimeri, T; Cea, M; Chauhan, D; Fulciniti, M; Gobbi, M; Hideshima, T; Munshi, N; Nencioni, A; Patrone, F; Richardson, P; Tai, YT; Zhong, MY | 1 |
| Giannotta, A; Guaragna, G; Mele, G; Melpignano, A; Quarta, G; Spina, A | 1 |
| De Bruyne, E; De Bryune, E; De Raeve, H; Handisides, D; Hart, CP; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D; Xu, S | 1 |
| Hata, H; Higuchi, M; Miyamoto, T; Morimoto, H; Muta, T; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K | 1 |
| Bringhen, S; Cerrato, C; Magarotto, V; Palumbo, A; Pautasso, C | 1 |
| Forsberg, PA; Mark, TM | 1 |
| Chng, WJ; Chung, TH; Fonseca, R; Mulligan, G | 1 |
| Bell, S; Desmond, PV; Goldberg, R; Smith, E; Thompson, A | 1 |
| Adam, Z; Adamova, D; Bacovsky, J; Gregora, E; Gumulec, J; Hajek, R; Jarkovsky, J; Maisnar, V; Melicharova, H; Minarik, J; Pavlicek, P; Pika, T; Plonkova, H; Pour, L; Radocha, J; Sandecka, V; Scudla, V; Spicka, I; Starostka, D; Straub, J; Walterova, L; Wrobel, M | 1 |
| Bao, L; Huang, X; Jiang, Q; Lai, Y; Liu, Y; Lu, J; Lu, X; Qin, Y; Zhao, X | 1 |
| Abe, D; Amagai, M; Hosokawa, R; Murakami, K; Ohyama, M; Okamoto, S; Yokoyama, K | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA | 1 |
| Akashi, K; Choi, I; Ito, Y; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shiratsuchi, M; Takamatsu, Y; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Koyama, D; Nobuyoshi, M; Wada, T; Yamada, S | 1 |
| El Azeeim, HA; El Husseiny, NM; Kasem, N; Mattar, MW | 1 |
| Attal, M; Bladé, J; Cakana, A; Cavo, M; Desai, A; Esseltine, DL; Goldschmidt, H; Lahuerta, JJ; Liu, K; Lokhorst, HM; Moreau, P; Rosiñol, L; Sonneveld, P; Tacchetti, P; van de Velde, H; Zamagni, E | 1 |
| Goebeler, M; Kneitz, H; Kolb-Mäurer, A | 1 |
| Cırak, MY; Emmez, H; Oner, AY; Pamukçuoğlu, M; Senol, E; Sucak, GT; Tunçcan, OG | 1 |
| Bai, QX; Chen, XQ; Dong, BX; Gao, GX; Gu, HT; Liang, R; Shu, MM; Yang, L; Zhang, T; Zhang, YQ | 1 |
| Klánová, M; Špička, I | 1 |
| Li, J; Liu, SS; Tsui, J; Wang, HH; Wang, XY | 1 |
| Alsina, M; Coutre, SE; Gasparetto, C; Khan, M; Lonial, S; Mukhopadhyay, S; Ondovik, MS; Paley, CS; Richardson, PG; Schlossman, RL; Weber, DM | 1 |
| Ise, M; Kumagai, K; Sakai, C | 1 |
| Morgan, GJ | 1 |
| Chan, NG; Hsia, CC | 1 |
| Beppu, M; Fujimaki, Y; Isose, S; Iwai, Y; Kuwabara, S; Misawa, S; Mitsuma, S; Nakaseko, C; Nasu, S; Ohmori, S; Ohwada, C; Sekiguchi, Y; Shibuya, K; Shimizu, N; Takeda, Y | 1 |
| Mark, TM; Meadows, JP | 1 |
| Belloni, D; Berenzi, A; Caligaris-Cappio, F; Ferrarini, M; Ferrero, E; Girlanda, S; Mazzoleni, G; Ponzoni, M; Steimberg, N | 1 |
| Attal, M; Avet-Loiseau, H; Blaise, D; Cornillon, J; El-Cheikh, J; Harousseau, JL; Labussière, H; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Morisset, S; Nicolini, FE; Reman, O; Sirvent, A; Sobh, M; Tabrizi, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Bertsch, U; Blau, IW; Bos, GM; Croockewit, S; Duehrsen, U; el Jarari, L; Goldschmidt, H; Hänel, M; Jie, KS; Kersten, MJ; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; van de Velde, H; van der Holt, B; van Marwijk-Kooy, M; Vellenga, E; Weisel, K; Wijermans, P; Wittebol, S; Zweegman, S | 1 |
| Ishida, T | 3 |
| Behera, M; Boise, LH; Flowers, CR; Gleason, C; Kaufman, JL; Langston, A; Lonial, S; Nooka, AK; Waller, EK | 1 |
| Anderson, KC; Bladé, J; Bourquelot, PM; Günther, A; LeBlanc, R; Mishra, KK; Mu, S; Richardson, PG; San-Miguel, JF; Sezer, O; Siegel, D; Sopala, M; Sutherland, H; Victoria Mateos, M | 1 |
| Eom, HS; Jo, DY; Jun, HJ; Kim, JS; Kim, K; Kim, KH; Kim, SH; Kim, SJ; Kim, YS; Kwak, JY; Lee, JH; Lee, JJ; Lee, JO; Min, CK; Moon, JH; Mun, YC; Park, SK; Ryoo, HM; Suh, C; Voelter, V; Yoon, SS | 1 |
| Cheung, G; Chung, KC; Erdmann, N; Keats, JJ; Leung-Hagesteijn, C; Reece, DE; Stewart, AK; Tiedemann, RE | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Manios, E; Migkou, M; Papadimitriou, C; Roussou, M; Terpos, E | 1 |
| Al Ali, H; Andrea, M; Bachmann, A; Becker, C; Bourgeois, M; Edelmann, T; Egert, M; Fricke, S; Heyn, S; Hoffmann, FA; Krahl, R; Kreibich, U; Lindner, T; Moll, B; Niederwieser, D; Petros, S; Pönisch, W; Remane, Y; Schliwa, T; Schmalfeld, M; Schwarzer, A; Stiegler, R; Vucinic, V; Weidhase, L | 1 |
| Anderson, KC; Blacklock, H; Dimopoulos, M; Eid, JE; Facon, T; Goldschmidt, H; Graef, T; Hajek, R; Houp, J; Hungria, V; Lonial, S; Palumbo, A; Qi, J; Rosinol, L; Siegel, DS; Spencer, A; Sun, L; Vuocolo, S; Williams, C | 1 |
| Sommer, T; Wolf, DH | 1 |
| Lin, M; Niu, S; Sheng, Z; Zou, Y | 1 |
| Nace, RA; Russell, SJ; Yarde, DN | 1 |
| Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K | 1 |
| Drach, J; Drach-Schauer, B; Eder, S; Lamm, W | 1 |
| Ballester, G; Ballester, O; Yaqub, S | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yoon, JH | 1 |
| Adami, F; Brancalion, A; Cabrelle, A; Cappellesso, R; Colpo, A; Di Maggio, SA; Gurrieri, C; Mandato, E; Manni, S; Marino, F; Piazza, F; Pizzi, M; Semenzato, G; Trentin, L; Tubi, LQ; Zaffino, F; Zambello, R | 1 |
| Atanackovic, D; Schilling, G | 1 |
| Fujiwara, S; Hata, H; Kawano, Y; Kikukawa, Y; Mitsuya, H; Okuno, Y; Wada, N | 1 |
| Anderson, K; Hideshima, T; Laubach, J; Richardson, P | 1 |
| Moreau, P; Touzeau, C | 2 |
| Liu, H; McCarthy, P | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Tacchetti, P; Zamagni, E; Zannetti, BA | 1 |
| Cain, R; Waight, CC | 1 |
| Lentzsch, S; Schecter, J | 1 |
| Akria, L; Azoulay, D; Ben-Yehuda, D; Braester, A; Gatt, ME; Horowitz, N; Lavie, D; Perlman, R; Suriu, C | 1 |
| Burlingame, AL; Julien, O; Urisman, A; Weissman, JS; Wells, JA; Wiita, AP; Wiita, PJ; Ziv, E | 1 |
| Fu, CC; Gu, B; Jin, S; Li, WY; Liu, H; Ma, L; Sun, AN; Wu, DP; Wu, Q; Xin, X; Xue, SL; Zhao, SF; Zhu, XM | 1 |
| Baughn, LB; Linden, MA; Mansoor, A; Stessman, HA; Van Ness, B; Zhan, F | 1 |
| An, G; Deng, S; Qiu, L; Shi, L; Shizhen, Z; Sui, W; Xie, Z; Xu, Y; Zhan, F | 1 |
| Anaclerico, B; Annino, L; Arcese, W; Avvisati, G; Cerchiara, E; Chierichini, A; Cudillo, L; De Fabritiis, P; Dentamaro, T; Giannotti, F; Marchesi, F; Mengarelli, A; Monarca, B; Montefusco, E; Petti, MC; Picardi, A; Porrini, R; Romeo, A; Tendas, A; Tirindelli, MC | 1 |
| Akar, M; Aktan Kosker, T; Buyukasik, S; Ersoy, O; Solakoglu, T | 1 |
| Aróstegui, JI; Bladé, J; Cibeira, MT; Elena, M; Fernández de Larrea, C; Filella, X; Pedrosa, F; Rosiñol, L; Tovar, N; Yagüe, J | 1 |
| Boise, LH; Casbourne, D; Gleason, C; Heffner, LT; Kaufman, JL; Langston, A; Lonial, S; Muppidi, S; Nooka, AK; Saxe, D | 1 |
| Van Damme, P | 1 |
| Engelhardt, M; Fiebig, HH; Klingner, K; May, AM; Schueler, J; Siegers, GM; Wäsch, R; Wider, D | 1 |
| Gahrton, G; Krishnan, A | 1 |
| Adam, Z; Greil, R; Kasparu, H; Leitgeb, C; Linkesch, W; Ludwig, H; Pour, L; Rauch, E; Seebacher, A; Weißmann, A; Zojer, N | 1 |
| Cao, B; Chen, G; Du, X; Han, K; Li, J; Mao, X; Shi, M; Tang, J; Wang, M; Xu, X; Zhang, Z | 1 |
| Akhtar, S; Ansell, SM; Carr, J; Chanan-Khan, A; Chitta, K; Dispenzieri, A; Foran, J; Kumar, S; Mikhael, JR; Miller, KC; Paulus, A; Personett, D; Reeder, CB; Rivera, CE; Roy, V; Thompson, KJ | 1 |
| Aljama, P; Alonso, C; Alvarez-Lara, MA; Caballero-Villarraso, J; Carracedo, J; Martín-Malo, A; Ojeda-López, R; Pendón-Ruiz de Mier, MV | 1 |
| Caba-Molina, M; Claver-Ferré, C; García-Marcos, SA; Gómez-Morales, M; Martín-Gómez, MA; Palacios-Gómez, ME | 1 |
| Malard, F; Mohty, B; Mohty, M; Moreau, P; Savani, B; Terpos, E | 1 |
| Barbee, MS; Harvey, RD; Hutcherson, DA; Kaufman, JL; Lonial, S; McKibbin, T; Shah, KS; Surati, M; Valla, K; Wilson, NM | 1 |
| Beksac, M; Boccadoro, M; Bringhen, S; Catalano, L; Cavalli, M; Cavo, M; Cerrato, C; Gentile, M; Gimsing, P; Gottardi, D; Isabel Turel, A; José Lahuerta, J; Juliusson, G; Larocca, A; Magarotto, V; Marina Liberati, A; Mazzone, C; Morabito, F; Musto, P; Offidani, M; Omedè, P; Oriol, A; Palumbo, A; Passera, R; Rossi, D; Rosso, S; San Miguel, J; Schaafsma, M; Sonneveld, P; Victoria Mateos, M; Waage, A; Wijermans, P; Zambello, R; Zweegman, S | 1 |
| Ahn, KS; Bae, EK; Choi, JH; Jung, WJ; Lee, C; Park, J; Yoon, SS | 1 |
| Cavallo, F; Cerrato, C; Mina, R; Palumbo, A | 1 |
| Bokhari, SW; Jones, FM | 1 |
| Alesiani, F; Discepoli, G; Leoni, P; Liberati, S; Morelli, MB; Nabissi, M; Offidani, M; Olivieri, A; Santoni, G; Santoni, M | 1 |
| Chen, L; Fu, JX; Ju, SG; Li, J; Wang, ZY; Yuan, YQ | 1 |
| An, G; Deng, S; Meng, H; Qiu, L; Shi, L; Sui, W; Wang, J; Xu, Y; Zhan, F; Zhu, G; Zou, D | 1 |
| Angelucci, E; Annese, T; Berardi, S; Caivano, A; Catacchio, I; Dammacco, F; De Luisi, A; Derudas, D; Ditonno, P; Frassanito, MA; Guarini, A; Minoia, C; Moschetta, M; Nico, B; Piccoli, C; Ria, R; Ribatti, D; Ruggieri, S; Ruggieri, V; Vacca, A | 1 |
| Fadeel, B; Feng, X; Henter, JI; Ji, C; Ma, D; Shao, N; Wang, J; Wang, X; Zheng, C | 1 |
| Aldrin, A; Alici, E; Aschan, J; Blimark, C; Carlson, K; Enestig, J; Flogegård, M; Forsberg, K; Gahrton, G; Gruber, A; Haglöf Kviele, H; Johansson, P; Lauri, B; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Näsman, P; Svensson, M; Swedin, A; Uttervall, K | 1 |
| Alexanian, R; Delasalle, K; Handy, B; Qazilbash, M; Wang, M; Wang, S; Weber, D | 1 |
| Hahn, T; McCarthy, PL | 1 |
| Anderson, KC; Carrasco, RD; Chauhan, D; D'Arcy, P; Hu, Y; Linder, S; Ray, A; Richardson, P; Tai, YT; Tian, Z; Wang, X | 1 |
| Baldassarre, FG; Cheung, MC; Haynes, AE; Imrie, K; Kouroukis, CT; Reece, DE | 1 |
| Munemoto, S; Murata, R; Nakajima, K; Nakao, S; Takamatsu, H; Terasaki, Y | 1 |
| Baldini, L; Capelli, C; Chiaramonte, R; D'Anca, M; Fabris, S; Inghirami, G; Introna, M; Lombardi, L; Mosca, L; Neri, A; Nobili, L; Pellegrino, E; Piva, R; Todoerti, K; Verdelli, D | 1 |
| Fukuda, Y; Gemma, A; Hatake, K; Katoh, T; Kudoh, S; Kusumoto, M; Miyao, M; Miyazawa, M; Mukai, HY; Ogawa, Y; Ohyashiki, K; Sakai, F; Sugiyama, Y; Yoshizawa, K | 1 |
| Anderson, KC; Berenson, JR; Berger, A; Bernard, H; Blakemore, SJ; Bolen, JB; Chattopadhyay, N; Di Bacco, A; Dorner, AJ; Esseltine, DL; Jagannath, S; Koenig, E; Li, B; Lichter, DI; Lonial, S; Mulligan, G; Neuwirth, R; Orlowski, RZ; Ricci, D; Richardson, PG; San Miguel, JF; Schu, M; Sonneveld, P; Stadtmauer, EA; Trepicchio, W; van de Velde, H | 1 |
| Chen, RL; Huang, BT; Li, BS; Tan, Y; Zeng, QC; Zhao, WH | 1 |
| Chang, TP; Gatla, HR; Manna, S; Poltoratsky, V; Sanacora, S; Singha, B; Vancura, A; Vancurova, I | 1 |
| Barthel, BG; Kostoff, D; Saad, SA; Zobniw, CM | 1 |
| Anderson, KC; Mitsiades, CS; Ocio, EM; Orlowski, RZ | 1 |
| Furukawa, Y; Hatano, K; Kikuchi, J; Nagai, T; Ozawa, K; Sripayap, P | 1 |
| Delimpasi, S; Dimopoulos, MA; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Konstantopoulos, K; Kyrtsonis, MC; Michael, M; Michalis, E; Parcharidou, A; Pouli, A; Repousis, P; Symeonidis, A; Terpos, E; Vassou, A | 1 |
| Chen, BY; Chen, WM; Liao, LS; Lin, Y; Qu, S; Wei, TN | 1 |
| Grandjean, C; Horger, M; Oehrlein, K; Schulze, M; Spira, D; Weisel, K; Zago, M | 1 |
| Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ | 1 |
| Berno, T; Kamalakar, A; Pappas, L; Suva, LJ; Tricot, G; Xu, H; Yang, Y; Yoon, D; Zangari, M; Zeng, M | 1 |
| Aylı, M; Cevik, C; Mandıroğlu, S | 1 |
| Devine, E; Krause, B; Krieter, DH; Lemke, HD; Storr, M; Wanner, C | 1 |
| Zhang, J; Zhong, Y | 1 |
| Choi, NR; Hoang, MD; Jung, SH; Kim, HJ; Lee, HJ; Lee, JJ; Lee, YK; Lim, MS; Nguyen-Pham, TN; Vo, MC | 1 |
| Anderson, KC; Bahlis, N; Baz, R; Belch, A; Chen, C; Chen, M; Hofmeister, CC; Jacques, C; Jagannath, S; Jakubowiak, A; Lacy, M; Lentzsch, S; Lonial, S; Matous, J; Mikhael, J; Raje, N; Richardson, PG; Shustik, C; Siegel, DS; Song, K; Vesole, D; Vij, R; Yu, Z; Zaki, MH | 1 |
| San Miguel, JF | 2 |
| Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W | 1 |
| Liu, G; Liu, L; Wang, SX; Wang, Y; Yao, Y; Zhang, YK | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Dichmann, R; Eshaghian, S; Gravenor, D; Hilger, JD; Nassir, Y; Patel-Donnelly, D; Stampleman, L; Swift, RA; Vescio, RA; Yellin, O | 1 |
| Chen, X; Chopra, R; Díaz-Rodríguez, E; Lopez-Girona, A; Miguel, JS; Mortensen, DS; Ocio, EM; Paiva, B; Pandiella, A | 1 |
| Blanco Cid, N; Dacal Quintas, R; Santalla Martínez, M | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Bryant, J; Clegg, A; Cooper, K; Picot, J | 1 |
| Hata, T; Li, C; Two, AM | 1 |
| Attal, M; Einsele, H; Giralt, S; McCarthy, PL | 1 |
| Chan, EY; Chim, CS; Ho, S; Kwong, YL; Lie, AK; Liu, H; Wong, M | 1 |
| Chang, CC; Choi, DS; Jiang, B; Su, J; Wen, J; Zhang, L; Zhang, W; Zhou, X | 1 |
| Collins, DJ; Davies, FE; deSouza, NM; Giles, SL; Messiou, C; Morgan, GJ; Morgan, VA; Simpkin, CJ; West, S | 1 |
| Anderson, KC; Chauhan, D; Coffman, RL; Das, DS; Ray, A; Richardson, P; Tian, Z | 1 |
| Midorikawa, K; Nagata, A; Noto, S; Ootsubo, K; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K | 1 |
| Boccadoro, M; Corradini, P; Crippa, C; Gambella, M; Gay, F; Ladetto, M; Omedè, P; Palumbo, A; Passera, R; Rocci, A; Romano, A; Rossi, D | 1 |
| Ahn, KS; Chng, WJ; Kannaiyan, R; Kumar, AP; Li, F; Mustafa, N; Sethi, G; Siveen, KS | 1 |
| Lentzsch, S | 1 |
| Bonnet, A; Bourcier, J; Chauvin, C; Lok, A; Mahé, B; Mocquard, J; Moreau, P; Redelsperger, L; Thomaré, P; Touzeau, C | 1 |
| Cao, JY; Cao, MN; Cao, XC; Gao, AH; Gao, LX; Han, MM; Li, J; Sheng, L; Su, MB; Wang, MK; Xu, L; Zhou, YB | 1 |
| Chairopoulos, K; Kilindireas, K; Koulieris, E; Koutra, E; Kyrtsonis, MC; Maltezas, D; Pangalis, GA; Pessach, I; Sachanas, SP; Tzenou, T; Zaroulis, CK | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Fuchida, S; Hino, M; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsumura, I; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Shimura, Y; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uoshima, N | 1 |
| Bodie, WW; Chen, S; Dai, Y; Felthousen, J; Grant, S; Kramer, LB; Orlowski, RZ; Pei, XY; Sanderson, MW; Takabatake, Y; Youssefian, LE; Zhou, L | 1 |
| Shah, BK; Sharma, LR; Subedi, A | 1 |
| Barchnicka, A; Grosicka, A; Grosicki, S; Jurczyszyn, A | 1 |
| Dong, LW; Du, J; Fan, JL; Fu, WJ; Hou, J; Jiang, H; Shi, HG; Wang, HY; Xi, H; Ye, F; Zhang, CY; Zhang, J | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH | 1 |
| Avigan, D; Kufe, D; Kufe, T; Yin, L | 1 |
| Blommestein, HM; Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Uyl-de Groot, CA | 1 |
| Corchete, LA; Garayoa, M; García-Sanz, R; Gutiérrez, NC; Krzeminski, P; Ocio, EM; Paíno, T; Paiva, B; Redondo, A; San-Miguel, JF; San-Segundo, L; Sarasquete, ME | 1 |
| Asaoku, H; Chou, T; Harada, T; Hayashi, K; Itagaki, M; Kuroda, Y; Mina, R; Murakami, H; Ozaki, S; Palumbo, A; Saitoh, T; Shimazaki, C; Shimizu, K; Suzuki, K; Yoshiki, Y | 1 |
| Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M | 1 |
| Fu, R; Gao, S; Liu, H; Shao, Z; Song, J; Wang, G; Wang, H; Xing, L | 1 |
| Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y | 1 |
| Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C | 1 |
| Bird, J; Bowcock, S; Cook, G; Davies, F; Lai, M; Low, E; Morgan, G; Owen, R; Pratt, G; Rabin, N; Snowden, J; Wechalaker, A; Yong, K | 1 |
| Iida, S; Ri, M | 1 |
| Chen, CY; Chen, YC; Chou, SJ; Chou, WC; Hou, HA; Huang, SY; Lin, CW; Lin, HH; Lu, HY; Tang, JL; Tien, HF; Tsay, W; Wu, SJ; Yao, M | 1 |
| Abildgaard, N; Godskesen, L; Kjeldsen, J; Krag, A | 1 |
| Furukawa, Y; Kikuchi, J; Koyama, D; Mukai, HY | 1 |
| Bernal, L; Boise, LH; Chen, J; Gu, Y; Harvey, RD; Kaufman, JL; Lonial, S; Matulis, SM; Sun, SY; Torre, C | 1 |
| Chuang, WH; Hsu, LF; Huang, SY; Hwang, SM; Liao, YH; Lin, HH; Sheen, YS; Wu, SJ | 1 |
| Ahn, SY; Choi, CW; Joo, YD; Jung, SH; Kim, K; Kim, SJ; Lee, JJ; Lee, SM; Lee, WS | 1 |
| Chang, WJ; Kang, ES; Kim, DW; Kim, K; Kim, SH; Kim, SJ; Lee, ST | 1 |
| An, G; Chang, H; Cheng, T; Deng, S; Hao, M; Li, F; Qi, J; Qin, X; Qin, Y; Qiu, L; Ru, K; Shi, L; Sui, W; Wang, H; Wang, J; Xu, Y; Yao, H; Yi, S; Zhu, G | 1 |
| Bringhen, S; Donato, F; Gay, F; Palumbo, A; Troia, R | 1 |
| Fujishima, Y; Ishida, Y; Ito, S; Kowata, S; Murai, K; Shimoyama, T; Yashima-Abo, A | 1 |
| Einsele, H | 2 |
| Anagnostopoulos, A; Christoforidou, A; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gastari, V; Giannakoulas, N; Giannopoulou, E; Hadjiaggelidou, C; Kastritis, E; Katodritou, E; Kelaidi, C; Konstantinidou, P; Kotsopoulou, M; Kouraklis, A; Kyrtsonis, MC; Papadaki, S; Papadopoulou, A; Polychronidou, G; Pouli, A; Stefanoudaki, E; Symeonidis, AS; Terpos, E; Verrou, E; Viniou, NA; Zervas, K | 1 |
| Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H | 1 |
| Cho, J; Kang, D; Kim, K; Kim, SJ; Lee, JY | 1 |
| Du, H; Hu, X; Huang, J; Jiang, H; Xuan, H | 1 |
| Bao, L; Huang, X; Jiang, B; Lai, Y; Li, J; Li, L; Liu, Y; Lu, J; Qin, Y; Shi, H; Wang, Y; Zhu, H | 1 |
| Abdi, J; Garssen, J; Mutis, T; Redegeld, FA | 1 |
| Abildgaard, N; Hansen, CT; Nielsen, LC; Pedersen, PT | 1 |
| Bladé, J; Grosicki, S; Laubach, J; Maloisel, F; Mateos, MV; Min, CK; Orlowski, RZ; Palumbo, A; Polo Zarzuela, M; Prasad, SV; Puchalski, T; Qin, X; Reddy, M; Robak, T; San-Miguel, J; Shpilberg, O; Spencer, A; Tee Goh, Y; Uhlar, C; van de Velde, H; Xie, H | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Hata, H; Mitsuya, H; Nishimura, N; Nosaka, K; Okuno, Y | 1 |
| Chen, L; Gao, L; Hu, X; Lyu, S; Qiu, H; Song, X; Wang, J; Xu, L; Xu, X; Yang, J; Zhang, W | 1 |
| Avigdor, A; Duek, A; Freidman, T; Kedmi, M; Leiba, M; Leiba, R; Nagler, A; Weiss, M | 1 |
| Barchnicka, A; Blajer-Olszewska, B; Blonska, D; Boguradzki, P; Charlinski, G; Dawidowska, D; Dmoszynska, A; Druzd-Sitek, A; Dzierzak-Mietla, M; Gawron, L; Gontarska, A; Grygoruk-Wisniowska, I; Grzasko, N; Holojda, J; Iskierka, E; Jachalska, A; Jurczyszyn, A; Kopacz, A; Lech-Maranda, E; Madro, E; Masternak, A; Nowicki, A; Olszewska-Szopa, M; Potoczek, S; Rybicka, M; Rymko, M; Rzepecki, P; Soroka-Wojtaszko, M; Subocz, E; Swiderska, A; Swistek, W; Torosian, T; Usnarska-Zubkiewicz, L; Walter-Croneck, A; Wisniewska-Piaty, K; Zielinska, P | 1 |
| Badros, AZ; Bao, T; Dorsey, SG; Goloubeva, O; Hester, L; Lao, L; Lapidus, R; Medeiros, M; Pelser, C; Porter, N; Primrose, J; Sadowska, M | 1 |
| Abe, Y; Honda, Y; Iki, S; Inoue, J; Miyazaki, K; Sekine, E; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Alexanian, R; Badillo, M; Chen, Y; Chiang, J; Cohen, L; Delasalle, K; Garcia, MK; Green, V; Guo, Y; Lee, R; Orlowski, RZ; Romaguera, J; Shah, J; Thomas, S; Wang, M; Weber, D; Wei, Q; You, B; Zhang, L; Zhou, Y | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Cvek, B; Škrott, Z | 1 |
| Ashley, JD; Bilgicer, B; Kiziltepe, T; Schroeder, VA; Stefanick, JF; Suckow, MA | 1 |
| Nixon, NA; Parhar, K | 1 |
| Bringhen, S; Donato, F; Gay, F; Mina, R; Palumbo, A; Troia, R | 1 |
| Chen, X; Dou, QP; Guan, L; Hua, X; Huang, H; Lan, X; Li, X; Liao, S; Liu, C; Liu, J; Liu, N; Liu, S; Song, W; Wang, S; Wang, X; Yang, C; Yi, S; Zhang, P; Zhao, C; Zhou, P | 1 |
| Huang, HB; Niu, WY; Wu, SQ; Xu, ZZ; Zhan, R | 1 |
| Cai, Z; Fu, J; Han, X; He, J; Huang, H; Huang, W; Li, L; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zhang, X; Zhao, Y; Zheng, G; Zheng, W | 1 |
| Akashi, K; Aoki, T; Ito, Y; Iwasaki, H; Kadowaki, M; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Shima, T; Shiratsuchi, M; Takase, K; Takashima, S; Takenaka, K; Teshima, T; Yoshimoto, G | 1 |
| De Bruyne, E; De Wever, O; Hendrix, A; Hernot, S; Lahoutte, T; Lemaire, M; Menu, E; Van Valckenborgh, E; Vanderkerken, K; Wang, J | 1 |
| de Zoysa, JR; Hutchison, CA; Lam-Po-Tang, M; Tan, J | 1 |
| Dytfeld, D; Gil, L; Kaźmierczak, M; Komarnicki, M; Nowicki, A; Rupa-Matysek, J; Wojtasińska, E | 1 |
| Ding, SH; Wang, QS; Wang, YS; Wang, ZT; Wu, F | 1 |
| Andrea, M; Becker, C; Behre, G; Bourgeois, M; Edelmann, T; Gutsche, K; Hammerschmidt, D; Hennig, E; Heyn, S; Hoffmann, FA; Holzvogt, B; Kaiser, T; Krahl, R; Kreibich, U; Lindner, T; Niederwieser, D; Plötze, M; Pönisch, W; Reifenrath, K; Remane, Y; Schliwa, T; Schwarz, M; Schwarzer, A; Vucinic, V; Winkelmann, C; Zehrfeld, T | 1 |
| Bai, Q; Chen, X; Liang, R; Liu, H; Liu, L; Liu, M; Shi, B; Tian, D; Zhang, Y | 1 |
| Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
| Atsumi, M; Ito, T; Kameda, K; Kiba, T; Kido, M; Kimura, A; Miyamae, F; Nakashima, T; Niimi, H; Okikawa, Y; Shitakubo, Y; Sumitani, Y; Tanaka, S | 1 |
| Anderson, KC; Cirstea, D; Hu, Y; Lu, D; Munshi, NC; Song, W | 1 |
| Chung, DJ; Devlin, S; Giralt, SA; Hassoun, H; Hilden, P; Koehne, G; Landau, H; Lendvai, N; Lesokhin, AM; Redling, K; Schaffer, WL; Tsakos, I | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Chen, H; Del Lourdes Cebrera-Muñoz, M; Huerta-Yepez, S; Liu, H; Maldonado-Valenzuela, A; Rivera-Pazos, C; Valencia-Hipolito, A; Vega, MI | 1 |
| Grob, SR; Jakobiec, FA; Rashid, A; Yoon, MK | 1 |
| Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M | 1 |
| Bergsagel, PL; Chen, C; Fonseca, R; Kukreti, V; Laumann, K; Leis, JF; Mikhael, JR; Reece, DE; Reeder, CB; Stewart, AK; Tiedemann, R; Trudel, S; Vohra, H | 1 |
| Hu, H; Jia, Y; Peng, J; Wang, L; Xu, H | 1 |
| Baron, R; Basto, P; Bertrand, N; Farokhzad, OC; Ghobrial, IM; Glavey, S; Kamaly, N; Liu, J; Lu, ZN; Manier, S; Memarzadeh, M; Mishima, Y; Moschetta, M; Nagano, K; Reagan, MR; Roccaro, AM; Sacco, A; Seevaratnam, D; Shi, J; Swami, A; Wu, J; Zhang, S; Zhang, Y | 1 |
| Amaravadi, RK; Bradner, JE; Chang, YC; Davis, LE; Heitjan, DF; Kaplan, J; Mallon, G; Nichols, CW; Paul, TM; Piao, S; Pontiggia, L; Porter, DL; Rangwala, R; Scott, EC; Stadtmauer, EA; Tan, KS; Vogl, DT | 1 |
| Numata, H; Ohgiya, D; Sasao, T; Suyama, T; Tsuboi, K; Tsuchiya, T; Watanabe, S | 1 |
| Choi, DR; Han, B; Jung, JY; Kim, HJ; Kim, HY; Zang, DY | 1 |
| Ali, SM; Chmielecki, J; Miller, VA; Morosini, D; Palmer, GA; Ross, JS; Sharman, JP; Stafl, J; Stephens, PJ | 1 |
| Dolloff, NG; Harding, T; Lulla, A; Mansoor, A; Mitra, A; Myers, CL; Stessman, HA; Van Ness, BG; Xia, T | 1 |
| Chen, D; Dou, QP; Guan, F; Wang, H; Yang, H | 1 |
| Kaneko, T; Kawakami, J; Mino, Y; Naito, T; Ohnishi, K; Osawa, T; Yamada, H | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Ba-Mancini, A; Comenzo, RL; Duh, MS; Gravel, J; Knopf, KB; Lafeuille, MH; Lefebvre, P; Ma, E; Niculescu, L; Shi, H | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Chretien, ML; Corre, J; Facon, T; Fruchart, C; Gentil, C; Hebraud, B; Hulin, C; Huynh, A; Lauwers-Cances, V; Leleu, X; Marit, G; Moreau, P; Pegourie, B; Robillard, N; Roussel, M; Stoppa, AM; Wuilleme, S | 1 |
| de Waal, TT; Gorter, MH; Tascilar, M | 1 |
| Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Joks, M; Jurczyszyn, A; Komarnicki, M; Machaczka, M; Skotnicki, AB | 1 |
| Cai, Z; Han, XY; He, DH; He, JS; Huang, H; Li, Y; Wang, LJ; Wu, C; Wu, WJ; Yang, L; Yang, Y; Yi, Q; Zhao, Y; Zheng, GF; Zi, FM | 1 |
| Chang, PY; Chao, TY; Chen, JH; Chen, YC; Dai, MS; Ho, CL; Huang, TC; Kao, WY; Wu, YY | 1 |
| Choi, YJ; Eom, KS; Jo, DY; Joo, YD; Kang, HJ; Kim, BS; Kim, CS; Kim, JS; Kim, SH; Kim, SJ; Kim, YJ; Kim, YS; Kwak, JY; Lee, JJ; Min, CK; Mun, YC; Park, CY; Park, JS; Suh, C; Yoon, SS | 1 |
| Azadeh, N; Fonseca, R; Kelemen, K | 1 |
| Fu, W; Hou, J; Huang, H; Peng, L; Zhang, C; Zhou, L | 1 |
| Fu, R; Guan, J; Li, L; Liu, H; Mei, S; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wu, Y; Xing, L | 1 |
| Nekova, TS; Stuhler, G | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N | 1 |
| Aujesky, D; Oestmann, A | 1 |
| Beimler, J; Breitkreutz, I; Egerer, G; Goldschmidt, H; Heiss, C; Ho, AD; Jäger, D; Neben, K; Perne, A; Raab, MS; Zeier, M | 1 |
| Dou, QP; Zonder, JA | 1 |
| Chung, MH; Kim, HS; Kim, I; Kim, KS; Koh, Y; Kwon, JH; Lee, SY; Park, S; Suh, SY; Yoon, SS | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; González, Y; Granell, M; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez, R; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Pérez, M; San-Miguel, JF; Teruel, AI | 1 |
| Auger, MJ; Bowles, KM; Murray, MY | 1 |
| Huang, L; Liu, W; Liu, Z; Luo, L; Mao, X; Meng, F; Qin, S; Sun, H; Zeng, W; Zheng, M; Zhou, J | 1 |
| Fujiwara, K; Higo, H; Inomata, T; Kameyama, N; Makimoto, G; Matsushita, M; Rai, K; Sato, K; Shibayama, T; Sunami, K; Watanabe, H | 1 |
| Ho, CH; Lo, CP; Tu, MC | 1 |
| Chim, CS; Wong, KY | 1 |
| Cerase, A; Gozzetti, A | 1 |
| Akpek, G; Armstrong, E; Elekes, A; Freytes, CO; Kato, K; Patil, S; Ratanatharathorn, V; Reece, DE; Rodriguez, TE; Sahovic, E; Shaughnessy, PJ; Smith, A; Solomon, SR; Stadtmauer, EA; Toro, JJ; Tricot, GJ; White, DJ; Yeh, RF; Yu, LH; Zhao, C | 1 |
| Kim, J; Kim, M; Kim, YJ; Lee, SE; Lee, SH; Min, CK | 1 |
| Baldini, L; Cavaletti, G; Cavo, M; Elice, F; Galli, M; Gozzetti, A; Lazzaro, A; Martello, M; Montefusco, V; Palumbo, A; Pantani, L; Peccatori, J; Petrucci, MT; Pezzi, A; Rocchi, S; Ruggieri, M; Tacchetti, P; Terragna, C; Tosi, P; Zamagni, E | 1 |
| Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E | 1 |
| Ju, D; Xie, Y | 1 |
| Chang, H; Chen, GA; Chen, J; Chen, Y; Evans, K; Qiu, L; Reece, D; Saha, MN; Yang, Y | 1 |
| Martin, TG | 1 |
| Hamdy, AA; Neemat, K; Rania, K; Tarek, M | 1 |
| Mateos, MV; Miguel, JF | 1 |
| Boise, LH; Lonial, S | 2 |
| Vij, R | 1 |
| Orlowski, RZ | 6 |
| Awai, K; Date, S; Kaichi, Y; Kiguchi, M; Kuroda, Y; Sakai, A; Sakoda, Y; Takasu, M; Tani, C | 1 |
| Dakhil, C; Haideri, N; Kumar, AK; Teeka Satyan, M | 1 |
| Chen, S; Dai, Y; Grant, S; Jones, R; Kmieciak, M; Leng, Y; Lin, H; Orlowski, RZ; Pei, XY; Zhang, Y; Zhou, L | 1 |
| Chinen, Y; Horiike, S; Kobayashi, T; Kuroda, J; Maegawa, S; Matsumoto, Y; Mizuno, Y; Mizutani, S; Nagoshi, H; Shimura, Y; Taniwaki, M; Tatekawa, S; Tsukamoto, T; Yamamoto-Sugitani, M | 1 |
| Ahn, JS; Jang, HC; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH | 1 |
| Facon, T; Hulin, C; Moreau, P | 2 |
| Vincent Rajkumar, S | 1 |
| Koeppen, S | 1 |
| Anderson, KC; Driscoll, JJ; Jagannathan, S; Vad, N; Vallabhapurapu, S | 1 |
| Beksac, M; Bengoudifa, BR; Binlich, F; Bladé, J; Cavenagh, JD; Chen, W; Chuncharunee, S; Corradini, P; Corrado, C; de la Rubia, J; Dimopoulos, MA; Einsele, H; Elghandour, A; Gimsing, P; Günther, A; Hou, J; Hungria, VT; Jedrzejczak, WW; Kaufman, JL; LeBlanc, R; Lee, JH; Lee, JJ; Lonial, S; Moreau, P; Nahi, H; Nakorn, TN; Numbenjapon, T; Ocio, EM; Pulini, S; Qiu, L; Richardson, PG; Salwender, H; San-Miguel, JF; Schlossman, RL; Shelekhova, T; Siritanaratkul, N; Sohn, SK; Sopala, M; Tan, D; Veskovski, L; Wang, MC; Warzocha, K; White, D; Yong, K; Yoon, SS | 1 |
| Cai, Q; Gao, Y; Wang, C; Wei, D; Wei, J; Zhao, C; Zhao, M | 1 |
| Cahu, J; DaCosta, L; Gaudichon, J; Martens, AC; Milano, F; Renoir, JM; Sola, B | 1 |
| Anderson, KC; Ataman, O; Beksac, M; Benboubker, L; Couturier, C; Dimopoulos, MA; Facon, T; Feng, H; Orlowski, RZ; Potamianou, A; Richardson, PG; Roddie, H; Sonneveld, P; van de Velde, H | 1 |
| Buchner, K; Eulberg, D; Facchetti, F; Ghobrial, IM; Klussmann, S; Kruschinski, A; Lonardi, S; Maasch, C; Maiso, P; Mishima, Y; Moschetta, M; Purschke, WG; Reagan, MR; Roccaro, AM; Rossi, G; Sacco, A; Ungari, M; Vater, A; Vonhoff, S; Zboralski, D; Zöllner, S | 1 |
| Batalo, MS; Bose, P; Grant, S; Holkova, B | 1 |
| Bories, C; Facon, T; Fouquet, G; Guidez, S; Herbaux, C; Javed, S; Leleu, X; Renaud, L | 1 |
| Hobeika, L; Self, SE; Velez, JC | 1 |
| Abdi, J; Faber, J; Garssen, J; Redegeld, FA | 1 |
| Bandekar, R; Bladé, J; Cavenagh, JD; Dimopoulos, MA; Gercheva, L; Goranova-Marinova, V; Maiolino, A; Masszi, T; Orlowski, RZ; Puchalski, TA; Reddy, M; Robak, T; Rossi, JF; Samoylova, O; Špička, I; Sutherland, H; Suvorov, A; van de Velde, H; Williams, C; Xie, H | 1 |
| Shibayama, H | 1 |
| Nakaseko, C | 1 |
| Tsurumi, H | 1 |
| Anderson, KC; Chauhan, D; Cirstea, D; Cottini, F; Gorgun, G; Hideshima, T; Jakubikova, J; Kikuchi, S; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Richardson, PG; Suzuki, R; Tai, YT; Utsugi, T; Yoshida, Y | 1 |
| Bátorová, A; Mistrík, M; Roziaková, L | 1 |
| Basnayake, K; Talbot, B; Wright, D | 1 |
| Izumi, H; Komatsu, N; Nakamura, N; Noguchi, M; Ohta, Y; Sawada, T; Sekiguchi, Y; Shimada, A; Sugimoto, K; Tomita, S; Wakabayashi, M | 1 |
| Guo, S; Li, Q; Qu, F; Wang, Y; Xia, B; Yang, H; Yuan, T; Zhang, Q; Zhang, Y; Zhao, W | 1 |
| Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K | 1 |
| Ádám, E; Andrikovics, H; Balassa, K; Koszarska, M; Kozma, A; Masszi, T; Mikala, G; Tordai, A; Varga, G | 1 |
| Dessanti, ML; Ensoli, F; Gumenyuk, S; Marchesi, F; Maschio, M; Mengarelli, A; Palombi, F; Pimpinelli, F; Pisani, F; Romano, A; Spadea, A | 1 |
| Dewan, VN; Grannis, CH; Wang, RC | 1 |
| Anglaret, B; Avet-Loiseau, H; Banos, A; Benboubker, L; Benramdane, R; Casassus, P; Chaleteix, C; Cony-Makhoul, P; Decaux, O; Dejoie, T; Dib, M; Fitoussi, O; Fontan, J; Garderet, L; Hulin, C; Jardel, H; Kolb, B; Leleu, X; Lenain, P; Mathiot, C; Moreau, P; Pegourie, B; Pétillon, MO; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Traullé, C; Vilque, JP | 1 |
| Fei, X; Li, J; Lu, H; Tang, Y; Xu, X; Yang, J; Zhu, Y | 1 |
| Anderson, KC; Dimopoulos, MA; Moreau, P; Richardson, PG | 1 |
| Che, XF; Gotoh, A; Hiramoto, M; Hirota, A; Inazu, M; Kawai, Y; Kokuba, H; Komatsu, S; Miyazawa, K; Moriya, S; Yamasaki, K | 1 |
| Hata, H; Hirata, S; Ide, K; Kawaguchi, T; Kikukawa, Y; Matsuno, N; Mitsuya, H; Miyakawa, T; Nakata, H; Nosaka, K; Okuno, Y; Yonemura, Y; Yuki, H | 1 |
| Cao, D; Guo, T; Hu, Y; Jin, L; Yu, W; Zhou, H | 1 |
| Acharya, C; An, G; Cheng, T; Deng, S; Feng, X; Hao, M; Li, Z; Qi, J; Qin, X; Qiu, L; Ru, K; Shi, L; Sui, W; Tai, YT; Wang, J; Xu, Y; Yi, S; Zang, M; Zhao, Y; Zou, D | 1 |
| Burhenne, J; Clemens, J; Haefeli, WE; Hose, D; Longo, M; Seckinger, A; Theile, D; Weiss, J | 1 |
| Driscoll, JJ; Jaganathan, S; Malek, E; Vallabhapurapu, S | 1 |
| Abenhardt, W; Aldaoud, A; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Münz, M; Nusch, A | 1 |
| Harrison, SJ; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Anderson, KC; Ghobrial, IM; Glavey, S; Görgün, GT; Kawano, Y; Manier, S; Moschetta, M; Roccaro, AM | 1 |
| Ando, Y; Fujiwara, S; Hata, H; Iida, S; Kawano, Y; Kikukawa, Y; Mitsuya, H; Nakashima, T; Okuno, Y; Ri, M; Shiotsu, Y; Tasaki, M; Ueda, M; Wada, N; Yoshinaga, K | 1 |
| Ahn, JS; Ahn, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH | 1 |
| Dong, F; Jing, HM; Ke, XY; Liu, Y; Wan, WL; Wang, J; Wang, JJ; Zhang, W | 1 |
| Li, Y; Qin, H; Tao, Q; Wang, H; Wang, Y; Wang, Z; Xiao, W; Xiong, S; Zhai, Z; Zhang, L | 1 |
| Anderson, KC; Dimopoulos, MA; Dow, E; Elliott, J; Mateos, MV; Niculescu, L; Palumbo, A; Richardson, PG; San Miguel, JF; Shi, H; van de Velde, H | 1 |
| Behler, C; Efebera, YA; Girnius, SK; Grady, T; Han, A; Hayes, TG; Houranieh, A; Kambhampati, S; Klein, CE; Lee, S; Lichtenstein, A; Mehta, P; Mohiuddin, A; Munshi, NC; Prabhala, RH; Roodman, GD; Rose, MG; Yellapragada, SV; Zimelman, A | 1 |
| Armenteros, E; Downward, J; Herledan, G; Kumar, M; Lach, A; Percy, L; Smith, D; Stubbs, M; Yong, K | 1 |
| Gu, J; Huang, B; Li, J; Liu, J; Wang, H; Xu, D; Zheng, D; Zou, W | 1 |
| Bladé, J; Fernández de Larrea, C; Rosiñol, L | 1 |
| Arnulf, B; Deraedt, W; Esseltine, DL; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, P; van de Velde, H | 1 |
| Areethamsirikul, N; Chen, C; Chu, CM; Jimenez-Zepeda, V; Kukreti, V; Masih-Khan, E; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Hashimoto, Y; Iida, S; Kimura, Y; Kizaki, M; Nemoto-Anan, T; Ri, M; Sagawa, M; Tabayashi, T; Tokuhira, M; Tomikawa, T; Watanabe, R | 1 |
| Takahashi, N | 1 |
| Furukawa, Y; Kikuchi, J | 1 |
| Nakaseko, C; Sakaida, E; Takeda, Y | 1 |
| Apewokin, S; Atrash, S; Barlogie, B; Crowley, J; Epstein, J; Grazziutti, M; Hoering, A; Khan, R; Kumar, S; Rosenthal, A; Shaughnessy, JD; Usmani, S; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Colson, K | 1 |
| Augustson, B; Baker, B; Campbell, P; Catalano, J; Copeman, M; Dean, J; Feng, H; Harrison, SJ; Link, E; Prince, HM; Quach, H; Romeril, K; Schwarer, A; Spencer, A; Van De Velde, H | 1 |
| Abe, Y; Achira, M; Ando, K; Iizuka, K; Kojima, M; Kuroda, J; Maruyama, D; Ogura, M; Suzuki, K; Suzuki, T; Taniwaki, M; Tobinai, K | 1 |
| Camarero, J; Flores, B; Gisselbrecht, C; Hanaizi, Z; Hemmings, R; Laane, E; Pignatti, F; Salmonson, T; Sancho-Lopez, A | 1 |
| Shen, Q; Zhuang, Y | 1 |
| Ahn, KS; Kim, C; Kim, SH; Lee, JH; Sethi, G | 1 |
| Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Morisaki, M; Yokoyama, T | 1 |
| Aljawai, Y; Asara, JM; Ghobrial, IM; Huynh, D; Kimmelman, AC; Maiso, P; Mishima, Y; Moschetta, M; Roccaro, AM; Sacco, A | 1 |
| Bertsch, U; Blau, IW; Dürig, J; Gerecke, C; Goldschmidt, H; Haenel, M; Hielscher, T; Hillengass, J; Hose, D; Huegle-Doerr, B; Jauch, A; Kunz, C; Lindemann, HW; Mai, EK; Merz, M; Munder, M; Neben, K; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Schurich, B; Seckinger, A; Weisel, K; Zeis, M | 1 |
| Açikel, C; Altayli, E; Astarci, E; Avcu, F; Elçi, MP; İde, T; Ilikçi Sağkan, R; Koru, Ö; Öngörü, Ö; Özenç, S; Sarper, M; Tok, D; Ural, AU | 1 |
| Adler, AI; Burke, MJ; George, E | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Mayampurath, A; Mellacheruvu, D; Nesvizhskii, AI; Ngoka, L; Richardson, PG; Rosebeck, S; Sreekumar, A; Volchenboum, S | 1 |
| Izumi, T | 1 |
| Chung, JS; Lee, GW; Lee, IS; Lee, JH; Lee, JJ; Lee, SM; Shin, DY; Song, IC; Song, MK | 1 |
| Borsi, E; Brioli, A; Cavo, M; De Sanctis, LB; Mancini, E; Mancuso, K; Marzocchi, G; Pantani, L; Pezzi, A; Rizzo, R; Rocchi, S; Santoro, A; Santostefano, M; Tacchetti, P; Terragna, C; Zamagni, E; Zannetti, BA | 1 |
| Cho, Y; Fujisawa, F; Hori, M; Kamoshita, M; Katsura, Y; Kojima, H; Komeno, T; Kudo, D; Mukai, HY; Okoshi, Y; Ota, I; Sasaki, K; Shimizu, S; Shinagawa, A; Tanaka, K; Yoshida, C | 1 |
| Bay, JO | 1 |
| Gotoh, Y; Ihara, K; Inomata, H; Kato, J; Koyama, R; Miyajima, N; Muramatsu, H; Nagamachi, Y; Nishisato, T; Nozawa, E; Okamoto, T; Yamauchi, N | 1 |
| Keller, S; Leibundgut, K; Mueller, BU; Novak, U; Pabst, T; Seipel, K; Taleghani, BM | 1 |
| Bergsagel, PL; Chesi, M; Colonna, M; Ferrari de Andrade, L; Guillerey, C; Hill, GR; Martinet, L; Miles, K; Ngiow, SF; Ritchie, DS; Smyth, MJ; Teng, MW; Vuckovic, S; Yong, MC | 1 |
| Hsieh, PY; Liu, CJ; Teng, CJ | 1 |
| Chen, Z; Hu, S; Rich, A; Tang, G; Wang, W | 1 |
| Fujimaki, K; Fujisawa, S; Fujita, H; Hagihara, M; Harano, H; Hashimoto, C; Hattori, Y; Ishigatsubo, Y; Kawasaki, R; Koharazawa, H; Kuwabara, H; Matsumoto, K; Numata, A; Sakai, R; Taguchi, J; Takemura, S; Tanaka, M; Tomita, N; Watanabe, R; Yamazaki, E | 1 |
| Chiba, S; Hasegawa, Y; Ito, Y; Kurita, N; Miyamoto, K; Obara, N; Ogawa, S; Otsu, K; Sakata, A; Sakata-Yanagimoto, M; Seki, M; Yokoyama, Y | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, J; Maglio, ME; Mitsiades, CS; Munshi, NC; O'Donnell, EK; Paba-Prada, C; Raje, N; Richardson, PG; Schlossman, R; Varga, C; Warren, D; Weinstock, M; Weller, E; Xie, W | 1 |
| Fenichel, MP | 1 |
| Mateos, MV; San Miguel, JF; Shi, H | 1 |
| Anderson, KC; Bianchini, G; Cottini, F; Hideshima, T; Richardson, PG; Suzuki, R; Tai, YT; Tonon, G | 1 |
| Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H | 1 |
| Katzel, JA; Lee-Ma, A; Vesole, DH | 1 |
| Dai, Y; Doeppner, TR; Hermann, DM; Jin, F; Kuckelkorn, U; Li, F; Li, W; Li, X; Li, Z; Liu, L; Qiu, L; Zang, M; Zhou, W | 1 |
| Abernethy, DR; Chudasama, VL; Mager, DE; Ovacik, MA | 1 |
| Chakraborty, R; Gertz, MA | 1 |
| Ding, Y; Gao, H; Liao, W; Sun, X; Wang, J; Wang, M; Wang, P; Xu, C; Zhong, Y | 1 |
| Chen, H; Hao, QY; Huang, XJ; Liu, KY; Lu, J; Wen, L | 1 |
| Tew, KD | 1 |
| An, N; Chen, SL; Huang, ZX; Li, X; Shen, M | 1 |
| Dimopoulos, MA; Kastritis, E; Rajkumar, SV | 1 |
| Garderet, L; Gorin, NC; Isnard, F | 1 |
| Cavallo, F; Esseltine, D; Fink, L; Guerrero, J; Prasad, HK; Zangari, M | 1 |
| Harousseau, JL | 8 |
| Bladé, J; Dimopoulos, MA; Kastritis, E; Ludwig, H; Rosinol, L | 1 |
| Belch, AR; Debes Marun, C; Kirshner, J; Martin, LD; Pilarski, LM; Reiman, T; Thulien, KJ | 1 |
| Barton, J; Farley, C; Greco, FA; Hainsworth, JD; Hon, J; Schreeder, M; Spigel, DR | 1 |
| Liu, X; Wang, H; Xu, B | 1 |
| Bush, D; Carew, JS; Casero, RA; Cleveland, JL; Goodwin, A; Houghton, JA; Marton, LJ; Nawrocki, ST; Reddy, VK; Rehg, JE | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Feng, R; Hager, JH; Hassig, CA; Lentzsch, S; Ma, H; Mapara, MY; Payne, JE; Smith, ND | 1 |
| Fujihara, S; Imataki, O; Kirizume, K; Ohnishi, H; Ohue, Y; Shintani, T; Waki, F | 1 |
| Kolesar, J; Utecht, KN | 1 |
| Argyriou, AA; Iconomou, G; Kalofonos, HP | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kubo, T; Kuroda, Y; Munemasa, S; Okikawa, Y; Sakai, A; Shimose, S | 1 |
| Anderson, KC; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Han, K; Jung, S; Kim, M; Kim, Y; Lim, J; Min, CK; Min, WS | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| Atkins, H; Belch, AR; Canning, LA; Kovacs, MJ; LeBlanc, R; Leitch, HA; Reece, DE; Voralia, M; White, D | 1 |
| Terpos, E | 2 |
| Chen, I; Chen-Kiang, S; Di Liberto, M; Garcia, J; Huang, X; Menu, E; Toogood, PL; Vanderkerken, K | 1 |
| Agrawal, SG; Gribben, JG; Jia, L; Liu, FT; Movasaghi, Z; Newland, AC; Rehman, IU; Wyatt, PB | 1 |
| Ohashi, K | 1 |
| Gonullu, E; Hacihanefioglu, A; Tarkun, P | 1 |
| Asaka, M; Fujita, N; Hashino, S; Imamura, M; Kahata, K; Kondo, T; Morita, R; Onozawa, M; Shirai, S | 1 |
| Carew, JS; Cleveland, JL; Courage, JF; Giles, FJ; Houghton, JA; Huang, P; Maclean, KH; McConkey, DJ; Nawrocki, ST | 1 |
| Chen, C; Kukreti, V; Mikhael, J; Pantoja, M; Reece, DE; Rodriguez, GP; Stewart, AK; Trudel, S; Xu, W | 1 |
| Beveridge, RA; Conner, TM; Doan, QD; LeBlanc, AL; Walters, IB | 1 |
| Auran-Schleinitz, T; Blaise, D; Bouabdallah, R; Coso, D; de Collela, JM; de Lavallade, H; El-Cheikh, J; Gastaut, JA; Mohty, M; Stoppa, AM | 1 |
| Anderson, KC; Bladé, J; Boral, AL; Coleman, M; Esseltine, DL; Facon, T; Harousseau, JL; Irwin, D; Niesvizky, R; Rajkumar, SV; Richardson, PG; Rosiñol, L; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Bao, L; Huang, XJ; Lu, XJ; Zhang, XH; Zhang, Y; Zhu, HH | 1 |
| Berenson, JR; Yellin, O | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| Ahn, KS; Bae, EK; Kim, BK; Kim, BS; Lee, YY; Park, J; Yoon, SS | 1 |
| Biron, P; Ghesquières, H; Labidi, SI; Nicolas, EV; Sebban, C | 1 |
| Callander, NS; Kahl, BS; Kim, J; Kim, K; Leith, CP; Markovina, S; Miyamoto, S; O'Connor, SL; Raschko, M; Werndli, JE | 1 |
| Anderson, KC; Ben-Yehuda, D; Chanan-Khan, A; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| McConkey, DJ | 1 |
| Anderson, KC; Bladé, J; Cavenagh, J; Esseltine, DL; Harousseau, JL; Jakubowiak, AJ; Lonial, S; Rajkumar, SV; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P | 1 |
| Li, JY; Lu, H; Qian, SX; Qiu, HX; Shen, WY; Wang, LX; Wu, HX; Wu, YJ; Zhang, JF | 1 |
| Chen, X; Dong, H; Gao, G; Gu, H | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Durie, BG | 1 |
| Calliada, F; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Golenkov, AK; Mitina, TA | 1 |
| Do, YR; Joo, YD; Kim, BS; Kim, H; Kim, HJ; Kim, I; Kim, K; Kim, SJ; Kwon, JH; Lee, HJ; Lee, JH; Lee, NR; Lee, WS; Nam, SH; Shin, HJ; Sohn, SK; Suh, C; Won, JH; Yoon, SS | 1 |
| Acharya, M; Coiteux, V; Harousseau, JL; Hulin, C; Leleu, X; Moreau, P; van de Velde, H | 1 |
| Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K | 1 |
| Hongming, H; Jian, H | 1 |
| Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, SA; Niesvizky, R; Richardson, PG; Siegel, DS | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| Braiteh, F; Giralt, SA; Hymes, SR; Jones, R | 1 |
| Colvin, LA; Fallon, M; Fleetwood-Walker, SM; Johnson, PR; Mitchell, R | 1 |
| Huang, J; Jin, J; Pan, HZ; Yang, M | 1 |
| Chen, LJ; Li, JY; Lu, H; Lu, SF; Shen, WY; Wang, LX | 1 |
| Alfonsi, E; Corso, A; Costa, A; Lazzarino, M; Lozza, A; Mangiacavalli, S; Moglia, A; Piccolo, G; Ravaglia, S; Varettoni, M; Zappasodi, P | 1 |
| Ackermann, H; Arnoldner, C; Baghi, M; Bisdas, S; Gstöttner, W; Hambek, M; Knecht, R; May, A; Wagenblast, J | 1 |
| Iida, S | 5 |
| Horiike, S; Inaba, T; Shimazaki, C; Shimura, K; Taniguchi, K; Taniwaki, M | 1 |
| Boccadoro, M; Bringhen, S; Falco, P; Gay, F; Magarotto, V; Palumbo, A | 1 |
| Adachi, D; Hattori, N; Nakamaki, T; Nakashima, H; Saito, B; Tomoyasu, S | 1 |
| Bladé, J; Rosiñol, L | 1 |
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P | 1 |
| Batár, P; Kiss, A; Méhes, L; Telek, B; Udvardy, M | 1 |
| Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL | 2 |
| Furukawa, Y; Kano, Y; Kikuchi, J; Mori, M; Muroi, K; Nagai, T; Noborio-Hatano, K; Nobuyoshi, M; Oh, I; Ozaki, K; Ozawa, K; Sato, K; Shimizu, R; Suzuki, T; Takatoku, M; Ueda, M; Wada, T | 1 |
| Roodman, GD | 4 |
| Fonseca, R; Rajkumar, SV | 1 |
| Casadonte, F; Focà, D; Macrina, L; Malara, N; Santoro, L; Savino, R; Scaramuzzino, M; Sesto, MF; Terracciano, R | 1 |
| Jin, J; Meng, H; Qian, W; Yang, C; Zhou, Y | 1 |
| Lonial, S | 5 |
| Khan, S; Li, X; Ling, W; Pennisi, A; Yaccoby, S; Zangari, M | 1 |
| Anderson, KC; Crawford, B; Dhawan, R; Gupta, S; Irwin, D; Lee, SJ; Massaro, J; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P | 1 |
| Aizawa, S; Heike, Y; Kim, SW; Kobayashi, Y; Maruyama, D; Nagase, K; Takahashi, N; Tobinai, K; Waki, F; Watanabe, T; Yamasaki, S; Yokoyama, H | 1 |
| Chang, M; Lee, ML; Whitmore, GA | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Battleman, DS; LeBlanc, A; Richardson, PG; Schuster, M; Walters, IB; Wolf, J | 1 |
| Hamaki, T; Hori, A; Kami, M; Kishi, Y; Kodama, Y; Komatsu, T; Matsumura, T; Narimatsu, H; Takita, M; Tanaka, Y; Yuji, K | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Plosker, GL | 1 |
| Asaoku, H; Katayama, Y; Kimura, A; Kuroda, Y; Matsui, H; Mizuno, M; Munemasa, S; Nakaju, N; Nishisaka, T; Ogawa, K; Okikawa, Y; Sakai, A; Tanaka, H; Tsuyama, N | 1 |
| Dammacco, F; Mangialardi, G; Ria, R; Vacca, A | 1 |
| Coleman, M; Mark, T; Niesvizky, R | 1 |
| DiPersio, JF; Fisher, NM; Goyal, SD; Oza, AY; Stockerl-Goldstein, K; Tomasson, MH; Uy, GL; Vij, R | 1 |
| Drake, MT; Rajkumar, SV | 1 |
| Deng, SH; Qiu, LG; Wang, Y; Wang, YF; Wu, T; Xu, Y; Zhao, YZ; Zou, DH | 1 |
| Belch, AR; Corso, A; Komarnicki, M; Lucio, MN; Maiolino, A; Mikhael, JR; Musto, P; Petrucci, MT; Prince, HM; Stewart, AK | 1 |
| Bao, L; Huang, XJ; Lu, XJ; Zhang, XH | 1 |
| Chen, Q; Hunsucker, SA; Kuhn, DJ; Orlowski, M; Orlowski, RZ; Voorhees, PM | 1 |
| Furtado, M; Rule, S | 1 |
| Abdalla, S; Hu, M; Karadimitris, A; Kotsianidis, I; Melo, V; Naresh, K; Rahemtulla, A; Reid, A; Spanoudakis, E; Terpos, E | 1 |
| Guerciolini, R; Hsieh, FY; Miwa, G; Pekol, TM; Tengstrand, E | 1 |
| Bladé, J; Cibeira, MT; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH | 1 |
| Baumann, P; Mandl-Weber, S; Oduncu, F; Schmidmaier, R | 2 |
| Ambrus, JL; Islam, A | 1 |
| Au, WY; Kwong, YL; Liang, RH; Shen, L; Shimizu, N; Srivastava, G; Tsuchiyama, J; Wong, KY | 1 |
| Hu, X; Huang, C; Lü, S; Ni, X; Qiu, H; Wang, J; Xu, X; Yang, J | 1 |
| Conti, AA; Dilaghi, B; Modesti, PA; Nozzoli, C | 1 |
| Allen, S; Mehta, J; Singhal, S; Vickrey, E | 1 |
| Kami, M; Komatsu, T; Tsubokura, M | 1 |
| Avvisati, G | 1 |
| García-Bustínduy, M; Martín-Herrera, A; Noda-Cabrera, A; Rodríguez-Martín, M; Sáez-Rodríguez, M | 1 |
| Anel, A; Balsas, P; Galán-Malo, P; López-Royuela, N; Marzo, I; Naval, J | 1 |
| Kaporskaia, TS; Kiselev, IV | 1 |
| Groll, M; Huber, R; Moroder, L | 1 |
| Dmoszyńska, A | 1 |
| Alt, C; Anderson, KC; Azab, AK; Azab, F; Burwick, N; Carlson, AL; Farag, M; Ghobrial, IM; Hideshima, T; Jia, X; Kung, AL; Leleu, X; Lin, CP; Melhem, MR; Moreau, AS; Munshi, NC; Ngo, HT; Ospina, B; Pitsillides, C; Roccaro, AM; Rollins, BJ; Runnels, JM; Sacco, A; Wright, R | 1 |
| Berdel, WE; Bisping, G; Gustavus, D; Hilberg, F; Kienast, J; Kropff, M; Mesters, RM; Müller-Tidow, C; Munzert, G; Roth, GJ; Stefanic, M; Stelljes, M; Volpert, S; Wenning, D | 1 |
| Dawson, MA; Donovan, M; Hertzberg, M; Horvath, N; McLean, CA; Monaghan, K; Opat, SS; Prince, HM; Roberts, AW; Spencer, A; Taouk, Y; Zammit, M | 1 |
| Anderson, KC; Carrasco, R; Chabner, B; Chauhan, D; Chhetri, S; Cirstea, D; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Mukherjee, S; Munshi, NC; Okawa, Y; Parikh, H; Podar, K; Pozzi, S; Raab, M; Raje, N; Richardson, PG; Rooney, M; Scadden, D; Sharma, S; Vallet, S | 1 |
| Amiot, M; Bataille, R; Descamps, G; Gomez-Bougie, P; Moreau, P; Venot, C | 1 |
| Amato, AA; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Lonial, S; Reece, D; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Wen, PY | 1 |
| Ales, M; Caravita, T; Cupelli, L; de Fabritiis, P; Dentamaro, T; Fratoni, S; Giovannini, M; Niscola, P; Santeusanio, G; Scaramucci, L; Siniscalchi, A; Tendas, A | 1 |
| Basu, S; Cavenagh, J; Cook, M; Craddock, C; Foot, N; Hallam, S; Harding, S; Joel, S; Oakervee, H; Odeh, L; Popat, R; Singer, C; Williams, C | 1 |
| Abaya, CD; Berenson, JR; Duvivier, H; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Yellin, O | 1 |
| Aguirre-Ghiso, JA; Schewe, DM | 1 |
| Cammarota, S; Cavaletti, G; Frigeni, B; Jann, S; Lanzani, F; Mattavelli, L; Petrò, D; Rossini, F | 1 |
| Borrello, I; Chaudhry, V; Cornblath, DR; Ferguson, A; Polydefkis, M | 1 |
| Higa, GM; Saad, AA; Sharma, M | 1 |
| Beck, A; Driessen, C; Gogel, J; Kalbacher, H; Kraus, M; Ovaa, H; Overkleeft, HS; Rückrich, T; Verdoes, M | 1 |
| Anagnostopoulos, N; Christoulas, D; Delimbassi, S; Dimopoulos, MA; Economopoulos, T; Gika, D; Kartasis, Z; Kastritis, E; Katodritou, E; Michali, E; Pouli, A; Roussou, M; Symeonidis, A; Terpos, E; Zervas, K; Zomas, A | 1 |
| Bergsagel, PL; Chen, C; Fonseca, R; Hentz, J; Kukreti, V; Leis, JF; Mikhael, JR; Noble, B; Pirooz, NA; Piza, JG; Reece, DE; Reeder, CB; Spong, JE; Stewart, AK; Trudel, S; Zepeda, VH | 1 |
| Abe, M; Fujii, S; Kagami, S; Kagawa, K; Lee, E; Matsumoto, T; Miki, H; Nakamura, S; Ozaki, S; Takeuchi, K; Takimoto, T; Tanaka, O; Watanabe, H; Yata, KI | 1 |
| Abaya, CD; Berenson, JR; Cartmell, A; Duvivier, H; Eades, B; Flam, MS; Hilger, J; Nassir, Y; Patel, R; Swift, RA; Woytowitz, D; Yellin, O | 1 |
| Barr, RJ; Cole, GW; Dyson, SW; Murase, JE; Theate, I; Wu, JJ | 1 |
| Chen, XQ; Dong, HJ; Gao, GX; Gao, Y; Gu, HT; Pan, YZ; Zhu, HF | 1 |
| Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Kastritis, E; Katodritou, E; Michalis, E; Pouli, A; Terpos, E; Tsiftsakis, E; Tsionos, K; Verrou, E; Zervas, K | 1 |
| Caravita, T; de Fabritiis, P; Del Poeta, G; Fratoni, S; Santeusanio, G; Siniscalchi, A | 1 |
| Handa, H; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saitoh, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A | 1 |
| Berdel, WE; Einsele, H; Gann, CN; Knop, S; Kropff, M; Liebisch, P; Wand, H; Weisel, K | 1 |
| Baker, RD; Finkbiner, KL; Henry, DW; Kettle, JK; Klenke, SE; Williams, CB | 1 |
| Hirakawa, T; Inokuchi, K; Yokose, N | 1 |
| Fujiwara Yamada, M; Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Ohguchi, H; Okuda, M; Onishi, Y; Sugawara, T; Tomiya, Y; Yamamoto, J | 1 |
| Bates, AL; Edwards, CM; Fowler, JA; Lwin, ST; Mundy, GR; Oyajobi, BO; Zhuang, J | 1 |
| Grünberg, K; Sonneveld, P; Wittgen, BP; Wondergem, MJ; Zweegman, S | 1 |
| Alexandrescu, DT; Dasanu, CA | 2 |
| Guan, M; Hughes, A; Somlo, G; Yen, Y; Zhou, B; Zhu, L | 1 |
| Chim, CS; Hwang, YY; Pang, C; Shek, TW | 1 |
| Cavenagh, J; Lonial, S | 1 |
| Chen, Q; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Voorhees, PM | 1 |
| Geffray, L | 1 |
| Chen, S; Goldenberg, DM; Smith, MR; Stein, R; Zalath, M | 1 |
| Anderson, KC; Baccarani, M; Calabrese, E; Cavo, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Ikeda, H; Okawa, Y; Perrone, G; Raje, N; Santo, L | 1 |
| Butcher, BE; Cannell, P; Horvath, N; Mikhael, JR; Prince, HM; Quach, H | 1 |
| Aggarwal, BB; Anand, P; Guha, S; Kunnumakkara, AB; Sethi, G; Sung, B | 1 |
| Knauf, WU; Kornacker, M; Otremba, B; Overkamp, F | 1 |
| Ahn, KS; Ayyappan, V; Bae, EK; Kim, BK; Kim, BS; Lee, C; Lee, YY; Park, J; Yoon, SS | 1 |
| Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG | 1 |
| Berenson, JR | 2 |
| Dun, XY; Hou, J; Li, YH; Yuan, ZG | 1 |
| Adam, Z; Buchler, T; Buresova, L; Hajek, R; Krejci, M; Krivanova, A; Pour, L; Sandecka, V; Vorlicek, J; Zahradova, L | 1 |
| Heider, U; Jakob, C; Kaiser, M; Lamottke, B; Mieth, M; Sezer, O; von Metzler, I | 1 |
| Abe, M | 1 |
| Anderson, KC; Carrasco, RD; Chauhan, D; Hideshima, T; Ikeda, H; Mitsiades, C; Munshi, NC; Okawa, Y; Podar, K; Raje, N; Richardson, PG | 1 |
| Curran, MP; McKeage, K | 1 |
| Andreoli, A; Briere, J; Cavelier Balloy, B; Petit, A; Thomas, M | 1 |
| Avenel-Audran, M; Croué, A; Dib, M; Hunault-Berger, M; Lissandre, S; Moles, MP; Tanguy-Schmidt, A; Zidane-Marinnes, M | 1 |
| Godley, LA; Goodenbour, JM; Pan, T; Wickrema, A; Zhou, Y | 1 |
| Li, J; Li, W; Luo, S; Su, C; Zou, WY | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Richardson, PG; Roccaro, AM | 1 |
| Dispenzieri, A; Gertz, MA; Kumar, S; Sadek, I | 1 |
| Ailawadhi, S; Barcos, M; Bernstein, ZP; Chanan-Khan, A; Czuczman, MS; Iancu, D; Lee, K; Miller, KC; Mohr, A; Musial, L; Padmanabhan, S; Patel, M; Sher, T; Yu, J | 1 |
| Cho, BS; Eom, HS; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, S; Min, CK; Min, WS | 1 |
| Cheong, JW; Jeong, TS; Kim, HJ; Kim, TY; Lee, DS; Lee, JH; Min, HJ; Oh, B; Park, J; Park, SB; Suh, C; Yoon, SS | 1 |
| Benavides, A; Frost, P; Hoang, B; Lichtenstein, A; Shi, Y | 1 |
| Boise, LH; Gutman, D; Morales, AA | 1 |
| Algarotti, A; Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Pica, GM; Varettoni, M; Zappasodi, P | 1 |
| Knopf, KB; Moretto, JC; Waller, JM | 1 |
| Amato, AA; Anderson, KC; Avigan, DE; Briemberg, HR; Chanan-Khan, AA; Doss, D; Esseltine, DL; Hassoun, H; Heffner, LT; Kesari, S; Kuter, DJ; Lonial, S; Mitsiades, C; Munshi, NC; Oaklander, AL; Richardson, PG; Schlossman, RL; Weller, E; Wen, PY; Xie, W | 1 |
| Accorsi, P; Antuzzi, G; Bavaro, P; Carrozza, F; Dell'Isola, M; Di Bartolomeo, P; Gigli, R; Giglio, G; Magri, M; Musacchio, M; Romito, S | 1 |
| Arts, J; Coulton, L; Croucher, P; De Raeve, H; Deleu, S; Lemaire, M; Menu, E; Van Camp, B; Van Valckenborgh, E; Vande Broek, I; Vanderkerken, K | 1 |
| Giralt, S; Krishnan, A; Mccarthy, P; Pasquini, MC; Somlo, G; Stadtmauer, E; Vesole, DH | 1 |
| Anderson, KC; Breitkreutz, I; Podar, K; Raab, MS; Richardson, PG | 1 |
| Aki, SZ; Erdem, O; Ozkurt, ZN; Sucak, GT; Yağci, M | 1 |
| Anderson, KC; Bensinger, W; Bergsagel, L; Blade, J; Cavo, M; Comenzo, RL; Durie, BG; Einsele, H; Giralt, S; Harousseau, JL; Kumar, S; Lentzsch, S; Lonial, S; Ludwig, H; Munshi, N; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Stadtmauer, EA; Tosi, P; Vesole, D | 1 |
| Gajate, C; Mollinedo, F; Reis-Sobreiro, M | 1 |
| Bryant, J; Clegg, A; Cooper, K; Green, C; Smith, A; Stephens, M; Takeda, A | 1 |
| Chou, T; Hasegawa, Y; Hirose, T; Imai, Y; Ishiguro, T; Kawahara, F; Nagai, H | 1 |
| Foley, PW; Hamilton, MS; Leyva, F | 1 |
| Bocchia, M; Defina, M; Gozzetti, A | 1 |
| Lattin, G; Sanders, O; Timpone, V | 1 |
| Ballon, DJ; Chang, CC; Chen, H; Feng, Y; Huang, W; Kamble, RT; Liao, B; Preti, HA; Rice, L; Wen, J; Zu, Y | 1 |
| Chen, SL; Zhong, YP | 1 |
| Camacho, ES; Crowley, J; Durie, BG; Gabayan, AE; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Wolf, JL | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V | 1 |
| Brunetti, AE; Cafforio, P; Dammacco, F; De Matteo, M; Maiorano, E; Silvestris, F | 1 |
| Badros, A; Baer, MR; Burger, AM; Egorin, MJ; Espinoza-Delgado, I; Goloubeva, O; Grant, S; Harris, C; Holleran, JL; Kolla, SS; Niesvizky, R; Philip, S; Wright, JJ; Zwiebel, J | 1 |
| Corso, A; Lazzarino, M; Mangiacavalli, S; Pascutto, C; Varettoni, M; Zappasodi, P | 1 |
| Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T; Nemoto, K | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Haessler, J; Nair, B; Shaughnessy, JD; van Rhee, F; Waheed, S; Zhou, Y | 1 |
| Andersen, RJ; Kennah, M; Krystal, G; Mui, AL; Nodwell, M; Ong, CJ; Yau, TY | 1 |
| Baryshnikov, AIu; Golenkov, AK; Klinushkina, EF; Kogarko, IN; Liubimova, NV; Mitina, TA | 1 |
| Focosi, D | 1 |
| Barbarousi, D; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Primenou, E; Roussou, M; Terpos, E; Zagouri, F | 1 |
| Afar, DE; Balasa, B; Barlogie, B; Chao, D; Dillon, M; Ganguly, B; Garg, TK; Li, X; Moreno-Bost, AM; Rice, AG; Shaughnessy, JD; Shi, J; Stone, MK; Szmania, SM; van Abbema, AM; van Rhee, F; Yaccoby, S; Yun, R; Zhan, F | 1 |
| Anderson, KC; Boral, A; Facon, T; Harousseau, JL; Irwin, D; Neuwirth, R; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA; Vogl, DT | 1 |
| Endo, T; Fujimoto, K; Goto, H; Kasahara, I; Koike, T; Nishio, M; Sato, N; Takeda, Y; Yamaguchi, K; Yamamoto, S | 1 |
| Dun, X; Fu, W; Hou, J; Yuan, Z; Zhang, C | 1 |
| Buda, G; Cecconi, N; Galimberti, S; Orciuolo, E; Petrini, M | 1 |
| Antognoni, F; Barale, R; Brunori, M; Buda, G; Galimberti, S; Gentile, M; Maggini, V; Martino, A; Morabito, F; Orciuolo, E; Petrini, M; Rossi, AM | 1 |
| Carloss, H; Druck, M; Kerr, R; Lee, M; Lopez, J; Noga, SJ; Sood, R; Walters, IB | 1 |
| Bai, QX; Bai, YN; Chen, XQ; Gu, HT; Liang, R; Shu, MM; Wang, WQ; Wang, YW; Yang, L; Zhang, T; Zhang, YQ; Zhu, HF | 1 |
| Anderson, RD; Chao, NJ; Chute, JP; Davis, PH; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Horwitz, ME; Keogh, G; Long, GD; Moore, JO; Neuwirth, R; Rizzieri, D; Sullivan, KM; Sutton, LM | 1 |
| Ahmed, A; Al-Zoubi, A; Braun, T; Brozo, C; Campagnaro, E; Jakubowiak, AJ; Kaminski, MS; Kendall, T; Khaled, Y; Mineishi, S; Talpaz, M | 1 |
| Orlowski, RZ; Shah, JJ | 1 |
| Anderson, KC; Carreau, N; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL | 1 |
| Cippitelli, M; Fionda, C; Iannitto, ML; Malgarini, G; Santoni, A; Soriani, A | 1 |
| Cai, Z; He, J; Huang, H; Huang, W; Li, L; Lin, M; Luo, Y; Shi, J; Wei, G; Wu, W; Xie, W; Xue, X; Ye, X; Zhang, J; Zheng, W | 1 |
| Anargyrou, K; Carney, W; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Hamer, P; Kastritis, E; Leitzel, K; Lipton, A; Migkou, M; Shrivastava, V; Terpos, E | 1 |
| Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E | 1 |
| San Miguel, J | 1 |
| Stadtmauer, EA | 1 |
| Anderson, KC; Bandi, M; Bianchi, G; Brahmandam, M; Carrasco, R; Chauhan, D; Hideshima, T; Jaye, DL; Kumar, SK; Mitsiades, C; Munshi, N; Podar, K; Raje, N; Richardson, P; Singh, AV; Tai, YT | 1 |
| Dowling, M; Hayat, A; Hayden, P; Meenaghan, T; Murray, M; O'Dwyer, M | 1 |
| Conticello, C; Di Raimondo, F | 1 |
| Hou, J; Jiang, H; Li, YH; Xi, H; Zhu, R; Zou, JF | 1 |
| Decaux, O; Karras, A | 1 |
| Barlogie, B; Chen, L; Entin, I; Epstein, J; Shaughnessy, JD; Wang, S; Wu, X; Xiong, W; Yaccoby, S; Zhan, F; Zhou, Y | 1 |
| Duan, MH; Jiao, L; Li, J; Shen, T; Zhang, W; Zhao, YQ; Zhou, DB | 1 |
| Alexeeva, J; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Kastritis, E; Khuageva, NK; Kropff, M; Liu, K; Masszi, T; Mateos, MV; Petrucci, MT; Richardson, PG; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; van de Velde, H | 1 |
| Akahane, D; Gotoh, M; Kitahara, T; Ohyashiki, K; Sakuta, J | 1 |
| Gozzetti, A | 1 |
| Anderson, KC; Carreau, NA; Chauhan, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, NC; Raje, N; Richardson, PG; Schlossman, RL | 1 |
| Araujo, C; Attal, M; Avet-Loiseau, H; Caillot, D; Danho, C; Dib, M; Dorvaux, V; Fruchart, C; Garderet, L; Harousseau, JL; Hulin, C; Huynh, A; Kolb, B; Lenain, P; Marit, G; Mary, JY; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Roussel, M; Royer, B; Stoppa, AM | 1 |
| Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y | 1 |
| Bernardeschi, P; Ferreri, MI; Fiorentini, G; Giustarini, G; Montenora, I; Pirrotta, MT; Simi, P | 1 |
| Attal, M; Bourin, P; Laroche, M; Lemaire, O | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Ordeltova, M; Pika, T; Scudla, V; Zemanova, M | 1 |
| Harvey, RD; Lonial, S; Nettles, J; Sun, SY; Wang, B | 1 |
| Dereure, O; Guillot, B; Michot, C | 1 |
| Khong, T; Monaghan, K; Smith, G; Spencer, A | 1 |
| D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A | 1 |
| Kanda, Y | 1 |
| Ozaki, S | 1 |
| Belloni, D; Caligaris-Cappio, F; Dell'Antonio, G; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L | 1 |
| Becker, P; Bensinger, WI; Camacho, E; Capo, G; Crowley, J; Durie, BG; Hilger, J; Irwin, D; Jagannath, S; Mazumder, A; McKinley, M; Potts, P; Vescio, R; Vesole, DH; Wolf, J | 1 |
| Ahn, JS; Kim, HJ; Kim, YK; Lee, JH; Lee, JJ; Moon, JH; Sohn, SK; Yang, DH | 1 |
| Anasetti, C; Dalton, W; Meads, M; Parquet, N; Perez, LE | 1 |
| Berenson, JR; Campbell, RA; Chen, H; Li, ZW; Sanchez, E; Shalitin, D; Steinberg, J | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Callea, V; Casulli, AF; Catalano, L; Cavo, M; Ciolli, S; Di Raimondo, F; Galimberti, S; Gentile, M; Mannina, D; Mele, G; Morabito, F; Musto, P; Offidani, M; Palmieri, S; Palumbo, A; Petrucci, MT; Pinotti, G; Piro, E; Tosi, P | 1 |
| Anderson, KC; Buon, L; Charalambous, E; Chauhan, D; Clynes, M; Daskalaki, E; Hayden, PJ; Hideshima, T; Kotoula, V; McMillin, DW; Mitsiades, CS; Mitsiades, N; Munshi, NC; O'Gorman, P; Ooi, MG; Raje, NS; Richardson, PG | 1 |
| Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN | 1 |
| Aggarwal, BB; Pandey, MK; Sung, B | 1 |
| Dimopoulos, MA; Terpos, E | 1 |
| Veselý, K | 1 |
| Adam, Z; Cermáková, Z; Feit, J; Hájek, R; Krejcí, M; Mayer, J; Pour, L; Vasků, V | 1 |
| Adam, Z; Buchler, T; Hajek, R; Koza, V; Kralova, D; Krejci, M; Krivanova, A; Mayer, J; Pour, L; Sandecka, V; Schutzova, M; Scudla, V; Tothova, E; Vorlicek, J; Zahradova, L | 1 |
| Atadja, P; Crusoe, E; de Alava, E; Fernández-Lázaro, D; Garayoa, M; Hernández-Iglesias, T; Maiso, P; Ocio, EM; Pandiella, A; San-Miguel, JF; San-Segundo, L; Shao, W; Vilanova, D; Yao, YM | 1 |
| Caravita, T; de Fabritiis, P; Dentamaro, T; Perrotti, A; Siniscalchi, A; Tatangelo, P | 1 |
| Huang, BH; Li, J; Su, C; Zeng, LJ; Zhao, Y | 1 |
| Berenson, JR; Bonavida, B; Chen, H; Li, M; Li, ZW; Sanchez, E; Shen, J; Steinberg, JA; Wang, C | 1 |
| Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M | 1 |
| Cherem, L; Kahan, BD; Kaposztas, Z; Katz, SM; Van Buren, CT | 1 |
| Gay, F; Palumbo, A | 3 |
| Mateos, MV; San-Miguel, JF | 1 |
| Stewart, AK | 1 |
| Ghobrial, IM; Stewart, AK | 1 |
| AKIYAMA, H; KATO, I; KOBAYASHI, T; MIYAZAWA, M; NAJIMA, Y; NAKANO, M; OHASHI, K; SAKAMAKI, H; SAWADA, T; YAMASHITA, T | 1 |
| Ding, Y; Gu, J; Huang, B; Li, J; Wang, Q; Zeng, L; Zhao, Y; Zheng, D | 1 |
| Chung, JS; Do, YR; Eom, HS; Jin, JY; Kim, CS; Kim, HJ; Kim, HY; Kim, K; Kim, YK; Lee, DS; Lee, JH; Oh, SJ; Seong, CM; Suh, C | 1 |
| Dana, K; Hana, S; Jaroslav, M; Jiri, V; Lucie, K; Ludek, P; Marta, K; Martina, A; Miroslav, P; Roman, H; Tomas, B; Zdenek, A | 1 |
| Chapman, C; Rosser, A; Swallow, G; Swann, RA | 1 |
| Lin, MF; Ouyang, GF | 1 |
| Jing, HM; Ke, XY; Yang, P; Zhang, WJ | 1 |
| Azaïs, I; Brault, R; Debiais, F | 1 |
| Bakan, CE; Benson, DM; Devine, SM; Elder, P; Hamadani, M; Hofmeister, CC; Krugh, D; O'Donnell, L; Panzner, K; Smith, MK | 1 |
| Yaccoby, S | 1 |
| Kumiega, B; Skotnicki, AB; Wolska-Smoleń, T | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Caltagirone, S; Corradini, P; Crippa, C; Falco, P; Gay, F; Giuliani, N; Guglielmelli, T; Liberati, AM; Montefusco, V; Musto, P; Offidani, M; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Rossi, G; Rossini, F | 1 |
| Bastida, J; Campos-Adsuar, C; Dehesa, L; Gómez-Duaso, J; Limeres-González, M | 1 |
| Al Diab, AR; Al Momen, AK; Aleem, A; Niaz, F; Qayum, A | 1 |
| Handa, H; Higeta, D; Hirato, J; Karasawa, M; Koiso, H; Mawatari, M; Murakami, H; Nojima, Y; Osaki, Y; Saito, T; Sekigami, T; Tahara, K; Tsukamoto, N; Uchiumi, H; Yokohama, A | 1 |
| Attal, M; Avet-Loiseau, H; Belhadj, K; Dorvaux, V; Fermand, JP; Garderet, L; Hulin, C; Minvielle, S; Moreau, P; Soulier, J; Yakoub-Agha, I | 1 |
| Arvanitis, A; Caulder, E; Combs, AP; Favata, M; Fridman, JS; Kelley, JA; Li, J; Newton, R; Rogers, JD; Scherle, PA; Solomon, KA; Sparks, RB; Thomas, B; Vaddi, K; Wen, X | 1 |
| Bauer, F; Dasanu, CA; Reale, MA | 1 |
| Beksac, M; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Ketterer, N; Kropff, M; Ludwig, H; Mendeleeva, L; Morgan, G; Palumbo, A; Plesner, T; San Miguel, J; Shpilberg, O; Sondergeld, P; Sonneveld, P; Zweegman, S | 1 |
| Adamo, V; Bronte, G; Cicero, G; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A | 1 |
| Campion, L; Charbonnel, C; Clément, M; Decaux, O; Gouraud, W; Loiseau, HA; Magrangeas, F; Minvielle, S | 1 |
| Lokhorst, HM; Minnema, MC; van de Donk, NW; van der Spek, E | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Hou, J; Jiang, H; Ma, YL | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| El-Cheikh, J; Harousseau, JL; Mohty, B; Mohty, M; Moreau, P; Yakoub-Agha, I | 1 |
| Anderson, K; Laubach, JP; Mitsiades, C; Richardson, PG; Schlossman, RL | 1 |
| Chang, H; Hsiao, SC; Pei, SN; Wang, MC | 1 |
| Aoki, K; Eda, H; Kato, S; Marumo, K; Ohkawa, K; Okawa, Y; Takada, K; Tanaka, T | 1 |
| Adachi, S; Ashihara, E; Hatake, K; Hirashima, M; Horiike, S; Kobayashi, T; Kuroda, J; Oomizu, S; Sasaki, N; Takagi, T; Taniwaki, M; Taniyama, A; Terui, Y; Yamamoto, M; Yamauchi, A | 1 |
| Alfonsi, E; Corso, A; De Amici, M; Lazzarino, M; Lozza, A; Mangiacavalli, S; Varettoni, M | 1 |
| Richards, T; Weber, D | 1 |
| Bocchia, M; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E; Oliva, S | 1 |
| Hoevenaren, A; Hoevenaren, IA; Levenga, H; Minnema, MC; Raymakers, R; van Vulpen, LF | 1 |
| Acharya, M; Burris, H; Chatta, G; Karol, M; Keith Stewart, A; Lonial, S; Mohrbacher, AF; Neuwirth, R; Reece, DE; Riordan, WJ; Shustik, C; Sullivan, D; Venkatakrishnan, K; von Moltke, LL; Zannikos, P | 1 |
| Boccadoro, M; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Ferrero, S; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Pagliano, G; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Santo, L | 1 |
| Chen, S; Deng, X; Khuri, FR; Li, C; Lonial, S; Sun, SY; Yue, P | 1 |
| Aguayo-Leiva, I; Carrillo-Gijon, R; Jaén-Olasolo, P; Vano-Galvan, S | 1 |
| de Maat, MP; Leebeek, FW; Libourel, EJ; Sonneveld, P; van der Holt, B | 1 |
| Bang, SM; Chung, J; Do, YR; Jin, JY; Joo, YD; Kang, HJ; Kim, BS; Kim, HY; Kim, K; Lee, DS; Lee, GW; Lee, JH; Lee, JJ; Lee, MH; Lee, SS; Park, J; Ryoo, HM; Shim, H; Suh, C; Yoon, SS | 1 |
| Brocca, CM; Coppi, MR; Giannotta, A; Loseto, G; Mele, G; Melpignano, A; Pinna, S; Quarta, G | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kikuchi, J; Mitsunaga, K; Noborio-Hatano, K; Nobuyoshi, M; Ozawa, K; Shimizu, R; Wada, T | 1 |
| Ludwig, H; Zojer, N | 1 |
| Dingli, D; Rajkumar, SV | 1 |
| Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A | 1 |
| Abdulkadyrov, KM; Cakana, A; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Schots, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Heider, U; Kaiser, M; Kleeberg, L; Rademacher, J; Sezer, O; von Metzler, I | 1 |
| Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Jagannath, S; Mazumder, A; Vesole, DH | 1 |
| Chang, J; Cho, SH; Kang, W; Kim, JS; Kim, SK; Park, MS | 1 |
| Adachi, T; Hayakawa, F; Iwasaki, T; Kurahashi, S; Narimatsu, H; Sawamoto, A; Sugimoto, T; Sugiura, I; Suzuki, H; Suzuki, K | 1 |
| Anderson, KC; Bandi, M; Bianchi, G; Calabrese, E; Carrasco, RD; Cirstea, D; Ecsedy, J; Görgün, G; Hideshima, T; Hu, Y; Ikeda, H; Mani, M; Munshi, N; Nahar, S; Perrone, G; Raje, N; Richardson, P; Santo, L; Tai, YT; Zheng, M | 1 |
| Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W | 1 |
| Goldschmidt, H; Ho, AD; Schmitt, S | 1 |
| Dasanu, CA | 1 |
| Bergsagel, PL; Chen, C; Fonseca, R; Hentz, J; Kukreti, V; Laumann, K; Leis, JF; Mikhael, JR; Pirooz, NA; Piza, JG; Reece, DE; Reeder, CB; Stewart, AK; Tiedemann, R; Trudel, S | 1 |
| Branch, DR; Chang, H; Jayakar, J; Jiang, H; Reece, D; Saha, MN | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Wang, M | 1 |
| Kumar, S | 3 |
| Cavo, M | 3 |
| Gleason, C; Kaufman, J; Lonial, S | 1 |
| Baldini, L; Boccadoro, M; Bringhen, S; Di Raimondo, F; Falco, P; Larocca, A; Magarotto, V; Palumbo, A | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Casassus, P; Doyen, C; Facon, T; Harousseau, JL; Hulin, C; Lenain, P; Leyvraz, S; Maisonneuve, H; Marit, G; Mathiot, C; Michallet, M; Moreau, P; Pégourié, B; Stoppa, AM | 1 |
| Chan, EY; Chan, SY; Cheung, SC; Chim, CS; Kwong, YL; Leung, YY; Liang, R; Lie, AK | 1 |
| Bruna, J; Clapés, V; Navarro, X; Petit, J; Velasco, R; Verdú, E | 1 |
| Ben Salem, C; Biour, M; Bouraoui, K; Elouni, B; Sakhri, J; Zamy, M | 1 |
| Kotani, T; Nakao, S; Okumura, H; Sawazaki, A; Takamatsu, H; Yamashita, T | 1 |
| Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C; Taverna, C | 1 |
| Aisa, Y; Iwabuchi, M; Kakimoto, T; Mihara, A; Nakazato, T; Sanada, Y; Suzuki, K | 1 |
| Mateos, MV | 4 |
| Dimopoulos, MA; Jagannath, S; Lonial, S | 1 |
| Cavaletti, G; Jakubowiak, AJ | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Hoering, A; Nair, B; Petty, N; Shaughnessy, JD; Szymonifka, J; van Rhee, F; Waheed, S | 1 |
| Adomat, H; Batey, RA; Chen, C; Cloos, J; Franke, NE; Guns, E; Jamal, N; Jansen, G; Kay, LE; Li, X; Li, ZH; Mao, X; Messner, H; Navon, A; Religa, TL; Rose, DR; Schimmer, AD; Sprangers, R; Trudel, S; Verbrugge, SE; Wang, X; Wood, TE; Zhang, Y | 1 |
| Bhandari, M; Callander, N; Flinn, I; Gasparetto, C; Glass, J; Grosman, D; Hari, P; Krishnan, A; Kumar, SK; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Sahovic, EA; Shi, H; Webb, IJ; Wolf, JL | 1 |
| Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gika, D; Grapsa, I; Kastritis, E; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Destian, S; Hwang, BJ; Jagannath, S; Mazumder, A; Méndez, CE; Vesole, DH | 1 |
| Bergsagel, PL; Buadi, F; Dingli, DD; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kapoor, P; Ketterling, RP; Kumar, S; Kyle, RA; Lacy, MQ; Rajkumar, SV; Sinha, S; Stewart, AK; Witzig, TE | 1 |
| Burnett, AK; Crooks, PA; Fegan, C; Hewamana, S; Pepper, C; Pratt, G; Walsby, EJ | 1 |
| Cook, WJ; Elkins, S; Gaston, RS; Kumar, V; Prendergast, MB; Reddy, V; Sanders, PW | 1 |
| Boothpur, R; Brennan, DC; Torrence, S | 1 |
| Abildgaard, N; Delaissé, JM; Garnero, P; Lund, T; Ormstrup, T; Pedersen, PT; Plesner, T; Søe, K | 1 |
| Bladé, J; Buda, G; Cohen, N; Favis, R; Harousseau, JL; Huang, CC; Orlowski, RZ; Ricci, D; Sonneveld, P; Zhuang, SH | 1 |
| Callandar, N; Dispenzieri, A; Fonseca, R; Greipp, PR; Jacobus, S; Vesole, DH | 1 |
| Chang, H; Jiang, NN; Qi, X; Reece, D; Trieu, Y; Xu, W | 1 |
| Fadeel, B; Feng, X; Henter, JI; Nordenskjöld, M; Wang, Y; Yan, J; Zheng, C; Zierath, JR | 1 |
| Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Miyazaki, H; Mori, F; Nakashima, T; Ri, M; Shiotsu, Y; Ueda, R | 1 |
| Bertsch, U; Goldschmidt, H; Schmitt, S | 1 |
| Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Marchini, E | 1 |
| Adam, Z; Büchler, T; Feit, J; Hájek, R; Krejcí, M; Pour, L | 1 |
| Gleason, C; Heffner, LT; Kaufman, JL; Lonial, S; Nooka, A; Vrana, M | 1 |
| Chen, F; Chen, H; Guo, H; Jiang, Y; Lu, M; Mao, J; Qian, X; Shen, Y; Sun, C; Sun, H; Xia, J; Yang, G; Zhou, X; Zhuang, Y | 1 |
| Fujieda, A; Ishibashi, M; Iwamoto, T; Katayama, N; Masuya, M; Okuda, M | 1 |
| Engelhardt, M; Felthaus, J; Follo, M; Hein, M; Ihorst, G; Ngo, BT; Wäsch, R; Wider, D | 1 |
| Gertz, MA; Tadmor, T | 1 |
| Brodoefel, H; Claussen, CD; Fenchel, M; Horger, M; Konaktchieva, M; Kraus, S; Weisel, K | 1 |
| Callander, NS; Hematti, P; Kim, J; Kim, K; Leith, CP; Markovina, S; Miyamoto, S; O'Connor, SL; Shi, Y; Trivedi, P; Xu, G | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Joo, YD; Kim, SG; Kim, SH; Lee, GW; Lee, HS; Lee, SM; Seol, YM; Shin, HJ; Song, MK; Yun, EY | 1 |
| Isayama, R; Mizutani, R; Nakagawa, M; Shiga, K; Shimazaki, C; Tokuda, T | 1 |
| Albitar, M; Anderson, KC; Badros, AZ; Berman, D; Jagannath, S; Messina, M; Richardson, PG; Tarantolo, S; Wolf, JL | 1 |
| Cakana, A; Cavo, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Golenkov, A; Harousseau, JL; Kentos, A; Komarnicki, M; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H | 1 |
| Fielding, K; Neeson, P; Quach, H; Ritchie, DS | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Campion, L; Facon, T; Guerin-Charbonnel, C; Harousseau, JL; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Minvielle, S; Moreau, P; Roussel, M; Stoppa, AM; Voillat, L; Wetterwald, M | 1 |
| Frey, B; Gaipl, US; Lang, VR; Meister, S; Schett, G; Schlötzer-Schrehardt, U; Voll, RE | 1 |
| Adamo, L; Amato, G; Anastasi, G; Colarossi, C; Conticello, C; De Maria, R; Di Raimondo, F; Giuffrida, R; Giustolisi, R; Gorgone, A; Gulisano, M; Iannolo, G; Martinetti, D; Romano, A; Salomone, E | 1 |
| Cos Arregui, E; González Asanza, C; Huerta Madrigal, A; Menchén Fernández-Pacheco, P; Merino Rodriguez, B; Nogales Rincón, O | 1 |
| Burbury, K; Harrison, SJ; Joyce, T; Peinert, S; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Rasmussen, HB; Søeby, K; Vangsted, AJ; Vogel, U; Werge, T | 1 |
| Belanger, E; Benavides, A; Cappia, S; Frost, P; Gera, J; Guglielmelli, T; Hoang, B; Lichtenstein, A; Pezeshkpour, G; Shi, Y | 1 |
| Chanan-Khan, A; Deeb, G; Lee, K; Miller, KC; Sher, T | 1 |
| Choo, C; Goh, YT; Hwang, W; Lao, ZT; Lau, LC; Lee, LH; Lee, YS; Lim, A; Lim, TH; Premalatha, P; Su, S; Tan, D; Teoh, G; Wee, HC; Wee, N; Yap, KC | 1 |
| Bo, J; Dou, LP; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, F; Li, HH; Wang, FF; Wang, QS; Wang, SH; Yu, L; Zhao, Y; Zhu, HY | 1 |
| Chen, SL; Gao, W; Jiang, B; Qiu, LG; Yu, L; Zhong, YP | 2 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; Cibeira, MT; de Arriba, F; de Paz, R; García-Laraña, J; García-Sanz, R; González, Y; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Mediavilla, JD; Miguel, JF; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ramos, ML; Ribera, JM; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Flowers, CR; Harvey, RD; Heffner, LT; Kaufman, J; Khoury, HJ; Langston, AA; Lechowicz, MJ; Lonial, S; McMillan, S; Nooka, A; Renfroe, H; Tighiouart, M; Torre, C; Waller, EK | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K | 1 |
| Vokurka, S | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D | 1 |
| Ackerman, E; Berenson, JR; Eades, B; Mapes, R; Swift, RA; Waterman, GN; Yellin, O | 1 |
| Chen, Z; Ge, F; Jia, H; Li, L; Lu, C; Lu, X; Zeng, H | 1 |
| He, Q; He, Y; Tan, D; Zhao, X | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Caillot, D; Casassus, P; Facon, T; Harousseau, JL; Hulin, C; Lenain, P; Maisonneuve, H; Maloisel, F; Marit, G; Mathiot, C; Michallet, M; Mohty, M; Moreau, P; Petillon, MO; Webb, I | 1 |
| Adam, Z; Autzinger, EM; Egyed, M; Gisslinger, H; Greil, R; Hajek, R; Keil, F; Lang, A; Ludwig, H; Thaler, J; Tóthová, E; Womastek, I; Zojer, N | 1 |
| Choi, I; Hata, H; Higuchi, M; Masaki, Y; Nagafuji, K; Sunami, K; Takamatsu, Y; Tamura, K; Uozumi, K | 1 |
| Berno, T; Briani, C; Campagnolo, M; Zambello, R | 1 |
| Bocchia, M; Crupi, R; Defina, M; Gozzetti, A | 1 |
| Guo, H; Jiang, Y; Shen, Y; Sun, C; Tong, Y; Wang, J; Wang, Z; Yang, G; Zhou, X | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J | 1 |
| Golenkov, AK; Kataeva, EV; Klinushkina, EF; Lutskaia, TD; Mitina, TA; Trifonova, EV | 1 |
| Bertsch, U; Broyl, A; Corthals, SL; de Knegt, Y; Durie, BG; el Jarari, L; Goldschmidt, H; Jongen, JL; Kuiper, R; Lokhorst, HM; Sonneveld, P; van der Holt, B; van Duin, M | 1 |
| Beysel, S; Yağci, M; Yeğın, ZA | 1 |
| Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL | 1 |
| Li, F; Rajendran, P; Sethi, G | 1 |
| Chou, T; Hirose, T; Igarashi, N; Imai, Y; Ishiguro, T | 1 |
| Mey, UJ | 1 |
| Adami, F; Cabrelle, A; Colpo, A; Gnoato, M; Gurrieri, C; Manni, S; Montini, B; Pavan, L; Piazza, F; Semenzato, G; Trentin, L; Tubi, LQ; Zambello, R | 1 |
| Akaogi, T; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata, E; Kiyota, M; Kobayashi, T; Kobayashi, Y; Koshida, M; Kuroda, J; Matsumoto, Y; Murakami, S; Okano, A; Shimazaki, C; Shimura, K; Tanaka, T; Taniwaki, M; Uchiyama, H; Ueda, S; Ueda, Y; Uoshima, N | 1 |
| Bi, LJ; Ge, F; He, QY; Jia, HT; Li, LP; Lu, CH; Tao, SC; Xiao, CL; Xiong, S; Yin, XF | 1 |
| Hagedorna-Tronina, R; Kraj, M; Kruk, B; Pogłód, R; Warzocha, K; Łetowska, M | 1 |
| Ding, N; Harrison, SJ; Howman, R; Khot, A; Pitman, M; Thakerer, A; Thompson, PA | 1 |
| Tsukamoto, S | 1 |
| Cao, TM; Li, G; Liu, Y; Salama, M; Shi, L; Tricot, G; Wang, S; Wu, Y; Xiao, F; Xu, C; Xu, H; Yang, Y; Zangari, M; Zhan, F | 1 |
| Bladé, J; Delforge, M; Dimopoulos, MA; Facon, T; Kropff, M; Ludwig, H; Palumbo, A; San-Miguel, JF; Sonneveld, P; Van Damme, P | 1 |
| Asmar, L; Beveridge, R; Boehm, KA; Greenspan, A; Kannarkat, GT; Mandanas, RA; Rifkin, RM; Schwerkoske, JF; Stephenson, JJ; Zhan, F | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cavalli, M; Ciccone, G; Falcone, AP; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Leonardi, G; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rizzo, M; Rossi, D | 1 |
| Fujita, Y; Fukushima, T; Hirose, Y; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Yahng, SA | 1 |
| Bae, SH; Do, YR; Kim, K; Kim, SJ; Lee, JJ; Yang, DH | 1 |
| Connolly, G | 1 |
| Cavallo, F; Esseltine, D; Gruenwald, JM; Kern, S; Kumar, NS; Pappas, L; Ranganathan, S; Suva, LJ; Tricot, G; Yaccoby, S; Zangari, M; Zhan, F | 1 |
| Fukunaga, K; Saeki, Y; Tanaka, K | 1 |
| Anderson, KC; Barlogie, B; Bladé, J; Cavo, M; Chanan-Khan, A; Comenzo, RL; Dimopoulos, MA; Durie, BG; Fermand, JP; Giralt, S; Harousseau, JL; Jagannath, S; Leung, N; Ludwig, H; Niesvizky, R; Palumbo, A; Rajkumar, SV; Richardson, PG; San Miguel, J; Sezer, O; Sonneveld, P; Terpos, E; Tosi, P | 1 |
| Chosa, M; Nagase, K; Tobinai, K; Watanabe, T | 1 |
| Palumbo, A | 2 |
| Hao, H; Hasegawa, S; Hirota, S; Lee-Kawabata, M; Masuyama, T; Naito, Y; Ogawa, H; Tamaki, H; Taniguchi, Y | 1 |
| Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K | 1 |
| Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Yamamoto, M | 1 |
| Guo, HF; Mao, JJ; Su, HL; Sun, C; Wang, J; Zhou, X | 1 |
| Ballanti, S; Corvatta, L; Gentili, S; Gozzetti, A; Leoni, P; Liberati, AM; Nozzoli, C; Offidani, M; Palumbo, A; Polloni, C; Pulini, S | 1 |
| Richardson, PG | 3 |
| Auwerda, JJ; Bertina, RM; de Maat, MP; Leebeek, FW; Osanto, S; Sonneveld, P; Yuana, Y | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Bouley, DM; Denko, NC; Koong, AC; Lust, S; Niwa, M; Offner, F; Olson, M; Papandreou, I; Solow-Cordero, DE; Tam, A; Van Melckebeke, H | 1 |
| Liedtke, M; Medeiros, BC | 1 |
| Anderson, K; Laubach, J; Richardson, P | 1 |
| Bo, J; Dou, LP; Gao, CJ; Han, XP; Huang, WR; Jing, Y; Li, HH; Wang, QS; Wang, SH; Yu, L; Zhao, Y; Zhu, HY | 1 |
| Chim, CS | 2 |
| Djulbegovic, B; Hozo, I; Kumar, A; Wheatley, K | 1 |
| Ahn, KS; Jang, HJ; Kim, HJ; Kim, SH; Kim, SM; Na, YS; Park, KR | 1 |
| Morgan, G | 2 |
| Chen, XQ; Dong, HJ; Gao, GX; Gu, HT; Shu, MM; Wang, YW; Yang, Y; Zhu, HF | 1 |
| Bai, QX; Fan, LN; Huang, GS; Wang, L; Yang, LJ; Yue, P; Zhang, XY; Zhao, H; Zhu, J | 1 |
| Barnett, MJ; Broady, R; Connors, JM; Forrest, DL; Hamata, L; Hogge, DE; Mourad, YA; Nantel, SH; Narayanan, S; Nevill, TJ; Nitta, J; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Venner, CP | 1 |
| Baccarani, M; Caravita, T; Cavo, M; Cellini, C; Corradini, P; Crippa, C; Deliliers, GL; Di Raimondo, F; Galli, M; Ledda, A; Narni, F; Offidani, M; Palumbo, A; Pantani, L; Patriarca, F; Pescosta, N; Petrucci, MT; Spadano, A; Tacchetti, P; Tosi, P; Zamagni, E | 1 |
| Jeon, SH; Kim, DH; Kwan, J; Lee, WS; Park, KS; Park, SD; Shin, SH; Woo, SI; Yi, HG | 1 |
| Alici, E; Gahrton, G; Jansson, M; Nahi, H; Sutlu, T | 1 |
| Chen, WM; Yang, GZ | 1 |
| Hanzawa, K; Kizaki, M; Mori, S; Nemoto, T; Sagawa, M; Tokuhira, M; Tomikawa, T; Watanabe, R | 1 |
| Ahn, KS; Chen, CY; Han, I; Jeong, SJ; Jung, JH; Kang, M; Kim, DK; Kim, SH; Kwon, TR; Lee, JW; Lee, SG; Yun, SM | 1 |
| Aries, PM; Fröhlich, K; Gross, WL; Holle, JU; Moosig, F | 1 |
| Che, XF; Itoh, M; Kawaguchi, T; Miyazawa, K; Moriya, S; Naito, M; Ohtomo, T; Tomoda, A | 1 |
| Einsele, H; Knop, S; Kortüm, M | 1 |
| Arai, J; Emi, N; Hasegawa, M; Hiki, Y; Ishii, J; Kato, M; Kondo, F; Murakami, K; Nabeshima, K; Nakai, S; Ohashi, A; Sugiyama, S; Tomita, M; Yamamoto, K; Yuzawa, Y | 1 |
| Chen, LJ; Li, CM; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W | 1 |
| Laubach, J; Richardson, P | 1 |
| Buda, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P | 1 |
| Blake, J; Brandner, S; D'Sa, S; Elliott, KJ; Lunn, MP; Rabin, N; Reilly, MM; Saifee, TA; Yong, KL | 1 |
| Anderson, KC; Buon, L; Delmore, J; Hayden, P; Jacobs, HM; Jakubikova, J; Laubach, J; Lengauer, C; McMillin, DW; Mitsiades, CS; Munshi, NC; Negri, J; Ooi, M; Richardson, PG; Schlossman, R | 1 |
| Du, J; Fu, W; Hou, J; Huo, J; Jiang, H; Shi, J; Yi, Q; Yuan, Z; Zhang, C | 1 |
| Broderick, E; Favis, R; Harousseau, JL; Levey, L; Meyers, M; Mulligan, G; Ricci, DS; Richardson, PG; Sun, Y; van de Velde, H | 1 |
| Borrello, I; Ferguson, A; Ghosh, N; Huff, CA; Ye, X | 1 |
| Annunziata, CM; Burris, J; Driscoll, JJ | 1 |
| Arnulf, B; Asli, B; Belhadj, K; Bories, JC; Bouscary, D; Brouet, JC; Chandesris, O; Choquet, S; Fermand, JP; Ghez, D; Hermine, O; Karlin, L; Macro, M; Malphettes, M; Porcher, R; Soulier, J | 1 |
| Fujita, J; Kanakura, Y; Kang, S; Mizuki, M; Otsuka, M | 1 |
| Ashcroft, J; Cavenagh, J; Cavet, J; Conn, J; Cook, G; Cook, M; Drake, M; Kazmi, M; Kettle, P; Marshall, S; Morris, C; Oakervee, H; Olujohungbe, A; Popat, R; Quinn, M; Snowden, J; Streetly, M; Tighe, J | 1 |
| Ashcroft, J; Cook, G; Cromack, J; Feyler, S; Owen, R; Parrish, C | 1 |
| Braggio, E; Bruins, LA; Keats, JJ; Mousses, S; Schmidt, JE; Sereduk, C; Shi, CX; Stewart, AK; Tiedemann, R; Yin, H; Zhu, YX | 1 |
| Borsini, W; Di Stasi, V; Donadio, V; Giannoccaro, MP; Gomis Pèrez, C; Liguori, R | 1 |
| Ando, K; Kojima, M; Moriuchi, M; Nakamura, N; Ogawa, Y; Ohmachi, K; Tsuboi, K | 1 |
| Amiot, M; Boccadoro, M; Cavallo, F; Descamps, G; Facon, T; Harousseau, JL; Hulin, C; Leleu, X; Mignard, D; Moreau, P | 1 |
| Anderson, KC; Laubach, JP; Mitsiades, CS; Richardson, PG; Schlossman, RL | 1 |
| Dokos, C; Hatzitolios, A; Kaiafa, G; Savopoulos, C | 1 |
| Bladé, J; Harousseau, JL; Lantz, K; Londhe, A; Lowery, C; Orlowski, RZ; Shah, J; Sonneveld, P | 1 |
| Lacy, MQ; Tefferi, A | 1 |
| Ahn, KS; Chen, CY; Jeong, SJ; Jung, JH; Kim, SH; Kim, SY; Kwon, TR; Lee, JC; Rhee, YH; Yoon, HJ; Zhu, S | 1 |
| Anderson, KC; Armand, P; Bagshaw, M; Banwait, R; Chuma, S; Dollard, A; Ghobrial, IM; Harris, B; Jakubowiak, AJ; Kunsman, J; Laubach, J; Leduc, R; Maiso, P; Munshi, NC; Poon, T; Richardson, PG; Roccaro, A; Rodig, S; Sam, A; Schlossman, R; Vij, R; Warren, D; Weller, E | 1 |
| Mateos, MV; San-Miguel, J | 1 |
| Abildgaard, N; Andersen, NF; Gimsing, P; Gregersen, H; Klausen, TW; Nexø, BA; Vangsted, AJ; Vogel, U | 1 |
| Schots, R | 1 |
| Li, J; Wu, XM; Zhang, DY | 1 |
| Abraham, J; Awan, FT; Craig, M; Gibson, L; Hamadani, M; Jillella, A; Kochuparambil, ST; Osman, S; Remick, SC | 1 |
| Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Goldschmidt, H; Khuageva, NK; Kropff, M; Liu, K; Magen-Nativ, H; Mateos, MV; Petrucci, MT; Ricci, DS; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Terpos, E; van de Velde, H | 1 |
| Fujisaki, T; Kan, S; Murakami, H; Muta, T; Nakanishi, H; Senba, S; Ueda, Y; Yasunaga, M | 1 |
| Emmerich, B; Frohn, C; Hess, G; Hrusovsky, I; Olie, RA; Pliskat, H; Taverna, C; Voegeli, J; von Rohr, A | 1 |
| Anderson, K; Cakana, A; Deraedt, W; Dimopoulos, M; Esseltine, DL; Hou, J; Khuageva, N; Kropff, M; Liu, K; Mateos, MV; Petrucci, MT; Richardson, P; Robak, T; Rossiev, V; San Miguel, JF; Schlag, R; Shpilberg, O; van de Velde, H; Vekemans, MC | 1 |
| Adam, Z; Buchler, T; Gregora, E; Hajek, R; Krejci, M; Krivanova, A; Mayer, J; Minarik, J; Pour, L; Scudla, V; Straub, J; Zahradova, L | 1 |
| Bolaman, Z; Dayanir, V; Dayanir, Y; Kadikoylu, G; Kocaturk, T; Yavasoglu, I | 1 |
| Fukami, K; Koike, K; Morishige, S; Okamura, T; Okuda, S; Taguchi, K; Yakushiji, K | 1 |
| Bosi, A; Maratea, D; Messori, A; Nozzoli, C | 1 |
| Haga, M; Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N | 1 |
| Adachi, K; Endoh, A; Nakamura, R; Oda, Y; Ooi, S; Urushidani, Y | 1 |
| Attal, M; Palumbo, A; Roussel, M | 1 |
| Lonial, S; Mitsiades, CS; Richardson, PG | 1 |
| Akimoto, T; Hamano, Y; Hanawa, S; Imai, T; Inoue, M; Kotoda, A; Kusano, E; Matsuyama, T; Muto, S; Ozawa, K; Saito, O; Ueda, M; Uehara, E; Yoshizawa, H; Yumura, W | 1 |
| Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A | 1 |
| Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR | 1 |
| Beksac, M; Bladé, J; Cavenagh, J; Cavo, M; Delforge, M; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Harousseau, JL; Hess, U; Kropff, M; Leal da Costa, F; Louw, V; Ludwig, H; Magen-Nativ, H; Mendeleeva, L; Nahi, H; Palumbo, A; Plesner, T; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Antoch, G; Buchbender, C; Nawatny, J | 1 |
| Gudkov, AV; Komarov, AP; Neznanov, N; Neznanova, L; Stanhope-Baker, P | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Lantz, KC; Nagler, A; Orlowski, RZ; Robak, T; San Miguel, JF; Sonneveld, P; Spencer, A; Sutherland, HJ; Zhuang, SH | 1 |
| Brioli, A; Cavo, M; Pantani, L; Tacchetti, P; Zamagni, E; Zannetti, B | 1 |
| Alvarez Fernández, GM; de Alarcón Jiménez, RM; García Hernández, MA; Jimeno Griñó, C; Molina Núñez, M; Navarro Parreño, MJ; Roca Meroño, S; Zarco Pedrinaci, E | 1 |
| Bergsagel, PL; Chesi, M; Chng, WJ; Chung, TH; Fonseca, R; Gonzalez-Paz, N; Huang, GF; Mulligan, G; Ng, SB; Troska-Price, T | 1 |
| Hayashi, T; Ikeda, H; Imai, K; Ishida, T; Kawakami, K; Kobayashi, T; Nishimura, S; Shinomura, Y; Takahashi, F; Yasui, H | 1 |
| Azab, AK; Bahlis, NJ; Boise, LH; Brentnall, M; Duggan, P; Ghobrial, IM; Gratton, K; Klimowicz, AC; Lin, C; Mansoor, A; Neri, P; Ren, L; Stewart, DA; Tassone, P | 1 |
| Aujay, M; Bahlis, N; Belch, A; Berno, T; Hetherington, KL; Jagannath, S; Jakubowiak, A; Keith Stewart, A; Kukreti, V; Lonial, S; Orlowski, RZ; Siegel, D; Singhal, S; Somlo, G; Tricot, G; Trudel, S; Vij, R; Wang, L; Zangari, M; Zhan, F | 1 |
| Gharwan, H; Truica, CI | 1 |
| Bringhen, S; Mateos, MV; Palumbo, A; San Miguel, JF | 1 |
| Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C | 1 |
| Moore, H; Romeril, K | 1 |
| Arnulf, B; Cavet, J; Deraedt, W; Esseltine, DL; Feng, H; Girgis, S; Grishunina, M; Grosicki, S; Harousseau, JL; Karamanesht, I; Kropff, M; Leleu, X; Masliak, Z; Moreau, P; Pylypenko, H; Rekhtman, G; Robak, T; Shubina, A; van de Velde, H | 1 |
| Kyle, RA; Steensma, DP | 1 |
| Boyd, KD; Davies, FE; Morgan, GJ | 1 |
| Attal, M; Facon, T; Harousseau, JL; Moreau, P; Roussel, M | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Gahrton, G | 1 |
| Benevolo, G; Boccadoro, M; Botto, B; Evangelista, A; Frairia, C; Gay, F; Gentile, M; Larocca, A; Morabito, F; Palumbo, A; Pregno, P; Vitolo, U | 1 |
| Abraham, J; Bridoux, F; Debiais, C; Delbès, S; Desport, E; Fermand, JP; Hanf, W; Jaccard, A; Lacotte-Thierry, L; Moumas, E; Touchard, G | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, T | 1 |
| An, G; Chang, H; Han, Y; Hao, M; Li, C; Meng, H; Qiu, L; Xie, Z; Xu, Y; Yu, Z; Zhang, L | 1 |
| Albitar, M; Alsina, M; Anderson, KC; Berman, D; Carroll, MP; Chanan-Khan, AA; Krishnan, AY; Lonial, S; Messina, M; Richardson, PG | 1 |
| Kupisiewicz, K | 1 |
| Goh, YT; Han, ST; Hwang, WY; Linn, YC; Mya, DH; Tan, DC | 1 |
| Fingerle-Rowson, G; Goldschmidt, H; Ho, AD; Neben, K; Pham, M; Schmitt, S; Storch-Hagenlocher, B | 1 |
| Ailawadhi, S; Chanan-Khan, A; Czuczman, MS; Hernandez-Ilizaliturri, FJ; Hong, F; Iancu, D; Jamshed, S; Lawrence, W; Lee, K; Manfredi, D; Masood, A; Miller, KC; Sher, T; Soniwala, S; Sood, R; Tan, W; Wilding, G; Wood, M | 1 |
| Khan, ML; Stewart, AK | 1 |
| An, G; Deng, SH; Li, CW; Li, Q; Liu, XP; Qi, JY; Qiu, LG; Wang, YF; Xu, Y; Zhao, YZ; Zou, DH | 1 |
| Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH | 1 |
| Chen, C; Hou, M; Zhao, CL | 1 |
| Fink, L; Tricot, G; Zangari, M; Zhan, F | 1 |
| Anderson, KC; Anderson, T; Barrickman, JC; Campagnaro, EL; Esseltine, DL; Griffith, KA; Harvey, CK; Hofmeister, CC; Jakubowiak, AJ; Kaminski, MS; Kelley, SL; Laubach, JP; Lonial, S; Mietzel, MA; Raje, NS; Reece, DE; Richardson, PG; Schlossman, RL; Tendler, CL; Wear, SM; Zimmerman, TM | 1 |
| Britton, M; Downey, SL; Filippov, DV; Florea, BI; Kisselev, AF; Mirabella, AC; Overkleeft, HS; Pletnev, AA; Shabaneh, TB; Verdoes, M | 1 |
| Aoki, T; Imahashi, N; Kitamura, K; Nishiyama, T | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hanamura, I; Heuck, CJ; Nair, B; Qu, P; Shaughnessy, JD; Stephens, O; Tian, E; Usmani, S; van Rhee, F; Waheed, S; Williams, R; Zhang, Q; Zhou, Y | 1 |
| Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE | 1 |
| Brunson, CY; Costa, LJ; Milligan, L; Rivell, GL; Stuart, RK | 1 |
| Sherman, MY | 1 |
| Andersson, BS; Champlin, RE; Decker, WK; Giralt, SA; Gocke, CD; Jones, RB; Jones, RJ; Lu, J; McMannis, JD; Ng, J; Nieto, Y; Parmar, S; Robinson, SN; Shah, N; Shpall, EJ; Steiner, D; Thomas, MW; Xing, D; Yang, H | 1 |
| Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T | 1 |
| Burnette, BL; Leung, N; Rajkumar, SV | 1 |
| Repasky, EA; Subjeck, JR | 1 |
| Allred, JB; Bergsagel, PL; Buadi, F; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, K; Lust, JA; Mandrekar, SJ; Mikhael, JR; Rajkumar, SV; Reeder, C; Roy, V; Russell, SJ; Short, KD; Stewart, AK; Zeldenrust, S | 1 |
| Ishak, J; Rodrigues, F | 1 |
| Alexanian, R; Delasalle, K; Fu, W; Hou, J; Song, S; Wang, J; Wang, M | 1 |
| Dytfeld, D; Friedman, J; Griffith, KA; Harvey, C; Jakubowiak, AJ; Kaminski, MS; Lebovic, D | 1 |
| Adam, Z; Hájek, R; Jakubcová, R; Klincová, M; Krejcí, M; Mayer, J; Pour, L; Szturz, P; Zahradová, L | 1 |
| Ju, S; Li, C; Wang, H; Wang, X; Wang, Y; Zhong, R | 1 |
| Colado, E; de Queiroz Crusoe, E; Delgado, M; Fernandez-Lazaro, D; Garayoa, M; Garcia-Gomez, A; Gutierrez, NC; Lee, FY; Maiso, P; Martin-Sanchez, J; Ocio, EM; San-Segundo, L | 1 |
| Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
| Bai, QX; Chen, JJ; Huang, GS; Yang, LJ; Zhang, XY; Zhao, H | 1 |
| Chen, YB; Hu, J; Shen, ZX; Tang, W; Wang, L; Wang, Y; Wu, W; Xu, L; Zhao, WL | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Balakrishnan, K; Gandhi, V | 1 |
| Chen, XQ; Chen, YL; Cheng, YX; Jin, J; Liang, HX; Liu, Y; Zhang, B; Zhang, FX; Zhou, GB | 1 |
| Aydin, F; Bayik, M; Firatli-Tuglular, T; Kaygusuz, I; Toptas, T; Uzay, A | 1 |
| Chiriva-Internati, M; Chui, K; Cobos, E; Jenkins, MR; John, CM; Mirandola, L; Yu, Y | 1 |
| Molica, S; Piro, E | 1 |
| Burns, CJ; Khong, T; Monaghan, KA; Spencer, A | 1 |
| Chung, JS; Eom, HS; Kang, HJ; Kim, CS; Kim, HJ; Kim, JS; Kim, K; Lee, DS; Lee, JH; Lee, JL; Lee, SJ; Park, JS; Seong, CM; Sohn, SK; Suh, C; Won, JH; Yoon, SS | 1 |
| Avet-Loiseau, H; Corthals, SL; Goldschmidt, H; Hajek, R; Johnson, DC; Kuiper, R; Magrangeas, F; Morgan, GJ; Sonneveld, P; van der Holt, B | 1 |
| de la Rubia, J; Roig, M | 1 |
| Liu, L; Ran, X; Sheng, Z; Wang, B; Wang, L | 1 |
| Bosi, A; Bruno, B; Corradini, P; Einsele, H; Fanin, R; Festuccia, M; Isola, M; Morabito, F; Nozza, A; Nozzoli, C; Patriarca, F; Sperotto, A; Spina, F; Stuhler, G | 1 |
| Chang, H; Jiang, A; Reece, D | 1 |
| Bello, C; Cohen, A; Comenzo, RL; Drullinsky, P; Hassoun, H; Hoover, E; Jhanwar, S; Landau, H; Lendvai, N; Lesokhin, A; Nimer, SD; Pandit-Taskar, N; Riedel, E; Schulman, P | 1 |
| Araujo, C; Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Caillot, D; Chaleteix, C; Decaux, O; Dib, M; Doyen, C; Escoffre, M; Facon, T; Fontan, J; Fuzibet, JG; Garderet, L; Harousseau, JL; Hulin, C; Kolb, B; Lenain, P; Lepeu, G; Lioure, B; Marit, G; Mathiot, C; Moreau, P; Pégourié, B; Randriamalala, E; Sebban, C; Stoppa, AM; Tiab, M; Traullé, C; Wetterwald, M | 1 |
| Adam, Z; Feit, J; Hájek, R; Klincová, M; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V; Zahradová, L | 1 |
| Khong, T; Spencer, A | 1 |
| Bergsagel, PL; Bjorklund, CC; Braggio, E; Bruins, LA; Chang, XB; Fonseca, R; Orlowski, RZ; Schmidt, JE; Shi, CX; Stewart, AK; Van Wier, S; Zhu, YX | 1 |
| Hino, N; Omura, H; Tanaka, T; Yamasaki, R | 1 |
| An, N; Chen, SL; Hu, Y; Li, X; Zhang, JJ; Zhong, YP | 1 |
| Bacovsky, J; Lochman, P; Minarik, J; Pika, T; Scudla, V; Tichy, T; Zadrazil, J | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Möller, J; Murthy, A; Nicklasson, L | 1 |
| Tokuhira, M | 1 |
| Bargay, J; Bengoechea, E; Bladé, J; de Arriba, F; Díaz-Mediavilla, J; Fernández, M; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Lahuerta, JJ; Martín, A; Martín-Mateos, ML; Martín-Ramos, ML; Martínez-López, J; Mateos, MV; Montalbán, MA; Oriol, A; Paiva, B; Palomera, L; Peñalver, FJ; Ribera, JM; San Miguel, JF; Sureda, A; Teruel, AI; Vidriales, MB | 1 |
| Bousquet, A; Join-Lambert, O; Malfuson, JV; Martinaud, C; Soler, C | 1 |
| Bellovich, K; El-Ghoroury, M; Goel, SK; Granger, D; Marin, M; Qu, H | 1 |
| Dean, J; Dickinson, M; Harrison, SJ; Januszewicz, H; Johnstone, R; Link, E; Neeson, P; Nichols, J; Prince, HM; Quach, H; Ritchie, DS; Ruell, S; Seymour, JF | 1 |
| Gertz, MA | 3 |
| Dimopoulos, MA; Mateos, MV; Redman, K; Richardson, PG; Spicka, I | 1 |
| Cserti-Gazdewich, C; Dzik, WH; Haspel, RL | 1 |
| Bridoux, F; Fermand, JP; Hutchison, C | 1 |
| Bahlis, NJ; Boise, LH; Duggan, P; Gratton, K; Johnson, J; Klimowicz, A; Lonial, S; Mansoor, A; Neri, P; Ren, L; Stebner, E; Stewart, DA; Tassone, P | 1 |
| Dimeski, G; Wood, P | 1 |
| Chongmei, H; Hui, C; Jianmin, Y; Shuqing, L; Wang, J | 1 |
| Assaraf, YG; Chan, ET; Cloos, J; Franke, NE; Geerke, DP; Jansen, G; Kaspers, GJ; Kirk, CJ; Niewerth, D; Schimmer, AD; van Meerloo, J; van Zantwijk, CH; Vojtekova, K; Zweegman, S | 1 |
| Delforge, M | 1 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Chen, CS; Eades, B; Hilger, J; Hilger, JD; Mapes, R; Nassir, Y; Patel, R; Swift, RA; Vescio, R; Wirtschafter, E; Yang, HH; Yellin, O; Yung, E | 1 |
| Anderson, KC; Bandi, M; Chauhan, D; Raje, N; Ray, A; Richardson, P; Singh, AV | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Cascavilla, N; Cavo, M; Di Raimondo, F; Gentile, M; Grasso, M; Guglielmelli, T; Majolino, I; Marasca, R; Mazzone, C; Montefusco, V; Morabito, F; Musolino, C; Musto, P; Nozzoli, C; Offidani, M; Palumbo, A; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, I | 1 |
| Gupta, A; Pandey, A; Sethi, S | 1 |
| Griskevicius, L; Janiulioniene, A; Matuzeviciene, R; Peceliunas, V; Zvirblis, T | 1 |
| Goel, A; Spitz, DR; Weiner, GJ | 1 |
| Baz, R; Chen, F; Li, M; Nefedova, Y; Pisklakova, A; Sullivan, DM | 1 |
| Alsina, M; Nishihori, T | 1 |
| Balsas, P; Galán-Malo, P; Marzo, I; Naval, J | 1 |
| Doss, S; Hay, N; Sutcliffe, F | 1 |
| Allerton, J; Anderson, KC; Bar, M; Colson, K; Densmore, J; Gardner, L; Ghobrial, IM; Hideshima, T; Irwin, D; Jakubowiak, A; Krishnan, A; Laubach, J; Lonial, S; Martin, T; Munshi, N; Poradosu, E; Raje, N; Richardson, PG; Schlossman, R; Sportelli, P; Wolf, J; Zonder, J | 1 |
| Al-Shabeeb, A; Allen, JD; Catalano, A; Fleming, S; Harrison, S; Ho, PJ; Horvath, N; Iland, H; Joshua, DE; Lau, EK; Ling, SC; Nikolic, A | 1 |
| Carew, JS; Coffey, M; Espitia, CM; Giles, FJ; Kelly, KR; Mahalingam, D; Nawrocki, ST; Oyajobi, BO | 1 |
| Chan, TH; Dou, QP; Kanwar, J; Mujtaba, T; Wan, SB | 1 |
| Dalmau, J; Fett, NM; Shinohara, MM; Toporcer, MB; Vogl, DT | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| Gräwert, MA; Groll, M | 1 |
| Chen, WM; Chen, XQ; Hou, J; Huang, XJ; Jin, J; Li, Y; Liu, ZG; Shen, ZX; Yuan, ZG | 1 |
| Fei, XM; Hu, HJ; Li, JX; Li, JY; Lu, H | 1 |
| Bai, H; Ling, YQ; Wang, CB; Wang, ML; Wu, B; Zhang, Q | 1 |
| Miwa, A; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N; Wagatsuma, M; Yamada, K | 1 |
| Cipok, M; Deutsch, VR; Farnoushi, Y; Goldstein, RS; Jan, H; Kay, S; Naparstek, E; Ohana, A | 1 |
| Chang, H; Chen, MH; Qi, C; Reece, D | 1 |
| Bratengeier, C; Christoulas, D; Delimpasi, S; Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Meletis, J; Michalis, E; Pouli, A; Terpos, E; Zervas, K | 1 |
| Ailawadhi, S; Bryant, B; Chanan-Khan, A; Gaile, DP; Lee, KP; Mashtare, T; Masood, A; Miecznikowski, J; Mulligan, G; Neuwirth, R; Sher, T; Stein, L; Wang, D; Wilding, GE | 1 |
| Brnjic, S; D'Arcy, P; De Cesare, M; Fryknäs, M; Hassan, M; Larsson, R; Linder, S; Lindsten, K; Olofsson, MH; Perego, P; Sadeghi, B | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG | 1 |
| Guo, H; Mao, J; Qian, X; Sun, C; Sun, H | 1 |
| Feng, H; Girgis, S; Hellmann, A; Louw, VJ; Patel, H; Rule, S; Shpilberg, O; Skee, DM; van de Velde, H; Walewski, J | 1 |
| Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, P; Hayman, S; Keith Stewart, A; Khan, ML; Kumar, SK; Lacy, MQ; Laumann, KM; Leif Bergsagel, P; Lust, J; Mikhael, JR; Reece, DE; Reeder, CB; Russell, S; Vincent Rajkumar, S; Zeldenhurst, S | 1 |
| Andrade, VC; Atanackovic, D; Caballero, OL; Camargo, AA; Colleoni, GW; Costa, ET; de Carvalho, F; Gregorio, JC; Masotti, C; Strauss, BE | 1 |
| Cao, Y; Chen, RA; Liang, Y; Liu, L; Tu, Y | 1 |
| Dang, N; De Bruyne, E; De Bryune, E; Hu, J; Menu, E; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K; Xu, D | 1 |
| Dimopoulos, MA; Eleftherakis-Papapiakovou, E; Gkotzamanidou, M; Grapsa, I; Kastritis, E; Nikitas, N; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM | 1 |
| Bansal, R; Boise, LH; Fink, EE; Hu, Q; Lee, KP; Liu, S; Mannava, S; Moparthy, KC; Nair, JR; Nikiforov, MA; Wawrzyniak, JA; Zhuang, D; Zucker, SN | 1 |
| Bryant, J; Clegg, AJ; Cooper, K; Picot, J | 1 |
| Reece, D; Scott, E | 1 |
| Bertsch, U; Blau, IW; Derigs, HG; Dührsen, U; Goldschmidt, H; Haenel, M; Hielscher, T; Ho, AD; Hose, D; Jauch, A; Lindemann, W; Lokhorst, HM; Martin, H; Neben, K; Peter, N; Pfreundschuh, M; Raab, MS; Salwender, H; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Teschendorf, C; van de Velde, H; van der Holt, B; Weisel, K | 1 |
| Knop, S | 2 |
| Fonseca, R | 2 |
| Li, LS; Shen, JK; Zhang, GS | 1 |
| Appel, A | 1 |
| Berglund, J | 1 |
| Anderson, KC; Avet-Loiseau, H; Beksac, M; Bladé, J; Cavo, M; Chng, WJ; Comenzo, R; Delforge, M; Dimopoulos, M; Durie, BG; Einsele, H; Harousseau, JL; Jagannath, S; Jongen, JL; Lahuerta, JJ; Lee, JH; Lonial, S; Mateos, MV; Mazumder, A; Merlini, G; Miguel, JS; Moreau, P; Morgan, G; Munshi, N; Niesvizky, R; Orlowski, R; Palumbo, A; Rajkumar, SV; Richardson, PG; Sezer, O; Siegel, D; Sonneveld, P; Terpos, E; Usmani, S; Vesole, D; Voorhees, P; Wen, P | 1 |
| Bachmann, AS; Ibarra-Rivera, TR; Opoku-Ansah, J; Pirrung, MC | 1 |
| Cai, JL; Duarte, L; Farol, L; Forman, SJ; Frankel, PH; Htut, M; Karanes, C; Kogut, NM; Krishnan, AY; Murata-Collins, JL; Parker, PM; Popplewell, LL; Reburiano, E; Ruel, C; Sahebi, F; Somlo, G; Spielberger, RT; Thomas, SH | 1 |
| Baumann, P; Junghanns, C; Mandl-Weber, S; Oduncu, F; Schmidmaier, R; Strobl, S | 1 |
| Terpos, E; Tricot, G; Zangari, M; Zhan, F | 1 |
| Gil, L; Komarnicki, M; Rupa-Matysek, J | 1 |
| Fukuda, Y; Gemma, A; Hatake, K; Katoh, T; Kudoh, S; Kusumoto, M; Mukai, H; Ohyashiki, K; Sakai, H; Sugiyama, Y | 1 |
| Anderson, KC; Buon, L; Delmore, JE; Hunter, ZR; Jacobs, HM; Kung, AL; McMillin, DW; Mitsiades, CS; Monrose, V; Richardson, PG; Smith, PG; Treon, SP; Yu, J | 1 |
| Beebe, DJ; Callander, NS; Kahl, BS; Miyamoto, S; Pak, C; Yang, DT; Young, EW | 1 |
| Apcher, S; Arnulf, B; Bono, C; Bories, JC; Fermand, JP; Galicier, L; Harel, S; Karlin, L; Labaume, S; Mouly, E; Sauvageon, H | 1 |
| Anderson, KC; Gaballa, MR; Ghobrial, IM; Laubach, JP; Mitsiades, CS; Munshi, N; Noonan, K; Redman, K; Richardson, PG; Schlossman, RL | 1 |
| Airia, P; Cockwell, P; Cook, M; Grima, D; Heyne, N; Hutchison, CA; Schindler, R; Zickler, D | 1 |
| Andreesen, R; Grube, M; Hafner, C; Hart, C; Wurm, S | 1 |
| Feliu, J; García-Muñoz, R; Olavarría, E; Zabalza, A | 1 |
| Kisselev, AF; Overkleeft, HS; van der Linden, WA | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Bladé, J; de Larrea, CF; Rosiñol, L | 1 |
| Afar, DE; Anderson, KC; Bensinger, W; Benson, DM; Jakubowiak, AJ; Mohrbacher, A; Richardson, PG; Siegel, DS; Singhal, AK; Zimmerman, TM | 1 |
| Berkowitz, A; Walker, S | 1 |
| Anderson, KC; Colson, K; Doss, D; Ghobrial, IM; Hideshima, T; Laubach, JP; Lunde, L; McKenney, M; Mitsiades, C; Munshi, NC; Noonan, K; Redman, KC; Richardson, PG; Schlossman, RL; Warren, D | 1 |
| Attal, M; Avet-Loiseau, H; Bourin, P; Cordelier, P; Corre, J; Espagnolle, N; Facon, T; Fournié, JJ; Gadelorge, M; Hébraud, B; Huynh, A; Klein, B; Labat, E; Moreau, P; Roussel, M | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kim, HJ; Kim, YK; Lee, JJ; Moon, JH; Park, HC; Sohn, SK; Yang, DH | 1 |
| Digumarthi, R; Gundeti, S; Linga, VG; Mallavarapu, KM; Rajappa, S; Uppin, SG | 1 |
| Chanan-Khan, AA; Dimopoulos, MA; Jagannath, S; Ludwig, H; San Miguel, JF | 1 |
| Chen, J; Chuang, M; Jiang, D; Que, W | 1 |
| Cumová, J; Hájek, R; Jedličková, L; Potáčová, A; Potěšil, D; Sedo, O; Stejskal, K; Zdráhal, Z | 1 |
| Anderson, K; Laubach, J; Mahindra, A; Munshi, N; Raje, N; Richardson, PG | 1 |
| Gallastegui, N; Groll, M | 1 |
| Bertsch, U; Goldschmidt, H; Hose, D; Schmitt, S | 1 |
| Berenson, JR; Bravin, E; Cartmell, A; Chen, CS; Flam, M; Hilger, JD; Kazamel, T; Nassir, Y; Swift, RA; Vescio, R; Woliver, T; Yellin, O | 1 |
| Choi, Y; Kang, YA; Kim, DY; Kim, SD; Lee, JH; Lee, KH; Seol, M | 1 |
| Chen, Y; Ge, QF; Lu, Y; Mu, QT; Ouyang, GF; Zhang, Y | 1 |
| Andersen, NF; Andréasson, B; Billström, R; Carlson, K; Carlsson, MS; Flogegård, M; Forsberg, K; Gimsing, P; Gulbrandsen, N; Hjertner, Ø; Hjorth, M; Holmberg, E; Karlsson, T; Knudsen, LM; Linder, O; Nahi, H; Othzén, A; Pedersen, PT; Swedin, A | 1 |
| Brunetti, O; Ciavarella, S; Dammacco, F; Dominici, M; Grisendi, G; Silvestris, F; Tucci, M | 1 |
| Callander, N; Estevam, J; Flinn, I; Hari, P; Kumar, S; Mulligan, G; Noga, SJ; Rajkumar, SV; Richardson, PG; Rifkin, R; Shi, H; Stewart, AK; Turturro, F; Webb, IJ; Wolf, J | 1 |
| Chinen, Y; Fuchida, S; Horiike, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ohshiro, M; Sakamoto, N; Sasaki, N; Shimazaki, C; Shimura, Y; Taniwaki, M; Uchiyama, H; Yamamoto-Sugitani, M | 1 |
| Alekshun, TJ; Alsina, M; Anasetti, C; Baz, R; Chen, DT; Dalton, W; Fernandez, HF; Fulp, W; Han, G; Kharfan-Dabaja, MA; Kim, J; Nishihori, T; Ochoa-Bayona, JL; Oliveira, V; Perez, L; Pidala, J; Raychaudhuri, J; Shain, K; Sullivan, DM; Yarde, DN | 1 |
| Gu, JL; Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zhou, ZH | 1 |
| Bergsagel, PL; Chesi, M; Garbitt, VM; Johnstone, RW; Lefebure, M; Matthews, GM; Palmer, SE; Shortt, J; Stewart, AK | 1 |
| Beckers, EA; Cornelis, T; Driessen, AL; Koek, GH; van der Sande, FM | 1 |
| Cakana, A; Delforge, M; Dhawan, R; Esseltine, DL; Meunier, J; Regnault, A; Richardson, PG; Robinson, D; San Miguel, JF; van de Velde, H | 1 |
| Silvennoinen, R; Sinisalo, M; Wirta, O | 1 |
| Barosi, G; Billio, A; Boccadoro, M; Cavo, M; Corradini, P; Marchetti, M; Massaia, M; Merlini, G; Palumbo, A; Tosi, P; Tura, S | 1 |
| Eiam-Ong, S; Susantitaphong, P; Tiranathanagul, K | 1 |
| Ballanti, S; Baraldi, A; Boccadoro, M; Brioli, A; Califano, C; Callea, V; Carella, AM; Cavo, M; Crippa, C; De Stefano, V; Derudas, D; Dessanti, ML; Donnarumma, D; Falcone, A; Ferrara, F; Furlan, A; Grasso, M; Marcatti, M; Masini, L; Musto, P; Nozza, A; Nozzoli, C; Palumbo, A; Pantani, L; Patriarca, F; Perrone, G; Petrucci, MT; Pezzi, A; Zamagni, E; Zambello, R | 1 |
| Garcia-Sanz, R; Mateos, MV; Ocio, E; San Miguel, JF | 1 |
| Giralt, S | 1 |
| Kyle, RA | 1 |
| Stockler, MR; Wilcken, NR | 1 |
| Bo, J; Gao, C; Huang, W; Kang, W; Li, H; Li, J; Yu, L; Zhao, Y; Zhou, D | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Haensch, CA; Isenmann, S; Katona, I; Schlemmer, H; Stratogianni, A; Tosch, M; Weis, J | 1 |
| Adam, Z; Al-Sahmani, M; Antošová, L; Antošová, M; Buliková, A; Hájek, R; Kaisarová, B; Kissová, J; Penka, M; Trnavská, I | 1 |
| Juul, JS; Larsen, T; Marcussen, N; Pedersen, EB | 1 |
| Anderson, KC; Blumenthal, M; Cirstea, D; Fabre, C; French, M; Fulciniti, M; Gorgun, G; Hokenson, M; Hu, Y; Ikeda, H; Kawano, Y; Kertesz, NL; Kiziltepe, T; Malyankar, UM; Mimura, N; Minami, J; Munshi, NC; Ohguchi, H; Patterson, JB; Pham, T; Richardson, PG; Santo, L; Tai, YT; Tam, V; Zeng, Q | 1 |
| Chen, XQ; Dong, HJ; Gao, GX; Gu, HT; Wang, YW; Yang, Y | 1 |
| Olie, RA; Taverna, C; Trojan, A; Voegeli, J; von Rohr, A | 1 |
| Chng, WJ; Goh, YT; Khin, MT; Koh, LP; Lee, LH; Ong, KH; Tan, D; Wong, SS | 1 |
| Alsina, M; Bahlis, NJ; Belch, A; Gabrail, NY; Jagannath, S; Jakubowiak, AJ; Kaufman, JL; Kukreti, V; Kunkel, LA; Lee, P; Lonial, S; Matous, JV; McDonagh, KT; Orlowski, RZ; Reu, FJ; Rosen, P; Sebag, M; Siegel, DS; Stewart, AK; Vesole, DH; Vij, R; Wang, M; Wear, SM; Wong, AF | 1 |
| Finke, J; Houet, L; Moeller, I; Spagnoli, GC; Veelken, H | 1 |
| Avet-Loiseau, H; Bladé, J; Boccadoro, M; Cavenagh, J; Cavo, M; Davies, F; de la Rubia, J; Delimpasi, S; Dimopoulos, M; Drach, J; Einsele, H; Facon, T; Goldschmidt, H; Hess, U; Ludwig, H; Mellqvist, UH; Moreau, P; Palumbo, A; San-Miguel, J; Sondergeld, P; Sonneveld, P; Udvardy, M | 1 |
| Asimakopoulos, F; Callander, NS; Denu, RA; Dollar, BA; Escalante, LE; Hematti, P; Kim, J; Kuether, JP | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Cantaffa, R; Carillio, G; Kropp, M; Lamberti, AG; Molica, S; Piro, E | 1 |
| Bergamo, S; di Meo, N; Dondas, A; Trevisan, G | 1 |
| Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M | 1 |
| Bai, QX; Zhang, XY | 1 |
| Feng, J; Li, Z; Ma, Y; Ren, H; Wang, Y; Zhao, J | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Rushworth, SA | 1 |
| Berenson, JR; Chen, H; Li, J; Li, M; Nichols, CM; Sanchez, E; Wang, C | 1 |
| Barthelemy, M; Boulanger, F; Cossment, C; Facon, T; Fouquet, G; Le Ray, E; Leleu, X; Manier, S; Noel, MP; Prod'homme, C; Samarcq, P; Terriou, L | 1 |
| Itoh, K; Sasaki, M; Yamaguchi, T | 1 |
| Ferrara, R; Obeid, KM; Sharma, M | 1 |
| Cavo, M; Harousseau, JL; Moreau, P; Orlowski, RZ; Palumbo, A; Richardson, PG; San Miguel, JF | 1 |
| Ahmad, N; Al Sayed, Y; Atrash, S; Barlogie, B; Chauhan, N; Crowley, J; Heuck, CJ; Hoering, A; Nair, B; Petty, N; Sexton, R; Usmani, SZ; van Rhee, F; Waheed, S | 1 |
| Chan, EY; Chim, CS; Kwong, YL; Lau, CW; Liang, R; Lie, AK; Liu, HS; Ma, ES; Sim, J; Tse, E; Wan, TS; Yip, SF | 1 |
| Chisholm, R; Houghton, J; O'Driscoll, BR; O'Riordan, D | 1 |
| Arnulf, B; Cakana, A; Deraedt, W; Feng, H; Grosicki, S; Karamanesht, I; Leleu, X; Moreau, P; Pylypenko, H; van de Velde, H | 1 |
| Anderson, KC; Benajiba, L; Fennessy, F; Laubach, J; Richardson, PG; Saboo, SS | 1 |
| Bladé, J; Cibeira, MT; de Larrea, CF; Escoda, L; Rosiñol, L; Rovira, M; Solé, M; Tovar, N | 1 |
| Brunetti, GA; Cartoni, C; Cupelli, L; D'Elia, GM; Efficace, F; Federico, V; Grammatico, S; Niscola, P; Petrucci, MT; Scaramucci, L; Tendas, A; Truini, A | 1 |
| Alimena, G; Breccia, M; Cartoni, C; Federico, V; Levi, A; Loglisci, G; Mansueto, G; Mercanti, C; Musto, P; Petrucci, MT | 1 |
| Molica, S | 1 |
| Hashimoto, S; Nakaseko, C; Sakai, S; Sakuma, I; Shimura, T; Takagi, T; Takeda, Y; Tanaka, H | 1 |
| Groll, M; Huber, EM | 1 |
| Bretz, J; Chen, I; Chen-Kiang, S; Di Liberto, M; Ely, S; Hahn, WC; Huang, X; Jayabalan, D; Liang, J; Louie, T; Moore, MA; Niesvizky, R; Randolph, S; Shaffer, AL; Staudt, LM | 1 |
| Kirk, CJ | 1 |
| Kapoor, P; Rajkumar, SV; Ramakrishnan, V | 1 |
| Broyl, A; Jongen, JL; Sonneveld, P | 1 |
| Goulston, C; Hanson, KE; Kim, JH; Lampas, M; Sanders, S; Tricot, G; Zangari, M | 1 |
| Guo, H; Shao, L; Sun, H; Xu, M; Zhou, X; Zhu, J | 1 |
| Guo, M; Hu, KX; Kang, Y; Qiao, JH; Sun, QY; Yu, CL; Zhao, YY | 1 |
| Haidl, F; Lund, T; Plesner, T | 1 |
| Abidi, MH; Abrams, J; Al-Kadhimi, Z; Ayash, L; Deol, A; Gul, Z; Lum, L; Mellon-Reppen, S; Ratanatharathorn, V; Uberti, J; Ventimiglia, M; Zonder, J | 1 |
| Dimopoulos, MA; Gkotzamanidou, M; Kastritis, E; Matsouka, C; Mparmparoussi, D; Nikitas, N; Psimenou, E; Roussou, M; Spyropoulou-Vlachou, M; Terpos, E | 1 |
| Blanco, JF; Collins, L; Garayoa, M; Garcia-Gomez, A; Hornick, MC; Hurchla, MA; Kirk, CJ; Li, A; Ocio, EM; Pandiella, A; Piwnica-Worms, D; San Miguel, JF; Tomasson, MH; Vij, R; Weilbaecher, KN | 1 |
| Fujiwara, S; Hata, H; Iyama, K; Izaki, M; Kawano, Y; Mitsuya, H; Okuno, Y; Sakai, A; Wada, N; Yamasaki, H; Yuki, H | 1 |
| Cai, X; Ding, K; Duan, Q; Han, Y; Liu, X; Sun, Z; Wang, A; Wu, J; Zhu, W | 1 |
| An, N; Chen, SL; Hu, Y; Li, X; Liu, XH; Sun, WJ; Zhang, JJ; Zhong, YP | 1 |
| Chen, M; Huang, BH; Li, J; Liu, JR; Xu, DR; Zheng, D; Zou, WY | 1 |
| Takamatsu, Y | 1 |
| Alegre, A; Besalduch, J; Bladé, J; Cibeira, MT; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Etxebeste, MA; González, Y; Granell, M; Gutiérrez, NC; Hernández, D; Hernández, MT; Lahuerta, JJ; López-Jiménez, J; Martín-Ramos, ML; Martínez, J; Mateos, MV; Oriol, A; Palomera, L; Rosiñol, L; San Miguel, J; Teruel, AI | 1 |
| Joshi, VR; Nagaraj, S; Sharma, V | 1 |
| Bertsch, U; Blau, IW; Bos, GM; Broyl, A; Duehrsen, U; El Jarari, L; Goldschmidt, HM; Hose, D; Jauch, A; Kersten, MJ; Lindemann, W; Lokhorst, HM; Pfreundschuh, M; Raymakers, R; Salwender, H; Schaafsma, MR; Scheid, C; Schmidt-Wolf, IG; Sonneveld, P; Stevens-Kroef, M; van der Holt, B; van der Velde, H; van Marwijk-Kooy, M; Vellenga, E; Weisel, KC; Wijermans, PW; Wittebol, S; Zweegman, S | 1 |
| Burlingame, AL; Hsu, GW; Mahrus, S; Nguyen, H; Shimbo, K; Trinidad, JC; Wells, JA | 1 |
| Crotty, TB; Dunne, O; Fennelly, D; Holian, J; Ward, F; Watson, A | 1 |
| Ahles, CP; Berenson, JR; Boccia, R; Bonavida, B; Chen, H; Crowley, J; Dreyer, MP; Kirk, DT; Kitto, A; Li, J; Li, M; Madden, E; Nichols, CM; Robinson, A; Sanchez, E; Swift, RA; Vescio, RA; Wang, CS; Waterman, GN; Yellin, O | 1 |
| Anderson, KC; Bobb, K; Carrasco, RD; Cirstea, D; Fabre, C; Gorgun, G; Hideshima, T; Hu, Y; Kong, SY; Meshulam, J; Mimura, N; Minami, J; Ohguchi, H; Richardson, PG; Tai, YT; Zhang, J | 1 |
| Bhaskar, B; Kassim, A; Paton, VE; Wamstad, K; White, D; Yi, J | 1 |
| Chung, HM; Clark, WB; Hazlett, AF; Kmieciak, M; Manjili, MH; McCarty, JM; Payne, KK; Roberts, CH; Sabo, RT; Sanford, K; Toor, AA; Williams, DC | 1 |
| Bacovsky, J; Langova, K; Minarik, J; Pika, T; Scudla, V | 1 |
| Amodio, N; Anderson, KC; Azab, AK; Blotta, S; Calimeri, T; Foresta, U; Jakubikova, J; Mitsiades, CS; Molica, S; Morabito, F; Munshi, NC; Neri, A; Roccaro, AM; Rossi, M; Tagliaferri, P; Tassone, P; Todoerti, K | 1 |
| Dennis, PA; Gills, JJ; Hollander, MC; Kawabata, S; Lopiccolo, J; Mercado-Matos, JR; Wilson, W | 1 |
| Bahlis, N; Belch, A; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; McDonagh, K; Siegel, DS; Stewart, AK; Vij, R; Wang, M; Wear, S; Wong, AF | 1 |
| Mehta, N; Niesvizky, R; Saxena, A | 1 |
| Berenson, JR; Eshaghian, S | 1 |
| Anderson, KC; Avet-Loiseau, H; Casassus, P; Decaux, O; Facon, T; Garderet, L; Godmer, P; Gouraud, W; Hulin, C; Lodé, L; Magrangeas, F; Marit, G; Minvielle, S; Moreau, P; Munshi, NC; Randriamalala, E; Stoppa, AM; Tiab, M; Voillat, L; Voog, E | 1 |
| Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S | 1 |
| Ai, L; Cui, G; Gowrea, B; Hu, Y; Li, M; Wang, Y | 1 |
| Du, HF; Lv, HY; Meng, J; Meng, YF; Song, XN; Yu, LJ; Zhang, JQ | 1 |
| Bargay, J; Bello, JL; Bengoechea, E; Bladé, J; de Arriba, F; García-Sanz, R; González, Y; Granell, M; Gutiérrez, N; Hernández, JM; Lahuerta, JJ; López de la Guía, A; López, J; Martín-Mateos, ML; Martínez-López, J; Mateos, MV; Oriol, A; Palomera, L; Peñalver, FJ; Pérez, M; Polo, M; Ribera, JM; San-Miguel, JF; Teruel, AI | 1 |
| Cockwell, P; Cook, M; Stringer, S | 1 |
| Bladé, J; Dimopoulos, MA; Kastritis, E | 1 |
| Cockwell, P; Cook, M | 1 |
| Haynes, R; Kyle, R; Leung, N; Winearls, CG | 1 |
| Bashir, Q; Bayraktar, UD; Champlin, RE; Ciurea, SO; Qazilbash, M | 1 |
| Baladandayuthapani, V; Berkova, Z; Bjorklund, CC; Davis, RE; Jones, RJ; Kuhn, DJ; Lin, P; Ma, W; Madden, TL; Orlowski, RZ; Shah, JJ; Thomas, SK; Wang, H; Wang, M; Weber, DM; Wei, C; Woessner, R | 1 |
| Fuchida, S; Haruyama, H; Hatsuse, M; Itoh, S; Murakami, S; Okano, A; Shimazaki, C | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Takashima, S; Yokota, N | 2 |
| Allen, JE; Aqui, N; Dicker, DT; Dolloff, NG; El-Deiry, WS; Malysz, J; Talamo, G; Vogl, D | 1 |
| Bockorny, B; Bockorny, M; Bona, R; Chakravarty, S; Schulman, P | 1 |
| Arbeille, B; Croué, A; Ifrah, N; Levaltier, X; Marchand, A; Martin, L | 1 |
| Jeong, SJ; Jung, JH; Kim, B; Kim, SH; Lee, MH; Sohn, EJ | 1 |
| Suzuki, K | 2 |
| Abbas, J; Costa, LJ; Kang, Y; Ortiz-Cruz, KL; Stuart, RK | 1 |
| Altun, M; Anderson, KC; Carrasco, R; Chauhan, D; Fulcinniti, M; Hideshima, T; Kessler, BM; Kingsbury, WD; Kodrasov, MP; Kumar, KG; Leach, CA; McDermott, JL; Minvielle, S; Munshi, N; Nicholson, B; Orlowski, R; Richardson, P; Shah, PK; Tian, Z; Weinstock, J; Zhou, B | 1 |
| Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L | 1 |
| Hashimoto, N; Hattori, Y; Kato, J; Koda, Y; Mori, T; Okamoto, S; Sadahira, K; Shimizu, T; Tsukada, Y; Yamane, A; Yokoyama, K | 1 |
| Botton, Sd; Boué, F; Bourhis, JH; Crickx, E; Danu, A; Ghez, D; Mariette, X; Miceli, C; Moreau, P; Pasquier, F; Ribrag, V; Wittnebel, S | 1 |
| Bruce, JT; Devine, SM; Elder, P; Hofmeister, CC; Mastronarde, JG; Phillips, G; Tran, JM; Wood, KL | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Lin, M; Meng, X; Shi, J; Wei, G; Wu, W; Xie, W; Yang, L; Ye, X; Zhang, J; Zheng, G; Zheng, W | 1 |
| Lee, KY; Levacque, Z; Rosales, JL | 1 |
| Arima, N; Kawada, H | 1 |
| Badros, A; Khan, RZ | 1 |
| Kim, JS; Lee, JW; Lee, MW; Roh, HS; Yu, HJ | 1 |
| Wang, X; Yao, C; Zhang, Z | 1 |
| Cakana, A; Deraedt, W; Domnikova, N; Doronin, VA; Esseltine, DL; Facon, T; Feng, H; Girgis, S; Hulin, C; Karamanesht, II; Kyselyova, MY; Leleu, X; Moreau, P; Schmidt, A; Skee, D; van de Velde, H; Venkatakrishnan, K; Vilchevska, KV | 1 |
| Alsina, M; Anderson, KC; Bladé, J; Cavenagh, J; Dalton, W; Danaee, H; Esseltine, DL; Façon, T; Lichter, DI; Lonial, S; Mulligan, G; Niesvizky, R; Pickard, MD; Ricci, D; Richardson, PG; Shi, H; Sintchak, M; Sonneveld, P; Tayber, O; Trepicchio, WL; van de Velde, H | 1 |
| Baran, Y; Sanlı-Mohamed, G; Turan, T | 1 |
| Cózar-Castellano, I; Joumady, I; Perdomo, G; Sáez-Benito, A; Tirado-Vélez, JM | 1 |
| Synhaeve, NE; Tijssen, CC; van der Heul, C | 1 |
| Akhundova, FM; Gal'tseva, IV; Gaponova, TV; Gretsov, EM; Kalinin, NN; Kuz'mina, LA; Mendeleeva, LP; Parovichnikova, EN; Pokrovskaia, OS; Savchenko, VG; Urnova, ES | 1 |
| Graef, T; Hardwick, JS; Hussein, M; Jagannath, S; Lupinacci, L; Schiller, GJ; Sobecks, RM; Weber, DM | 1 |
| Bahlis, N; Jagannath, S; Jakubowiak, AJ; Kunkel, LA; Lonial, S; Orlowski, RZ; Reiman, T; Siegel, DS; Somlo, G; Stewart, AK; Trudel, S; Vij, R; Wong, A | 1 |
| Adam, Z; Feit, J; Hájek, R; Krejčí, M; Mayer, J; Pour, L; Szturz, P; Vašků, V | 1 |
| Brown, CO; Goel, A; Salem, K; Schibler, J | 1 |
| Cavenagh, J; Joel, S; Maharaj, L; Oakervee, H; Popat, R | 1 |
| Heelan, K; McKenna, DB | 1 |
| Chari, A; Pri-Chen, H | 1 |
| Harvey, RD; Kaufman, JL; Surati, M; Walker, BF; Wilson, N | 1 |
| Cakana, A; Dmoszynska, A; Enny, C; Esteves, G; Feng, H; Greil, R; Hajek, R; Harousseau, JL; Ludwig, H; Masszi, T; Paiva, B; Ricci, D; Robinson, D; Shpilberg, O; Spicka, I; Stoppa, AM; van de Velde, H; Vidriales, MB; Viterbo, L | 1 |
| Boccadoro, M; Bringhen, S; Foà, R; Gentilini, F; Grammatico, S; Larocca, A; Levi, A; Palumbo, A; Petrucci, MT; Russo, S; Scotti, S; Siniscalchi, A | 1 |
| Aisa, Y; Ito, C; Mihara, A; Nakazato, T | 1 |
| Buda, G; Carulli, G; Cervetti, G; Galimberti, S; Ghio, F; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| De Bruyne, E; Hu, J; Menu, E; Schots, R; Van Valckenborgh, E; Vanderkerken, K; Xu, D | 1 |
| Kakpakova, ES; Kalitin, NN; Karamysheva, AF; Kostyukova, MN; Tupitsyn, NN | 1 |
| Chang, MX; Jia, G; Lu, H; Lu, YJ; Ma, YP; Zhang, L | 1 |
| Burbury, K; Doo, NW; Harrison, SJ; Joyce, T; Prince, HM; Ritchie, D; Seymour, JF; Stokes, K; Thompson, PA; Wolf, M | 1 |
| Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA | 1 |
| Burnett, CT; Santoro, FA | 1 |
| Cavalli, M; Chiarenza, A; Consoli, U; Conticello, C; Coppolino, F; Di Raimondo, F; Forte, S; Palumbo, GA; Romano, A; Uccello, G; Vetro, C | 1 |
| Bruno, B; Corradini, P; Dodero, A; Fanin, R; Montanari, M; Montefusco, V; Mussetti, A; Offidani, M; Patriarca, F; Scortechini, I; Sperotto, A; Spina, F; Valagussa, P | 1 |
| Wirk, B | 1 |
| Berenson, JR; Bessudo, A; Boccia, RV; Gorak, EJ; Gravenor, DS; Kewalramani, T; Mayo, D; Nassir, Y; Noga, SJ; Patel-Donnelly, D; Siegel, RS; Swift, RA; Yellin, O | 1 |
| Cao, B; Li, J; Mao, X | 1 |
| Bergsagel, PL; Gutierrez, NC; Mateos, MV; Rajkumar, SV; San Miguel, JF | 1 |
| Bakhanashvili, M; Beery, E; Bulvick, S; Cohen, O; Kanfer, G; Lahav, M; Magen-Nativ, H; Nordenberg, J; Ram, R; Shilo, N; Uziel, O; Weiss, C; Wolach, O | 1 |
| Ludwig, H; Sonneveld, P | 1 |
| Hashimoto, N; Okamoto, S; Sadahira, K; Tsukada, Y; Ueda, T; Yokoyama, K | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
| Ali, HA; Aßmann, M; Becker, C; Bourgeois, M; Edelmann, T; Hensel, G; Heyn, S; Hoffmann, FA; Hurtz, HJ; Jäkel, N; Krahl, R; Löschcke, K; Mohren, M; Moll, B; Niederwieser, D; Pönisch, W; Rohrberg, R; Schmalfeld, M; Schönfelder, U; Schwarzer, A; Wagner, I; Zehrfeld, T | 1 |
| Hildebrandt, GC; Panu, LD; Shahan, JL | 1 |
| Agosti, V; Amodio, N; Anderson, KC; Caraglia, M; Conforti, F; Di Martino, MT; Ferrarini, M; Foresta, U; Fulciniti, M; Gullà, AM; Leone, E; Leotta, M; Lionetti, M; Misso, G; Morabito, F; Munshi, NC; Neri, A; Pitari, MR; Rossi, M; Tagliaferri, P; Tassone, P | 1 |
| Benson, DM; Byrd, JC; Devine, SM; Dunavin, NC; Efebera, YA; Elder, P; Greenfield, C; Heerema, N; Hofmeister, CC; Ketcham, J; Merritt, L; Penza, S; Phillips, GS; Rieser, G; Rose, KS; Wei, L | 1 |
| Henry, RW; Hovde, S; Hurchla, MA; Lansdell, TA; Tepe, JJ; Weilbaecher, KN; Xiang, J | 1 |
| Cavenagh, J; Cook, G; Cook, M; Davies, F; Elliott, P; Gumbleton, T; Jacobson, E; Oakervee, H; Plesner, T; Popat, R | 1 |
| Anttila, P; Honkanen, T; Juvonen, V; Kairisto, V; Kuittinen, T; Lundán, T; Luukkaala, T; Opas, J; Pelliniemi, TT; Penttilä, K; Putkonen, M; Remes, K; Säily, M; Sikiö, A; Silvennoinen, R | 1 |
| Chihara, D; Iwama, K; Matsue, K; Nishida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Blumenreich, MS; Dispenzieri, A; Mauermann, ML; Staff, NP | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Kawanami, T; Masaki, Y; Miki, M; Motoo, Y; Nakajima, A; Nakajima, H; Nakamura, T; Okazaki, T; Sakai, T; Sato, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Cavallo, F; Palumbo, A | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Abdulkadyrov, KM; Anderson, KC; Cakana, A; Delforge, M; Deraedt, W; Dimopoulos, MA; Dmoszynska, A; Esseltine, DL; Jiang, B; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Petrucci, MT; Richardson, PG; Samoilova, OS; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; van de Velde, H | 1 |
| Camaschella, C; Campanella, A; Cenci, S; Fontana, F; Frenquelli, M; Marcatti, M; Santambrogio, P; Sitia, R; Tonon, G | 1 |
| Alsina, M; Anand, P; Anderson, KC; Baz, R; Bilotti, E; Chen, M; Doss, D; Ghobrial, IM; Jacques, C; Kelley, SL; Larkins, G; Laubach, J; Loughney, N; McBride, L; Munshi, NC; Nardelli, L; Richardson, PG; Schlossman, R; Siegel, D; Sullivan, D; Wear, S; Zaki, MH | 1 |
| Andrulis, M; Bargou, RC; Beilhack, A; Bogen, B; Bumm, T; Chatterjee, M; Einsele, H; Heimberger, T; Riedel, S; Schraud, H; Stühmer, T | 1 |
| Huang, BH; Li, J; Liu, JR; Su, C; Zheng, D; Zou, WY | 1 |
| Alexanian, R; Delasalle, K; Wang, M | 1 |
| Aggarwal, S; Bhargava, M; Khan, AA; Siraj, F | 1 |
| Chen, X; Hu, C; Huang, Q; Liu, B; Ma, Y; Miao, P; Qian, L; Shen, L; Wang, L; Wang, P; Yu, Q; Yuan, X; Zhang, D; Zhang, J | 1 |
| Binder, G; Borrello, I; Durie, B; Hussein, M; Khan, Z; Pashos, C | 1 |
| Grosicki, S | 1 |
| Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R | 1 |
| Doki, N; Endo, I; Kakihana, K; Kamata, N; Kobayashi, T; Kojima, A; Ohashi, K; Oshikawa, G; Sakamaki, H; Tsuda, H | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Atwal, S; D'Sa, S; Johnston, R; Khan, I; Moore, S; Narat, S; Percy, L; Rabin, N; Sachchithanantham, S; Schey, S; Streetly, M; Yong, K | 1 |
| Ba-Mancini, A; Henk, HJ; Huang, H; Teitelbaum, A | 1 |
| Ba-Mancini, A; Cakana, A; Chen, K; Corzo, D; Dhawan, R; Duh, MS; Garrison, LP; Huang, H; Korves, C; Shi, H; van de Velde, H; Wang, ST | 1 |
| McCarthy, PL | 1 |
| Lonial, S; Miguel, JF | 1 |
| Mina, R; Palumbo, A | 1 |
| Alsina, M; Anderson, KC; Bensinger, W; Biermann, JS; Cohen, AD; Devine, S; Djulbegovic, B; Faber, EA; Gasparetto, C; Hernandez-Illizaliturri, F; Huff, CA; Kassim, A; Krishnan, AY; Kumar, R; Liedtke, M; Meredith, R; Raje, N; Schriber, J; Shead, DA; Singhal, S; Somlo, G; Stockerl-Goldstein, K; Treon, SP; Weber, D; Yahalom, J; Yunus, F | 1 |
| Heider, U; Kaiser, MF; Mieth, M; Sezer, O; von Metzler, I; Zang, C | 1 |
| Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Bréchignac, S; Caillot, D; Decaux, O; Escoffre-Barbe, M; Facon, T; Fermand, JP; Garderet, L; Hennache, B; Hulin, C; Kolb, B; Leleu, X; Macro, M; Marit, G; Mathiot, C; Meuleman, N; Michallet, M; Moreau, P; Pegourie, B; Petillon, MO; Roussel, M; Royer, B; Stoppa, AM; Thielemans, B; Traulle, C | 1 |
| Anderson, JL; Anderson, KC; Görgün, GT; Hideshima, T; Laubach, J; Maguire, C; Munshi, NC; Raje, N; Richardson, PG; Whitehill, G | 1 |
| Fujiwara, S; Hata, H; Kawano, Y; Mitsuya, H; Nosaka, K; Okuno, Y; Yuki, H | 1 |
| Hoy, SM | 1 |
| Bae, SH; Chung, JS; Eom, HS; Jo, DY; Kim, HJ; Kim, JS; Kim, K; Kim, MK; Kim, SH; Kim, YS; Lee, HS; Lee, JH; Min, CK; Mun, YC; Suh, C; Yoon, SS | 1 |
| Ahn, JS; Bae, SY; Jung, SH; Kang, SJ; Kim, HJ; Kim, YK; Lee, JJ; Yang, DH | 1 |
| Chen-Kiang, S; Christos, PJ; Coleman, M; Ely, S; Jayabalan, DS; Lane, ME; Manco, M; Mark, TM; Mathews, L; Niesvizky, R; Pearse, RN; Pekle, K; Shore, TB; Skerret, D; Stern, J; Ward, M; Xiang, Z; Zafar, F | 1 |
| Admasie, J; Alici, E; Aschan, J; Barendse, M; Carlson, K; Deneberg, S; Liwing, J; Lund, J; Mellqvist, UH; Nahi, H; Uttervall, K | 1 |
| Jia, G; Ma, YP; Zhang, L | 1 |
| Collet, P; Marotte, H; Nizeica, V | 1 |
| Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Henzan, T; Iwasaki, H; Kamimura, T; Kato, K; Miyamoto, T; Muta, T; Ohno, Y; Takamatsu, Y; Takenaka, K; Teshima, T | 1 |
| Bladé, J; Cibeira, MT; Díaz, T; Fernández de Larrea, C; Martín-Antonio, B; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N; Urbano-Ispizua, A | 1 |
| Schenkein, D | 1 |
| Cheson, BD | 1 |
| Adams, J; Anderson, KC; Catley, LP; Goloubeva, O; Gupta, D; Hideshima, T; LeBlanc, R; Lentzsch, S; Mitsiades, CS; Mitsiades, N; Munshi, NC; Neuberg, D; Pien, CS; Richardson, PG | 1 |
| Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Treon, SP | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, NC; Podar, K; Richardson, P; Schlossman, R | 1 |
| Anderson, KC; Bailey, C; Chauhan, D; Fanourakis, G; Gu, X; Hideshima, T; Joseph, M; Libermann, TA; Mitsiades, CS; Mitsiades, N; Munshi, NC; Poulaki, V; Richardson, PG; Schlossman, R; Tai, YT | 1 |
| Anderson, KC | 6 |
| Barlogie, B; Shaughnessy, J; Tricot, G; Zangari, M | 1 |
| Mundy, GR; Oyajobi, BO | 1 |
| Adams, J; Altamirano, C; Berenson, JR; Borad, MJ; Frantzen, M; Friedman, JM; Ma, MH; Manyak, S; Mikail, A; Neeser, J; Parker, K; Roussos, E; Sjak-Shie, N; Vescio, RA; Wu, ZQ; Yang, HH | 1 |
| Mehta, J; Singhal, S | 1 |
| Alsina, M; Djulbegovic, B; Durie, BG; Kumar, A; Loughran, T | 1 |
| Cusack, JC | 1 |
| Richardson, P | 4 |
| Twombly, R | 1 |
| Hattori, Y | 1 |
| Mitchell, BS | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Hideshima, T; Irwin, D; Jagannath, S; Kauffman, M; Kuter, D; Lee, S; Limentani, SA; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, D; Singhal, S; Srkalovic, G | 1 |
| Frantz, S; Paramore, A | 1 |
| Gisslinger, H; Kees, M | 1 |
| Faix, JD | 1 |
| Meisler, AI | 1 |
| Dai, Y; Grant, S; Pei, XY | 2 |
| Berenson, JR; Schenkein, D; Vescio, R; Yang, HH | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, NC; Podar, K; Richardson, PG | 1 |
| Stanford, BL; Zondor, SD | 1 |
| Hu, WX; Shi, YW; Tang, LJ | 1 |
| Bross, PF; Farrell, AT; Kane, RC; Pazdur, R | 1 |
| Jákó, J; Mikala, G; Vályi-Nagy, I | 1 |
| Anderson, KC; Auclair, D; Chauhan, D; Chen, LB; Hideshima, T; Li, G; Mitsiades, C; Mitsiades, N; Munshi, N; Podar, K; Saxena, S | 1 |
| Barlogie, B | 1 |
| Kikuchi, S; Komatsu, N; Mori, M; Muroi, K; Noborio-Hatano, K; Ozawa, K; Takahashi, S; Takatoku, M | 1 |
| Chen, SL | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Gribble, GW; Hideshima, T; Honda, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R; Shringarpure, R; Sporn, MB; Suh, N; Tai, YT | 1 |
| Reddy, GK | 1 |
| Gilles, F; Goy, A | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Shringarpure, R; Yew, PR | 1 |
| Kaufman, J; Lonial, S | 1 |
| Adams, J | 2 |
| Anderson, KC; Chauhan, D; Cotter, FE; Hideshima, T; Li, G; Mitsiades, C; Munshi, N; Podar, K; Richardson, P; Schlossman, R | 1 |
| Abraham, S; Benson, K; Bradley, S; Bross, PF; Brower, ME; Farrell, AT; Gobburu, JV; Goheer, A; Kane, R; Lee, SL; Leighton, J; Liang, CY; Lostritto, RT; McGuinn, WD; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Verbois, SL; Wang, YC; Williams, G | 1 |
| Hatake, K; Mishima, Y; Terui, Y | 1 |
| Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Adams, J; Alexanian, R; Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Esseltine, DL; Irwin, D; Jagannath, S; Kauffman, M; Limentani, SA; Niesvizky, R; Richardson, PG; Schenkein, DP; Siegel, D | 1 |
| Anderson, KC; Chauhan, D; Hamasaki, M; Hideshima, H; Hideshima, T; Higgins, LS; Ishitsuka, K; Mitsiades, C; Munshi, NC; Navas, T; Nguyen, AN; Podar, K; Raje, N; Richardson, PG; Schreiner, G; Tai, YT | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Ishitsuka, K; Podar, K; Richardson, PG; Sattler, M; Shringarpure, R; Simoncini, M; Tai, YT | 1 |
| Kyle, RA; Rajkumar, SV | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Duff, SB; Gupta, S; Mehta, J | 1 |
| Anderson, KC; Burger, R; Catley, L; Chauhan, D; Denis, L; Hideshima, T; Munshi, NC; Podar, K; Richardson, P; Shringarpure, R; Son, MT; Tai, YT; Tassone, P | 1 |
| Aguado, B; Alegre, A; Bladé, J; Esparís-Ogando, A; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Schenkein, D | 1 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG | 2 |
| Davies, FE; Morgan, GJ | 1 |
| Hempstead, BL; Li, Y; Pearse, RN; Rafii, D; Swendeman, SL | 1 |
| Dalton, WS; Holle, L; Jung, L | 1 |
| Davidson, T; Schwartz, R | 1 |
| Alexanian, R; Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Jagannath, S; Nix, D; Orlowski, RZ; Richardson, PG; Singhal, S; Srkalovic, G | 1 |
| Carvajal-Vergara, X; Esparís-Ogando, A; Gutiérrez, N; López-Pérez, R; Mateo, G; Montero, JC; Pandiella, A; Parmo-Cabañas, M; San Miguel, JF; Tabera, S; Teixidó, J | 1 |
| Jung, W; Schroers, R; Zettl, F | 1 |
| Bruno, B; Fanin, R; Patriarca, F; Prosdocimo, S; Tomadini, V; Vasciaveo, A | 1 |
| Anderson, KC; Bonham, L; Chauhan, D; Hideshima, H; Hideshima, T; Ishitsuka, K; Kumar, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Singer, JW; Yasui, H | 1 |
| Crawford, CL | 1 |
| Bladé, J; Cibeira, MT; Montoto, S; Rosiñol, L | 1 |
| Berdel, WE; Bisping, G; Kienast, J; Kropff, MH; Tchinda, J; Volpert, S; Wenning, D | 1 |
| Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P | 1 |
| Engelhardt, M; Maier, W; Müller, AM; Wäsch, R | 1 |
| Chou, T | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Mitsiades, C; Richardson, P | 1 |
| Fuchida, SI; Inaba, T; Nakano, S; Namura, K; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R | 1 |
| Anderson, KC; Berkers, CR; Fiebiger, E; Galardy, PJ; Kessler, BM; Lichtman, E; Ovaa, H; Ploegh, HL; Verdoes, M | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Dorr, RT; Landowski, TH; Lynch, RM; Megli, CJ; Nullmeyer, KD | 1 |
| Jagannath, S | 3 |
| Anderson, KC; Bradner, JE; Chauhan, D; Hideshima, T; Richardson, P; Schreiber, SL; Wong, J | 1 |
| Agrawal, S; Cavenagh, JD; Curry, N; Drake, M; Esseltine, DL; Morris, C; Oakervee, HE; Popat, R; Schenkein, D; Smith, P; Stec, J | 1 |
| Camacho, E; Crowley, J; Durie, BG; Gabayan, E; Irwin, D; Jagannath, S; Lutzky, J; Mazumder, A; McKinley, M; Schenkein, D; Wolf, J | 1 |
| Dimopoulos, MA; Rahemtulla, A; Terpos, E | 1 |
| Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, J; Dalton, WS; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Porter, JB; Reece, D; Richardson, PG; San-Miguel, JF; Schenkein, D; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Agterof, MJ; Biesma, DH | 1 |
| Dispenzieri, A | 2 |
| Dispenzieri, A; Goel, A; Greipp, PR; Mesa, RA; Russell, SJ; Witzig, TE | 1 |
| Bankier, A; Drach, J; Kalhs, P; Krauth, MT; Valent, P | 1 |
| Lokhorst, HM; Sonneveld, P; van Wieringen, W; Vellenga, E; Wu, KL; Zweegman, S | 1 |
| Azizi, L; Bories, D; Coppo, P; Fouillard, L; Garderet, L; Gorin, NC; Paubelle, E | 1 |
| Heinrich, B | 1 |
| Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C | 1 |
| Chanan-Khan, A; Miller, KC | 1 |
| Anderson, KC; Barlogie, B; Berenson, J; Esseltine, D; Hideshima, T; Irwin, D; Jagannath, S; Rajkumar, SV; Richardson, PG; Schenkein, D; Singhal, S; Xiao, H | 1 |
| Bennett, F; Bodner, B; Bonish, BK; Chaturvedi, V; Hendrix, MJ; Miele, L; Nickoloff, BJ; Pollock, PM; Qin, JZ; Rizzo, P; Stennett, L; Trent, JM; Ziffra, J | 1 |
| Delaney, TF; Harmon, DC; Mohiuddin, MM | 1 |
| Apperley, JF; Karadimitris, A; Kotsianidis, I; Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Ahmad, K | 1 |
| Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Francis, D; Giusti, S; Giver, CR; Heffner, LT; Jagannath, S; Jaye, DL; Lonial, S; Orlowski, RZ; Richardson, PG; Schenkein, DP; Singhal, S; Torre, C; Waller, EK; Xiao, H | 1 |
| Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T | 1 |
| Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Bladé, J; Cibeira, MT; Rosiñol, L | 1 |
| Chen, J; David, E; Khuri, FR; Lonial, S; Sun, SY; Waller, EK | 1 |
| Alexandre, J | 1 |
| Altun, M; Anderson, KC; Galardy, PJ; Hideshima, T; Kessler, BM; LeBlanc, R; Ploegh, HL; Shringarpure, R | 1 |
| Anderson, KC; Farrell, AT; Pazdur, R | 1 |
| Musch, A | 1 |
| Anderson, KC; Carver, B; Chang, Y; Chauhan, D; He, D; Hideshima, T; Li, G; Mitsiades, N; Neri, P; Podar, K; Richardson, P; Schindler, J | 1 |
| Glasmacher, A; von Lilienfeld-Toal, M | 1 |
| Barlogie, B; Burns, MJ; Elice, F; Esseltine, D; Kang, SH; Lee, CK; Najarian, K; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Caccese, E; Cecchi, M; Messori, A | 1 |
| Facon, T; Giaccone, G; Khayat, D; Ludwig, H | 1 |
| Kroep, JR; Vandenbroucke, JP | 1 |
| Adam, Z; Gregora, E; Hájek, R; Klener, P; Maisnar, V; Schutzova, M; Scudla, V; Spicka, I; Straub, J; Vytrasová, M | 1 |
| Ferrant, A; Jacquemain, A; Knoops, L; Tennstedt, D; Theate, I; Van den Neste, E | 1 |
| Joshua, DE | 1 |
| Alexanian, R; Alsina, M; Anderson, K; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Limentani, S; Niesvizky, R; Rajkumar, SV; Richardson, PG; Schenkein, DP; Siegel, DT; Singhal, S; Srkalovic, G; Trehu, E | 1 |
| Frost, P; Gera, J; Lichtenstein, A; Shi, Y; Yan, H | 1 |
| Apperley, JF; Crawley, D; Lampert, I; Naresh, K; Politou, M; Rahemtulla, A; Terpos, E | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Harousseau, JL; Moreau, P | 1 |
| Sonneveld, P; Wu, KL | 1 |
| Akiyama, M; Anderson, KC; Bailey, C; Chauhan, D; Davies, FE; Gu, X; Hideshima, T; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Morgan, G; Munshi, NC; Poulaki, V; Richardson, PG; Rosen, NS; Shringarpure, R | 1 |
| Anderson, KC; Hideshima, T; Mitsiades, CS; Mitsiades, N; Richardson, PG | 1 |
| Anderson, KC; Richardson, PG | 1 |
| Anderson, KC; Berkers, C; Catley, L; Chao, TH; Chauhan, D; Hideshima, T; Letai, A; Li, G; Mitsiades, C; Mitsiades, N; Neuteboom, ST; Nicholson, B; Ovaa, H; Palladino, MA; Podar, K; Richardson, P; Velankar, M; Yasui, H | 1 |
| Bay, JO; Blay, JY; Rixe, O; Spano, JP | 1 |
| Bosi, A; Ciolli, S; Gigli, F; Leoni, F; Rigacci, L | 1 |
| Greipp, P | 1 |
| Berrebi, A | 1 |
| Buisson, JP; Magdelenat, H; Monneret, C | 1 |
| Saunders, G | 1 |
| Anderson, KC; Dammacco, F; Hideshima, T; Ishitsuka, K; Kumar, S; Nico, B; Raje, N; Ribatti, D; Richardson, PG; Roccaro, AM; Shiraishi, N; Vacca, A; Yasui, H | 1 |
| Bladé, J; Boccadoro, M; Cavenagh, J; Glasmacher, A; Jagannath, S; Lonial, S; Ludwig, H; Orlowski, RZ; San Miguel, J; Sonneveld, P | 1 |
| Fujii, T; Kami, M; Kawabata, M; Matsumura, T; Miyakoshi, S; Narimatsu, H; Oshimi, K; Ozawa, K; Sasaki, M; Takatoku, M; Taniguchi, S; Yuji, K | 1 |
| Adams, J; Berenson, JR; Jarutirasarn, SG; Lee, SP; Mapes, R; Morrison, B; Purner, M; Sadler, K; Schenkein, D; Swift, R; Vescio, RA; Wilson, J; Yang, HH | 1 |
| Dispenzieri, A; Geyer, SM; Goel, A; Greiner, S; Peng, KW; Russell, SJ | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| de la Loge, C; Dhawan, R; Dubois, D; Esseltine, D; Gupta, S; van de Velde, H; Viala, M | 1 |
| Jaehde, U; Scheulen, ME; Simons, S | 1 |
| Adachi, M; Hayashi, T; Ikeda, H; Ikeda, Y; Imai, K; Ishida, T; Nojima, M; Yasui, H | 1 |
| Murakami, H | 1 |
| Cho, CS; Eom, KS; Kim, CC; Kim, YJ; Lee, JW; Lee, S; Min, CK; Min, WS; Park, G | 1 |
| Chim, CS; Ooi, GC | 1 |
| De Raeve, H; Lambert, J; Rombouts, S; Schroyens, W; Van de Velde, A; Van de Voorde, K; Van Regenmortel, N | 1 |
| Hajek, R; Krejci, M; Krivanova, A; Pour, L; Vorlicek, J; Zdenek, A | 1 |
| Alsina, M; Anderson, KC; Barlogie, B; Berenson, J; Irwin, DH; Jagannath, S; Rajkumar, SV; Richardson, PG; Singhal, S; Srkalovic, G | 1 |
| Gaczynska, M; Osmulski, PA; Tan, X | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Kaufman, JL; Lonial, S; Sinha, R | 1 |
| Boise, LH; Carlson, LM; Gutman, DM; Harrington, WJ; Lee, KP; Obeng, EA | 1 |
| Colland, F | 1 |
| Bladé, J; Cibeira, MT; Laura, R; Montserrat, E; Salamero, O; Uriburu, C; Yantorno, S | 1 |
| Coiteux, V; Facon, T; Leleu, X | 1 |
| Badros, A; Gahres, N | 1 |
| Hussein, MA | 2 |
| Kyle, RA; Vincent Rajkumar, S | 1 |
| Fei, XM; Li, JY; Lin, RF; Liu, P; Lu, H; Shen, WY; Wu, YJ; Zhang, JF | 1 |
| Ferreri, AJ | 1 |
| Ayuk, FA; Corradini, P; Goldschmidt, H; Hegenbart, U; Kröger, N; Lokhorst, HM; Montefusco, V; Nagler, A; Perez-Simon, JA; Raymakers, RA; San Miguel, JF; van de Donk, NW; van Oers, MH; Verdonck, LF; Zijlmans, M | 1 |
| Kaufman, JL; Lonial, S | 1 |
| Handa, H; Murakami, H | 1 |
| Baccarani, M; Cangini, D; Cavo, M; Ceccolini, M; Perrone, G; Tacchetti, P; Tosi, P; Zamagni, E | 1 |
| Anderson, KC; Chakravarty, S; Dugar, S; Haghnazari, E; Henson, M; Hideshima, T; Higgins, LS; Kapoun, AM; Kerr, I; Luedtke, G; Ma, JY; Mavunkel, B; Medicherla, S; Navas, TA; Nguyen, AN; O'Young, G; Perumattam, J; Protter, AA; Reddy, M; Schreiner, GF; Stebbins, EG | 1 |
| Bohlius, J; Engert, A; Hülsewede, H; Kober, T | 1 |
| Hess, U | 1 |
| Farrell, AT; Kane, RC; Pazdur, R; Sridhara, R | 1 |
| Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A | 1 |
| Anderson, KC; Atadja, P; Catley, L; Chauhan, D; Hideshima, T; Kiziltepe, T; Munshi, NC; Neri, P; Tai, YT; Tassone, P; Weisberg, E | 1 |
| Atadja, P; Carvajal-Vergara, X; Gutiérrez, N; López-Pérez, R; Maiso, P; Mateo, G; Ocio, EM; Pandiella, A; San Miguel, JF | 1 |
| Alexanian, R; Alsina, M; Amato, AA; Anderson, KC; Barlogie, B; Berenson, J; Briemberg, H; Esseltine, D; Irwin, D; Jagannath, S; Limentani, S; Najarian, K; Orlowski, RZ; Rajkumar, SV; Richardson, PG; Schuster, M; Siegel, DS; Singhal, S; Srkalovic, G; Wen, PY | 1 |
| Devereux, S; Gupta, S; Mufti, GJ; Pagliuca, A; Schey, S | 1 |
| Bang, SM; Cho, KS; Jo, DY; Kim, CC; Kim, CS; Kim, K; Lee, JH; Lee, JJ; Lee, KH; Lee, NR; Min, CK; Min, YH; Park, S; Seong, CM; Sohn, SK; Suh, C; Yoon, HJ; Yoon, SS | 1 |
| Albanell, J; Montagut, C; Rovira, A | 1 |
| Goranov, SE; Goranova-Marinova, VS | 1 |
| Boccadoro, M; Bonifazi, F; Bruno, B; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Díaz-Mediavilla, J; Esseltine, DL; Fuertes, M; García-Laraña, J; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Swieboda-Sadlej, A | 1 |
| Ambrosini, MT; Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Cavallo, F; Falco, P; Falcone, A; Gay, F; Massaia, M; Musto, P; Palumbo, A; Rus, C; Scalzulli, PR | 1 |
| Cavenagh, J; Joel, S; Oakervee, H; Popat, R | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Cavenagh, JD | 1 |
| Bladé, J; San-Miguel, J | 1 |
| Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Irwin, D; Jagannath, S; Richardson, PG; Schenkein, DP; Singhal, S; Srkalovic, G | 1 |
| Berdel, WE; Bisping, G; Kienast, J; Kropff, M; Wenning, D | 1 |
| Amadori, S; Boccadoro, M; Caravita, T; de Fabritiis, P; Palumbo, A | 1 |
| Colson, K; Jagannath, S; Richardson, P | 1 |
| Nguyen, CA; Romaguera, J; Wang, M; Zhang, L; Zhou, Y | 1 |
| Burtrum, D; Ludwig, DL; Moore, MA; Wu, KD; Zhou, L | 1 |
| Armando, S; Nozza, A; Siracusano, L | 1 |
| Ascensao, JL; Batra, RB; Boyer, JE; Schechter, GP | 1 |
| Anderson, KC; Hunter, T; Joazeiro, CA | 1 |
| Hönemann, D; Kenealy, MK; Prince, HM | 1 |
| Inaba, T; Kobayashi, Y; Shimazaki, C; Taniwaki, M | 1 |
| Orlowski, RZ; Voorhees, PM | 2 |
| Arpaci, F; Ataergin, S; Cetin, T; Gunhan, O; Kaya, A; Kaya, T | 1 |
| Alloro, E; Brocca, MC; Coppi, MR; Mele, G; Pinna, S; Quarta, G | 1 |
| Hughes, M; Micallef-Eynaud, P | 1 |
| Hideshima, T; Yasui, H | 1 |
| Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Müller, C; Schulz, CO; Sezer, O; Zavrski, I | 1 |
| Davies, MJ | 1 |
| Barrick, M | 1 |
| Chen, LJ; Li, JY; Qian, SX; Zheng, WJ; Zhu, GR | 1 |
| Ali, R; Kurt, M; Ozan, U; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A | 1 |
| Moreau, P | 1 |
| Bours, V; Olivier, S; Robe, P | 1 |
| Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M | 1 |
| Arai, A; Koyama, T; Kurosu, T; Miki, T; Miura, O; Murakami, N; Oshikawa, G; Tohda, S | 1 |
| Anderson, K; Ghobrial, I; Mitsiades, C; Richardson, PG | 1 |
| Chang, H; Qi, X; Reece, D; Stewart, KA; Trieu, Y; Xu, W | 1 |
| Arenillas, L; Bladé, J; Cibeira, MT; Mercadal, S; Muntañola, A; Salamero, O | 1 |
| Alacacioglu, I; Ceneli, S; Demirkan, F; Lebe, B; Ozcan, MA; Ozsan, GH; Piskin, O; Turgut, N; Undar, B | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Ghobrial, I; Hideshima, T; Munshi, N; Podar, K; Raje, N; Richardson, P; Schlossman, R; Velankar, M | 1 |
| Cavallo, F; Esseltine, D; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Abonour, R; Juliar, BE; Smith, GG; Suvannasankha, A | 1 |
| Cabanillas, M; Peteiro, C; Toribio, J | 1 |
| Okamoto, S | 1 |
| Attal, M; Avet-Loiseau, H; Benboubker, L; Fuzibet, JG; Harousseau, JL; Hulin, C; Leleu, X; Moreau, P; Pegourie, B; Renaud, M; Stoppa, AM; Troncy, J | 1 |
| Heule, F; Lam, K; Sonneveld, P; Wu, KL | 1 |
| Watts, G | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Ackermann, J; Drach, J; Kaufmann, H; Küenburg, E; Ludwig, H; Odelga, V; Sagaster, V; Wieser, R; Zielinski, C; Zojer, N | 1 |
| Ballestrero, A; Brossart, P; Grünebach, F; Nencioni, A; Patrone, F | 2 |
| Anderson, KC; Cowan, JM; Facon, T; Harousseau, JL; Irwin, D; Jagannath, S; Richardson, PG; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Kenealy, M; Prince, HM | 1 |
| Avonto, I; Boccadoro, M; Bringhen, S; Magarotto, V; Palumbo, A | 1 |
| Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K | 1 |
| Gupta, V; Malani, AK; Rangineni, R | 1 |
| Borroni, G; Corso, A; Lazzarino, M; Mangiacavalli, S; Rosso, R; Varettoni, M; Vassallo, C; Zappasodi, P | 1 |
| Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y | 1 |
| Altavilla, G; Arrigo, C; Naro, C; Pitini, V | 1 |
| Chanan-Khan, AA; Kaufman, JL; Lonial, S; Mehta, J; Miller, KC; Munshi, NC; Richardson, PG; Schlossman, R; Singhal, S; Tariman, J | 1 |
| Biehn, SE; Dees, EC; Garcia, RA; Lehman, MJ; Moore, DT; Orlowski, RZ; Voorhees, PM | 1 |
| Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P | 1 |
| Aggarwal, BB; Bhardwaj, A; Bueso-Ramos, C; Gaur, U; Nair, AS; Sethi, G; Shishodia, S; Takada, Y; Vadhan-Raj, S | 1 |
| Ribatti, D; Vacca, A | 1 |
| Anderson, KC; Dammacco, F; Hideshima, T; Ribatti, D; Richardson, PG; Roccaro, AM; Russo, D; Vacca, A | 1 |
| Anderson, KC; Hideshima, T; Ikeda, H; Ishitsuka, K; Jin, J; Kiziltepe, T; Moss, N; Ocio, EM; Okawa, Y; Pargellis, C; Podar, K; Raje, N; Richardson, PG; Vallet, S; Yasui, H | 1 |
| Arrue, I; García-Romero, D; Rodríguez-Peralto, JL; Sánchez-Largo, ME; Sanz-Robles, H; Vanaclocha, F | 1 |
| Burton, AW; Cata, JP; Dougherty, PM; Giralt, S; Villareal, H; Weng, HR | 1 |
| Rukavitsyn, OA | 1 |
| Anderson, KC; Bergsagel, PL; Boral, A; Broyl, A; Bryant, B; Chng, WJ; Esseltine, DL; Fergus, A; Huang, Y; Koenig, E; Mitsiades, C; Mulligan, G; Richardson, P; Roels, S; Schenkein, D; Shaughnessy, JD; Sonneveld, P; Trepicchio, WL; Zhan, F | 1 |
| Dan, K; Gotoh, A; Hotta, T; Ikeda, Y; Ohyashiki, K; Oshimi, K; Usui, N | 2 |
| Bo, J; Da, WM; Gao, CJ; Huang, WR; Jing, Y; Li, R; Wang, QS; Wu, XX; Yu, L; Zhang, YZ | 1 |
| Daniels, TR; Feldman, R; Li, W; Lichtenstein, A; Maxwell, CA; Penichet, ML; Pilarski, L; Reiman, T; Sen, S; Shi, Y | 1 |
| Angitapalli, R; Dhodapkar, MV; Hutchinson, A; Jagannath, S; Kukreja, A; Mazumder, A; O'connor, OA; Vesole, D | 1 |
| Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S | 1 |
| Boral, AL; Esseltine, DL; Jakob, C; Mehta, J; Richardson, P; Sezer, O; Singhal, S; Stadtmauer, E; Vesole, DH | 1 |
| Kim, CC; Kim, M; Kim, Y; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS; Moon, SJ; Park, G | 1 |
| Cheriyath, V; Hussein, MA; Jacobs, BS | 1 |
| Boccadoro, M; Cavenagh, J; Dicato, M; Harousseau, JL; Ludwig, H; San Miguel, J; Sonneveld, P | 1 |
| Betlloch, I; Botella, C; Lucas, A; Mataix, J; Villarrubia, B | 1 |
| Stadtmauer, EA; Stoopler, ET; Vogl, DT | 1 |
| Charalambous, A; Dhodapkar, MV; Jagannath, S; Mazumder, A; Spisek, R; Vesole, DH | 1 |
| Mileshkin, L; Prince, HM; Schenkel, B | 1 |
| Engel, J; Fagbemi, S; Olatosi, B; Onitilo, AA | 1 |
| Berrebi, A; Duek, A; Feldberg, E; Haran, M | 1 |
| Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J | 1 |
| Burger, R; Gramatzki, M; Hahn, S; Herrmann, K; Herrmann, M; Jäck, HM; Meister, S; Neubert, K; Schreiber, S; Schubert, U; Voll, RE; Wilhelm, S | 1 |
| Chanan-Khan, AA; Manochakian, R; Miller, KC | 2 |
| Chew, E; Filshie, R; Wei, A | 1 |
| Low, E | 1 |
| Chen, YB; Fu, WJ; Hou, J; Xi, H; Yang, SL; Yuan, ZG; Zhou, F | 1 |
| Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Richardson, P; Schlossman, R | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Bonomini, S; Crugnola, M; Ferrari, L; Giuliani, N; Lazzaretti, M; Mancini, C; Martella, E; Morandi, F; Rizzoli, V; Tabilio, A; Tagliaferri, S | 1 |
| Boccadoro, M; Bruno, B; Carnevale-Schianca, F; Corradini, P; Fanin, R; Giaccone, L; Guidi, S; Mattei, D; Milone, G; Montefusco, V; Patriarca, F; Peccatori, J; Petrucci, MT; Rotta, M; Sorasio, R | 1 |
| Busemann, C; Dölken, G; Kiefer, T; Krüger, WH; Lotze, C; Schüler, F | 1 |
| Strobeck, M | 1 |
| Bergsagel, L; Bryant, B; Chng, WJ; Mulligan, G | 1 |
| Ahmann, G; Bergsagel, PL; Bryant, B; Carpten, J; Chng, WJ; Chung, TH; Dispenzieri, A; Fonseca, R; Gertz, M; Greipp, P; Henderson, K; Kim, S; Kumar, S; Kyle, R; Lacy, M; Mulligan, G; Price-Troska, T; Rajkumar, SV; Vanwier, S | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M | 1 |
| Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Iida, S; Yano, H | 1 |
| Janssen, JJ; Lokhorst, HM; Zweegman, S | 1 |
| Castagna, L; Mazza, R; Nozza, A; Rahal, D; Santoro, A; Sarina, B; Todisco, E | 1 |
| Anagnostopoulos, A; Bamias, A; Barmparousi, D; Dimopoulos, MA; Gika, D; Grapsa, I; Kastritis, E; Matsouka, C; Psimenou, E; Roussou, M | 1 |
| Croucher, P; Dimopoulos, MA; Sezer, O; Terpos, E | 1 |
| Germain, D; Ishii, Y; Waxman, S | 1 |
| Aggarwal, BB; Bhutani, M; Guha, S; Kunnumakkara, AB; Nair, AS; Pathak, AK; Sethi, G | 1 |
| Fang, B; Ma, J; Song, Y; Zhao, RC | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Abouladze, M; Baudard, M; Dreano, M; Goldschmidt, H; Hose, D; Jourdan, M; Klein, B; Mahtouk, K; Moreaux, J; Rème, T; Robert, N; Romanelli, A; Rossi, JF; Vos, JD | 1 |
| Amiot, M; Bataille, R; Gomez-Bougie, P; Ménoret, E; Philippe, M; Robillard, N; Trichet, V; Wuillème-Toumi, S | 1 |
| Burns, MJ; Cavallo, F; Elice, F; Esseltine, D; Neuwirth, R; Richardson, P; Sonneveld, P; Tricot, G; Yaccoby, S; Zangari, M | 1 |
| Brugnatelli, S; Brunetti, L; Corazza, GR; Gobbi, PG; Palladini, G; Perfetti, V; Sgarella, A | 1 |
| Alexanian, R; Delasalle, K; Giralt, S; Handy, B; Wang, M | 1 |
| Hulin, C | 1 |
| Antonio, S; Daniele, V; Enrico, O; Gabriele, B; Giulia, C; Mario, P; Nadia, C; Sara, G | 1 |
| Bhandari, M; Jagannath, S | 1 |
| Bocchia, M; Cerase, A; Fabbri, A; Gozzetti, A; Lauria, F; Pirrotta, MT; Tarantino, A | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ikeda, H; Ishitsuka, K; Kiziltepe, T; Ocio, EM; Okawa, Y; Pozzi, S; Raje, N; Shiraishi, N; Vallet, S; Yasui, H | 1 |
| Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Kleeberg, L; Krebbel, H; Manz, RA; Mieth, M; Sezer, O; Sterz, J; von Metzler, I | 1 |
| Barlogie, B; Crowley, J; van Rhee, F | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Bennett, MK; Chanan-Khan, AA; Chen, Q; Demo, SD; Kuhn, DJ; Orlowski, RZ; Shenk, KD; Strader, JS; Sun, CM; van Leeuwen, FW; Voorhees, PM | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Cottler-Fox, M; Crowley, J; Epstein, J; Gurley, J; Haessler, J; Hollmig, K; Jenkins, B; Mohiuddin, A; Petty, N; Pineda-Roman, M; Shaughnessy, JD; Steward, D; Sullivan, E; Tricot, G; van Rhee, F; Zangari, M | 1 |
| Anderson, K; Mitsiades, C; Munshi, N; Richardson, PG; Schlossman, R | 1 |
| Adena, M; Hertel, J; Prince, HM; Smith, DK | 1 |
| Dimopoulos, MA; Sezer, O; Terpos, E | 1 |
| Ali, R; Beksac, M; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A | 1 |
| Berdel, WE; Bisping, G; Dechow, T; Einsele, H; Engelhardt, M; Heinecke, A; Hentrich, M; Kienast, J; Kröger, N; Kropff, M; Lang, N; Liebisch, P; Metzner, B; Salwender, H; Schuck, E; Sezer, O; Volpert, S; Wolf, HH | 1 |
| Davies, FE; Kanagasabaphy, P; Morgan, GJ | 1 |
| Cohen, JI; Kawada, J; Pesnicak, L; Zou, P | 1 |
| Calderoni, A; Cornu, P; Freimann, H; Olie, R | 1 |
| Tobinai, K | 2 |
| Jack, A | 1 |
| Astori, C; Castagnola, C; Corso, A; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Davies, FE; Jenner, M; Morgan, GJ; Saso, R; Srikanth, M; Wu, P | 1 |
| Amiot, M; Anderson, KC; Chauhan, D; Gouill, SL; Harousseau, JL; Hideshima, T; Opferman, JT; Podar, K; Tai, YT; Zhang, J; Zorn, E | 1 |
| Akpek, G; Badros, A; Can, I; Dalal, JS; Fenton, RG; Goloubeva, O; Heyman, M; Rapoport, AP; Thompson, J | 1 |
| Baumann, P; Bumeder, I; Emmerich, B; Meinhardt, G; Schmidmaier, R; Straka, C | 1 |
| Astori, C; Castagnola, C; Corso, A; Dore, R; Lazzarino, M; Mangiacavalli, S; Varettoni, M; Zappasodi, P | 1 |
| Bladé, J; Dmoszynska, A; Hajek, R; Harousseau, JL; Horvath, N; Nagler, A; Orlowski, RZ; Parekh, T; Rackoff, W; Robak, T; San Miguel, J; Sonneveld, P; Spencer, A; Spicka, I; Sutherland, HJ; Suvorov, AN; Xiu, L; Yuan, Z; Zhuang, SH | 1 |
| Fassas, AB; Tricot, G | 1 |
| Alsina, M; Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, A; Cavenagh, J; Dalton, W; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Jakubowiak, A; Lacy, M; Lonial, S; Miguel, JS; Rajkumar, SV; Reece, D; Richardson, PG; Schenkein, D; Schuster, M; Sonneveld, P; Stadtmauer, E | 1 |
| Lü, SQ; Wang, JM; Yang, JM | 1 |
| Bensinger, W | 1 |
| Anderson, KC; Ghobrial, IM; Ghobrial, J; Hatjiharissi, E; Hideshima, T; Leleu, X; Mitsiades, C; Moreau, AS; Richardson, P; Roccaro, A; Schlossman, R | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, H; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Munshi, NC; Ocio, E; Okawa, Y; Podar, K; Raje, N; Richardson, PG; Tai, YT; Vallet, S; Yasui, H | 1 |
| Li, X; Pennisi, A; Sawyer, JR; Shaughnessy, JD; Yaccoby, S; Zhan, F | 1 |
| Drach, J; Graf, H; Lang, A; Ludwig, H; Meran, JG | 1 |
| Etxebarria, J; Hernández, E; Lopez, O; Mateos-Mazon, J; Pérez-Simón, JA; San Miguel, JF | 1 |
| Anderson, KC; Breitkreutz, I; Raab, MS | 1 |
| Alegre, A; Bladé, J; de la Rubia, J; García-Sánchez, P; Gutiérrez, N; Herrero, C; Lahuerta, JJ; Liu, X; Mateos, MV; Oriol, A; Rosiñol, L; San Miguel, J; Sureda, A; Van de Velde, H | 1 |
| Bialik, TE; Demina, EA; Falaleeva, NA; Gromova, EG; Kochergina, NV; Kupryshina, NA; Osmanov, DSh; Riabukhina, IuE; Timofeeva, OL; Votiakova, OM | 1 |
| Snively, A | 1 |
| Amen, K | 1 |
| McGee, L | 1 |
| Garber, K | 2 |
| Chim, CS; Wong, LG | 1 |
| Abe, M; Asano, J; Choraku, M; Fujii, S; Hashimoto, T; Kagawa, K; Kitazoe, K; Matsumoto, T; Miki, H; Ozaki, S; Shigekiyo, Y; Takeuchi, K; Tanaka, O | 1 |
| Kurtis, B; Lacouture, ME; Mekki, M; Newman, MA; Paiva, CM; Singhal, S | 1 |
| Daguindau, N; Feugier, P; Perrot, A; Tomowiak, C | 1 |
| Anderson, KC; Hayden, PJ; Mitsiades, CS; Richardson, PG | 1 |
| Anderson, G; Belani, C; Feng, R; Lentzsch, S; Mapara, MY; Oton, A | 1 |
| Cavenagh, JD; Oakervee, H; Popat, R | 1 |
| Moran, E; Nencioni, A | 1 |
| Barlogie, B; Garg, TK; Kellum, RE; Malaviarachchi, PA; Mulder, A; Shaughnessy, JD; Shi, J; Storrie, B; Szmania, SM; Tricot, GJ; van Rhee, F | 1 |
| Dytfeld, D; Komarnicki, M; Lewandowski, K; Matuszak, M | 1 |
| Ganser, A; Peest, D | 1 |
| Björkstrand, B; Gahrton, G | 1 |
| Ando, K; Hotta, T; Itoh, K; Kagami, Y; Kobayashi, Y; Maruyama, D; Minami, H; Morishima, Y; Nakata, M; Ogawa, Y; Ogura, M; Taji, H; Tobinai, K; Tsuchiya, T; Watanabe, T | 1 |
| Dammacco, F; Merchionne, F; Perosa, F | 1 |
| Chen, Q; Corringham, RE; Hunsucker, SA; Kuhn, DJ; Nemeth, JA; Orlowski, RZ; Small, GW; Strader, JS; Voorhees, PM; Zaki, MH | 1 |
| Iannitto, E; Minardi, V; Tripodo, C | 1 |
| Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L | 1 |
| Dimopoulos, MA; Kastritis, E; Mitsiades, CS; Richardson, PG | 1 |
| Anderson, KC; Brahmandam, M; Chauhan, D; Hideshima, T; Munshi, N; Palladino, MA; Podar, K; Richardson, P; Singh, A | 1 |
| Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R | 1 |
| Allievi, C; Berkers, C; Bernareggi, A; Bussolati, B; Camussi, G; Cassin, M; Coscia, M; Costa, G; de Feudis, P; di Giovine, S; Ferracini, R; Ferrero, D; Giai, V; Hunter, K; Inghirami, G; Jones-Bolin, S; Massaia, M; Neri, A; Nicoli, P; Ovaa, H; Palumbo, A; Peola, S; Pescalli, N; Pezzoni, G; Piva, R; Roato, I; Ruggeri, B; Strepponi, I; Tamagno, I; Williams, M; Zhao, H | 1 |
| Congdon, LM; Dorr, RT; Escalante, AM; Landowski, TH; Pourpak, A | 1 |
| Faiman, B | 1 |
| Bruns, I; Czibere, A; Fenk, B; Fenk, R; Graef, T; Haas, R; Kobbe, G; Michael, M; Neumann, F; Zohren, F | 1 |
| Handa, H; Murakami, H; Saitoh, T | 1 |
| Gotoh, A; Ohyashiki, K | 1 |
| Shimazaki, C | 1 |
| Takatoku, M | 1 |
| Kizaki, M | 1 |
| Mateos, MV; San Miguel, JF | 1 |
| Dagher, R; Farrell, AT; He, K; Justice, R; Ning, YM; Pazdur, R; Sridhara, R | 1 |
| Miwa, A | 1 |
| Davies, FE; Morgan, GJ; Srikanth, M | 1 |
| Eom, KS; Han, K; Kim, CC; Kim, M; Kim, Y; Lee, JW; Lee, MJ; Lee, S; Lim, J; Min, CK; Min, WS | 1 |
| Ambinder, RF; Barber, JP; Borrello, I; Brennan, S; Huff, CA; Jones, RJ; Lin, L; Matsui, W; McNiece, I; Peacock, C; Smith, BD; Wang, Q; Watkins, DN | 1 |
| Bladé, J; Cibeira, MT; Cid, MC; Filella, X; Lozano, E; Rosiñol, L; Rozman, M; Segarra, M | 1 |
| Blau, IW; Busse, A; Driessen, C; Keilholz, U; Kraus, M; Na, IK; Rietz, A; Scheibenbogen, C; Thiel, E | 1 |
| Barlogie, B; Bryant, B; Mulligan, G; Shaughnessy, JD; Zhan, F | 1 |
| Clay, D; Gauduchon, J; Marsaud, V; Renoir, JM; Seguin, A; Sola, B | 1 |
| DiPersio, JF; Fisher, NM; Peles, S; Tomasson, MH; Trivedi, R; Uy, GL; Vij, R; Zhang, QJ | 1 |
| Cavenagh, JD; Davies, FE; Jackson, GH; Morgan, GJ | 1 |
| Corral, J; de Arriba, F; Ferrer, F; González, M; Hernández-Espinosa, D; Martínez, C; Miñano, A; Mota, RA; Ordoñez, A; Pérez-Ceballos, E; Vicente, V | 1 |
| Berges, O; Decaudin, D; Kirova, YM; Servois, V | 1 |
| Anderson, KC; Ben-Yehuda, D; Bladé, J; Boccadoro, M; Boral, AL; Cavenagh, JD; Esseltine, DL; Facon, T; Goldschmidt, H; Harousseau, JL; Irwin, D; Lonial, S; Neuwirth, R; Reece, D; Richardson, PG; San-Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Anderson, KC; Carrasco, DR; Dranoff, G; Jinushi, M; Munshi, NC; Neuberg, D; Prabhala, RH; Ritz, J; Tai, YT; Vanneman, M | 1 |
| Dietrich, PY; Favet, L; Kerl, K; Piguet, V; Sanchez-Politta, S | 1 |
| Bocchia, M; Bucalossi, A; Cerase, A; Defina, M; Gozzetti, A; Lauria, F; Pirrotta, MT | 1 |
| Blaise, D; de Lavallade, H; El-Cheikh, J; Faucher, C; Fürst, S; Hardan, I; Michallet, M; Mohty, M; Nagler, A; Nicolini, FE; Revesz, D; Shimoni, A; Sobh, M | 1 |
| Anargyrou, K; Angelopoulou, MK; Christoulas, D; Dimitriadou, EM; Dimopoulos, MA; Kalpadakis, C; Kyrtsonis, MC; Masouridis, S; Panayiotidis, P; Pangalis, GA; Pouli, A; Sachanas, S; Terpos, E; Tsionos, K; Tzenou, T; Vassilakopoulos, TP | 1 |
| Bladé, J; Hajek, R; Harousseau, JL; Nagler, A; Orlowski, RZ; Robak, T; Sonneveld, P; Spencer, A; Zhuang, SH | 1 |
| Anaissie, E; Barlogie, B; Crowley, J; Haessler, J; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Zangari, M | 1 |
| Alegre, A; Bargay, J; Bladé, J; Carrera, D; de Arriba, F; de la Rubia, J; Esseltine, DL; Fuertes, M; García-Laraña, J; Garcia-Sanchez, P; García-Sanz, R; Gutiérrez, NC; Hernández, JM; Hernández, MT; Lahuerta, JJ; Mateo, G; Mateos, MV; Oriol, A; Palomera, L; Prósper, F; Ribas, P; San Miguel, JF; Sureda, A; Terol, MJ; van de Velde, H | 1 |
| Avonto, I; Boccadoro, M; Bringhen, S; Bruno, B; Callea, V; Caravita, T; Cascavilla, N; Falcone, A; Gay, F; Magarotto, V; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Ruggeri, M | 1 |
| Caligaris-Cappio, F; Cozza, S; Ferrarini, M; Nerini-Molteni, S; Sitia, R | 1 |
| Chim, CS; Hwang, YY; Shek, TW | 1 |
| Kami, M; Tsubokura, M | 1 |
| Cavenagh, JD; Curry, N; Drake, M; Esseltine, DL; Foot, N; Hallam, S; Morris, C; Oakervee, HE; Odeh, L; Popat, R | 1 |
| Aguirre Errasti, C; Alonso Alonso, JJ; Barreiro García, JG; Cánovas Fernández, A | 1 |
| Andersen, TL; Boissy, P; Delaissé, JM; Kupisiewicz, K; Lund, T; Plesner, T | 1 |
| Anderson, KC; Campbell, RM; Chauhan, D; Dios, AD; Hideshima, T; Ishitsuka, K; Kiziltepe, T; Munshi, N; Neri, P; Ocio, EM; Okawa, Y; Raje, N; Shen, Z; Shih, C; Shiraishi, N; Starling, JJ; Tamura, K; Tassone, P; Vallet, S | 1 |
| Bosi, A; Breschi, C; Casini, C; Ciolli, S; Leoni, F; Santini, V | 1 |
| Ding, Y; Huang, BH; Li, J; Luo, SK; Peng, AH; Su, C; Tong, XZ; Wang, HH; Zhao, Y; Zheng, D | 1 |
| Anaissie, E; Barlogie, B; Crowley, J; Epstein, J; Hoering, A; Petty, N; Pineda-Roman, M; Shaughnessy, J; Szymonifka, J; van Rhee, F; Zangari, M | 1 |
| Encinas García, S; Izarzugaza Perón, Y; Khosravi Shahi, P; Pérez Manga, G; Sabin Domínguez, P | 1 |
| Li, X; Pennisi, A; Yaccoby, S | 1 |
| López-Pérez, R; Montero, JC; Pandiella, A; San Miguel, JF | 1 |
| Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O | 1 |
| Barmparousi, D; Dimopoulos, MA; Grapsa, I; Kastritis, E; Matsouka, C; Migkou, M; Psimenou, E; Roussou, M; Terpos, E | 1 |
| Dimopoulos, MA; Roussou, M; Terpos, E | 1 |
| Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L | 1 |
| Gladney, SP; Kaufman, JL; Lonial, S | 1 |
| Adams, J; Anderson, KC; Chauhan, D; Elliott, PJ; Hideshima, T; Palombella, VJ; Richardson, P | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Richardson, P; Schlossman, R | 1 |
| Berenson, JR; Ma, HM; Vescio, R | 1 |
| Adams, J; Anderson, KC; Castro, A; Chauhan, D; Dang, L; Hayashi, T; Hideshima, T; Mitsiades, C; Mitsiades, N; Munshi, N; Palombella, V; Richardson, P | 1 |
353 review(s) available for pyrazines and Kahler Disease
| Article | Year |
|---|---|
Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Vincristine | 2013 |
Molecular pathogenesis of multiple myeloma: basic and clinical updates.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosomes, Human; Cyclin D; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin M; Incidence; Multiple Myeloma; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Risk Factors; Sex Factors; Somatic Hypermutation, Immunoglobulin; Survival Rate; Translocation, Genetic; Trisomy; United States | 2013 |
Continuous treatment with new agents for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
[Proteasome inhibitors in treatment of multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2013 |
Bortezomib for the treatment of previously untreated multiple myeloma.
Topics: Boronic Acids; Bortezomib; Drug Evaluation; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction | 2013 |
Boron chemicals in diagnosis and therapeutics.
Topics: Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Fluorescent Dyes; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Immune System; Immunotherapy; Lenalidomide; Multiple Myeloma; Oligopeptides; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Thalidomide | 2013 |
Diagnosis and therapy of multiple myeloma.
Topics: Age Factors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Current treatments for renal failure due to multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Transplantation; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2013 |
Effects of bortezomib on the immune system: a focus on immune regulation.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immune System; Multiple Myeloma; Pyrazines | 2013 |
Safety and effectiveness of low-dose lenalidomide therapy for multiple myeloma complicated with bortezomib-associated interstitial pneumonia.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstitial; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
[Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Multiple Myeloma; Polyneuropathies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines | 2013 |
Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
[Multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Prognosis; Pyrazines; Thalidomide | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Retreatment; Thalidomide | 2013 |
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate | 2013 |
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2014 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
Second autologous transplant as salvage therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Humans; Interferon-alpha; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Reoperation; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Clinical translation in multiple myeloma: from bench to bedside.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2013 |
Initial treatment of transplant candidates with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Medicine; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
New developments in post-transplant maintenance treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Postoperative Period; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Role of consolidation therapy in transplant eligible multiple myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide | 2013 |
Allogeneic transplantation in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Gamma Rays; Graft vs Host Disease; Histocompatibility Testing; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous | 2014 |
The effects of bortezomib on bone disease in patients with multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Evidence-Based Medicine; Humans; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Pyrazines; Signal Transduction | 2014 |
Role of consolidation/maintenance therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients.
Topics: Angiogenesis Inhibitors; Autografts; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Remission Induction; Thalidomide; Time Factors; Transplantation Conditioning | 2013 |
Future agents and treatment directions in multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines | 2014 |
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
Topics: Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Bortezomib-induced acute congestive heart failure: a case report and review of literature.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Heart Failure; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2014 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors | 2014 |
Monoclonal antibodies currently in Phase II and III trials for multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Microenvironment | 2014 |
Bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines | 2014 |
Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2014 |
Linking the activity of bortezomib in multiple myeloma and autoimmune diseases.
Topics: Animals; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Drug Design; Humans; Multiple Myeloma; Neoplasm Staging; Proteasome Inhibitors; Pyrazines | 2014 |
An analysis of the safety profile of proteasome inhibitors for treating various cancers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasms; Proteasome Inhibitors; Pyrazines | 2014 |
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Hematologic Diseases; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Pneumonia; Proteasome Inhibitors; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome | 2014 |
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2015 |
Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Induction Chemotherapy; Multiple Myeloma; Neoadjuvant Therapy; Neutropenia; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Humans; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Signal Transduction; Ubiquitin-Protein Ligase Complexes; Ubiquitin-Protein Ligases; Ubiquitin-Specific Proteases; Ubiquitination | 2014 |
Overcoming bortezomib resistance in multiple myeloma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines | 2014 |
Novel agents in CNS myeloma treatment.
Topics: Animals; Blood-Brain Barrier; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence | 2013 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2011 |
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Recurrence | 2011 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System Diseases; Oligopeptides; Pyrazines; Recurrence; Thalidomide; Venous Thromboembolism | 2011 |
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2011 |
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Thalidomide; Translocation, Genetic | 2014 |
Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Bortezomib for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2014 |
Pomalidomide for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Thalidomide | 2014 |
[Supportive care in multiple myeloma for continuing anti-myeloma therapies].
Topics: Anemia; Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Humans; Hypercalcemia; Kidney Diseases; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2014 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
[Treatment of untreated multiple myeloma patients ineligible for autologous stem cell transplantation].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Practice Guidelines as Topic; Prednisone; Pyrazines; Risk Factors; Thalidomide | 2014 |
[Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Topics: Administration, Oral; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide | 2014 |
Current treatment landscape for relapsed and/or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2015 |
Targeting the bone marrow microenvironment in multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Microenvironment | 2015 |
Treatment-related symptom management in patients with multiple myeloma: a review.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Multiple Myeloma; Oligopeptides; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Quality of Life; Thalidomide | 2015 |
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Europe; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Thalidomide | 2015 |
Treatment of plasma cell dyscrasias with lenalidomide.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Pyrazines; Renal Insufficiency; Thalidomide; Thromboembolism; Waldenstrom Macroglobulinemia | 2008 |
Maintenance treatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Stem Cell Transplantation; Survival Analysis; Thalidomide | 2008 |
Pathogenesis and treatment of renal failure in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Frontline treatment of multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Health Services for the Aged; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate; Thalidomide | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Bortezomib: a novel chemotherapeutic agent for hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrazines | 2008 |
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Risk Factors | 2008 |
Bortezomib in the front-line treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2008 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2008 |
[Clinical implications of bortezomib in frontline treatment of newly-diagnosed multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Transplantation; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Transplantation, Homologous | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
The role of novel drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
[Treatment for multiple myeloma: current status and future strategy in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Immunologic Factors; Japan; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide; Time Factors; Transplantation, Autologous | 2008 |
Advances in therapy of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous; Treatment Outcome | 2008 |
Novel targets for myeloma bone disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Denosumab; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; RANK Ligand | 2008 |
Practical considerations for multiple myeloma: an overview of recent data and current options.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2008 |
Pathogenesis of myeloma bone disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Denosumab; Fractures, Spontaneous; Glucocorticoids; Humans; Hypercalcemia; Immunologic Factors; Interleukins; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteoclasts; Osteolysis; Pyrazines; RANK Ligand; Stromal Cells; Wnt Proteins | 2009 |
The persisting challenge of selective and specific proteasome inhibition.
Topics: Boronic Acids; Bortezomib; Catalytic Domain; Drug Design; Humans; Models, Molecular; Molecular Structure; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Pyrazines | 2009 |
Diagnosis and the current trends in multiple myeloma therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2008 |
Treatment of multiple myeloma in the targeted therapy era.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning | 2009 |
Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2009 |
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide | 2009 |
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines | 2009 |
[Multiple myeloma].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Boronic Acids; Bortezomib; Diphosphonates; Fractures, Bone; Humans; Hypercalcemia; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib: a review of its use in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2009 |
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Waldenstrom Macroglobulinemia | 2009 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Genetic Predisposition to Disease; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Proteasome inhibitors in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lactones; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Pyrroles | 2009 |
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide; Treatment Outcome | 2009 |
Characteristics, pathogenesis, and novel treatments for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Translocation, Genetic | 2004 |
Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2004 |
Proteasome inhibition for treatment of multiple myeloma: clinical update.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2004 |
Novel therapies in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2009 |
Multiple myeloma, painful neuropathy, acupuncture?
Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pain; Pain Management; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2009 |
[Hematopoietic stem cell transplantation for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Doxorubicin; Drug Discovery; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vincristine | 2009 |
[New treatment strategies for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Diagnosis, Differential; Doxorubicin; Drug Discovery; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisolone; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide; Vincristine | 2009 |
[IgA pemphigus accompanying multiple myeloma has disappeared following the treatment with bortezomib (Velcade), cyclophosphamide and dexamethasone. Case study and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin A; Multiple Myeloma; Paraproteinemias; Pemphigus; Pyrazines; Skin Diseases, Vesiculobullous | 2009 |
How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
Topics: Acute Kidney Injury; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Comorbidity; Disease Management; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Peripheral Nervous System Diseases; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning; Venous Thrombosis | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
Novel therapies for relapsed myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drugs, Investigational; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mice; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Nitrogen Mustard Compounds; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Salvage Therapy; Thalidomide | 2009 |
ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Evidence-Based Medicine; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Interferon-alpha; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Future directions in immunomodulatory therapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2010 |
New treatments for myeloma.
Topics: Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Neoplasm Staging; Prednisone; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide | 2010 |
Osteoblastogenesis and tumor growth in myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Intercellular Signaling Peptides and Proteins; Models, Biological; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Tumor Burden | 2010 |
Bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2010 |
Current multiple myeloma treatment strategies with novel agents: a European perspective.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Decision Making; Decision Trees; Humans; Kidney Failure, Chronic; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2010 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Recurrence; Thalidomide | 2010 |
Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrazines; Recurrence; Thalidomide | 2010 |
How best to use new therapies in multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Glucocorticoids; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence | 2010 |
[Molecular-targeted therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Drug Delivery Systems; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2010 |
Role of autologous stem cell transplantation in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Patient Selection; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Current status of bortezomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Kidney Failure, Chronic; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Stromal Cells; Transplantation, Autologous | 2007 |
Treatment of relapsed and refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2009 |
Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Plasma Cells; Pyrazines; Retreatment; Switzerland; Thalidomide | 2010 |
Management of treatment-related adverse events in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disorders of Excessive Somnolence; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Venous Thromboembolism | 2010 |
Multiple myeloma - current issues and controversies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2010 |
Optimising patient outcomes in myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Management; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Risk Assessment; Thalidomide; Treatment Outcome | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Transcription, Genetic | 2010 |
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2010 |
Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Dura Mater; Fatal Outcome; Humans; Lenalidomide; Male; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
Drug-mediated and cellular immunotherapy in multiple myeloma.
Topics: Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cancer Vaccines; Combined Modality Therapy; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunologic Memory; Immunotherapy; Immunotherapy, Active; Immunotherapy, Adoptive; Killer Cells, Natural; Lenalidomide; Multiple Myeloma; Pyrazines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Thalidomide; Tumor Escape | 2010 |
Plasma cell leukaemia and other aggressive plasma cell malignancies.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2010 |
[Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transplantation, Homologous | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Survival Rate; Sweden; Thalidomide | 2010 |
[Current treatment strategies for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide | 2010 |
[Study on natural products for drug development].
Topics: Animals; Antineoplastic Agents; Aspergillus; Axinella; Biological Products; Boronic Acids; Bortezomib; Drug Design; Enzyme Inhibitors; Humans; Imidazoles; Indole Alkaloids; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteins; Pyrazines; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases | 2010 |
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Risk Assessment; Risk Factors; Thalidomide; Treatment Outcome | 2010 |
[Proteasome inhibitors].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2010 |
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Topics: Boronic Acids; Bortezomib; Glomerular Filtration Rate; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Thalidomide; Transplantation, Autologous | 2010 |
Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Plasma cell leukemia: concepts and management.
Topics: Aged; Antigens, CD20; Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Humans; Lenalidomide; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasms, Second Primary; Palliative Care; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Hypercalcemia; Immunologic Factors; Lenalidomide; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2011 |
Ten years of improvement in the management of multiple myeloma: 2000-2010.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Clinical impact of chromosomal aberrations in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Graft vs Host Disease; Humans; Immunomodulation; Models, Animal; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2011 |
Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation | 2012 |
Management of older patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Primary Myelofibrosis; Protease Inhibitors; Pyrazines; Thalidomide | 2011 |
Treatment of newly diagnosed myeloma in patients not eligible for transplantation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
[Classification and synthesis of ubiquitin-proteasome inhibitor].
Topics: Acetylcysteine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Dipeptides; Humans; Multiple Myeloma; Peptides, Cyclic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2009 |
Treatment of newly diagnosed multiple myeloma in transplant-eligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Female; Humans; Male; Medical Oncology; Multiple Myeloma; Neoplasm Staging; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Medical Oncology; Models, Biological; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide | 2011 |
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Congresses as Topic; Disease-Free Survival; Europe; Evidence-Based Practice; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2011 |
[Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chronic Disease; Combined Modality Therapy; Dexamethasone; Down-Regulation; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin lambda-Chains; Kidney Diseases; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Remission Induction; Renal Dialysis; Transplantation, Autologous | 2011 |
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.
Topics: ADAM Proteins; ADAMTS13 Protein; Boronic Acids; Bortezomib; Female; Fever of Unknown Origin; Humans; Middle Aged; Multiple Myeloma; Purpura, Thrombotic Thrombocytopenic; Pyrazines | 2011 |
Novel drugs in myeloma: harnessing tumour biology to treat myeloma.
Topics: Alkylating Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromatin; Histone Deacetylase Inhibitors; Humans; Janus Kinase 2; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Unfolded Protein Response; Wnt Proteins | 2011 |
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Standard of Care; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2011 |
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
[New insights in the treatment of myeloma with renal failure].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Contraindications; Cyclophosphamide; Dexamethasone; Fluid Therapy; Humans; Hypercalcemia; Immunoglobulin Light Chains; Kidney Failure, Chronic; Lenalidomide; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Myeloma Proteins; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Renal Dialysis; Thalidomide | 2011 |
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Topics: Antineoplastic Agents, Phytogenic; Bone and Bones; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Multiple Myeloma; Osteoblasts; Osteoclasts; Protease Inhibitors; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; Wnt Proteins | 2011 |
Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines; Risk; Thalidomide; Venous Thromboembolism | 2011 |
A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Humans; Kidney; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2011 |
Bortezomib for previously untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic | 2011 |
Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Transplantation, Autologous | 2012 |
Genomic stratification of multiple myeloma treated with novel agents.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Genomics; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2012 |
[Current treatment strategies with novel agents for multiple myeloma].
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous | 2011 |
Bortezomib for previously untreated multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2011 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy | 2012 |
Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.
Topics: Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship | 2012 |
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2011 |
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Cyclophosphamide; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide | 2011 |
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Early Diagnosis; Humans; Immunologic Factors; Incidence; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
Impact of bortezomib on bone health in myeloma: a review of current evidence.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Osteogenesis; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
[Thrombotic complications following the treatment of multiple myeloma with new agents].
Topics: Anthracyclines; Anticoagulants; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Thrombosis | 2011 |
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Prednisone; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
Proteasome inhibitors: an expanding army attacking a unique target.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lactones; Multiple Myeloma; Peptides, Cyclic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide; Treatment Outcome | 2012 |
Latest advances and current challenges in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Prognosis; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Thalidomide | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Evidence-Based Practice; Hematology; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Grading; Practice Guidelines as Topic; Pyrazines; Societies, Medical; Thalidomide | 2012 |
European perspective on multiple myeloma treatment strategies: update following recent congresses.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Congresses as Topic; Europe; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Proteasome inhibitors in multiple myeloma: 10 years later.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Humans; Medical Oncology; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Time Factors | 2012 |
[Development and clinical application of novel proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Drug Design; Drug Therapy, Combination; Drug Tolerance; Lymphoma; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
Topics: Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Drug Discovery; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Subunits; Pyrazines; T-Lymphocytes | 2012 |
Discovery and development of second-generation proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Structure-Activity Relationship | 2012 |
Bortezomib combination therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Quality of Life | 2012 |
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Induction Chemotherapy; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2012 |
Multiple myeloma: improved outcomes with new therapeutic approaches.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Achieving an early myeloma response in patients with kidney impairment.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Glomerular Filtration Rate; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Multiple Myeloma; Oligopeptides; Pyrazines; Thalidomide | 2012 |
The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Dialysis | 2012 |
Myeloma kidney: improving clinical outcomes?
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Multiple Myeloma; Plasma Exchange; Prognosis; Proteasome Inhibitors; Pyrazines; Renal Dialysis; Stem Cell Transplantation | 2012 |
Fifty years of melphalan use in hematopoietic stem cell transplantation.
Topics: Adenine Nucleotides; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Graft Survival; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Middle Aged; Multiple Myeloma; Myocarditis; Proteasome Inhibitors; Pyrazines | 2012 |
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.
Topics: Aged; Amyloidosis; Bence Jones Protein; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light-chain Amyloidosis; Kidney; Lenalidomide; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Renal Insufficiency; Thalidomide | 2012 |
[Update on treatment of multiple myeloma: including myeloma kidney and molecular targeting drugs].
Topics: Boronic Acids; Bortezomib; Drug Design; Humans; Immunologic Factors; Kidney Neoplasms; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Plasmacytoma; Pyrazines; Thalidomide | 2012 |
Distinct variant of Sweet's syndrome: bortezomib-induced histiocytoid Sweet's syndrome in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome | 2012 |
Dissecting bortezomib: development, application, adverse effects and future direction.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Drug Resistance, Neoplasm; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2013 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Time Factors | 2012 |
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comprehension; Drug-Related Side Effects and Adverse Reactions; Humans; Kinetics; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Time Factors | 2012 |
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy; Humans; Lenalidomide; Medical Oncology; Melphalan; Models, Biological; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Risk; Thalidomide; Treatment Outcome | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Carfilzomib (Kryprolis) for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Pyrazines | 2012 |
[Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines | 2012 |
Bortezomib-induced posterior reversible encephalopathy syndrome in a patient with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Recovery of Function; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2013 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
Induction therapy for newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Part II: role of maintenance therapy in transplant-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Vincristine | 2013 |
Subcutaneous bortezomib: in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Injections, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Proteasome inhibitors in the treatment of B-cell malignancies.
Topics: Acetylcysteine; Animals; Boronic Acids; Bortezomib; Cell Cycle Proteins; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzymes; Gene Expression Regulation; Hodgkin Disease; Humans; Leukemia, B-Cell; Leupeptins; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Mice; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Oncogene Proteins; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Substrate Specificity; Transcription Factors; Treatment Outcome | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
Moving disease biology from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Endothelial Growth Factors; Humans; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Interferons; Killer Cells, Natural; Lymphokines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Signal Transduction; Stem Cell Transplantation; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
High-dose therapy and immunomodulatory drugs in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gene Expression Profiling; Humans; Interferons; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2002 |
Novel therapies in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2003 |
Management of multiple myeloma: a systematic review and critical appraisal of published studies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Clinical update: proteasome inhibitors in hematologic malignancies.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Down-Regulation; Drug Administration Schedule; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Dexamethasone; Drug Therapy, Combination; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Thalidomide | 2003 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
Bortezomib treatment for multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Pyrazines | 2003 |
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Approval; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2003 |
[Proteasome inhibition: a new therapeutic approach for the treatment of multiple myeloma].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Cysteine Endopeptidases; Drug Administration Schedule; Enzyme Inhibitors; Humans; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic | 2004 |
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arkansas; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Protease Inhibitors; Pyrazines; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Universities | 2003 |
Bortezomib and its role in the management of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Clinical Trials as Topic; Cysteine Endopeptidases; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Models, Biological; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Multiple myeloma: the role of transplant and novel treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2004 |
The development of proteasome inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Ubiquitins | 2004 |
A review of the proteasome inhibitor bortezomib in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Dexamethasone; Humans; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[Proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Kidney Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Humans; Lenalidomide; Multiple Myeloma; Paraproteinemias; Protease Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide | 2004 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Proteasome inhibition in the treatment of cancer.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cyclins; Drug Evaluation, Preclinical; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Evolving treatment strategies for myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Discovery, Development, and clinical applications of bortezomib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors | 2004 |
Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors | 2004 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid | 2005 |
Clinical update: novel targets in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
Proteasome inhibitor therapy in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Treatment of myeloma in patients not eligible for transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Pyrazines; Salvage Therapy; Thalidomide | 2005 |
Proteasome inhibitors in cancer therapy.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Novel approaches to the management of myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Doxorubicin; Humans; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Transplantation, Autologous; Vincristine | 2005 |
Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2005 |
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Models, Molecular; Multiple Myeloma; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured | 2005 |
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Therapy; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Stem Cell Transplantation; Transplantation, Autologous | 2005 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Immunosuppressive Agents; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Treatment Outcome; Vincristine | 2005 |
Proteasome inhibitors as therapeutics.
Topics: Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Bortezomib: a novel therapy approved for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2003 |
Proteasome inhibition: a new approach for the treatment of malignancies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Primates; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rodentia | 2005 |
Treatment paradigms for the newly diagnosed patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2005 |
Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; Interleukin-6; Lenalidomide; Models, Immunological; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2005 |
[A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin | 2005 |
Overview of drug therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide | 2005 |
A practical update on the use of bortezomib in the management of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Survival Analysis; Thrombocytopenia | 2006 |
[Bortezomib].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Humans; Kidney Neoplasms; Leukemia; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Pyrazines | 2006 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Drug Design; Humans; Ligands; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Substrate Specificity | 2006 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drug Design; Heat-Shock Proteins; Histones; Humans; Lenalidomide; Multiple Myeloma; Oncogene Protein v-akt; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Recurrence; Remission Induction; Signal Transduction; Thalidomide | 2006 |
[Prognostic factors and new treatments of multiple myeloma].
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Pharmacotherapy of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2006 |
Treatment of multiple myeloma: an emphasis on new developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Proteasome inhibition: novel therapy for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Practice Patterns, Physicians'; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
[New treatment strategy of multiple myeloma for cure].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Medical Oncology; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2006 |
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Europe; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Meta-Analysis as Topic; Multicenter Studies as Topic; Multiple Myeloma; National Institutes of Health (U.S.); Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Procarbazine; Pyrazines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; United States; Vinblastine; Vincristine | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
The proteasome: a novel target for anticancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Drug Design; Humans; Multiple Myeloma; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Randomized Controlled Trials as Topic; Ubiquitin | 2006 |
Bortezomib (Velcade)--a new therapeutic strategy for patients with refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Molecular Structure; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines | 2005 |
[Current therapy for multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide | 2005 |
Bortezomib for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Therapy, Combination; Humans; Multiple Myeloma; Product Surveillance, Postmarketing; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2006 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Separation; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Stem Cells | 2006 |
Proteasome inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Ubiquitin | 2006 |
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Lymphoma; Multiple Myeloma; Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma; Pyrazines; Waldenstrom Macroglobulinemia | 2006 |
Emerging role of novel combinations for induction therapy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Thalidomide; Treatment Outcome | 2006 |
[Proteasome inhibitor bortezomib as an anticancer drug].
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Clinical Trials as Topic; Cytokines; Heat-Shock Proteins; Humans; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2006 |
Advancing access to myeloma treatment: administration, side effects, and implications for survival.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Health Services Accessibility; Humans; Immunosuppressive Agents; Information Services; Lenalidomide; Multiple Myeloma; Nurse's Role; Oncology Nursing; Patient Education as Topic; Protease Inhibitors; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Survival Rate; Thalidomide | 2006 |
Advances in the treatment of multiple myeloma: a nursing perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Protease Inhibitors; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
[New drugs for myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Boronic Acids; Bortezomib; Glucocorticoids; Humans; I-kappa B Kinase; Multiple Myeloma; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines | 2006 |
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2006 |
Response to bortezomib and activation of osteoblasts in multiple myeloma.
Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Osteoprotegerin; Parathyroid Hormone; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2006 |
[Recent progress in diagnosis of and therapy for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Thalidomide | 2006 |
Proteasome inhibitors: antitumor effects and beyond.
Topics: Boronic Acids; Bortezomib; Cardiovascular Diseases; Dendritic Cells; Graft vs Host Disease; Humans; Lymphocytes; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2007 |
Current status of new drugs for the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Investigational treatments for multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Remission Induction; Risk Factors; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Bortezomib as an antitumor agent.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Ubiquitin | 2006 |
[Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
Topics: Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Remission Induction; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2006 |
Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Randomized Controlled Trials as Topic | 2007 |
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Administration Schedule; Hemoglobins; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Quality of Life; Thalidomide | 2006 |
Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Drug Synergism; Humans; Models, Biological; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Treatment Outcome | 2007 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Thalidomide | 2007 |
The proteasome and its inhibitors in immune regulation and immune disorders.
Topics: Animals; Antigen Presentation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Therapy; Humans; Immune System; Immune System Diseases; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction | 2006 |
Emerging drugs in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
[Recent progress in the treatment of multiple myeloma].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Diphosphonates; Drug Design; Football; Humans; Immunosuppressive Agents; Melphalan; Multiple Myeloma; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Reference Standards; Thalidomide | 2007 |
[Proteasome inhibitors for multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
Myeloma bone disease and proteasome inhibition therapies.
Topics: Bone Diseases; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2007 |
Targeting the ubiquitin-proteasome pathway in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2007 |
[New treatment of multiple myeloma].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2007 |
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Drug Evaluation, Preclinical; Humans; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2007 |
New drugs for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma.
Topics: Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Multiple Myeloma; Pyrazines | 2007 |
Proteasome inhibition and multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2007 |
[Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Design; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
Tandem transplants in the treatment of multiple myeloma. Pro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Remission Induction; Reoperation; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2004 |
[Effects of proteasome inhibitors on leukemias].
Topics: Animals; Boronic Acids; Bortezomib; Humans; Leukemia; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
Initial Therapy of Multiple Myeloma in Patients who are Candidates for Stem Cell Transplantation.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2007 |
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Signal Transduction; Thalidomide | 2007 |
Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2007 |
Targeted treatments to improve stem cell outcome: old and new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2007 |
[Multiple myeloma and intravenous immunoglobulins].
Topics: Agammaglobulinemia; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins, Intravenous; Infections; Male; Multicenter Studies as Topic; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Time Factors | 2007 |
Novel therapies in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Mobilization; Humans; Leukocyte Common Antigens; Mice; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Stem Cell Transplantation; Stem Cells; Transplantation Conditioning | 2007 |
Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2007 |
The role of proteasome in malignant diseases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome; Ubiquitin | 2007 |
[Therapy of multiple myeloma: indications and options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Remission Induction; Thalidomide; Tumor Burden | 2007 |
High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Feasibility Studies; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Registries; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
New therapies in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Management of relapsed and relapsed refractory myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2007 |
Clinical updates and nursing considerations for patients with multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Disease Progression; Doxorubicin; Drug Administration Schedule; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Patient Compliance; Patient Education as Topic; Practice Guidelines as Topic; Prednisone; Pyrazines; Quality of Life; Survival Rate; Thalidomide; Treatment Outcome | 2007 |
[Diagnosis and management guideline for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Reference Standards; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2007 |
[Chemotherapy for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Humans; Melphalan; Meta-Analysis as Topic; Multiple Myeloma; Prednisolone; Pulse Therapy, Drug; Pyrazines; Thalidomide; Vincristine | 2007 |
[Role of bortezomib in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Humans; Liposomes; Melphalan; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide | 2007 |
[Role of stem cell transplantation in treatment of multiple myeloma].
Topics: Age Factors; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Middle Aged; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Heterologous | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
[Situation of translational research and development of molecular-targeted agents for multiple myeloma].
Topics: Animals; Antineoplastic Agents; Biomedical Research; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Clinical Trials as Topic; Cytokines; Drug Design; Gene Targeting; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines | 2007 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Metabolic Networks and Pathways; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin | 2007 |
[Advances in therapeutic strategies for multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Humans; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2007 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2008 |
Position statement on the use of bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Multiple myeloma: novel approaches for relapsed disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2007 |
Current therapy of myeloma induced renal failure.
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2008 |
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency; Treatment Outcome | 2008 |
Bortezomib in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2008 |
Proteasome inhibition in cancer: development of PS-341.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Hematologic Neoplasms; Humans; Multienzyme Complexes; Multiple Myeloma; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship | 2001 |
The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; I-kappa B Proteins; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Polymorphism, Genetic; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2001 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome | 2002 |
298 trial(s) available for pyrazines and Kahler Disease
| Article | Year |
|---|---|
A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Imidazoles; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2021 |
[Prophylaxis of Bortezomib-Induced Peripheral Neuropathy in Patients with Multiple Myeloma by High-Dose Intravenous Mecobalamin].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Vitamin B 12; Vitamins | 2017 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; C-Reactive Protein; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infection Control; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy | 2013 |
Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Treatment Outcome | 2013 |
[Clinical study of bortezomib in the treatment of multiple myeloma patients with renal failure].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2013 |
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Quality of Life; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2013 |
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclosporine; Drug Synergism; Female; Graft vs Host Disease; Hematologic Diseases; Humans; Immunosuppressive Agents; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Reoperation; Salvage Therapy; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Vincristine | 2013 |
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2013 |
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning; Transplantation, Autologous | 2013 |
The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Topics: Administration, Oral; Animals; Anisoles; Antineoplastic Agents; Azepines; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines | 2013 |
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Pyrazines | 2013 |
Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2013 |
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Transplantation, Autologous; Treatment Outcome | 2014 |
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate | 2013 |
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Panobinostat; Pyrazines | 2013 |
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Salvage Therapy; Survival Rate; Vorinostat | 2013 |
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2013 |
[Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma].
Topics: Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Remission Induction | 2013 |
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Follow-Up Studies; Gene Dosage; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Survival Rate | 2014 |
Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Survival Analysis | 2014 |
Value of novel agents and intensive therapy for patients with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; GTP Phosphohydrolases; Humans; Membrane Proteins; Multiple Myeloma; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Survival Analysis | 2014 |
[Effect of bortezomib combined with bisphosphonates on bone metabolism index in multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Diphosphonates; Drug Therapy, Combination; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand | 2013 |
Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Death; Cytokines; Dendritic Cells; Down-Regulation; Female; Humans; Male; Multiple Myeloma; Pyrazines; STAT3 Transcription Factor; Triterpenes; Tumor Cells, Cultured; Up-Regulation | 2014 |
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Substitution; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Pyrazines; Treatment Outcome | 2014 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Pyrazines; Regulatory Factor X Transcription Factors; Survival Rate; Transcription Factors; X-Box Binding Protein 1 | 2014 |
Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Cost-Benefit Analysis; Feasibility Studies; Follow-Up Studies; Health Policy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Netherlands; Outcome Assessment, Health Care; Policy Making; Pyrazines; Reimbursement Mechanisms; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Uncertainty | 2014 |
Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Patient Selection; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Young Adult | 2014 |
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Monitoring; Female; Half-Life; Humans; Immunoglobulin Light Chains; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Prospective Studies; Pyrazines; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2014 |
Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin A; Interleukin-6; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2014 |
A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Topics: Acupuncture Therapy; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Feasibility Studies; Humans; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pilot Projects; Pyrazines; Time Factors; Treatment Outcome | 2014 |
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electroacupuncture; Feasibility Studies; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Time Factors; Treatment Outcome | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Risk Factors; Thalidomide; Treatment Outcome | 2014 |
Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Recurrence | 2014 |
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélo
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Female; France; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2014 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Recurrence; Survival Analysis; Thalidomide; Transplantation, Autologous | 2015 |
Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study.
Topics: Adult; Biomarkers; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Steroids; Treatment Outcome | 2014 |
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2014 |
Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Busulfan; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Prospective Studies; Pyrazines; Survival Rate; Transplantation Conditioning | 2014 |
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Topics: Actin Cytoskeleton; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axons; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neurogenesis; Peripheral Nervous System Diseases; Plasma Cells; Pyrazines; Survival Analysis; Syndecan-1; Thalidomide; Transplantation, Autologous | 2014 |
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; NF-kappa B; Nootropic Agents; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Severity of Illness Index; Treatment Outcome | 2014 |
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxamic Acids; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Panobinostat; Prognosis; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2014 |
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Double-Blind Method; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2015 |
NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Homozygote; Humans; Male; Middle Aged; Multiple Myeloma; NF-kappa B p50 Subunit; Polymorphism, Genetic; Pyrazines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Prognosis; Pyrazines; Survival Rate | 2015 |
Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Mutation; Predictive Value of Tests; Pyrazines; Risk Factors; Survival Analysis; Thalidomide | 2015 |
Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2014 |
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2015 |
A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Rate; Veterans | 2015 |
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Topics: Administration, Cutaneous; Administration, Intravenous; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Renal Insufficiency; Treatment Outcome | 2015 |
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Odds Ratio; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Interleukin-6; Japan; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines | 2015 |
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Remission Induction; Survival Rate | 2015 |
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Plasma Cells; Polyethylene Glycols; Precision Medicine; Proteomics; Pyrazines; Thalidomide | 2015 |
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Susceptibility; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Proteasome Endopeptidase Complex; Pyrazines | 2015 |
Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Factor V; Female; Hemostasis; Humans; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Platelet Aggregation; Protein C; Pyrazines; Recurrence; Treatment Outcome | 2008 |
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis | 2008 |
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis | 2008 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
[Bortezomib-based combination therapy for newly diagnosed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome; Vincristine | 2008 |
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Recurrence; Virus Activation | 2008 |
[Clinical study of bortezomib in combination with dexamethasone for the treatment of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Routes; Humans; Middle Aged; Multiple Myeloma; Prospective Studies; Proteasome Inhibitors; Pyrazines | 2008 |
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone and Bones; Bone Remodeling; Boronic Acids; Bortezomib; Cytokines; Dexamethasone; Female; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Neovascularization, Physiologic; Pyrazines; Recurrence; Survival Rate; Thalidomide | 2008 |
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2008 |
Update on recent developments for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Interactions; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2008 |
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Treatment Outcome | 2008 |
Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Lymphocyte Subsets; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Survival Analysis; T-Lymphocytes, Cytotoxic; Transplantation, Autologous; Treatment Outcome; Virus Activation | 2009 |
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Recurrence; Treatment Outcome | 2009 |
[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Treatment Outcome | 2008 |
Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Epirubicin; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
[Experience with velcade administration in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Multiple; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2008 |
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Statistics, Nonparametric; Survival Rate | 2009 |
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Statistics, Nonparametric; Thrombocytopenia | 2009 |
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Ethylenediamines; Humans; Maximum Tolerated Dose; Multiple Myeloma; Organophosphonates; Platelet Count; Pyrazines; Radioisotopes; Recurrence; Samarium | 2009 |
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines | 2008 |
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2009 |
[Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2009 |
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cystatin C; Female; Humans; Immunoassay; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Remission Induction | 2009 |
Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Germany; Hematology; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Physicians' Offices; Pyrazines; Secondary Prevention; Treatment Outcome | 2009 |
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Interactions; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Omeprazole; Proton Pump Inhibitors; Pyrazines | 2009 |
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Salvage Therapy; Steroids; Thalidomide; Treatment Outcome | 2009 |
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2009 |
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2009 |
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neuralgia; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2010 |
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Case-Control Studies; Female; Flow Cytometry; Gene Expression Profiling; Humans; Immunohistochemistry; Membrane Glycoproteins; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Transplantation, Heterologous | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2009 |
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2009 |
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Statistics as Topic; Transplantation, Autologous; Treatment Outcome | 2010 |
Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Stem Cell Transplantation; Survival Analysis | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Glucocorticoids; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Renal Insufficiency; Treatment Outcome | 2009 |
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Melphalan; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Treatment Outcome | 2009 |
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Demography; Disease Progression; Dose-Response Relationship, Drug; Female; France; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous | 2010 |
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2010 |
Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multip
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Korea; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Prednisolone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Female; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Recurrence; Thrombospondins | 2010 |
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Italy; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Polyethylene Glycols; Prednisone; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2010 |
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Risk Factors; Thalidomide | 2010 |
Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Neuralgia; Prospective Studies; Pyrazines; Th2 Cells | 2010 |
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2011 |
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Polymerase Chain Reaction; Pyrazines; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome; Tumor Burden | 2010 |
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Europe; Female; Humans; Israel; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States | 2010 |
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Fatigue; Hematologic Diseases; Humans; Lenalidomide; Multiple Myeloma; Pain; Pyrazines; Remission Induction; Sensation Disorders; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome | 2010 |
Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Multiple Myeloma; Neoplasm Staging; Pyrazines | 2010 |
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
Topics: Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukapheresis; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2010 |
A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2010 |
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Pyrazines | 2010 |
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2010 |
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome | 2010 |
Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2010 |
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HSP70 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukocyte Count; Male; Middle Aged; Multiple Myeloma; Neutrophils; Platelet Count; Pyrazines; Recurrence; Treatment Outcome | 2010 |
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prednisone; Prognosis; Pyrazines; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome; Young Adult | 2010 |
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myelom
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Spain; Thalidomide; Time Factors; Treatment Outcome | 2010 |
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation Conditioning | 2010 |
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Doxorubicin; Europe; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Staging; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Time Factors; Transplantation, Autologous; Treatment Outcome; Vincristine | 2010 |
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Europe; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Prospective Studies; Protease Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
[Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention | 2010 |
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Europe; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Prospective Studies; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine; Young Adult | 2010 |
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Risk Factors | 2011 |
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Time Factors; Transplantation, Autologous; Treatment Failure; United States | 2012 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Melphalan; Multiple Myeloma; Prednisone; Proportional Hazards Models; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cell-Derived Microparticles; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Thromboplastin; Venous Thrombosis; Vincristine | 2011 |
[The efficacy and safety of PAD and VAD regimens for untreated multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Vincristine | 2010 |
Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Calcium-Calmodulin-Dependent Protein Kinases; Death-Associated Protein Kinases; Dexamethasone; Disease-Free Survival; Factor Analysis, Statistical; Humans; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2010 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Reoperation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Successful treatment with a modified bortezomib schedule of weekly and longer intervals for patients with refractory/resistance multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
[Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Young Adult | 2010 |
Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Humans; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Pyrazines; Recurrence | 2011 |
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Sirolimus | 2011 |
Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2012 |
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Diseases; Bone Remodeling; Boronic Acids; Bortezomib; Cell Differentiation; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoblasts; Prednisone; Pyrazines; Radiotherapy, Adjuvant | 2011 |
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agent
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Erythrocyte Transfusion; Female; Hematinics; Humans; Incidence; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisolone; Pyrazines; Survival Rate; Thromboembolism | 2011 |
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Thalidomide; Treatment Outcome | 2011 |
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Osteogenesis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Blood Cells; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Europe; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; South America; Treatment Outcome | 2011 |
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Multiple Myeloma; Pyrazines; Salvage Therapy | 2011 |
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2011 |
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
Carfilzomib: a novel second-generation proteasome inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Multiple Myeloma; Neutropenia; Oligopeptides; Proteasome Inhibitors; Protein Binding; Pyrazines; Thrombocytopenia | 2011 |
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Survival Rate; Thalidomide | 2011 |
[The efficacy and safety of bortezomib plus thalidomide in treatment of newly diagnosed multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2011 |
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors | 2011 |
Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Busulfan; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2011 |
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Failure; Treatment Outcome | 2011 |
Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-bas
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Models, Statistical; Multiple Myeloma; Myeloma Proteins; Polyethylene Glycols; Prognosis; Pyrazines; Survival Analysis; Treatment Outcome | 2011 |
Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2012 |
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Factors | 2011 |
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Sarcoma, Myeloid; Survival Rate; Thalidomide | 2012 |
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Survival Analysis; Thalidomide; Time Factors; Transplantation, Autologous; Treatment Outcome | 2011 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.
Topics: Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; DNA, Neoplasm; Drug Administration Schedule; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Multiple Myeloma; Ploidies; Prognosis; Pyrazines; Time Factors; Treatment Outcome | 2011 |
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Depsipeptides; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Survival Analysis; Thrombocytopenia | 2011 |
An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2011 |
A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Prospective Studies; Pyrazines | 2011 |
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Induction Chemotherapy; Kidney Diseases; Maintenance Chemotherapy; Male; Melphalan; Multiple Myeloma; Neoadjuvant Therapy; Prednisone; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phosphorylcholine; Pyrazines; Recurrence | 2011 |
Different dose combinations of bortezomib and dexamethasone in the treatment of relapsed or refractory myeloma: an open-label, observational, multi-center study in China.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines | 2011 |
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Dexamethasone; Drug Combinations; Enzyme Induction; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Rifampin | 2011 |
Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2012 |
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Cohort Studies; Female; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Smith-Magenis Syndrome; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Young Adult | 2012 |
Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2012 |
A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Polyethylene Glycols; Prognosis; Prospective Studies; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2012 |
Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cross-Over Studies; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence; Thalidomide | 2012 |
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Thalidomide; Treatment Outcome | 2012 |
Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Fanconi Anemia Complementation Group Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Signal Transduction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Quality of Life; Treatment Outcome | 2012 |
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2012 |
High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Risk Factors; Singapore; Survival Rate; Time Factors | 2012 |
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Demography; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2012 |
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Thalidomide | 2012 |
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate | 2012 |
[Clinical study of bortezomib for treating multiple myeloma with renal impairment].
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2012 |
Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Female; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cells; Thalidomide; Transplantation, Autologous | 2012 |
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Vincristine | 2012 |
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrazines; Treatment Outcome | 2013 |
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Boronic Acids; Bortezomib; Dexamethasone; DNA Methylation; Doxorubicin; Drug Administration Schedule; Epigenesis, Genetic; Female; Humans; Immunity, Cellular; Lenalidomide; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Prospective Studies; Pyrazines; T-Cell Antigen Receptor Specificity; Thalidomide; Transplantation, Autologous | 2012 |
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Gastrointestinal Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2012 |
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Maintenance Chemotherapy; Male; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2012 |
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Humans; Injections, Subcutaneous; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2012 |
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Multiple Myeloma; Polymorphism, Single Nucleotide; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines; Recurrence; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2012 |
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Synergism; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Secondary Prevention; Vorinostat | 2012 |
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Pyrazines; Secondary Prevention | 2012 |
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Risk Assessment; Thalidomide | 2013 |
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: a multicenter, open label phase 1/2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Recurrence | 2013 |
Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2013 |
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Treatment Outcome | 2013 |
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Dehydration; Drug Resistance, Neoplasm; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Resveratrol; Salvage Therapy; Stilbenes; Treatment Failure; Vomiting | 2013 |
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Transplantation, Autologous; Young Adult | 2013 |
Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide | 2013 |
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia | 2013 |
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Neoplasms, Second Primary; Odds Ratio; Prednisone; Proportional Hazards Models; Pyrazines; Risk; Spain; Treatment Outcome | 2013 |
Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen.
Topics: Adipose Tissue; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies | 2013 |
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2012 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Lenalidomide; Medical Oncology; Middle Aged; Multiple Myeloma; Pyrazines; Societies, Medical; Thalidomide; Treatment Failure; Treatment Outcome | 2013 |
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Filgrastim; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplastic Stem Cells; Pyrazines; Recombinant Proteins; Signal Transduction | 2013 |
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemoglobins; Humans; Male; Middle Aged; Multienzyme Complexes; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Recurrence | 2003 |
A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Safety; Treatment Outcome | 2003 |
New developments with bortezomib in treating multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Division; Doxorubicin; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Liposomes; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Renal Insufficiency; Treatment Outcome | 2004 |
Approval summary for bortezomib for injection in the treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Female; Humans; Male; Middle Aged; Models, Chemical; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Time Factors; United States; United States Food and Drug Administration | 2004 |
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2004 |
Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cost-Benefit Analysis; Delphi Technique; Economics, Pharmaceutical; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2004 |
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Treatment Outcome | 2005 |
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2005 |
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Count; Protease Inhibitors; Pyrazines; Recurrence; Survival Rate | 2005 |
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Herpes Zoster; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2005 |
Proteasome inhibitor for treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Risk Factors; Thrombocytopenia; Treatment Outcome | 2005 |
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors | 2005 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous | 2006 |
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Time Factors; Treatment Outcome | 2005 |
APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant
Topics: Boronic Acids; Bortezomib; Clinical Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Patient Selection; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy | 2003 |
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Treatment Outcome | 2006 |
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2006 |
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Europe; Female; Humans; Male; Middle Aged; Multiple Myeloma; Patient Satisfaction; Predictive Value of Tests; Prognosis; Pyrazines; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2006 |
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Time Factors; Treatment Outcome | 2006 |
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous | 2006 |
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2006 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Disease-Free Survival; Humans; Immunophenotyping; Maximum Tolerated Dose; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2006 |
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thalidomide | 2006 |
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Treatment Outcome | 2006 |
Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Middle Aged; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteolysis; Protease Inhibitors; Pyrazines | 2006 |
Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate | 2006 |
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; France; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Cohort Studies; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Survival Analysis | 2007 |
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
Topics: Aged; Boronic Acids; Bortezomib; Doxorubicin; Drug Therapy, Combination; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Time Factors; Treatment Outcome | 2007 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Tolerance; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Recurrence; Safety; Salvage Therapy; Thalidomide | 2007 |
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Predictive Value of Tests; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2007 |
Targeting aurora kinases as therapy in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Boronic Acids; Bortezomib; Cell Line, Transformed; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Matrix Proteins; G2 Phase; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematopoietic Stem Cells; Histones; Humans; Hyaluronan Receptors; Interleukin-6; Lymphocytes; Multiple Myeloma; Mutation; Phosphorylation; Ploidies; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazines | 2007 |
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Deletion; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclosporine; Drug Interactions; Humans; Immunosuppressive Agents; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Homologous | 2007 |
Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Multiple Myeloma; Neoplasm Proteins; Ploidies; Pyrazines; Recurrence; Survival Rate | 2007 |
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Diploidy; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Multigene Family; Multiple Myeloma; Prognosis; Protein Biosynthesis; Pyrazines; Trisomy | 2007 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2007 |
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia | 2007 |
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Proteinuria; Pyrazines; Thalidomide; Treatment Outcome; Vincristine | 2007 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2007 |
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2007 |
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chi-Square Distribution; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate | 2007 |
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2007 |
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.
Topics: Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy; Simvastatin | 2007 |
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines | 2007 |
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Time Factors; Treatment Outcome | 2007 |
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Linear Models; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
[Velcade in multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2007 |
Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines; Treatment Outcome | 2007 |
Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Drug Approval; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; United States | 2007 |
Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Electrophoresis; Female; Humans; Immunoglobulin Light Chains; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Recurrence | 2007 |
Bortezomib inhibits osteoclast activity in patients with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Combined Modality Therapy; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Melphalan; Multiple Myeloma; Osteoclasts; Patient Selection; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
Topics: Alleles; alpha 1-Antitrypsin; Animals; Antineoplastic Agents; Antithrombins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Factor Xa Inhibitors; Fibrinogen; Humans; Immunohistochemistry; Injections, Intravenous; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Mice; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Proteins; Pyrazines; Serpins; Ubiquitin | 2008 |
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Survival Analysis; Treatment Outcome | 2008 |
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Polyethylene Glycols; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Epidemiologic Methods; Female; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction; Treatment Outcome | 2008 |
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Melphalan; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Survival Analysis | 2008 |
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy | 2008 |
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Survival Analysis; Treatment Outcome | 2008 |
The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide; Treatment Outcome | 2008 |
VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2008 |
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia | 2008 |
1142 other study(ies) available for pyrazines and Kahler Disease
| Article | Year |
|---|---|
Herpesviral encephalitis associated with bortezomib use in a patient with multiple myeloma and associated light-chain amyloidosis.
Topics: Acyclovir; Amyloidosis; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Encephalitis, Herpes Simplex; Herpesvirus 3, Human; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2022 |
Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Multiple Myeloma; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Tumor Microenvironment | 2022 |
Dietary Flavonoids with Catechol Moiety Inhibit Anticancer Action of Bortezomib: What about the other Boronic Acid-based Drugs?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechols; Flavonoids; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Humans; Hyaluronic Acid; Matrix Metalloproteinase 2; Multiple Myeloma; NF-kappa B; Proteoglycans; Pyrazines; Signal Transduction; Tumor Microenvironment | 2022 |
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Exonucleases; Humans; Interferons; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2022 |
A Landmark Paper That Introduced Proteasome Inhibition in Myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2023 |
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians.
Topics: Bortezomib; Humans; Multiple Myeloma; Physicians; Pyrazines; Standard of Care | 2023 |
The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Female; Humans; Male; Mice; Mitosis; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Experimental; Polycomb Repressive Complex 1; Pyrazines; Xenograft Model Antitumor Assays | 2020 |
Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Heat-Shock Response; Hot Temperature; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteostasis; Pyrazines; Signal Transduction; Ubiquitin; Ubiquitination | 2020 |
Targeting Adaptive IRE1α Signaling and PLK2 in Multiple Myeloma: Possible Anti-Tumor Mechanisms of KIRA8 and Nilotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Cross-Sectional Studies; Endoribonucleases; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Prognosis; Protein Serine-Threonine Kinases; Pyrazines; Pyrimidines; Retrospective Studies; Tumor Cells, Cultured | 2020 |
[Analysis of Risk Factors of Herpes Zoster in Patients with Multiple Myeloma Treated with Bortezomib].
Topics: Boronic Acids; Bortezomib; Herpes Zoster; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors | 2020 |
The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Topics: Animals; Benzimidazoles; Bortezomib; Cell Cycle Checkpoints; Cell Proliferation; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Mice; Microtubules; Multiple Myeloma; Polymerization; Proteasome Inhibitors; Pyrazines; Tubulin; Xenograft Model Antitumor Assays | 2021 |
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway.
Topics: Animals; Apoptosis; bcl-X Protein; Benzamides; Caspases; Humans; Male; Mice; Mice, Nude; Mitochondria; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction | 2021 |
Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2017 |
[Clinical Analysis of Maintenance Therapy with Thalidomine and Bortezomib for Multiple Myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.
Topics: Aminopyridines; Benzamides; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Hypoxia; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Sulfonamides; Tumor Cells, Cultured | 2019 |
In silico investigations of potential anabolic treatments in multiple myeloma-induced bone disease.
Topics: Anabolic Agents; Bone Diseases; Boronic Acids; Bortezomib; Calibration; Cell Count; Computer Simulation; Diphosphonates; Drug Therapy, Combination; Humans; Models, Biological; Multiple Myeloma; Organ Size; Osteoblasts; Osteoclasts; Pamidronate; Pyrazines; Reproducibility of Results; User-Computer Interface | 2013 |
[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
The clinical relevance of cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transcriptome; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2013 |
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Disease Models, Animal; Gene Expression; Genes, Reporter; Graft Survival; Humans; Injections; Luciferases; Luminescent Measurements; Magnetic Resonance Imaging; Melphalan; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Paraproteins; Plasma Cells; Pyrazines; Syndecan-1; Tibia; Tumor Microenvironment | 2013 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Disease Management; Drug Administration Routes; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Recurrence; Risk; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2013 |
Bortezomib influences the expression of malignant plasma cells membrane antigens.
Topics: Animals; Antigens; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Insulin-Like Growth Factor I; Interleukin-6; Membrane Proteins; Mice; Mice, SCID; Multiple Myeloma; Plasma Cells; Proteasome Inhibitors; Pyrazines; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Time Factors | 2013 |
Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Cell Line, Tumor; Cyclophilins; Drug Resistance, Neoplasm; Female; Humans; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; Peptidyl-Prolyl Isomerase F; Pyrazines; Reactive Oxygen Species; Superoxide Dismutase; Transcriptome | 2013 |
Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Polycomb-Group Proteins; Primary Cell Culture; Pyrazines; Side-Population Cells; Signal Transduction; Syndecan-1; Ubiquitins | 2013 |
[Loss of CD23 expression after bortezomib plus dexamethasone therapy in CCND1/IGH-positive multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin D1; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Receptors, IgE | 2013 |
Bortezomib and bone health in adults: can we extend these findings to children?
Topics: Adult; Animals; Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Male; Mice; Multiple Myeloma; Pyrazines | 2013 |
"IM iD"eally treating multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Carfilzomib for the treatment of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Oligopeptides; Pyrazines | 2013 |
Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib.
Topics: Aerobiosis; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Chloroacetates; Drug Synergism; Glycolysis; Humans; Mice; Multiple Myeloma; Oxygen Consumption; Pyrazines; Pyruvate Dehydrogenase Complex; Superoxides | 2013 |
Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Topics: Animals; Blotting, Western; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 9; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Lenalidomide; Mice, SCID; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Xenograft Model Antitumor Assays | 2013 |
Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Topics: Animals; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Transgenic; Multiple Myeloma; Pyrazines | 2013 |
Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.
Topics: Antineoplastic Agents; Azacitidine; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Decitabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Hydrogen Peroxide; Hydroxamic Acids; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxidants; Prognosis; Pyrazines; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Scavenger Receptors, Class A | 2013 |
Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Quality of Life; Remission Induction; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Multiple myeloma: so much progress, but so many unsolved questions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Outcome Assessment, Health Care; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2013 |
NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Down-Regulation; Drug Synergism; Humans; Multiple Myeloma; NF-kappa B; Nitrobenzenes; Pyrazines; Signal Transduction; Sulfonamides; Treatment Outcome | 2013 |
Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells.
Topics: Animals; Apoptosis; Autophagy; Azithromycin; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Endoplasmic Reticulum Stress; Erythromycin; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Mice; Multiple Myeloma; Pyrazines; Transcription Factor CHOP | 2013 |
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Transplantation, Autologous | 2013 |
Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Calpain; Cell Line, Tumor; Cell Survival; Drug Synergism; HIV Protease Inhibitors; Humans; Mice; Mice, SCID; Multiple Myeloma; Nelfinavir; Pyrazines; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2013 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Pyrazines; Recurrence; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cellular Microenvironment; Coculture Techniques; Drug Resistance, Neoplasm; Fluorescent Dyes; Gene Expression Regulation; Humans; Multiple Myeloma; Pyrazines; Rhodamine 123; Stromal Cells | 2013 |
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Blood Component Removal; Boronic Acids; Bortezomib; Dexamethasone; Female; Filgrastim; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recombinant Proteins; Retrospective Studies; Thalidomide; Transplantation, Autologous | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Focusing on boron in medicinal chemistry.
Topics: Antineoplastic Agents; Boron Compounds; Boron Neutron Capture Therapy; Boronic Acids; Bortezomib; Chemistry, Pharmaceutical; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines | 2013 |
Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Retrospective Studies; Skin; Thalidomide | 2014 |
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Forecasting; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Evolution of sequential bortezomib-dexamethasone treatment followed by autologous hematopoietic stem cell transplantation in hemodialysis treatment.
Topics: Boronic Acids; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Lenalidomide; Logistic Models; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Pyrazines; Retrospective Studies; Risk Factors; Survival Analysis; Thalidomide | 2014 |
[The appearance of t(9;22)(q34;q11.2) in BJP-λ type multiple myeloma during maintenance therapy including lenalidomide].
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Translocation, Genetic | 2013 |
[Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2013 |
[The efficacy and safety analysis of bortezomib retreatment in 76 patients with relapsed/refractory multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2013 |
[Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Retrospective Studies; Transplantation, Autologous | 2013 |
Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Female; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Biosynthesis; Pyrazines; Signal Transduction; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2013 |
Therapeutic effects of lenalidomide on hemorrhagic intestinal myeloma-associated AL amyloidosis.
Topics: Aged; Amyloid; Amyloidosis; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Diseases; Boronic Acids; Bortezomib; Carpal Tunnel Syndrome; Dexamethasone; Disease Progression; Doxorubicin; Duodenal Diseases; Female; Femur Head; Fractures, Spontaneous; Gastrointestinal Hemorrhage; Hip Fractures; Humans; Jejunal Diseases; Lenalidomide; Melphalan; Multiple Myeloma; Osteolysis; Prednisolone; Pyrazines; Thalidomide; Vincristine | 2013 |
Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Thalidomide; Treatment Outcome | 2013 |
Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
Topics: Blood Coagulation; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Phosphatidylserines; Pyrazines; Thalidomide; Thromboplastin | 2013 |
Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
Topics: Aminoglycosides; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Enediynes; Humans; JNK Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Pyrazines | 2013 |
The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma.
Topics: Administration, Oral; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib.
Topics: 3T3 Cells; Activating Transcription Factor 4; Animals; Antineoplastic Agents; Biomarkers; Bone Marrow Cells; Boronic Acids; Bortezomib; Calcification, Physiologic; Cells, Cultured; Endoplasmic Reticulum Stress; Gene Expression Regulation; Gene Silencing; Humans; Mice; Multiple Myeloma; Neoplasm Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Stromal Cells | 2013 |
Bortezomib-induced polyneuropathy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Humans; Multiple Myeloma; Polyneuropathies; Pyrazines; Retrospective Studies | 2013 |
Correlation between burden of 17P13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Dexamethasone; Disease Progression; Female; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Plasma Cell; Male; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Sequence Deletion; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Mice; Multiple Myeloma; Prognosis; Pyrazines; Receptors, CXCR4; Sarcoma, Myeloid; Survival Rate | 2013 |
Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Cohort Studies; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Health Care Costs; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Thalidomide; Time Factors; Transplantation Conditioning; Treatment Outcome | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Databases, Pharmaceutical; France; Heart Failure; Heart Function Tests; Humans; Male; Middle Aged; Multiple Myeloma; Pharmacovigilance; Pyrazines; Treatment Outcome | 2014 |
Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Flow Cytometry; Follow-Up Studies; Humans; Immunohistochemistry; Multiple Myeloma; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2013 |
Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
Topics: Adult; Aged; Antigens, CD34; Blood Component Removal; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2014 |
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide | 2013 |
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting | 2013 |
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Republic of Korea; Singapore; Survival Rate; Tertiary Care Centers; Thalidomide | 2013 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Topics: Acrylamides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Case-Control Studies; Caspases; Cell Proliferation; Drug Synergism; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; NAD; Neoplasm Recurrence, Local; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Oligonucleotide Array Sequence Analysis; Piperidines; Poly(ADP-ribose) Polymerases; Prognosis; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitroimidazoles; Phosphoramide Mustards; Pyrazines; Signal Transduction | 2013 |
Pomalidomide in the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomal Instability; Clinical Trials as Topic; Comparative Genomic Hybridization; DNA Damage; DNA Repair; Humans; Multiple Myeloma; Multivariate Analysis; Prognosis; Proportional Hazards Models; Pyrazines; Risk; Transcriptome; Treatment Outcome | 2013 |
Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Hepatitis B; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisone; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Thalidomide; Time Factors; Young Adult | 2013 |
CXCR4 is a good survival prognostic indicator in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chemokine CXCL12; Chromosome Aberrations; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Receptors, CXCR4; Survival Rate; Thalidomide | 2013 |
Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2014 |
Multiple myeloma: a descriptive study of 217 Egyptian patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Cytarabine; Dexamethasone; Egypt; Female; Hospitals, Urban; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Retrospective Studies; Severity of Illness Index; Thalidomide; Vincristine | 2014 |
Sweet-like syndrome induced by bortezomib.
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome; Treatment Outcome | 2013 |
Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Abscess; Female; Host-Pathogen Interactions; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Nocardia; Nocardia Infections; Pyrazines; Thalidomide | 2014 |
[Efficacy comparison between standard and reduced doses of bortezomib combined with adriamycin and dexamethasone in the treatment of patients with multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2013 |
Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines; Tomography, X-Ray Computed | 2014 |
Meningeal myelomatosis developed after treatment with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cerebrospinal Fluid; Dexamethasone; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Multiple Myeloma; Plasma Cells; Pyrazines; Thalidomide | 2013 |
Transplants for the elderly in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2013 |
Light chain deposition.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin Light Chains; Kidney Diseases; Kidney Tubules; Male; Multiple Myeloma; Prognosis; Pyrazines | 2013 |
Bortezomib-induced neuropathy: axonal membrane depolarization precedes development of neuropathy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axons; Boronic Acids; Bortezomib; Female; Humans; Male; Membrane Potentials; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Sodium-Potassium-Exchanging ATPase | 2014 |
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.
Topics: Adult; Aged; Angiopoietin-2; Animals; beta 2-Microglobulin; Bioreactors; Bone and Bones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Culture Techniques; Female; Genetic Markers; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Proteasome Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Tibia; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
[Myeloma therapy(2) Treatment of transplant-ineligible patients].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Korea; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Topics: Activating Transcription Factor 6; Boronic Acids; Bortezomib; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Immunophenotyping; Membrane Proteins; Multiple Myeloma; Mutation; Plasma Cells; Precursor Cells, B-Lymphoid; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Signal Transduction; Transcription Factors; X-Box Binding Protein 1 | 2013 |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Serum Response Element; Thalidomide; Transplantation, Autologous | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies | 2013 |
The ubiquitin-proteasome-system.
Topics: Animals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin; Ubiquitination | 2014 |
Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Cricetinae; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Mice; Multiple Myeloma; NF-kappa B; Oncolytic Virotherapy; Pyrazines; Real-Time Polymerase Chain Reaction; Vesicular Stomatitis; Vesicular stomatitis Indiana virus; Virus Replication | 2013 |
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia | 2013 |
Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Injections, Subcutaneous; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Failure | 2014 |
Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.
Topics: Adenosine Triphosphate; Analysis of Variance; Apoptosis; Base Sequence; Blotting, Western; Boronic Acids; Bortezomib; Casein Kinase II; Cell Line, Tumor; DNA Primers; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lymphoma, Mantle-Cell; Molecular Sequence Data; Multiple Myeloma; Naphthyridines; NF-kappa B; Phenazines; Pyrazines; Real-Time Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor | 2013 |
Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.
Topics: Aldehyde Oxidoreductases; Antigens, CD20; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Down-Regulation; Humans; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Neoplastic Stem Cells; Oxygen; PAX5 Transcription Factor; Peptides; Pyrazines; Receptors, CXCR4; Syndecan-1; Tretinoin; Tumor Microenvironment | 2013 |
Initial treatment of nontransplant patients with multiple myeloma.
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Monitoring; Home Care Services; Humans; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Scotland; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome | 2014 |
Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Global cellular response to chemotherapy-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genome, Human; Heat Shock Transcription Factors; Humans; Multiple Myeloma; Protease Inhibitors; Protein Biosynthesis; Proteolysis; Pyrazines; Ribosomes; Stress, Physiological; Transcription Factors; Transcription, Genetic | 2013 |
Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Biomarkers; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lectins, C-Type; Mice; Multiple Myeloma; Plasma Cells; Pyrazines | 2013 |
High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Cohort Studies; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Humans; Immunocompromised Host; Incidence; Induction Chemotherapy; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2014 |
Is bortezomib a rare cause of acute pancreatitis?
Topics: Abdominal Pain; Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines | 2013 |
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.
Topics: Adult; Aged; Antibodies, Neoplasm; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Boronic Acids; Bortezomib; Chaperonin 60; Combined Modality Therapy; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Male; Melphalan; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Oligoclonal Bands; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2014 |
Dissecting apoptosis the omics way.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Transcription Factors | 2013 |
Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Disease Models, Animal; Flow Cytometry; Humans; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, Interleukin-2 | 2013 |
An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; NF-kappa B; Pyrazines; Random Allocation; Signal Transduction; Thiadiazines; Xenograft Model Antitumor Assays | 2014 |
AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Gossypol; Humans; Lenalidomide; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thalidomide; Waldenstrom Macroglobulinemia | 2014 |
Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Topics: Acute Kidney Injury; Adsorption; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Hemodiafiltration; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Ion Exchange Resins; Male; Membranes, Artificial; Middle Aged; Multiple Myeloma; Myeloma Proteins; Polymers; Pyrazines; Serum Albumin; Thalidomide; Treatment Outcome | 2013 |
Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
Topics: Acute Kidney Injury; Anemia; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Drug Monitoring; Drug Substitution; Flank Pain; Humans; Immunoglobulin kappa-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pyrazines; Renal Dialysis; Thalidomide | 2013 |
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Patient Preference; Pyrazines | 2013 |
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Case-Control Studies; Disease-Free Survival; Drug Evaluation; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Melphalan; Multiple Myeloma; Nervous System Diseases; Prednisone; Prognosis; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Syndecan-1; Thalidomide; Ubiquitination | 2014 |
Hyperammonemic encephalopathy in multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cannabidiol; Cell Cycle; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; In Situ Hybridization, Fluorescence; Membrane Potential, Mitochondrial; Multiple Myeloma; NF-kappa B; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TRPV Cation Channels; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2014 |
[Sensitivity to bortezomib of RPIM8226 cells after co-cultured with down-regulated Cav-1 expression HUVECs].
Topics: Apoptosis; Boronic Acids; Bortezomib; Caveolin 1; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; Multiple Myeloma; Pyrazines | 2013 |
Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide; Transplantation, Autologous | 2014 |
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Endothelial Cells; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Panobinostat; Proteome; Pyrazines; Reactive Oxygen Species; Thalidomide; Transcription, Genetic | 2014 |
Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Immunotherapy; Interleukin-12; Killer Cells, Natural; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Pyrazines | 2014 |
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population.
Topics: Adult; Age Distribution; Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Registries; Survival Analysis; Sweden; Thalidomide; Treatment Outcome | 2014 |
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Multiple Myeloma; Piperidones; Protease Inhibitors; Pyrazines; Ubiquitin Thiolesterase; Up-Regulation | 2014 |
Bortezomib in multiple myeloma: a practice guideline.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Thalidomide; Transplantation Conditioning | 2013 |
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Interleukin-6; MAP Kinase Signaling System; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Transcriptome | 2014 |
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Incidence; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk | 2014 |
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Survival Rate | 2014 |
Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Chemokine CCL2; Chemokine CXCL5; Early Growth Response Protein 1; Female; Gene Expression Regulation, Leukemic; Humans; I-kappa B Kinase; Interleukin-8; Multiple Myeloma; Ovarian Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Transcription Factor RelA | 2014 |
Bortezomib-induced Sweet's syndrome confirmed by rechallenge.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Sweet Syndrome | 2014 |
Romidepsin overcomes cell adhesion-mediated drug resistance in multiple myeloma cells.
Topics: Boronic Acids; Bortezomib; Cell Adhesion; Cell Line; Depsipeptides; Dexamethasone; Down-Regulation; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Integrin alpha4; Integrin beta1; Melphalan; Multiple Myeloma; Pyrazines; RNA, Messenger; RNA, Neoplasm; Syndecan-1 | 2014 |
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Male; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Risk; Thalidomide; Treatment Outcome | 2014 |
Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiation Dosage; Retrospective Studies; Risk Factors; Sclerosis; Tomography, X-Ray Computed; Whole Body Imaging | 2014 |
Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2013 |
Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Humans; Male; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Receptor, Parathyroid Hormone, Type 1 | 2014 |
Acupuncture for neuropathic pain due to bortezomib in a patient with multiple myeloma.
Topics: Acupuncture Therapy; Aged; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Neuralgia; Pyrazines | 2014 |
Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Models, Theoretical; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide | 2014 |
Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Decompression, Surgical; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm Invasiveness; Prognosis; Pyrazines; Retrospective Studies; Spinal Canal; Spinal Cord Compression; Treatment Outcome | 2015 |
Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2014 |
Acquired Fanconi syndrome with proximal tubular cytoplasmic fibrillary inclusions of λ light chain restriction.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cytoplasm; Dexamethasone; Fanconi Syndrome; Humans; Immunoglobulin Light Chains; Kidney Tubules, Proximal; Male; Microscopy, Fluorescence; Microscopy, Immunoelectron; Multiple Myeloma; Myeloma Proteins; Phagosomes; Proteinuria; Pyrazines; Thalidomide | 2014 |
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Line; Cell Proliferation; Cell Survival; Coculture Techniques; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiple Myeloma; Multiprotein Complexes; Pyrazines; RNA Interference; Signal Transduction; Sirolimus; Stromal Cells; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2014 |
Bortezomib-induced lung toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Substitution; Female; Humans; Lenalidomide; Lung Diseases; Multiple Myeloma; Pyrazines; Spirometry; Thalidomide | 2014 |
Comparative cost-effectiveness models for the treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Models, Economic; Multiple Myeloma; Prednisolone; Pyrazines; Survival Analysis; Thalidomide; United Kingdom | 2014 |
A case of eosinophilic dermatosis of hematologic malignancy in a patient with multiple myeloma.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Eosinophilia; Herpes Simplex; Herpes Zoster; Humans; Insect Bites and Stings; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Paraneoplastic Syndromes; Pemphigoid, Bullous; Pyrazines; Skin Diseases | 2014 |
Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Time Factors; Transplantation, Autologous; Treatment Outcome | 2014 |
Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling.
Topics: Benzylamines; Boronic Acids; Bortezomib; Chemokine CXCL12; Computer Simulation; Cyclams; Drug Delivery Systems; Drug Synergism; Heterocyclic Compounds; Humans; Markov Chains; Models, Biological; Monte Carlo Method; Multiple Myeloma; Neoplastic Stem Cells; Paracrine Communication; Pyrazines; Tumor Microenvironment | 2014 |
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diffusion Magnetic Resonance Imaging; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Prospective Studies; Pyrazines; Reproducibility of Results; Thalidomide; Treatment Outcome; Whole Body Imaging | 2014 |
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Dendritic Cells; Humans; Lenalidomide; Lymphocyte Activation; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Pyrazines; T-Lymphocytes; Thalidomide; Toll-Like Receptor 9 | 2014 |
Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 8; Disease-Free Survival; Female; Follow-Up Studies; Gene Amplification; Gene Expression; Genes, myc; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies | 2014 |
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; NF-kappa B; Pyrazines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Bendamustine: the remedy that came in from the cold.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2014 |
Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Curcusone D, a novel ubiquitin-proteasome pathway inhibitor via ROS-induced DUB inhibition, is synergistic with bortezomib against multiple myeloma cell growth.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Diterpenes; Humans; Jatropha; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Reactive Oxygen Species; Ubiquitin-Specific Proteases | 2014 |
Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neurologic Examination; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2014 |
Limited value of the international staging system for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prednisolone; Prognosis; Pyrazines; Retreatment; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Checkpoint Kinase 1; Cytoprotection; Down-Regulation; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins; Pyrazines; Syndecan-1; Up-Regulation | 2014 |
Bortezomib for the treatment of multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Half-Life; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Transplantation, Autologous | 2014 |
URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Pyrazines; Repressor Proteins; RNA Interference; Side-Population Cells; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transcription Factor RelA; Transcription, Genetic; Transfection; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Disease-Free Survival; Female; Humans; Immunoglobulin Light Chains; Kaplan-Meier Estimate; Leukemia, Plasma Cell; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Plasmacytoma; Prognosis; Proteasome Inhibitors; Pyrazines; Recurrence; Republic of Korea; Retrospective Studies; Salvage Therapy | 2014 |
Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mucin-1; Multiple Myeloma; Peptides; Phosphoric Monoester Hydrolases; Protein Subunits; Pyrazines; Reactive Oxygen Species | 2014 |
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Copy Number Variations; Doxorubicin; Heterografts; Humans; Immunophenotyping; Melphalan; Mice, SCID; Multiple Myeloma; Neoplastic Stem Cells; Phenotype; Plasma Cells; Precursor Cells, B-Lymphoid; Pyrazines; Syndecan-1 | 2014 |
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Drugs, Investigational; Europe; Female; Humans; Japan; Kaplan-Meier Estimate; Lenalidomide; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients.
Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome | 2014 |
[Culture and regulation of osteoblasts in multiple myeloma patients].
Topics: Adult; Aged; Bone Marrow Cells; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Serum; Tumor Cells, Cultured; Young Adult | 2014 |
[Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Treatment Outcome | 2014 |
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2014 |
United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Clinical Trials as Topic; Consolidation Chemotherapy; Disease Management; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Remission Induction; Survival Analysis; Thalidomide; United Kingdom | 2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Paraffin Embedding; Peptide Hydrolases; Prednisolone; Pyrazines; Salvage Therapy; Survival Analysis; Syndecan-1; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2014 |
A rare cause of severe hepatomegaly with an improving outcome.
Topics: Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Hepatomegaly; Humans; Male; Multiple Myeloma; Pyrazines | 2014 |
Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Fibronectins; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Tumor Microenvironment | 2014 |
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Multiple Myeloma; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Ubiquitin-Activating Enzymes; Up-Regulation | 2014 |
The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.
Topics: Adipose Tissue; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cycloheximide; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Osteogenesis; Pyrazines; Remission Induction; Thalidomide; Transplantation, Autologous | 2014 |
Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Cyclophosphamide; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Evaluation; Drug Substitution; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Sensation Disorders; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival.
Topics: Antigens, CD19; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Proto-Oncogene Proteins c-kit; Pyrazines | 2014 |
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Topics: Amides; Animals; Antineoplastic Agents; Blood Platelets; Bone Marrow; Boronic Acids; Bortezomib; Colony-Forming Units Assay; Disease Models, Animal; Male; Megakaryocyte Progenitor Cells; Megakaryocytes; Mice; Multiple Myeloma; Platelet Count; Pyrazines; Pyridines; rho-Associated Kinases; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2014 |
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Disease Progression; Female; Greece; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplasm Recurrence, Local; Plasmacytoma; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Patient Outcome Assessment; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.
Topics: Azacitidine; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Tetraspanin 29 | 2014 |
Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Real-Time Polymerase Chain Reaction; Young Adult | 2014 |
Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Humans; Integrins; Lipopeptides; Multiple Myeloma; Pyrazines; Stromal Cells; Toll-Like Receptor 1; Toll-Like Receptor 2 | 2014 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Complete remission achieved in a multiple myeloma patient with elevated serum KL-6 level by a combination regimen with bortezomib, cyclophosphamide, and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diplopia; Female; Humans; Mucin-1; Multiple Myeloma; Pyrazines; Remission Induction | 2014 |
[Analysis of Bortezomib-containing combinations in newly-diagnosed multiple myeloma patients: a comparative study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2014 |
Effective control of skin reaction by air sandwich technique in a patient with IgE-κ myeloma treated with subcutaneous bortezomib injection.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin E; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome | 2014 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Esters; Humans; Liposomes; Mice, SCID; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Prodrugs; Proteasome Endopeptidase Complex; Pyrazines | 2014 |
Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Fatal Outcome; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Neuroimaging; Posterior Leukoencephalopathy Syndrome; Pyrazines | 2014 |
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; HEK293 Cells; Hep G2 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Organometallic Compounds; Peptide Hydrolases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrazines; Pyridines; Ubiquitin; Ubiquitin-Specific Proteases | 2014 |
ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Mice; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Primary Cell Culture; Pyrazines | 2014 |
The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2014 |
Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2014 |
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Movement; Cell Proliferation; Cytokines; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C57BL; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2014 |
Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
Topics: Aged; Antineoplastic Agents; Antineoplastic Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Remission Induction; Renal Dialysis; Thalidomide; Treatment Outcome | 2014 |
Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Pyrazines; Thalidomide; Venous Thromboembolism | 2014 |
[Safety and efficacy of subcutaneous administration of bortezomib in the treatment of multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies | 2014 |
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Survival Rate | 2014 |
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lactate Dehydrogenases; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
CSNK1α1 mediates malignant plasma cell survival.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Casein Kinase Ialpha; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Progression; Gene Expression Profiling; Humans; Interleukin-3; Lentivirus; Mice; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasma Cells; Plasmacytoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2015 |
Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Pyrazines; YY1 Transcription Factor | 2014 |
Chalazia associated with bortezomib therapy for multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chalazion; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Disease Progression; Drug Evaluation; Feasibility Studies; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Sensation Disorders; Thalidomide; Thromboembolism; Transplantation, Autologous | 2014 |
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Boronic Acids; Bortezomib; Coagulants; Coagulation Protein Disorders; Dexamethasone; Doxorubicin; Female; Hematoma; Hematuria; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2014 |
Engineered nanomedicine for myeloma and bone microenvironment targeting.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Delivery Systems; Heterografts; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Multiple Myeloma; Nanoparticles; Neoplasm Transplantation; Neoplasms, Experimental; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrazines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
New data on subcutaneous bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2015 |
An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arm; Boronic Acids; Bortezomib; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2015 |
The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines | 2014 |
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Combined Modality Therapy; Dexamethasone; Disease Progression; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Male; Mediastinal Neoplasms; Middle Aged; Multiple Myeloma; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Osteolysis; Palliative Care; Plasmacytoma; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines; Remission Induction; Salvage Therapy; Sulfonamides; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vemurafenib | 2014 |
High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2014 |
Blood distribution of bortezomib and its kinetics in multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Erythrocyte Count; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma; Pyrazines | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
[Gastrointestinal amyloidosis in a patient with multiple myeloma].
Topics: Abdominal Pain; Amyloidosis; Biopsy; Boronic Acids; Bortezomib; Colon, Sigmoid; Dexamethasone; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Coculture Techniques; Endopeptidases; Gelatinases; Humans; Membrane Proteins; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Serine Endopeptidases; Signal Transduction | 2014 |
The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Taiwan; Treatment Outcome | 2015 |
Amitriptyline-induced agranulocytosis with bone marrow confirmation.
Topics: Agranulocytosis; Amitriptyline; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diagnosis, Differential; Febrile Neutropenia; Female; Filgrastim; Fractures, Spontaneous; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Multiple Myeloma; Osteolysis; Peripheral Nervous System Diseases; Pyrazines; Recombinant Proteins; Urinary Tract Infections | 2014 |
Hepcidin and GDF15 in anemia of multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Dexamethasone; Female; Ferritins; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; Hemoglobins; Hepcidins; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; RNA, Messenger | 2014 |
Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DEAD-box RNA Helicases; Humans; Multiple Myeloma; Mutation; Pyrazines; Ribonuclease III; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2014 |
[Hyperammonemic encephalopathy in multiple myeloma].
Topics: Alkalosis, Respiratory; Ammonia; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Dyspnea; Fatal Outcome; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Rett Syndrome | 2014 |
Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure.
Topics: Adult; Aged; Antineoplastic Agents; Autografts; Boronic Acids; Bortezomib; Disease-Free Survival; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning | 2014 |
Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Topics: Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Asian People; Boronic Acids; Bortezomib; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Treatment Outcome | 2014 |
Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Retrospective Studies; Survivin; Thalidomide; Vincristine | 2014 |
Diffuse parenchymal pulmonary amyloidosis showing an objective response to bortezomib-based chemotherapy.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome | 2014 |
Bortezomib-induced posterior reversible encephalopathy syndrome: clinical and imaging features.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Posterior Leukoencephalopathy Syndrome; Pyrazines; Syndrome | 2014 |
Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunoglobulin G; Karyotyping; Male; Middle Aged; Multiple Myeloma; Mutation; Nitrogen Mustard Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; ras Proteins; Recurrence; Signal Transduction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2014 |
Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human; DNA Copy Number Variations; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prednisone; Pyrazines | 2015 |
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Multiple Myeloma; Propiophenones; Proteasome Inhibitors; Pyrazines | 2014 |
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Myristoylated Alanine-Rich C Kinase Substrate; Neoplasm Transplantation; Phosphorylation; Primary Cell Culture; Pyrazines; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Signal Transduction; Survival Analysis | 2015 |
Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Case-Control Studies; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide; Treatment Outcome | 2014 |
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density; Bone Diseases; Boronic Acids; Bortezomib; Case-Control Studies; Female; Humans; Lenalidomide; Male; Middle Aged; Multidetector Computed Tomography; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Doxorubicin; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Lactams, Macrocyclic; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous | 2014 |
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Membrane Proteins; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Multiple Myeloma; Proto-Oncogene Proteins; Pyrazines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Injections, Subcutaneous; Male; Multiple Myeloma; Pyrazines | 2015 |
Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Female; Humans; Incidence; Infections; Levofloxacin; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2014 |
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lentivirus; Mice; Mice, Inbred NOD; MicroRNAs; Multiple Myeloma; Neoplasm Transplantation; Nuclear Proteins; Ornithine Decarboxylase; Phagosomes; Primary Cell Culture; Proteasome Endopeptidase Complex; Pyrazines; RNA, Small Interfering; Signal Transduction; Survival Analysis | 2015 |
[Modified bortezomib-based combination therapy for multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2014 |
Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Mice; Multiple Myeloma; Polycomb Repressive Complex 2; Pyrazines; Syndecan-1; Xenograft Model Antitumor Assays | 2014 |
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Matched-Pair Analysis; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Survival Rate | 2015 |
SDF-1 inhibition targets the bone marrow niche for cancer therapy.
Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Boronic Acids; Bortezomib; Chemokine CXCL12; Female; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Metastasis; Oligonucleotides; Polyethylene Glycols; Pyrazines | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Edema; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Hypertension, Renal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Oligopeptides; Podocytes; Proteasome Inhibitors; Proteinuria; Pyrazines; Recurrence; Shock, Septic; Teniposide; Thalidomide; Thrombotic Microangiopathies | 2014 |
Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells.
Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acid; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Gene Expression Regulation; Humans; Leukocytes, Mononuclear; Membrane Potential, Mitochondrial; Mitochondria; Multiple Myeloma; NF-kappa B; Pyrazines | 2014 |
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; HSP90 Heat-Shock Proteins; Humans; Mice; Mice, SCID; Monomeric GTP-Binding Proteins; Multiple Myeloma; Mutation; Neoplasm Transplantation; Pyrazines; Pyrazoles; Retinal Pigment Epithelium | 2015 |
The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Electrophoresis; Humans; Immunoglobulin Light Chains; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Thalidomide | 2014 |
A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Examination; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drug Substitution; Female; Humans; Immunohistochemistry; Lenalidomide; Leukemia, Plasma Cell; Leukocyte Common Antigens; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasma Cells; Pyrazines; Remission Induction; Thalidomide; Time Factors; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2014 |
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazines; Pyrazoles; Pyrimidines; Quinazolinones | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Failure | 2015 |
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Dexamethasone; Doxorubicin; Female; Humans; Immunologic Factors; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Vincristine | 2014 |
Resolution of bilateral cystoid macular edema and subfoveal serous retinal detachments after treatment with bortezomib in a patient with "smoldering" multiple myeloma.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Macular Edema; Male; Multiple Myeloma; Pyrazines; Retinal Detachment; Treatment Outcome | 2014 |
In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Case-Control Studies; Cell Line, Tumor; Chemokine CXCL12; Chemotaxis; Coculture Techniques; Humans; I-kappa B Proteins; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Inhibitors; Pyrazines; Serum; Signal Transduction; Tumor Necrosis Factor-alpha | 2014 |
Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress‑mediated cell death in multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Vorinostat | 2015 |
Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Japan; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Pyrazines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Inhibition of PGC-1α after chemotherapy-mediated insult confines multiple myeloma cell survival by affecting ROS accumulation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bortezomib; Catalase; Cell Line, Tumor; Cell Survival; Dexamethasone; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Multiple Myeloma; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pyrazines; Reactive Oxygen Species; RNA, Small Interfering; Superoxide Dismutase; Transcription Factors | 2015 |
Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger | 2015 |
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockout Techniques; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Pyrazines; Transfection | 2014 |
Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Germany; Glucocorticoids; Hematology; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prospective Studies; Pyrazines; Registries | 2014 |
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer Hospital.
Topics: Aged; Antineoplastic Agents; Australia; Boronic Acids; Bortezomib; Cost of Illness; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Pyrazines; Respiratory Tract Infections; Risk Factors; Thalidomide | 2015 |
Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Imidazoles; Indoles; Multiple Myeloma; Naphthoquinones; Necrosis; Proteasome Inhibitors; Purine Nucleosides; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; X-Box Binding Protein 1 | 2015 |
[Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2014 |
Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Cell Communication; Cell Growth Processes; Cytokines; Disease Progression; Female; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Pyrazines; T-Lymphocytes, Regulatory; Treatment Outcome | 2015 |
RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Genes, ras; Humans; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2015 |
[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2014 |
How I treat relapsed myeloma.
Topics: Adult; Allografts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation | 2015 |
CyBorD induction therapy in clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Pyrazines; Remission Induction | 2015 |
TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzyl Alcohols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Janus Kinase 2; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quantitative Structure-Activity Relationship; STAT3 Transcription Factor | 2015 |
[Multiple myeloma and renal impairment].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Kidney Diseases; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines | 2015 |
[The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Stromal Cells; Tumor Microenvironment | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2015 |
Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
Topics: Aged; Bone Marrow Cells; Boronic Acids; Bortezomib; C-Reactive Protein; Creatinine; Disease Progression; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Metaphase; Middle Aged; Multiple Myeloma; Multivariate Analysis; Plasma Cells; Prognosis; Proportional Hazards Models; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2015 |
[Latest advances on the maintenance therapy of multiple myeloma].
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Farnesol; Female; Humans; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
[Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrocardiography; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines | 2015 |
Metabolic signature identifies novel targets for drug resistance in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycolysis; Hexokinase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Mice, SCID; Multiple Myeloma; Pyrazines; Xenograft Model Antitumor Assays | 2015 |
An in vitro and in vivo investigation of the cytotoxic effects of caffeic acid (3,4-dihydroxycinnamic acid) phenethyl ester and bortezomib in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caffeic Acids; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Interleukin-6; Mice; Mice, Inbred BALB C; Multiple Myeloma; NF-kappa B; Phenylethyl Alcohol; Pyrazines; Survival Analysis | 2015 |
NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Topics: Boronic Acids; Bortezomib; Disease-Free Survival; Drug Approval; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2015 |
[Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Humans; Multiple Myeloma; Pyrazines | 2015 |
[Complications and managements in treatment of melphalan, prednisone and new agents].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide | 2015 |
Risk stratification model in elderly patients with multiple myeloma: clinical role of magnetic resonance imaging combined with international staging system and cytogenetic abnormalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Humans; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Models, Biological; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Radiography; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide | 2015 |
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatinine; Female; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Induction Chemotherapy; Kidney; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis | 2015 |
[Carfilzomib in multiple myeloma relapses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Heart; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide | 2015 |
[Improvement of hepatomegaly after treatment with autologous hematopoietic stem cell transplantation followed by bortezomib and dexamethasone in Bence-Jones protein κ-type of multiple myeloma with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bence Jones Protein; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transplantation, Autologous | 2015 |
Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Pyrazines; Vinblastine; Vinorelbine | 2015 |
Immunosurveillance and therapy of multiple myeloma are CD226 dependent.
Topics: Animals; Antibodies, Monoclonal; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Boronic Acids; Bortezomib; CD8-Positive T-Lymphocytes; Crosses, Genetic; CTLA-4 Antigen; Cyclophosphamide; Disease Progression; Genes, myc; Genetic Predisposition to Disease; Immunologic Surveillance; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Pore Forming Cytotoxic Proteins; Programmed Cell Death 1 Receptor; Pyrazines; Receptors, Virus; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2015 |
Immortal time bias and reverse causality in retrospective analysis: Comment on "effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2015 |
Myeloid sarcoma as the initial presentation of chronic myelogenous leukemia, medullary chronic phase in era of tyrosine kinase inhibitors: A report of 11 cases.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Protein Kinase Inhibitors; Pyrazines; Sarcoma, Myeloid; Survival Analysis | 2015 |
[Analysis of prognostic factors in transplant-eligeble newly diagnosed myeloma patients treated with bortezomib plus dexamethasone as induction therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2015 |
[Multiple myeloma recurring as small intestinal polyposis after autologous hematopoietic stem cell transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Polyposis; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2015 |
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Neoplasms, Second Primary; Plasmacytoma; Pyrazines; Remission Induction; Risk; Thalidomide; Treatment Outcome | 2015 |
FDA approves new agent for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Approval; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2015 |
Authors' Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2015 |
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell Survival; Chromosomal Instability; Cluster Analysis; Disease Progression; DNA Damage; DNA Replication; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxidative Stress; Prognosis; Proto-Oncogene Proteins c-myc; Pyrazines; Reactive Oxygen Species; Sulfones | 2015 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Lymphoma, Mantle-Cell; Multiple Myeloma; Oligopeptides; Phosphorylation; Piperidines; Proteasome Inhibitors; Pyrazines; Pyrazoles; Pyrimidines | 2015 |
Safety of a second-generation tyrosine kinase inhibitor and novel targeted therapy for the treatment of a patient with chronic myeloid leukemia and multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiple Myeloma; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines | 2015 |
Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Butanes; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
Topics: Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Logic; Multiple Myeloma; NF-kappa B; Poly(ADP-ribose) Polymerases; Pyrazines; Signal Transduction | 2015 |
Life beyond bortezomib: increasing treatment options in refractory myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines | 2016 |
CSTMP induces apoptosis and mitochondrial dysfunction in human myeloma RPMI8226 cells via CHOP-dependent endoplasmic reticulum stress.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Cytochromes c; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Humans; Mitochondria; Multiple Myeloma; Pyrazines; Resveratrol; Stilbenes; Transcription Factor CHOP; Unfolded Protein Response | 2016 |
[A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents".
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2016 |
[A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2016 |
[Treatment of myeloma in the elderly].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide | 2008 |
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma.
Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Aberrations; Clone Cells; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Melphalan; Models, Biological; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Rats; Stromal Cells; Tumor Cells, Cultured | 2008 |
[Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Receptor, Notch1; Signal Transduction; Tumor Cells, Cultured | 2008 |
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Colony-Forming Units Assay; Drug Synergism; Drug Therapy, Combination; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, SCID; Multiple Myeloma; Oxidoreductases Acting on CH-NH Group Donors; Polyamine Oxidase; Polyamines; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; Humans; Ketones; Membrane Potential, Mitochondrial; Mice; Mitochondria; Multiple Myeloma; Oxidative Stress; Protein Transport; Pyrazines; Pyridines; Signal Transduction; Sulfonamides; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2008 |
[Aggravated post-herpetic neuralgia due to bortezomib].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia, Postherpetic; Protease Inhibitors; Pyrazines; Recurrence | 2008 |
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Osteoblasts; Osteoclasts; Pyrazines; Thalidomide; Transforming Growth Factor beta | 2008 |
[Serum free light chains for diagnosis and follow-up of multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Immunoelectrophoresis; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Reagent Kits, Diagnostic | 2008 |
New treatments in multiple myeloma: beyond optimal treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide | 2008 |
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Osteoclasts; Pulse Therapy, Drug; Pyrazines | 2008 |
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neoplasm Transplantation; Piperazines; Pyrazines; Pyridines | 2008 |
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boric Acids; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Cytochromes c; Diet; Flavonoids; Free Radical Scavengers; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Multiple Myeloma; Protease Inhibitors; Pyrazines; Quercetin | 2008 |
Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib.
Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Heart Failure; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2008 |
Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Pyrazines; Thrombosis | 2008 |
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus Structures; Cycloheximide; Diploidy; Drug Synergism; Endoplasmic Reticulum; Fibroblasts; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Multiple Myeloma; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrazines; RNA, Small Interfering; Vorinostat | 2008 |
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulins; Male; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; United States | 2008 |
Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Time; Treatment Outcome | 2008 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Genes, Reporter; Humans; Interleukin-6; Interleukin-7; Luciferases; Multiple Myeloma; NF-kappa B; Phosphorylation; Pyrazines; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2008 |
Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Etoposide; Hepatic Veno-Occlusive Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genes, Reporter; Green Fluorescent Proteins; Humans; Multiple Myeloma; NF-kappa B; Proteasome Inhibitors; Pyrazines; Stromal Cells | 2008 |
20S ways to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p27; Humans; Multiple Myeloma; Peptides, Cyclic; Protease Inhibitors; Protein Folding; Pyrazines | 2008 |
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Female; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pulmonary Embolism; Pyrazines; Recombinant Proteins; Recurrence; Risk; Treatment Outcome; Venous Thrombosis | 2008 |
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Caspase 2; Cell Line, Tumor; Endoplasmic Reticulum; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Pyrazines; RNA Interference; Subcellular Fractions | 2008 |
Treatment of myeloma--are we making progress?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Melphalan; Multiple Myeloma; Outcome Assessment, Health Care; Prednisone; Pyrazines | 2008 |
Infiltration of the spinal cord in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Disease Progression; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Pyrazines; Spinal Cord Neoplasms | 2008 |
[Clinical characteristics of velcade cumulative effect in resistant and recurrent multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Outcome | 2008 |
Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2008 |
Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Differentiation; Down-Regulation; Humans; Macrophage Colony-Stimulating Factor; Monocytes; Multiple Myeloma; Osteoclasts; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; TNF Receptor-Associated Factor 6 | 2009 |
Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Psoriasis; Pyrazines; Remission Induction | 2008 |
From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Menthol; Middle Aged; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; TRPM Cation Channels | 2008 |
Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dexamethasone; Diterpenes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Epoxy Compounds; Humans; I-kappa B Proteins; Inhibitor of Apoptosis Proteins; Mitochondria; Multiple Myeloma; NF-kappa B; Phenanthrenes; Phosphatidylinositol 3-Kinases; Protein Transport; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptors, Glucocorticoid; Up-Regulation | 2008 |
Bortezomib in combination with dexamethasone for a young multiple myeloma with t(8; 14).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Dexamethasone; Fractures, Bone; Humans; Humerus; In Situ Hybridization, Fluorescence; Male; Multiple Myeloma; Pyrazines; Translocation, Genetic | 2009 |
Immune-mediated neuropathies in myeloma patients treated with bortezomib.
Topics: Action Potentials; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Polyneuropathies; Pyrazines; Reaction Time | 2008 |
Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Esophageal Neoplasms; Fibroblasts; Humans; Mouth Neoplasms; Multiple Myeloma; Pyrazines | 2009 |
Bortezomib-induced neurogenic bladder in patients with multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome; Urinary Bladder, Neurogenic | 2009 |
Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Cyclosporine; Dexamethasone; Drug Hypersensitivity; Exanthema Subitum; Herpesvirus 3, Human; Herpesvirus 6, Human; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prednisone; Pyrazines; Syndrome; Virus Activation | 2009 |
A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin G; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma; Pleura; Pleural Effusion, Malignant; Pyrazines; Tomography, X-Ray Computed | 2009 |
[Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Humans; Leukemia, Plasma Cell; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2008 |
[Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].
Topics: Apoptosis; beta Catenin; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger | 2008 |
Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Integrin alpha Chains; Integrin alpha4; Integrin alpha4beta1; Multiple Myeloma; Neoplasm Proteins; Pyrazines; Vincristine | 2009 |
Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.
Topics: Adenoviridae; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Coumarins; Ergosterol; Genetic Vectors; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; S Phase; Signal Transduction; STAT3 Transcription Factor; Withanolides | 2008 |
Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Mice; Mice, SCID; Multiple Myeloma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Development; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Protease Inhibitors; Pyrazines; Rabbits | 2009 |
Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytokines; Female; Fever; Humans; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stromal Cells | 2008 |
A threshold regression mixture model for assessing treatment efficacy in a multiple myeloma clinical trial.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Health Status Indicators; Humans; Likelihood Functions; Multiple Myeloma; Proportional Hazards Models; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Stochastic Processes; Time Factors; Treatment Outcome | 2008 |
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cooperative Behavior; Drug Industry; Health Knowledge, Attitudes, Practice; Humans; Interdisciplinary Communication; Internet; Japan; Lung Diseases; Mass Media; Medical Staff; Multiple Myeloma; Newspapers as Topic; Patient Selection; Periodicals as Topic; Practice Guidelines as Topic; Pyrazines; Risk Assessment; Societies, Medical | 2008 |
Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Dexamethasone; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Phosphorylation; Pyrazines; Retinoblastoma Protein; Thalidomide; Time Factors; Transfection; Up-Regulation; Vincristine | 2008 |
Delayed complete remission in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Remission Induction; Time Factors | 2008 |
Novel agents in myeloma: an exciting saga.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Thrombosis | 2009 |
Effects of bortezomib on bone disease in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Humans; Mice; Multiple Myeloma; Osteoclasts; Osteolysis; Pyrazines | 2009 |
[Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2008 |
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
Topics: Anti-Inflammatory Agents; Apoptosis; Binding, Competitive; Boronic Acids; Bortezomib; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Humans; Immunoblotting; Multiple Myeloma; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Umbilical Veins | 2009 |
Bortezomib-associated tumor lysis syndrome in multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome | 2008 |
Regulation of multiple myeloma survival and progression by CD1d.
Topics: Antibodies, Monoclonal; Antigens, CD1d; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Aggregation; Cell Survival; Dexamethasone; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Plasma Cells; Pyrazines; Tumor Cells, Cultured | 2009 |
Elucidation of potential bortezomib response markers in mutliple myeloma patients.
Topics: Aged; Antineoplastic Agents; Apolipoprotein C-I; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Chromatography, Liquid; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Mass Spectrometry; Middle Aged; Molecular Weight; Multiple Myeloma; Protein Isoforms; Pyrazines; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Time Factors | 2009 |
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Doxorubicin; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies | 2008 |
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; G1 Phase; Humans; Imidazoles; Melphalan; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinolines; Recombinant Proteins; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2008 |
Induction therapy in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Humans; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2008 |
Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; DNA Fragmentation; Flow Cytometry; Humans; Inhibitory Concentration 50; Killer Cells, Natural; Lymphoma; Mitosis; Models, Biological; Multiple Myeloma; Pyrazines | 2008 |
New evidence in oncologic and cardiocirculatory medicine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Breast Neoplasms; Cardiology; Diagnosis, Computer-Assisted; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Mammography; Medical Oncology; Melphalan; Multiple Myeloma; Prednisone; Pyrazines | 2009 |
Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Herpes Zoster; Herpesvirus 3, Human; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Virus Activation | 2009 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Rate | 2008 |
Bortezomib plus melphalan and prednisone for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Disease Progression; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Survival Analysis; Thalidomide | 2008 |
Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Eruptions; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Salvage Therapy; Vincristine | 2008 |
Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Multiple Myeloma; Pyrazines; TNF-Related Apoptosis-Inducing Ligand | 2009 |
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Survival; Coculture Techniques; Colony-Forming Units Assay; Cyclams; Drug Resistance, Neoplasm; Fibronectins; Flow Cytometry; Heterocyclic Compounds; Humans; Immunoblotting; Immunoenzyme Techniques; Integrin alpha4beta1; Intercellular Adhesion Molecule-1; Lentivirus; Male; Mice; Mice, SCID; Multiple Myeloma; Pyrazines; Receptors, CXCR4; RNA, Messenger; RNA, Small Interfering; Stromal Cells; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Dexamethasone; Enzyme Inhibitors; Fibroblast Growth Factor 3; Humans; In Situ Hybridization, Fluorescence; Multiple Myeloma; Mutation; Protein-Tyrosine Kinases; Pyrazines; Translocation, Genetic | 2009 |
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cohort Studies; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Female; Humans; Immunohistochemistry; Male; Middle Aged; Multiple Myeloma; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Caspases; Cell Adhesion; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Flavones; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Interleukin-6; Male; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Pyrazines; Retinoblastoma Protein; Stromal Cells; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Enzyme Activation; Humans; Leukocyte Common Antigens; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Receptor, IGF Type 1; Tumor Cells, Cultured | 2009 |
Bortezomib-related colon mucositis in a multiple myeloma patient.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colonic Diseases; Humans; Male; Middle Aged; Mucositis; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2009 |
Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Death; Cell Survival; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; G1 Phase; Humans; Leupeptins; Multiple Myeloma; Phosphorylation; Pyrazines; Resting Phase, Cell Cycle | 2009 |
Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Electrophysiology; Female; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prevalence; Pyrazines; Thalidomide | 2008 |
Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance; Gene Expression Regulation; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Protein Biosynthesis; Protein Stability; Protein Subunits; Pyrazines; Ubiquitin; Up-Regulation | 2009 |
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
Topics: Age Factors; Aged; Analysis of Variance; Boronic Acids; Bortezomib; Drug Evaluation; Female; Greece; Humans; Lenalidomide; Male; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma.
Topics: Antibodies; Boronic Acids; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Middle Aged; Multiple Myeloma; Platelet Transfusion; Pyrazines; Salvage Therapy; Transplantation, Homologous | 2009 |
Bortezomib-induced histiocytoid Sweet syndrome.
Topics: Aged; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Sweet Syndrome | 2009 |
[Bortezomib-induced BiP expression and apoptosis in multiple myeloma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger | 2009 |
Cutaneous involvement in multiple myeloma and bortezomib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin A; Melphalan; Multiple Myeloma; Myeloma Proteins; Paresthesia; Peripheral Nervous System Diseases; Plasma Cells; Prednisone; Pyrazines; Remission Induction; Skin; Thalidomide; Xerophthalmia | 2009 |
[Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lumbar Vertebrae; Male; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Plasmacytoma; Protease Inhibitors; Pyrazines; Spinal Neoplasms | 2009 |
Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cystitis; Female; Hemorrhage; Humans; Multiple Myeloma; Pyrazines | 2009 |
A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Disease Progression; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome | 2009 |
Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Enzyme Activation; Immunoglobulin G; Mice; Multiple Myeloma; Neoplasm Transplantation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Burden | 2009 |
Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyrazines | 2009 |
Does bortezomib induce de facto varicella zoster virus reactivation in patients with multiple myeloma?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Herpesvirus 3, Human; Humans; Killer Cells, Natural; Leukocyte Common Antigens; Multiple Myeloma; Pyrazines; Virus Activation | 2009 |
Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; STAT3 Transcription Factor; Transfection | 2009 |
Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome | 2009 |
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
Topics: Antibodies, Monoclonal; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Interleukin-6; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence | 2009 |
[Therapeutic news in multiple myeloma. Congress of the French National Society of Internal Medicine, December 2008, Bordeaux].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; France; Humans; Internal Medicine; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Societies, Medical; Thalidomide | 2009 |
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Dexamethasone; DNA Fragmentation; Doxorubicin; Histocompatibility Antigens Class II; Humans; Mice; Mice, SCID; Multiple Myeloma; Pyrazines | 2009 |
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
Topics: Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2009 |
Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Australia; Boronic Acids; Bortezomib; Cohort Studies; Female; Gastrointestinal Diseases; Humans; International Cooperation; Male; Middle Aged; Multiple Myeloma; New Zealand; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Curcumin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Curcumin; Cytokines; Drug Synergism; Humans; Inflammation Mediators; Multiple Myeloma; Pyrazines; Stromal Cells | 2008 |
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Melphalan; Multicenter Studies as Topic; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines; Remission Induction | 2009 |
Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Virus Activation | 2009 |
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Topoisomerase II Inhibitors | 2009 |
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; I-kappa B Proteins; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Protease Inhibitors; Protein Processing, Post-Translational; Pyrazines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
[Bortezomib-induced neutrophilic dermatosis with CD30+ lymphocytic infiltration].
Topics: Antigens, CD; Antineoplastic Agents; Boronic Acids; Bortezomib; Exanthema; Female; Humans; Ki-1 Antigen; Lymphocytes; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Skin Diseases | 2009 |
[Bortezomib-induced acute neutrophilic dermatosis].
Topics: Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Neutrophils; Pyrazines; Skin Diseases; Sweet Syndrome | 2009 |
High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Proteasome Inhibitors; Protein Biosynthesis; Protein Transport; Pyrazines; RNA, Transfer; Transfer RNA Aminoacylation | 2009 |
New targets of PS-341: BAFF and APRIL.
Topics: Aged; Antineoplastic Agents; B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Delivery Systems; Female; Growth Inhibitors; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Transcription Factors; Tumor Cells, Cultured | 2010 |
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Treatment Outcome | 2009 |
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Interactions; Flavonoids; Humans; Multiple Myeloma; Phenols; Polyphenols; Pyrazines | 2009 |
Effect of autophagy on multiple myeloma cell viability.
Topics: Adenine; Antifungal Agents; Antimalarials; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Boronic Acids; Bortezomib; Cell Proliferation; Chloroquine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunoblotting; Membrane Proteins; Microscopy, Fluorescence; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sirolimus; Thapsigargin; Tumor Cells, Cultured | 2009 |
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Multiple Myeloma; Oligopeptides; Phenotype; Protease Inhibitors; Pyrazines | 2009 |
Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Time Factors | 2009 |
Multiple significant bortezomib-related toxicities in one patient: case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Pruritus; Pyrazines; Testis | 2009 |
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Peripheral Nervous System Diseases; Polyneuropathies; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2.
Topics: Adult; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Immunoglobulin Light Chains; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation, Autologous | 2009 |
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Disease Models, Animal; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Multiple Myeloma; Neovascularization, Pathologic; Osteolysis; Pyrazines | 2009 |
Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Meta-Analysis as Topic; Multiple Myeloma; Pyrazines; Research Design; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous | 2009 |
Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2009 |
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Consensus Development Conferences as Topic; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Medical Oncology; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 10; Caspase 8; Cell Line, Tumor; Drug Synergism; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, T-Cell; Membrane Microdomains; Microscopy, Confocal; Mitochondria; Multiple Myeloma; Phosphorylcholine; Pyrazines; Resveratrol; Signal Transduction; Stilbenes | 2009 |
Bortezomib for the treatment of multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical | 2009 |
[Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
Topics: Acyclovir; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies | 2009 |
Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Fibrosis; Gadolinium; Heart Failure; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Myocardium; Pyrazines | 2010 |
Cutaneous myeloma and bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Skin Neoplasms; Treatment Outcome | 2009 |
Worsening low back pain.
Topics: Acute Kidney Injury; Adult; Biopsy, Needle; Bone Marrow; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diagnosis, Differential; Disease Progression; Family Practice; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Function Tests; Low Back Pain; Male; Multiple Myeloma; Pain Measurement; Plasmapheresis; Pyrazines; Renal Dialysis; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed | 2009 |
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Synergism; Enzyme Activation; HSP27 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Pyrazines; STAT3 Transcription Factor | 2010 |
[A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Plasmacytoma; Prognosis; Pyrazines; Thalidomide | 2009 |
Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Separation; Cyclophosphamide; Dexamethasone; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Thalidomide; Treatment Outcome | 2009 |
Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 2; Boronic Acids; Bortezomib; Case-Control Studies; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Humans; Lenalidomide; Multiple Myeloma; Osteoblasts; Pyrazines; RNA, Messenger; Sp7 Transcription Factor; Thalidomide; Transcription Factors; Tumor Cells, Cultured | 2010 |
[Very good partial response and long time to progression by short-term bortezomib plus dexamethasone therapy for a patient with relapsed and refractory multiple myeloma-a case report].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Time Factors | 2009 |
Donor cell-derived acute lymphocytic leukemia after allogeneic stem cell transplantation for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Tissue Donors; Transplantation, Homologous | 2009 |
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Follow-Up Studies; Gene Deletion; Humans; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Activation of SHIP via a small molecule agonist kills multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Inositol Phosphates; Inositol Polyphosphate 5-Phosphatases; Mice; Multiple Myeloma; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Phosphorylation; Polycyclic Compounds; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction | 2009 |
[Pharmacodynamic characteristics of velcade efficacy in resistant and recurrent multiple myeloma: determination of free light chains of blood serum immunoglobulins].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Neoplasm Staging; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence | 2009 |
Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
Topics: Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neuralgia, Postherpetic; Peripheral Nervous System Diseases; Pyrazines | 2009 |
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Recurrence; Renal Insufficiency; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Cord blood transplantation with a reduced-intensity conditioning regimen for patients with relapsed aggressive multiple myeloma after cytoreduction with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Humans; Insomnia, Fatal Familial; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Transplantation Conditioning | 2009 |
Severe pulmonary complications after bortezomib treatment in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Respiratory Insufficiency; Survival Rate | 2010 |
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Liposomes; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation | 2009 |
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polymorphism, Single Nucleotide; Prognosis; Pyrazines | 2009 |
[PAD regimen for relapsed or refractory patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2009 |
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Topics: Benzoquinones; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; HSP90 Heat-Shock Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Lactams, Macrocyclic; Ligands; Multiple Myeloma; Protein Folding; Pyrazines; Up-Regulation | 2009 |
Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2009 |
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Tissue Inhibitor of Metalloproteinase-1 | 2010 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2009 |
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Case-Control Studies; Cell Communication; Cell Proliferation; Cell Survival; Chemotaxis; Coculture Techniques; Cytokines; Dendritic Cells; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Mice; Mice, SCID; Multiple Myeloma; Oligodeoxyribonucleotides; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, Immunologic; Signal Transduction; T-Lymphocytes; Time Factors; Toll-Like Receptors; Transplantation, Heterologous; Tumor Cells, Cultured | 2009 |
Home administration of bortezomib: making a difference to myeloma patients' lives.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Home Care Services; Humans; Injections, Intravenous; Ireland; Male; Multiple Myeloma; Pilot Projects; Pyrazines; Treatment Outcome | 2010 |
Captivating bortezomib: an active but still mysterious drug.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; NF-kappa B; Pyrazines; Signal Transduction; Treatment Outcome | 2010 |
[Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Myeloma Proteins; Proteome; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
[Update in multiple myeloma: international criteria for treatment response and renal complications].
Topics: Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; France; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Immunologic Factors; International Cooperation; Kidney Diseases; Multiple Myeloma; Practice Guidelines as Topic; Prevalence; Pyrazines; Renal Dialysis; Renal Insufficiency; Sensitivity and Specificity; Societies, Medical | 2009 |
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mesenchymal Stem Cells; Microtubule-Associated Proteins; Multiple Myeloma; Osteoclasts; Phenotype; Plasma Cells; Prognosis; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrazines; Risk Factors; Signal Transduction; Survivin | 2010 |
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Humans; Hyperlipidemias; Lipoma; Male; Middle Aged; Multiple Myeloma; Neoplasms, Multiple Primary; Pyrazines | 2010 |
Bortezomib and restoration of chemosensitivity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines | 2009 |
Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clone Cells; Disease Progression; Female; Humans; Leukemia, Plasma Cell; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Humans; Intercellular Signaling Peptides and Proteins; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide | 2010 |
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Drug Interactions; Humans; Multiple Myeloma; Pyrazines | 2009 |
Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Topics: Acneiform Eruptions; Aged; Boronic Acids; Bortezomib; Candida albicans; Candidiasis; Desonide; Dexamethasone; Doxycycline; ErbB Receptors; Fluconazole; Folliculitis; Humans; Immunologic Factors; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
CYT997 causes apoptosis in human multiple myeloma.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Fluorescent Antibody Technique; G2 Phase; Humans; Mice; Mitosis; Multiple Myeloma; Polymerization; Pyrazines; Pyridines; Pyrimidines; Survival Analysis; Time Factors; Tubulin | 2011 |
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid | 2010 |
Bortezomib induces autophagic death in proliferating human endothelial cells.
Topics: Adenine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Endothelial Cells; Fibroblast Growth Factors; Humans; Microtubule-Associated Proteins; Multiple Myeloma; Protease Inhibitors; Pyrazines; Reactive Oxygen Species | 2010 |
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.
Topics: Apoptosis; Boronic Acids; Bortezomib; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytokines; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Escape | 2010 |
Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Myeloma Proteins; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2010 |
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cardiovascular Diseases; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Gastrointestinal Diseases; Glomerular Filtration Rate; Hematologic Diseases; Humans; Italy; Kidney Diseases; Male; Melphalan; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Proteins; Peripheral Nervous System Diseases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Survival Analysis; Thalidomide | 2010 |
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Survival; Humans; Imidazoles; Multiple Myeloma; Mutation, Missense; Neoplasms, Glandular and Epithelial; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Suppressor Protein p53 | 2009 |
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB | 2009 |
Betulinic acid suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase SHP-1 in human multiple myeloma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Luciferases; Multiple Myeloma; Pentacyclic Triterpenes; Protease Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thalidomide; Triterpenes; Tumor Cells, Cultured | 2010 |
Hematology: first-line bortezomib benefits patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Prognosis; Pyrazines | 2009 |
[IgA pemphigus accompanying multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Immunoglobulin A; Multiple Myeloma; Paraproteinemias; Pemphigus; Proteasome Inhibitors; Pyrazines | 2009 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2009 |
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cells, Cultured; Dexamethasone; Disease Models, Animal; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Panobinostat; Pyrazines; Random Allocation; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2010 |
[Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2009 |
The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Male; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Threonine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation | 2010 |
Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Melphalan; Multiple Myeloma; Paraproteinemias; Pyrazines; Recurrence; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2009 |
Multiple myeloma with multiple and bulky extramedullary plasmacytomas as initial presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pyrazines; Salvage Therapy; Tomography, X-Ray Computed; Vincristine | 2009 |
Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Catechin; Cell Line, Tumor; Humans; Multiple Myeloma; Polymerase Chain Reaction; Pyrazines; RNA, Messenger; Tea; Transcription Factor RelA | 2009 |
Salmonella enteritidis necrotising fasciitis in a multiple myeloma patient receiving bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fasciitis, Necrotizing; Humans; Male; Multiple Myeloma; Pyrazines; Salmonella enteritidis; Salmonella Infections | 2010 |
Treatment of multiple myeloma: 2009 update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2009 |
Combined effects of bortezomib and daunorubicin on multiple myeloma cell KM3 in vitro.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Pyrazines | 2009 |
[Retrospective analysis of 71 cases of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2009 |
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Topics: Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Pyrazines; Thalidomide; Transplantation, Autologous; Vincristine | 2010 |
[IgA multiple myeloma with adverse prognostic factors--a case report].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Humans; Immunoglobulin A; Male; Multiple Myeloma; Prognosis; Pyrazines; Thalidomide | 2009 |
Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Ki-1 Antigen; Male; Multiple Myeloma; Pyrazines; T-Lymphocyte Subsets | 2009 |
Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recovery of Function; Renal Insufficiency; Time Factors; Treatment Outcome | 2010 |
[IgM-lambda multiple myeloma presenting with systemic amyloidosis].
Topics: Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Fatal Outcome; Humans; Immunoglobulin M; Male; Middle Aged; Multiple Myeloma; Paraproteinemias; Pyrazines; Vincristine | 2009 |
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2010 |
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Melphalan; Mice; Mice, SCID; Molecular Structure; Multiple Myeloma; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyridines; STAT3 Transcription Factor; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Topics: Antineoplastic Agents; Bone Remodeling; Boronic Acids; Bortezomib; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Osteoblasts; Osteolysis, Essential; Pyrazines; Sp7 Transcription Factor; Transcription Factors | 2010 |
Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclin D1; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppression Therapy; Lenalidomide; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Second Primary; Pyrazines; Rituximab; Thalidomide; Transplantation, Autologous | 2010 |
Bortezomib: a new pro-apoptotic agent in cancer treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Clinical Trials as Topic; Dexamethasone; Humans; Mice; Multiple Myeloma; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Proteasome Inhibitors; Pyrazines | 2010 |
Inhibition of mTORC1 activity by REDD1 induction in myeloma cells resistant to bortezomib cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Size; Dexamethasone; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Pyrazines; Transcription Factors; Transcriptional Activation | 2010 |
[2-methoxyestradiol disrupts aggresomes induction by bortezomib and potentiates apoptosis in multiple myeloma cells.].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Multiple Myeloma; Pyrazines | 2009 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Risk Management; Risk Reduction Behavior; Thalidomide | 2010 |
Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Capillary Leak Syndrome; Dexamethasone; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Secondary Prevention | 2010 |
The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Topics: 3T3 Cells; Acyltransferases; Animals; Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; DNA Primers; Fibroblast Growth Factor 2; Humans; Mice; Models, Biological; Multiple Myeloma; Osteoblasts; Osteogenesis; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recombinant Proteins; RNA, Messenger; Transcription Factors | 2010 |
Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Galectins; Gene Expression Profiling; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Multiple Myeloma; Mutation; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proto-Oncogene Proteins; Pyrazines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Whole-Body Irradiation; Xenograft Model Antitumor Assays | 2010 |
Multiple myeloma patients experience high response rate with new three-drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Humans; Lenalidomide; Leukocytes; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2009 |
Weekly bortezomib, pegylated liposomal doxorubicin, and dexamethasone is a safe and effective therapy for elderly patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Pyrazines | 2010 |
Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Tissue Donors; Transplantation, Homologous | 2011 |
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Topics: Active Transport, Cell Nucleus; Apoptosis; Boronic Acids; Bortezomib; Calpain; Caspase 8; Cell Line, Tumor; Cell Nucleus; Humans; I-kappa B Proteins; Multiple Myeloma; NF-KappaB Inhibitor alpha; Protease Inhibitors; Pyrazines; Transcription Factor RelA | 2010 |
Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lupus Erythematosus, Cutaneous; Male; Multiple Myeloma; Pyrazines | 2010 |
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Thrombosis; Vincristine | 2010 |
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Frail Elderly; Humans; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Salvage Therapy; Treatment Outcome | 2010 |
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Cell Line, Tumor; Depsipeptides; Down-Regulation; Drug Synergism; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Sp1 Transcription Factor; Xenograft Model Antitumor Assays | 2010 |
Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Renal Insufficiency; Thalidomide; Time Factors; Treatment Outcome; X-Rays | 2010 |
Hyperlipidemia in a myeloma patient after bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Hyperlipidemias; Multiple Myeloma; Pyrazines | 2010 |
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Boronic Acids; Bortezomib; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; T-Lymphocytes | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate Use Trials; Dexamethasone; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Research; Stem Cell Transplantation; Thalidomide | 2010 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease Progression; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Vorinostat | 2010 |
Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lung Diseases, Interstitial; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2010 |
[Analysis of high-risk multiple myeloma patients treated with high-dose chemotherapy].
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pulse Therapy, Drug; Pyrazines; Risk; Survival Rate; Thalidomide; Transplantation, Autologous | 2010 |
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Doxorubicin; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrimidines; Spindle Apparatus; Time Factors; Transplantation, Heterologous; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2010 |
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Multiple Myeloma; Panobinostat; Pyrazines; Thalidomide; Treatment Failure; Treatment Outcome | 2010 |
Complete heart block secondary to bortezomib use in multiple myeloma.
Topics: Aged, 80 and over; Antineoplastic Agents; Autonomic Nervous System; Boronic Acids; Bortezomib; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart Block; Humans; Multiple Myeloma; Pacemaker, Artificial; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2011 |
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2010 |
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Nervous System Diseases; Peripheral Blood Stem Cell Transplantation; Pyrazines; Remission Induction; Retrospective Studies; Thalidomide; Time Factors; Transplantation, Autologous | 2010 |
Treatment of newly diagnosed multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2008 |
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Cohort Studies; Female; Humans; Incidence; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neurologic Examination; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Severity of Illness Index; Vincristine | 2010 |
Bortezomib-induced acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatitis; Pyrazines | 2010 |
Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Coronary Vessels; Dexamethasone; Female; Humans; Multiple Myeloma; Myocardial Infarction; Pyrazines | 2010 |
[Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunoglobulin A; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Severity of Illness Index | 2010 |
Clinical management of myeloma--state of the art.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Pyrazines; Receptors, Glucocorticoid; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyquinolines; Immunoblotting; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Transplantation, Heterologous | 2010 |
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Thalidomide | 2010 |
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytogenetic Analysis; Female; Humans; Immunomodulation; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Thalidomide | 2010 |
The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Caspase 3; Cell Adhesion; Cell Death; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; NF-kappa B; Protein Binding; Pyrazines; Sesquiterpenes; Transcription Factor RelA | 2010 |
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin kappa-Chains; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Living Donors; Multiple Myeloma; Mycophenolic Acid; Protease Inhibitors; Pyrazines; Recurrence; Syndecan-1; Tacrolimus | 2009 |
Bortezomib does not reduce ABO-isoagglutinin titers and may not be useful for ABO-incompatible transplant desensitization.
Topics: ABO Blood-Group System; Antiviral Agents; Blood Group Incompatibility; Boronic Acids; Bortezomib; Cytomegalovirus Infections; Doxorubicin; Ganciclovir; Hemagglutinins; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Valganciclovir | 2009 |
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Sub-Family B Member 4; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Kaplan-Meier Estimate; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrazines; Recurrence; Retrospective Studies; Time Factors | 2010 |
Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Survival Analysis | 2011 |
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Topics: Adult; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Degranulation; Cell Line, Tumor; Cytotoxicity, Immunologic; DNA Primers; Down-Regulation; Humans; In Vitro Techniques; Interleukin-2; K562 Cells; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Frontline regimens for multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Design; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Humans; Multiple Myeloma; Mutation; Neoplasm Proteins; Point Mutation; Proteasome Endopeptidase Complex; Protein Denaturation; Pyrazines; Ubiquitin | 2010 |
Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Multiple Myeloma; Pyrazines | 2010 |
IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; IgA Deficiency; Middle Aged; Multiple Myeloma; Paraproteinemias; Pemphigus; Pyrazines; Remission Induction | 2010 |
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Time Factors | 2010 |
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Humans; Itraconazole; Japan; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Secondary Prevention; Thrombocytopenia; Treatment Outcome | 2010 |
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cyclin D1; Cyclin D2; Cyclin D3; DNA; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Polymerase Chain Reaction; Pyrazines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Individualizing cancer therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin D1; Humans; Multiple Myeloma; Precision Medicine; Pyrazines; Treatment Outcome | 2010 |
Early response assessment in patients with multiple myeloma during anti-angiogenic therapy using arterial spin labelling: first clinical results.
Topics: Aged; Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Reproducibility of Results; Sensitivity and Specificity; Spin Labels; Thalidomide; Treatment Outcome | 2010 |
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Humans; Interleukin-8; Multiple Myeloma; NF-kappa B; Pyrazines; Stromal Cells | 2010 |
Clinical value of absolute lymphocyte counts before bortezomib-dexamethasone therapy in relapsed multiple myeloma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines; Recurrence; Remission Induction; Salvage Therapy | 2010 |
Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Muscular Diseases; Plaque, Amyloid; Protease Inhibitors; Pyrazines | 2010 |
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 4; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; France; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Neoadjuvant Therapy; Prospective Studies; Protease Inhibitors; Pyrazines; Time Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2010 |
Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calcium Channel Blockers; Cell Death; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stress, Physiological; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response; Verapamil | 2010 |
NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Humans; Immunohistochemistry; Mesoderm; Multiple Myeloma; NF-kappa B; Plasma Cells; Pyrazines | 2011 |
Rectal bleeding and diarrhea caused by bortezomib-induced colitis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colitis; Diarrhea; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Rectum | 2010 |
Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2011 |
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Boronic Acids; Bortezomib; Cyclophosphamide; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; DNA, Neoplasm; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Pyrazines; Retrospective Studies; Survival Rate; Thalidomide | 2010 |
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carrier Proteins; Cell Line; Cell Proliferation; Cells, Cultured; Drug Synergism; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Multiple Myeloma; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrazines; Rapamycin-Insensitive Companion of mTOR Protein; TOR Serine-Threonine Kinases | 2010 |
An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Boronic Acids; Bortezomib; Cohort Studies; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Male; Metaphase; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome | 2010 |
[Adverse effects of PAD and VAD regimens in multiple myeloma patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Vincristine | 2010 |
Optimising bortezomib in newly diagnosed multiple myeloma.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thalidomide; Time Factors; Treatment Outcome | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis | 2010 |
A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2011 |
Proteomics of apoptosis of multiple myeloma cells induced by proteasome inhibitor PS-341.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Humans; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Proteome; Proteomics; Pyrazines | 2010 |
[Effect of Velcade combined with Dexamethasone on multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2010 |
Lenalidomide for bortezomib-resistant multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Health Status Indicators; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Failure | 2010 |
Lenalidomide efficacy in bortezomib-resistant myeloma.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Gene Deletion; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Risk Factors; Thalidomide; Treatment Failure | 2010 |
Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Thromboembolism | 2011 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |
Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hepatitis B; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2010 |
Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inositol Polyphosphate 5-Phosphatases; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphoric Monoester Hydrolases; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide; Vanadates | 2010 |
Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2010 |
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Nucleus; Cell Proliferation; Gene Expression Regulation; Gene Silencing; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Membrane Potentials; Multiple Myeloma; Phosphorylation; Pyrazines; RNA Interference; Signal Transduction | 2010 |
Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Secondary Prevention; Young Adult | 2010 |
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Humans; Multiple Myeloma; Phosphoproteins; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteomics; Pyrazines | 2010 |
Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin E; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Transplantation, Autologous | 2010 |
Bortezomib, cyclophosphamide, and dexamethasone: highly effective for rapid reversal of myeloma-associated hyperammonemic encephalopathy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Diseases; Cyclophosphamide; Dexamethasone; Humans; Hyperammonemia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; MAP Kinase Kinase 1; Multiple Myeloma; Pyrazines; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tumor Cells, Cultured | 2010 |
Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Plasmacytoma; Pyrazines; Tomography, X-Ray Computed | 2010 |
Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Diagnostic Imaging; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Protective Agents; Pyrazines | 2011 |
Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
The impact of bortezomib on the risk of thrombosis in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Risk Factors; Thrombosis | 2011 |
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
Topics: Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Parathyroid Hormone; Prognosis; Prospective Studies; Protease Inhibitors; Pyrazines | 2011 |
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Clonazepam; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Multiple Myeloma; Neurilemmoma; Protein Folding; Proteostasis Deficiencies; Pyrazines; Rats; Schwann Cells | 2010 |
First-line treatment of elderly multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Thalidomide | 2010 |
Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.
Topics: Amyloidosis; Antineoplastic Agents; Boronic Acids; Bortezomib; Echocardiography; Heart Diseases; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Myocardium; Protease Inhibitors; Pyrazines; Stroke Volume; Treatment Outcome | 2010 |
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid | 2011 |
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2010 |
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Recurrence; Stroke; Thrombosis; Treatment Outcome | 2010 |
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Gene Expression Profiling; Gene Frequency; Genetic Predisposition to Disease; Humans; Multiple Myeloma; Neoplasm Staging; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vincristine | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Endoribonucleases; Humans; Mice; Models, Biological; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Substrate Specificity; Sulfonamides; Thiophenes; Xenograft Model Antitumor Assays | 2011 |
Role of bortezomib for the treatment of previously untreated multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Transplantation, Autologous | 2008 |
Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
Topics: Apoptosis; Benzopyrans; Boronic Acids; Bortezomib; Butyrates; Caspase 3; Cell Line, Tumor; Cyclin D1; DNA; G1 Phase; Humans; Interleukin-6; Janus Kinase 2; Multiple Myeloma; Phosphorylation; Pyrazines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Drug Discovery; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide; Treatment Outcome | 2010 |
[Effects of xbp-1 gene silencing on bortezomib-induced apoptosis in human multiple myeloma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA-Binding Proteins; Gene Silencing; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; RNA, Small Interfering; Transcription Factors; X-Box Binding Protein 1 | 2010 |
[Bortezomib depresses osteoblast apoptosis induced by mouse myeloma cells].
Topics: 3T3 Cells; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Mice; Multiple Myeloma; Pyrazines | 2010 |
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Survival Rate; Thalidomide; Transplantation, Autologous; Young Adult | 2011 |
A new standard of care in newly diagnosed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoadjuvant Therapy; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Standard of Care; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Complete atrioventricular block secondary to bortezomib use in multiple myeloma.
Topics: Atrioventricular Block; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2011 |
[Bortezomib-based regimen for the treatment of 110 multiple myeloma patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2010 |
Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Multiple Myeloma; Pyrazines; Signal Transduction; STAT3 Transcription Factor; Thalidomide | 2011 |
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome | 2011 |
Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Synergism; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; HL-60 Cells; Humans; Lysosomes; Macrolides; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stress, Physiological; U937 Cells; Unfolded Protein Response | 2011 |
Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Therapy, Combination; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Treatment Outcome | 2010 |
Hematology: Bortezomib and dexamethasone induction for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Remission Induction | 2011 |
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Mitoxantrone; Multiple Myeloma; Polyethylene Glycols; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome; Vincristine | 2011 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Drug Costs; Drug Resistance, Neoplasm; Drug Utilization; Female; France; Health Care Costs; Hospitals, University; Humans; Lenalidomide; Male; Medical Records; Middle Aged; Multiple Myeloma; Practice Patterns, Physicians'; Pyrazines; Recurrence; Retrospective Studies; Thalidomide | 2011 |
Bortezomib-induced inflammatory neuropathy.
Topics: Boronic Acids; Bortezomib; Humans; Inflammation; Inflammation Mediators; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nervous System Diseases; Pyrazines | 2010 |
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinases; Cytokines; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Pyrazines; Signal Transduction; Stromal Cells; Survival Analysis; Transcription, Genetic; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Boronic Acids; Bortezomib; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; I-kappa B Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; NF-kappa B p52 Subunit; Polymorphism, Single Nucleotide; Pyrazines; Risk Assessment; Risk Factors; TNF Receptor-Associated Factor 3; Treatment Outcome | 2011 |
Genetic variation associated with bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; Cathepsins; Clinical Trials, Phase III as Topic; CTLA-4 Antigen; Female; Genetic Association Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Pyrazines; Randomized Controlled Trials as Topic; Schwann Cells; Transcription Factor 4; Transcription Factors | 2011 |
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Death; Cell Survival; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Biological; Multiple Myeloma; Phagosomes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Denaturation; Pyrazines | 2011 |
Clinical and biological features of t(4;14) multiple myeloma: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Flow Cytometry; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Survival Rate; Translocation, Genetic | 2011 |
Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Multiple Myeloma; Plasma Cells; Point Mutation; Pyrazines; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2011 |
Re-transplantation after bortezomib-based therapy.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies | 2011 |
Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Cohort Studies; Female; Health Services for the Aged; Humans; Male; Multiple Myeloma; Pyrazines | 2011 |
RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genome, Human; High-Throughput Screening Assays; Humans; Microarray Analysis; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Fluorescent Antibody Technique; Humans; Male; Middle Aged; Multiple Myeloma; Neuralgia; Polyneuropathies; Pyrazines; Skin | 2011 |
Three cases of bortezomib-resistant multiple myeloma with extramedullary masses.
Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2010 |
Multiple myeloma: interplay between osteoblastogenesis and adipogenesis.
Topics: Adipogenesis; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines | 2011 |
Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Humans; In Situ Nick-End Labeling; Iridoid Glycosides; Iridoids; Multiple Myeloma; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor | 2011 |
A new combination for advanced multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Pyrazines | 2011 |
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Denmark; Female; Genetic Association Studies; Humans; Interferon-alpha; Interleukin-1beta; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; NF-kappa B p50 Subunit; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prognosis; Promoter Regions, Genetic; Pyrazines; Recombinant Proteins; Survival Analysis; Thalidomide | 2011 |
Recent advances in myeloma treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Medical Oncology; Melphalan; Multiple Myeloma; Oligopeptides; Prednisone; Pyrazines; Quality of Life; Salvage Therapy; Stem Cell Transplantation; Thalidomide | 2011 |
[Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Creatine; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2011 |
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Female; Germany; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Retreatment; Retrospective Studies; Survival Rate; Switzerland; Treatment Outcome | 2010 |
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
Successful treatment of early relapse of ocular myeloma with bortezomib and steroid after autologous stem cell transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Eye Neoplasms; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Plasmacytoma; Prednisolone; Pyrazines; Recurrence; Stem Cell Transplantation | 2010 |
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Pyrazines; Zoledronic Acid | 2011 |
[Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].
Topics: Aged; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
[A case of aggressive multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prednisolone; Pyrazines | 2011 |
Renal failure caused by plasma cell infiltration in multiple myeloma.
Topics: Bence Jones Protein; Boronic Acids; Bortezomib; Female; Humans; Kidney; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines; Renal Insufficiency | 2011 |
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Control Studies; Cytokine Receptor gp130; Female; GATA2 Transcription Factor; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Receptors, CXCR4; T-Lymphocyte Subsets; Thalidomide; Transplantation, Autologous | 2011 |
[Meningeal plasmacytoma: delayed diagnosis with sequelae].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Edema; Cerebral Hemorrhage; Contrast Media; Delayed Diagnosis; Dexamethasone; Diagnostic Errors; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Multiple Myeloma; Neurologic Examination; Pyrazines; Tomography, X-Ray Computed | 2011 |
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; HCT116 Cells; Heat-Shock Response; HeLa Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteostasis Deficiencies; Puromycin; Pyrazines | 2011 |
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Doxorubicin; Female; Humans; Male; Multiple Myeloma; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies | 2011 |
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
Topics: Activated Protein C Resistance; Aged; Anticoagulants; Aspirin; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunologic Factors; International Normalized Ratio; Lenalidomide; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Risk Factors; Thalidomide; Thrombosis; Venous Thromboembolism; Warfarin | 2011 |
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Transformation, Neoplastic; Gene Expression Profiling; Humans; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Mutation; Proto-Oncogene Proteins c-myc; Pyrazines; ras Proteins; Survival Rate | 2011 |
[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease Progression; Drug Therapy, Combination; Graft vs Tumor Effect; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2011 |
Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Boronic Acids; Bortezomib; Cadherins; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Fibronectins; Focal Adhesion Kinase 1; Gene Knockdown Techniques; Gene Silencing; Humans; Integrin beta Chains; Melphalan; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-maf; Pyrazines; rac1 GTP-Binding Protein; src-Family Kinases; Stem Cell Transplantation; Sumoylation; Transcription Factor RelA; Transplantation, Autologous; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Bortezomib-based chemotherapy for light chain deposition disease presenting as acute renal failure.
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Immunoglobulin kappa-Chains; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Remission Induction | 2012 |
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival; Thalidomide; Thrombocytopenia; Time Factors | 2011 |
Subcutaneous bortezomib: a step towards optimised drug use.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Injections, Subcutaneous; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Quality of Life; Recurrence | 2011 |
History of multiple myeloma.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Bence Jones Protein; Boronic Acids; Bortezomib; History, 19th Century; History, Ancient; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Paraproteinemias; Prednisone; Proteinuria; Pyrazines; Stem Cell Transplantation; Thalidomide; Urethane | 2011 |
Allogeneic transplantation in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Mice; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Thalidomide; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Autophagy; Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; Free Radical Scavengers; Multiple Myeloma; Neuroprotective Agents; Peripheral Nervous System Diseases; Pyrazines; Rats; Schwann Cells | 2011 |
Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; MicroRNAs; Multiple Myeloma; Pyrazines; Stromal Cells; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2011 |
Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Comorbidity; Endemic Diseases; Female; Hepatitis B; Humans; Immunologic Factors; Incidence; Lamivudine; Male; Middle Aged; Multiple Myeloma; Prevalence; Prospective Studies; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Stem Cell Transplantation; Transplantation, Autologous; Virus Activation | 2012 |
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Boronic Acids; Bortezomib; Female; Humans; Magnetic Resonance Imaging; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2011 |
[The significances of 13q14 deletion for development and prognosis of multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 13; Female; Flow Cytometry; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines | 2011 |
[Effect of different regimens on bone disease of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand; Thalidomide | 2011 |
[The clinical study on treatment with bortezomib for multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2011 |
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catalytic Domain; Cell Line, Tumor; Cell Membrane Permeability; Humans; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Trypsin | 2011 |
Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
Topics: Acyclovir; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome | 2011 |
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Middle Aged; Multiple Myeloma; Pharmacogenetics; Prognosis; Proteasome Endopeptidase Complex; Pyrazines; Risk; RNA-Binding Proteins; Up-Regulation | 2011 |
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cyclophosphamide; Drug Resistance, Neoplasm; Hospitals, University; Humans; Immunologic Factors; Leukemia, Plasma Cell; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Severity of Illness Index; Survival Analysis | 2011 |
Proteotoxic stress targeted therapy (PSTT).
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytoprotection; Drug Resistance, Neoplasm; Drug Synergism; Heat-Shock Proteins; Humans; Hyperthermia, Induced; Molecular Chaperones; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Folding; Pyrazines | 2011 |
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Separation; Hematopoietic Stem Cells; Humans; Magnetics; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Rituximab; Transplantation, Autologous | 2011 |
Renal improvement in myeloma with bortezomib plus plasma exchange.
Topics: Acute Kidney Injury; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Glomerular Filtration Rate; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines | 2011 |
Heat shock proteins and cancer therapy: the trail grows hotter!
Topics: Animals; Antineoplastic Agents; Boronic Acids; Humans; Multiple Myeloma; Proteasome Inhibitors; Proteostasis Deficiencies; Pyrazines | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kaplan-Meier Estimate; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Sweden; Thalidomide | 2011 |
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2012 |
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clodronic Acid; Femur; Humans; Male; Multiple Myeloma; Osteolysis; Pyrazines; Radiography; Recurrence; Remission Induction | 2011 |
Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Cell Survival; Coculture Techniques; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Multiple Myeloma; Pyrazines; Stromal Cells; Up-Regulation | 2011 |
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Transcriptome | 2012 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
[Effect of curcumin in combination with bortezomib on proliferation and apoptosis of human multiple myeloma cell line H929 and its mechanism].
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Drug Therapy, Combination; Humans; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor RelA | 2011 |
[Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Treatment Outcome; Young Adult | 2011 |
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2011 |
The micros in harmony: microRNA and microenvironment.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Humans; MicroRNAs; Multiple Myeloma; Pyrazines | 2011 |
Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma.
Topics: Animals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Dexamethasone; Doxorubicin; Female; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor I; Interleukin-6; Lactones; Mice; Mitosis; Multiple Myeloma; Protective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Stromal Cells; Xenograft Model Antitumor Assays | 2011 |
Bortezomib in patients with renal impairment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Diarrhea; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Survival Analysis | 2011 |
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotaxis; Dependovirus; Drug Synergism; Endothelial Cells; Fibroblast Growth Factor 2; Galectin 3; Green Fluorescent Proteins; Humans; Immunoglobulin E; Immunoglobulin lambda-Chains; Integrin alphaVbeta3; Mice; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Pyrazines; Umbilical Veins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Janus Kinase 1; Melphalan; Multiple Myeloma; Phosphorylation; Pyrazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Stromal Cells | 2011 |
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous | 2012 |
Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunoglobulin A; Lenalidomide; Middle Aged; Multiple Myeloma; Pemphigus; Pyrazines; Remission Induction; Thalidomide | 2011 |
Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Checkpoints; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; G1 Phase; HSP90 Heat-Shock Proteins; Humans; MAP Kinase Kinase Kinases; Multiple Myeloma; Pyrazines; Pyridones; Pyrimidines; Signal Transduction; STAT3 Transcription Factor | 2011 |
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Chromosome Aberrations; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Models, Biological; Multiple Myeloma; Peptide Hydrolases; Pyrazines; RNA, Small Interfering; Thalidomide; Ubiquitin-Protein Ligases | 2011 |
Successful bone reconstruction after bortezomib therapy in a myeloma patient.
Topics: Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Pyrazines; Radiography; Treatment Outcome | 2011 |
[Effects of bortezomib combined with methylprednisolone in treatment of 33 cases of relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Retrospective Studies; Treatment Outcome | 2011 |
Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Middle Aged; Multiple Myeloma; Prognosis; Proteinuria; Pyrazines; Remission Induction | 2012 |
Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Models, Economic; Multiple Myeloma; Norway; Pyrazines; Quality of Life; Quality-Adjusted Life Years; Thalidomide | 2011 |
[Pneumonia and Rothia dentocariosa].
Topics: Actinomycetales Infections; Amoxicillin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Immunocompromised Host; Melphalan; Micrococcaceae; Middle Aged; Multiple Myeloma; Pneumonia, Bacterial; Pyrazines | 2011 |
Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Kidney Diseases; Kidney Transplantation; Multiple Myeloma; Plasmapheresis; Pyrazines; Remission Induction | 2011 |
Managing light chain deposition disease.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney Failure, Chronic; Male; Multiple Myeloma; Pyrazines | 2012 |
Renal improvement in myeloma with plasma exchange.
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Multiple Myeloma; Plasma Exchange; Pyrazines | 2011 |
Renal improvement in myeloma with plasma exchange.
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Immunoglobulin Light Chains; Multiple Myeloma; Plasma Exchange; Pyrazines | 2011 |
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; BRCA1 Protein; Cell Line, Tumor; Cells, Cultured; DNA Repair; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Rad51 Recombinase; RNA, Messenger; Survival Analysis; Xenograft Model Antitumor Assays | 2011 |
Sudden significant total protein concentration change: not an analytical problem.
Topics: Aged; Antineoplastic Agents; Blood Proteins; Boronic Acids; Bortezomib; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Serum Albumin; Serum Globulins; Thalidomide | 2011 |
Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Endopeptidase Complex; Pyrazines; Thalidomide; Up-Regulation | 2011 |
A third-generation IMiD for MM.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Lenalidomide; Male; Multiple Myeloma; Pyrazines; Thalidomide | 2011 |
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
Topics: Amino Acid Substitution; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Mutation; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Immunohistochemistry; Mice; Multiple Myeloma; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2011 |
Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Heart Failure; Humans; Multiple Myeloma; Pyrazines | 2012 |
Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Multivariate Analysis; Neoplastic Cells, Circulating; Plasma Cells; Prognosis; Prospective Studies; Pyrazines; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma.
Topics: Amyloid Precursor Protein Secretases; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Flow Cytometry; Humans; Multiple Myeloma; Pyrazines; Real-Time Polymerase Chain Reaction | 2011 |
Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Multiple Myeloma; Polyploidy; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Humans; Multiple Myeloma; Practice Guidelines as Topic; Pyrazines; Quality-Adjusted Life Years; State Medicine; Thalidomide; Treatment Outcome; United Kingdom | 2011 |
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Topics: Activating Transcription Factor 6; Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; HEK293 Cells; HeLa Cells; Humans; Immunoglobulins; Jurkat Cells; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Transcription Factors; Treatment Outcome; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cells, Cultured; Endoplasmic Reticulum Stress; Humans; Mice; Multiple Myeloma; Neoplasm Transplantation; Oncolytic Virotherapy; Orthoreovirus, Mammalian; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transplantation, Heterologous | 2012 |
Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Synergism; Humans; Immunoblotting; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2012 |
Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Scleromyxedema | 2011 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
[Effect of proteasome inhibitor on migration ability and hepatocyte growth factor expression of bone marrow mesenchymal stem cells in multiple myeloma patients].
Topics: Adult; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Movement; Female; Hepatocyte Growth Factor; Humans; Male; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2011 |
[Bortezomib combined with autologous peripheral blood hematopoietic stem cell transplantation for therapy of patients with multiple myeloma].
Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Transplantation Conditioning | 2011 |
Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin D; Multiple Myeloma; Pyrazines; Treatment Outcome | 2011 |
Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Flow Cytometry; Humans; Multiple Myeloma; Neoplasm Transplantation; Pyrazines; Real-Time Polymerase Chain Reaction; Turkeys; Xenograft Model Antitumor Assays | 2011 |
Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Nucleus; Chromosomes, Human, Pair 1; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Pyrazines | 2012 |
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Morphogenetic Proteins; Bone Remodeling; Boronic Acids; Bortezomib; Female; Genetic Markers; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Microarray Analysis; Multicenter Studies as Topic; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Treatment Failure; Up-Regulation | 2012 |
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Breast Neoplasms; Carboxypeptidases; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Microarray Analysis; Multiple Myeloma; Piperidones; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin Thiolesterase; Ubiquitination | 2011 |
Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.
Topics: Adult; Aged; Antibiotic Prophylaxis; Boronic Acids; Bortezomib; Drugs, Chinese Herbal; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Isatis; Male; Middle Aged; Multiple Myeloma; Phytotherapy; Plant Roots; Pyrazines | 2011 |
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thalidomide; Treatment Outcome | 2012 |
Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Proliferation; G2 Phase; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Proteins; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering | 2011 |
Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Unfolded Protein Response | 2012 |
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Survival Analysis; Thalidomide; Treatment Outcome | 2011 |
KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Panobinostat; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors | 2012 |
What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous stem cell transplantation in multiple myeloma and what is the risk of developing a secondary primary malignancy?
Topics: Boronic Acids; Bortezomib; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Risk Factors; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
From the observation DAC: romidepsin revisited.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Depsipeptides; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2011 |
Innovation in myeloma treatments PARP excellence!
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Enzyme Inhibitors; Humans; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2011 |
[Effect of BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib in multiple myeloma cells in vitro].
Topics: B-Cell Activating Factor; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Multiple Myeloma; Pyrazines; RNA, Messenger; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Orthopaedics: Structural support.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Boronic Acids; Bortezomib; Diphosphonates; Etidronic Acid; Humans; Intercellular Signaling Peptides and Proteins; Kyphoplasty; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines | 2011 |
Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neuroblastoma; Peptides, Cyclic; Proteasome Inhibitors; Pyrazines; Urea | 2012 |
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Topics: Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2012 |
[Lung injury associated with bortezomib therapy in Japan].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Product Surveillance, Postmarketing; Pyrazines | 2011 |
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Gene Expression Profiling; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NEDD8 Protein; Pyrazines; Treatment Outcome; Ubiquitin-Activating Enzymes; Ubiquitination; Ubiquitins; Xenograft Model Antitumor Assays | 2012 |
Microscale functional cytomics for studying hematologic cancers.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cells, Cultured; Cellular Microenvironment; Coculture Techniques; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Immunohistochemistry; Multiple Myeloma; NF-kappa B; Pyrazines; STAT3 Transcription Factor; Stromal Cells; Tumor Necrosis Factor-alpha | 2012 |
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Genes, Reporter; Histone Deacetylase Inhibitors; HIV Protease Inhibitors; Humans; Luciferases; Mice; Multiple Myeloma; Nelfinavir; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Xenograft Model Antitumor Assays | 2012 |
Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Combined Modality Therapy; Databases, Factual; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis; Thalidomide | 2012 |
[Unusual skin alterations in a 72-year-old patient with multiple myeloma].
Topics: Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Skin Diseases; Treatment Outcome | 2012 |
[Modern times: back to past, back to future].
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multiple Myeloma; Pyrazines; Rituximab; Vidarabine | 2012 |
Incorporating monoclonal antibodies into the therapy of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Severity of Illness Index | 2012 |
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2012 |
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Growth Differentiation Factor 15; Humans; Lenalidomide; Male; Melphalan; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Signal Transduction; Thalidomide | 2012 |
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Salvage Therapy; Thalidomide | 2012 |
Multiple myeloma presenting with hepatosplenomegaly.
Topics: Abdomen; Adult; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnosis, Differential; Fatal Outcome; Female; Hepatomegaly; Humans; Multiple Myeloma; Pyrazines; Splenomegaly; Tomography, X-Ray Computed; Ultrasonography | 2011 |
Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Inhibitory Concentration 50; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor Protein-Tyrosine Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
[Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens].
Topics: Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Boronic Acids; Bortezomib; Electrophoresis, Gel, Two-Dimensional; Female; Humans; Male; Mass Spectrometry; Multiple Myeloma; Proteomics; Pyrazines | 2012 |
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Crystallography, X-Ray; Drug Design; Enzyme Inhibitors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Saccharomyces cerevisiae; Threonine | 2012 |
Timing of the high-dose therapy in the area of new drugs.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Humans; Melphalan; Multiple Myeloma; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2011 |
Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Pyrazines | 2012 |
In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
Topics: Adipose Tissue; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemotaxis; Coculture Techniques; Culture Media, Conditioned; Gene Expression; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Metaphase; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
[Current perspectives in the treatment of multiple myeloma - news and views].
Topics: Age Factors; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Melphalan; Multiple Myeloma; Prognosis; Pyrazines; Renal Insufficiency; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous | 2012 |
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Estradiol; Humans; Multiple Myeloma; Pyrazines; Regulatory Factor X Transcription Factors; Transcription Factors; Tretinoin; Tumor Cells, Cultured; X-Box Binding Protein 1 | 2012 |
Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, myc; Humans; Mice; Mice, Congenic; Mice, Inbred C57BL; Mice, Transgenic; Multiple Myeloma; Myeloma Proteins; Neoplasm Transplantation; Predictive Value of Tests; Pyrazines | 2012 |
Bortezomib-associated fatal liver failure in a haemodialysis patient with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury; Cholestasis; Fatal Outcome; Humans; Liver Failure; Male; Multiple Myeloma; Pyrazines; Renal Dialysis | 2012 |
High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Renal Dialysis; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2012 |
Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Hemodiafiltration; Humans; Immunoglobulin Light Chains; Kidney; Kidney Diseases; Multiple Myeloma; Pyrazines | 2012 |
Multiple myeloma: treatment evolution.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Melphalan; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Young Adult | 2012 |
Frontline treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Stem cell transplantation for multiple myeloma: current and future status.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Developing Countries; History, 20th Century; History, 21st Century; Humans; Lenalidomide; Multiple Myeloma; Patient Care; Pyrazines; Stem Cell Transplantation; Thalidomide | 2012 |
Targeted therapy of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Pyrazines; Secondary Prevention; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2012 |
Why is management of cancer pain still a problem?
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Colorectal Neoplasms; Female; Healthcare Disparities; Humans; Lung Neoplasms; Male; Multiple Myeloma; Pain Management; Practice Patterns, Physicians'; Prostatic Neoplasms; Pyrazines | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Bortezomib-induced severe autonomic neuropathy.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Severity of Illness Index | 2012 |
[Prognostic significance of morphology in multiple myeloma].
Topics: Aged; Antineoplastic Agents; Bone Marrow; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous | 2012 |
[Improved prognosis in light chain nephropathy due to multiple myeloma].
Topics: Acute Kidney Injury; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Kidney Diseases; Middle Aged; Multiple Myeloma; Paraproteinemias; Prognosis; Pyrazines; Stem Cell Transplantation | 2012 |
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Activation; Enzyme Inhibitors; Humans; Interleukin-6; Lactams, Macrocyclic; Mice; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; RNA Splicing; RNA, Messenger; Signal Transduction; Stromal Cells; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
[Effects of triptolide on bortezomib-induced apoptosis in multiple myeloma cells].
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Humans; Multiple Myeloma; Phenanthrenes; Pyrazines | 2012 |
Effective response with bortezomib retreatment in relapsed multiple myeloma--a multicentre retrospective survey in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Switzerland; Time Factors; Treatment Outcome | 2012 |
Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Topics: Antigen-Antibody Complex; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Gamma Rays; Humans; Melanoma; Multiple Myeloma; Neoplasm Proteins; Pinocytosis; Pyrazines; Skin Neoplasms; Treatment Outcome | 2012 |
Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
Topics: Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Communication; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Coculture Techniques; Humans; Interleukin-6; Lipopolysaccharide Receptors; Macrophages; Mesenchymal Stem Cells; Multiple Myeloma; Pyrazines | 2012 |
[Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Constipation; Dexamethasone; Female; Humans; Intestinal Pseudo-Obstruction; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence | 2012 |
Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
Topics: Antineoplastic Agents; Antiprotozoal Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Italy; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Multiple Myeloma; Opportunistic Infections; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2012 |
Bortezomib and bilateral herpes zoster.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation | 2012 |
Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-κB/JNK.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Curcumin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines; Transcription Factor RelA | 2012 |
Effects of brucine on bone metabolism in multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone and Bones; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Culture Media; Humans; Inhibitory Concentration 50; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteoprotegerin; Polymerase Chain Reaction; Pyrazines; RANK Ligand; RNA, Messenger; RNA, Neoplasm; Stem Cells; Strychnine | 2012 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygenase-1; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide; Tumor Cells, Cultured | 2012 |
Anti-myeloma effects of the novel anthracycline derivative INNO-206.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Humans; Hydrazones; Mice; Multiple Myeloma; Neoplasms, Experimental; Neovascularization, Pathologic; Pyrazines | 2012 |
Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prognosis; Pyrazines; Remission Induction; Retrospective Studies; Stem Cells; Thalidomide; Vincristine | 2012 |
Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Infusions, Subcutaneous; Male; Multiple Myeloma; Pyrazines | 2012 |
Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Remission Induction; Survival Rate; Thalidomide; Treatment Outcome; Vincristine | 2012 |
Breathless on bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pyrazines | 2011 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Humans; Lenalidomide; Liver Neoplasms; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Recurrence; Thalidomide; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
Topics: Adult; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
Topics: Administration, Oral; Aged; Analgesics, Opioid; Antineoplastic Agents; Boronic Acids; Bortezomib; Delayed-Action Preparations; Humans; Middle Aged; Multiple Myeloma; Oxycodone; Peripheral Nervous System Diseases; Pyrazines; Rome | 2012 |
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Plasma Cells; Pyrazines | 2012 |
Extramedullary involvement: an emerging problem in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines | 2012 |
Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy : case report.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA, Viral; Hepatitis B; Hepatitis B virus; Humans; Male; Multiple Myeloma; Pyrazines; Virus Activation | 2012 |
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cytotoxins; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factors; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Substrate Specificity; Time Factors; Xenograft Model Antitumor Assays | 2012 |
Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
Topics: Aged; Antiviral Agents; Boronic Acids; Bortezomib; Cytomegalovirus; Cytomegalovirus Infections; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Pyrazines; Retrospective Studies; Risk Factors; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Viral Load; Viremia; Virus Activation | 2012 |
Family haploidentical donor-derived cytokine-induced killer cell biotherapy combined with bortezomib in two patients with relapsed multiple myeloma in a non-allogeneic transplant setting.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Cytokine-Induced Killer Cells; Humans; Immunotherapy, Adoptive; Male; Multiple Myeloma; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome | 2013 |
Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines | 2012 |
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Prednisone; Prognosis; Pyrazines; Renal Insufficiency; Survival Rate; Thalidomide; Vincristine | 2013 |
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Epoxy Compounds; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Oligopeptides; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Interferon Regulatory Factors; Lenalidomide; Multiple Myeloma; PAX5 Transcription Factor; Phenotype; Positive Regulatory Domain I-Binding Factor 1; Prognosis; Proto-Oncogene Proteins c-bcl-6; Pyrazines; Regulatory Factor X Transcription Factors; Repressor Proteins; Syndecan-1; Thalidomide; Transcription Factors; X-Box Binding Protein 1 | 2012 |
[Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Plasmacytoma; Prognosis; Pyrazines; Retrospective Studies | 2012 |
[The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2012 |
[It is not necessary to use novel agents to all patients with newly diagnosed myeloma as an initial therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Analysis; Thalidomide | 2012 |
Shoulder X-ray--a clue to multiple myeloma.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Diagnosis, Differential; Female; Humans; Multiple Myeloma; Pyrazines; Radiography; Shoulder Joint; Shoulder Pain; Synovitis; Treatment Outcome | 2012 |
Transplantation for myeloma: work in progress.
Topics: Boronic Acids; Bortezomib; Female; Humans; Male; Multiple Myeloma; Pyrazines | 2012 |
Quantitative profiling of caspase-cleaved substrates reveals different drug-induced and cell-type patterns in apoptosis.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Boronic Acids; Bortezomib; Caspases; Cytotoxins; Drug Screening Assays, Antitumor; Humans; Jurkat Cells; Kinetics; Multiple Myeloma; Neoplasm Proteins; Proteome; Pyrazines | 2012 |
Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Humans; Ireland; Kidney Function Tests; Middle Aged; Multiple Myeloma; Pyrazines; Renal Dialysis | 2012 |
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.
Topics: Animals; B-Cell Maturation Antigen; Bone Marrow; Boronic Acids; Bortezomib; Cell Membrane; Culture Media, Conditioned; Cyclophosphamide; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunoglobulin G; Kaplan-Meier Estimate; Mice; Mice, SCID; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Plasma Cells; Pyrazines; Tumor Burden; Tumor Cells, Cultured | 2012 |
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cyclohexanones; Doxorubicin; Epoxy Compounds; Humans; Leukocytes, Mononuclear; Mice; Multiple Myeloma; NF-kappa B; Osteoclasts; Pyrazines; RANK Ligand; Signal Transduction; Transplantation, Heterologous | 2012 |
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2012 |
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, SCID; Multiple Myeloma; Patched Receptors; Patched-1 Receptor; Plasma Cells; Pyrazines; Pyridines; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Syndecan-1 | 2012 |
Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Topics: Activating Transcription Factor 3; Animals; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Mice; Mice, Nude; Multiple Myeloma; Nelfinavir; Protease Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2012 |
Bortezomib-induced thrombotic thrombocytopaenic purpura.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Boronic Acids; Bortezomib; Confusion; Female; Humans; Multiple Myeloma; Plasma Exchange; Plasmapheresis; Platelet Count; Prognosis; Purpura, Thrombotic Thrombocytopenic; Pyrazines; Severity of Illness Index; Treatment Outcome | 2012 |
Minor clone provides a reservoir for relapse in multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Boronic Acids; Bortezomib; Chromosome Aberrations; Clone Cells; Dexamethasone; Disease Progression; Evolution, Molecular; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Sequence Data; Multiple Myeloma; Mutation; Neoplasm Recurrence, Local; NF-kappa B; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Pyrazines; Real-Time Polymerase Chain Reaction; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid; Tumor Suppressor Protein p53 | 2013 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Muscle Weakness; Neutropenia; Pneumonia; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome | 2013 |
Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; I-kappa B Kinase; I-kappa B Proteins; Male; Mice; Mice, Nude; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Pyrazines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Profiling; Humans; Imidazoles; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Pyrazines; Receptor, IGF Type 1; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Immunoglobulin Light Chains; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2012 |
Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythema; Humans; Injections, Subcutaneous; Multiple Myeloma; Phlebitis; Pyrazines | 2012 |
Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Screening Assays, Antitumor; Flavonoids; Humans; Mice; Multiple Myeloma; Oncogenes; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyrimidine Nucleosides; Translocation, Genetic; Treatment Outcome; Tubercidin | 2012 |
Cutaneous amyloid elastosis revealing multiple myeloma with systemic amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Dexamethasone; Diagnostic Errors; Elastic Tissue; Fatal Outcome; Female; Humans; Melphalan; Multiple Myeloma; Predictive Value of Tests; Pseudoxanthoma Elasticum; Pyrazines; Skin; Treatment Outcome | 2013 |
Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Multiple Myeloma; Protein Binding; Pyrazines | 2012 |
Outcomes of patients with multiple myeloma and renal impairment treated with bortezomib, cyclophosphamide, and dexamethasone without plasma exchange.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Creatinine; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Exchange; Pyrazines; Renal Insufficiency; Retrospective Studies; Treatment Outcome | 2012 |
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Lenalidomide; Mice; Mice, SCID; Molecular Sequence Data; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Proto-Oncogene Proteins c-mdm2; Pyrazines; Random Allocation; Thalidomide; Thiophenes; Ubiquitin Thiolesterase; Ubiquitin-Specific Peptidase 7; Xenograft Model Antitumor Assays | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezomib; Caspases; Cell Survival; Humans; I-kappa B Proteins; Lenalidomide; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Nitriles; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA, Messenger; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2013 |
[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Drug Therapy, Combination; Humans; Intestinal Pseudo-Obstruction; Itraconazole; Middle Aged; Multiple Myeloma; Mycoses; Pyrazines; Pyrimidines; Triazoles; Voriconazole | 2012 |
Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Immunologic Factors; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Salvage Therapy; Stem Cell Transplantation | 2013 |
Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pyrazines; Respiratory Function Tests; Risk Factors; Thalidomide | 2012 |
A retrospective analysis of cytogenetic and clinical characteristics in patients with multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies | 2013 |
Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Multiple Myeloma; Pyrazines; Recurrence | 2012 |
How to select among available options for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Radiation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2012 |
Role of carfilzomib in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Multiple Myeloma; Oligopeptides; Peptide Hydrolases; Proteasome Inhibitors; Pyrazines; Thalidomide | 2012 |
Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Movement; Cell Proliferation; Cells, Cultured; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Vascular Endothelial Growth Factor A | 2012 |
Changes in protein profiles of multiple myeloma cells in response to bortezomib.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Matrix Metalloproteinases; Multiple Myeloma; Proteome; Proteomics; Pyrazines | 2013 |
Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Carbohydrate Metabolism; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cerulenin; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Epoxy Compounds; Fatty Acids; G1 Phase Cell Cycle Checkpoints; Glucose; Humans; Lactones; Lipid Metabolism; Multiple Myeloma; Orlistat; Oxidation-Reduction; Pyrazines; Retinoblastoma Protein | 2012 |
Intracranial mass of multiple myeloma with good response to chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Dexamethasone; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome | 2012 |
[Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2012 |
Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Phenotype; Pyrazines; Remission Induction; Scleredema Adultorum | 2013 |
Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Coculture Techniques; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Radiation Tolerance; Signal Transduction; Stromal Cells; Superoxide Dismutase; Transcriptional Activation; Tumor Cells, Cultured | 2013 |
Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Synergism; Humans; Melphalan; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib-induced cutaneous lupus in a patient with myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Lupus Erythematosus, Cutaneous; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2013 |
Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosis.
Topics: Amyloidosis; Boronic Acids; Bortezomib; Erectile Dysfunction; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2013 |
Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Humans; Hyperbilirubinemia; Liver; Middle Aged; Multiple Myeloma; Plasma Cells; Pyrazines | 2013 |
Lenalidomide is effective for the treatment of bortezomib-resistant extramedullary disease in patients with multiple myeloma: report of 2 cases.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide | 2013 |
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Female; Humans; Immunophenotyping; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Benzoflavones; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Multiple Myeloma; Pyrazines; Receptors, Notch; Up-Regulation | 2012 |
Expression of vascular endothelial growth factor receptors VEGFR1 in cultured multiple myeloma cells: correlation with immunophenotype and drug resistance.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD56 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression; Humans; Immunophenotyping; Leukocyte Common Antigens; Multiple Myeloma; Organ Specificity; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor D; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
Topics: Acetylation; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines | 2012 |
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Drug Costs; Health Care Costs; Hospitalization; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Multivariate Analysis; Netherlands; Prognosis; Pyrazines; Recurrence; Regression Analysis; Retrospective Studies; Thalidomide; Young Adult | 2013 |
Extramedullary plasmacytomas presenting as asymptomatic nodules on the buttocks and thighs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Buttocks; Dexamethasone; Humans; Middle Aged; Multimodal Imaging; Multiple Myeloma; Positron-Emission Tomography; Pyrazines; Skin Diseases; Thigh; Tomography, X-Ray Computed | 2012 |
Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Treatment Outcome | 2013 |
Bortezomib-related diffuse alveolar hemorrhage.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Hemorrhage; Humans; Lung Diseases; Male; Multiple Myeloma; Pulmonary Alveoli; Pyrazines | 2012 |
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide; Treatment Outcome | 2013 |
Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; DNA Methylation; Down-Regulation; Humans; Multiple Myeloma; Phosphorylation; Promoter Regions, Genetic; Protein Kinase C-alpha; Proto-Oncogene Proteins c-akt; Pyrazines; Telomerase | 2012 |
Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Topics: Adult; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Complications; Drug Synergism; Female; Humans; Inactivation, Metabolic; Incidence; Itraconazole; Male; Middle Aged; Multiple Myeloma; Mycoses; Opportunistic Infections; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Protease Inhibitors; Proton Pump Inhibitors; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy | 2012 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Recurrence; Retrospective Studies | 2013 |
Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.
Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Boronic Acids; Bortezomib; Combined Modality Therapy; Creatine Kinase, MM Form; Cyclohexanecarboxylic Acids; Dexamethasone; Drug Synergism; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunologic Factors; Kidney Diseases; Lenalidomide; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Polyneuropathies; Pravastatin; Pyrazines; Rhabdomyolysis; Thalidomide | 2012 |
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; MicroRNAs; Multiple Myeloma; Pyrazines; Sp1 Transcription Factor; Tumor Cells, Cultured | 2012 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2013 |
Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HeLa Cells; Humans; I-kappa B Proteins; Imidazoles; Mice; Molecular Structure; Multiple Myeloma; Proteasome Endopeptidase Complex; Pyrazines; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neural Conduction; Peripheral Nerves; Pyrazines; Systemic Vasculitis | 2012 |
Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Topics: Acyclovir; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Valacyclovir; Valine; Virus Activation | 2012 |
Have drug combinations supplanted stem cell transplantation in myeloma?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy; Female; Genomics; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Pyrazines; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2012 |
Iron increases the susceptibility of multiple myeloma cells to bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Ferritins; Humans; Inhibitory Concentration 50; Iron; Multiple Myeloma; Plasma Cells; Pyrazines | 2013 |
The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cells, Cultured; Diterpenes; DNA-Binding Proteins; Down-Regulation; Epoxy Compounds; Female; Gene Knockdown Techniques; Heat Shock Transcription Factors; Heat-Shock Proteins; Humans; Immunohistochemistry; Isoxazoles; Mice; Mice, Inbred BALB C; Multiple Myeloma; Neoplasm Transplantation; Phenanthrenes; Plasma Cells; Proteasome Endopeptidase Complex; Pyrazines; Resorcinols; RNA, Small Interfering; Transcription Factors; Transplantation, Heterologous | 2013 |
High frequencies of response after limited primary therapy for multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Thalidomide; Treatment Outcome | 2013 |
Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Castleman Disease; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Remission Induction | 2012 |
BlyS: a potential hallmark of multiple myeloma.
Topics: Aged; Aged, 80 and over; Apoptosis; B-Cell Activating Factor; B-Cell Activation Factor Receptor; B-Lymphocytes; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2013 |
Total cost comparison in relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fees, Pharmaceutical; Health Expenditures; Humans; Lenalidomide; Models, Economic; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide | 2013 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosomes, Human, Pair 1; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Pyrazines; Recurrence; Thalidomide; Treatment Outcome; Trisomy | 2013 |
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Health Care Costs; Health Resources; Hospitalization; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide | 2013 |
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; Markov Chains; Melphalan; Multiple Myeloma; Neoplasm Staging; Prednisone; Pyrazines; Thalidomide; United States | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Humans; Hydroxamic Acids; Lenalidomide; Multiple Myeloma; Nitrogen Mustard Compounds; Oligopeptides; Peripheral Nervous System Diseases; Practice Guidelines as Topic; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Vorinostat | 2013 |
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
Topics: Base Sequence; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Osteoblasts; Osteocalcin; Osteoclasts; Osteopontin; Proteasome Inhibitors; Pyrazines; Receptors, Calcitriol; Recombinant Proteins; RNA, Messenger; Signal Transduction; Transfection; Up-Regulation; Vitamin D Deficiency | 2013 |
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; CD11b Antigen; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Flow Cytometry; HLA-DR Antigens; Humans; Immunologic Factors; Lenalidomide; Lewis X Antigen; Lipopolysaccharides; Multiple Myeloma; Myeloid Cells; Pyrazines; Reactive Oxygen Species; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Thalidomide; Tumor Burden; Tumor Microenvironment | 2013 |
PDK1 inhibition is a novel therapeutic target in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Dichloroacetic Acid; Glucose; Glycolysis; Humans; Lactate Dehydrogenases; Lactic Acid; Molecular Targeted Therapy; Multiple Myeloma; Protein Serine-Threonine Kinases; Pyrazines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; RNA, Small Interfering | 2013 |
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Registries; Retrospective Studies; Stem Cell Transplantation; Treatment Outcome | 2013 |
Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Infections; Lymphopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Risk Factors | 2013 |
A combination regimen of bortezomib, cyclophosphamide and betamethasone gives quicker, better and more durable response than VAD/CyBet regimens: results from a Swedish retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sweden; Treatment Outcome; Vincristine | 2013 |
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Pyrazines | 2012 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid | 2013 |
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
[Effect of bortezomib-based induction therapy on the peripheral blood stem cell harvest in multiple myeloma].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome | 2013 |
Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Substrate Specificity | 2013 |
Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2001 |
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Dose-Response Relationship, Drug; Humans; Male; Mice; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Down-Regulation; Gene Expression Profiling; Heat-Shock Proteins; Humans; Insulin-Like Growth Factor I; Multienzyme Complexes; Multiple Myeloma; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin | 2002 |
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle Proteins; Cell Death; DNA-Activated Protein Kinase; DNA-Binding Proteins; Enzyme Activation; Gene Expression; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Nuclear Proteins; Phosphorylation; Phosphoserine; Protease Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Role of the bone marrow microenvironment in multiple myeloma.
Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Melphalan; Middle Aged; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Pyrazines; Recurrence; Tumor Cells, Cultured | 2003 |
Moving disease biology from the lab to the clinic.
Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide | 2003 |
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma.
Topics: Animals; Antibodies, Monoclonal; Boronic Acids; Bortezomib; Carrier Proteins; Chemokine CCL3; Chemokine CCL4; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Disease Models, Animal; Glycoproteins; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Mice; Multienzyme Complexes; Multiple Myeloma; Osteolysis; Osteoprotegerin; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor | 2003 |
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Topics: Active Transport, Cell Nucleus; Adenoviridae; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Division; Cell Nucleus; Cell Survival; Cysteine Endopeptidases; Cytosol; Dose-Response Relationship, Drug; Genes, Dominant; Humans; I-kappa B Proteins; Melphalan; Microscopy, Fluorescence; Multienzyme Complexes; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proteasome Endopeptidase Complex; Pyrazines; Tetrazolium Salts; Thiazoles; Time Factors; Transfection; Tumor Cells, Cultured; Ubiquitin | 2003 |
First proteasome inhibitor approved for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Drug Approval; Drugs, Investigational; Humans; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; United States; United States Food and Drug Administration | 2003 |
The proteasome--an emerging therapeutic target in cancer.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; NF-kappa B; Peptide Hydrolases; Phosphorylation; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2003 |
Bortezomib (velcade) for multiple myeloma.
Topics: Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Economics, Pharmaceutical; Fees, Pharmaceutical; Humans; Multiple Myeloma; Nausea; Pyrazines | 2003 |
Bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Industry; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome; United States | 2003 |
Bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Humans; Multiple Myeloma; Paraproteins; Protease Inhibitors; Pyrazines | 2003 |
Bortezomib in multiple myeloma.
Topics: Amyloid beta-Peptides; Boronic Acids; Bortezomib; Diagnostic Techniques, Neurological; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines | 2003 |
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cysteine Endopeptidases; Cytochrome c Group; Dexamethasone; Humans; Membrane Potentials; Mitochondria; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Tumor Cells, Cultured | 2003 |
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Caspases; Contactins; Cysteine Endopeptidases; Down-Regulation; Humans; Interleukin-6; Multienzyme Complexes; Multiple Myeloma; Neural Cell Adhesion Molecules; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction | 2003 |
[Gene expression profile changes in human multiple myeloma].
Topics: Adult; Aged; Boronic Acids; Bortezomib; Epidermal Growth Factor; Female; Gene Expression; Gene Expression Profiling; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Protein Tyrosine Phosphatases; Pyrazines; RNA, Messenger | 2003 |
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Topics: 2-Methoxyestradiol; Actins; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Resistance, Neoplasm; Estradiol; Heat-Shock Proteins; Humans; Multiple Myeloma; Peptides; Proteasome Inhibitors; Pyrazines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2004 |
[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Thalidomide | 2004 |
[Targeted in therapies multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2004 |
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Genes, bcl-2; Humans; Imidazoles; Insulin-Like Growth Factor I; Interleukin-6; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Mutation; NF-kappa B; Oleanolic Acid; Protease Inhibitors; Pyrazines; Recombinant Proteins; Transfection | 2004 |
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligase Complexes | 2004 |
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Membranes; Membrane Glycoproteins; Membrane Potentials; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxidative Stress; Oxygen; Protease Inhibitors; Proteins; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Sodium Oxybate; Syndecan-1; Syndecans; Tumor Suppressor Proteins; Vorinostat; X-Linked Inhibitor of Apoptosis Protein | 2004 |
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Survival; Cytochromes c; Drug Resistance, Neoplasm; Drug Synergism; GABA-A Receptor Antagonists; Humans; Insulin-Like Growth Factor I; Interleukin-6; Isoquinolines; JNK Mitogen-Activated Protein Kinases; Lymphocytes; Membrane Potentials; Mitochondria; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Stromal Cells; Superoxides; Tumor Cells, Cultured | 2004 |
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome | 2004 |
Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Humans; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2004 |
Proteasome inhibition therapy: assessing the clinical implications in hematologic diseases.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nursing Assessment; Oncology Nursing; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2004 |
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Heat-Shock Proteins; Humans; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Pyrazines | 2004 |
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Caveolin 1; Caveolins; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Endothelium, Vascular; Humans; Multiple Myeloma; Phosphorylation; Proteins; Pyrazines; Recombinant Proteins; Retinoblastoma-Like Protein p130; src-Family Kinases; Transfection; Tyrosine; Vascular Endothelial Growth Factor A | 2004 |
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Camptothecin; Cell Communication; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Activation; fas Receptor; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Lymphoma; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Stromal Cells; Up-Regulation | 2004 |
Bortezomib is an efficient agent in plasma cell leukemias.
Topics: Anemia; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Pyrazines; Thrombocytopenia; Time Factors | 2005 |
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival.
Topics: Autocrine Communication; Boronic Acids; Bortezomib; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dexamethasone; Humans; Multiple Myeloma; Nerve Growth Factors; Paracrine Communication; Pyrazines; Receptor, trkB; Signal Transduction; Stromal Cells | 2005 |
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Recurrence; Renal Insufficiency; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2005 |
Multifunctional role of Erk5 in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Dexamethasone; Enzyme Activation; Humans; Interleukin-6; Mitogen-Activated Protein Kinase 7; Multiple Myeloma; Pyrazines; Signal Transduction; Tumor Cells, Cultured | 2005 |
[Multiple myeloma -- therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose-Response Relationship, Drug; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Radiotherapy, Adjuvant; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Tomography, X-Ray Computed; Transplantation, Autologous; Transplantation, Homologous | 2005 |
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Topics: Acyltransferases; Adenosine Triphosphate; Apoptosis; Apoptosis Regulatory Proteins; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; G2 Phase; Humans; Immunoblotting; In Situ Nick-End Labeling; Multiple Myeloma; Necrosis; Phosphorylation; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Proteins; Pyrazines; Time Factors; Treatment Outcome | 2005 |
Multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Thalidomide | 2005 |
Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chemical and Drug Induced Liver Injury, Chronic; Humans; L-Lactate Dehydrogenase; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2005 |
Bortezomib therapy following first relapse.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome | 2005 |
Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 13; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Salvage Therapy; Sequence Deletion; Treatment Outcome | 2005 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Pyrazines; Recurrence; Thalidomide | 2005 |
Severe irreversible bilateral hearing loss after bortezomib (VELCADE) therapy in a multiple myeloma (MM) patient.
Topics: Boronic Acids; Bortezomib; Hearing Loss, Bilateral; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2005 |
High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation.
Topics: Alkaline Phosphatase; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Pyrazines; Spinal Fractures | 2005 |
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leupeptins; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2005 |
Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Calcium; Caspases; Cell Line, Tumor; Endoplasmic Reticulum; Enzyme Activation; Gene Expression; Humans; Isoenzymes; Mitochondria; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Protease Inhibitors; Pyrazines | 2005 |
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Topics: Anilides; Boronic Acids; Bortezomib; Cell Line, Tumor; Dose-Response Relationship, Drug; Flow Cytometry; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Inhibitory Concentration 50; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteins; Pyrazines; RNA, Small Interfering; Tubulin | 2005 |
Images in clinical Medicine. Bortezomib-induced skin lesions.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2005 |
Bortezomib for myeloma -- much ado about something.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Research Design | 2005 |
PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Multiple Myeloma; Pyrazines; Radiation-Sensitizing Agents; Radiation, Ionizing | 2005 |
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
Topics: Boronic Acids; Bortezomib; Female; Humans; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Remission Induction; Salvage Therapy; Spinal Neoplasms | 2005 |
Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks.
Topics: Antineoplastic Agents; Boronic Acids; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Humans; Multiple Myeloma; Pyrazines; Treatment Outcome | 2005 |
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.
Topics: Boronic Acids; Bortezomib; Follow-Up Studies; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Plasmacytoma; Pyrazines; Remission Induction; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2005 |
[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lymphoma; Multiple Myeloma; Prognosis; Pyrazines; Radioimmunotherapy; Thalidomide | 2005 |
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Fatal Outcome; Humans; Immunoglobulin D; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Remission Induction; Salvage Therapy; Thalidomide | 2005 |
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Female; Humans; Melanocytes; Melanoma; Mice; Mice, Nude; Mitochondria; Multiple Myeloma; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2005 |
Severe acute enteritis in a multiple myeloma patient receiving bortezomib and spinal radiotherapy: case report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Enteritis; Female; Humans; Multiple Myeloma; Palliative Care; Pyrazines; Radiation Injuries; Spinal Neoplasms | 2005 |
No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Multiple Myeloma; Mutation; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2006 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Topics: Apoptosis; Boronic Acids; Bortezomib; Down-Regulation; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Phosphorylation; Piperidines; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Topics: Animals; Bone Marrow; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytokines; HeLa Cells; Humans; Interferon-gamma; Mice; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2005 |
Development of effective new treatments for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Design; Humans; Multiple Myeloma; Pyrazines; United States; United States Food and Drug Administration | 2005 |
[Bortezomib in second-line therapy].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasms; Pyrazines; Randomized Controlled Trials as Topic | 2005 |
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dexamethasone; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Galectin 3; Humans; I-kappa B Proteins; Lymphocytes; Multiple Myeloma; NF-KappaB Inhibitor alpha; Polysaccharides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Vascular Endothelial Growth Factor A | 2005 |
New therapies for the treatment of multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Platelet Aggregation Inhibitors; Polydeoxyribonucleotides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Differentiation; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Retrospective Studies; Thalidomide; Treatment Outcome | 2005 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Drug Costs; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate | 2005 |
Bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Data Interpretation, Statistical; Dexamethasone; Follow-Up Studies; Humans; Multiple Myeloma; Pyrazines; Recurrence; Research Design; Survival Analysis | 2005 |
[Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence | 2005 |
Bortezomib-induced Sweet syndrome.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Sweet Syndrome | 2005 |
Multiple myeloma: the present and the future.
Topics: Antineoplastic Agents, Alkylating; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Immunosuppressive Agents; Medical Oncology; Melphalan; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2005 |
Bortezomib increases survival of patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Pyrazines; Survival Rate | 2005 |
New agents and approaches in the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide; Treatment Outcome | 2003 |
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Enzyme Activation; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor I; Mice; Mice, SCID; Multiple Myeloma; Phosphatidylinositol 3-Kinases; Phosphoproteins; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Receptor, IGF Type 1; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2005 |
Anti-angiogenic effect of bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Microcirculation; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Ribonuclease, Pancreatic; Vascular Endothelial Growth Factor A | 2005 |
Antimyeloma activity of heat shock protein-90 inhibition.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Drug Synergism; Estrogens; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Kinase; Lactams, Macrocyclic; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Pyrazines; raf Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Interleukin-6; Rifabutin; Signal Transduction; Tumor Cells, Cultured | 2006 |
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Movement; Cell Proliferation; Drug Synergism; Genes, bcl-2; Humans; Lactones; Lymphocytes; Mice; Mitochondria; Multiple Myeloma; NF-kappa B; Plasmacytoma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Tumor Cells, Cultured | 2005 |
The ubiquitin proteasome pathway from bench to bedside.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhibitors; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2005 |
New treatment approaches in multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Congresses as Topic; Female; Humans; Incidence; Israel; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide | 2005 |
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Growth Processes; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Humans; Insulin-Like Growth Factor I; Interleukin-6; Multiple Myeloma; Neovascularization, Pathologic; Neovascularization, Physiologic; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2006 |
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Japan; Lung; Male; Middle Aged; Multiple Myeloma; Pleural Effusion; Protease Inhibitors; Pyrazines; Respiratory Insufficiency | 2006 |
Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Protease Inhibitors; Pyrazines; Radiopharmaceuticals | 2006 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
[Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Treatment Outcome | 2005 |
Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.
Topics: Boronic Acids; Bortezomib; Cytokines; Humans; Inflammation; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Vasculitis, Leukocytoclastic, Cutaneous | 2006 |
Bulbar palsy in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Bulbar Palsy, Progressive; Combined Modality Therapy; Cranial Fossa, Posterior; Cranial Nerve Diseases; Cyclosporine; Dexamethasone; Disease Progression; Doxorubicin; Fatal Outcome; Female; Graft vs Host Disease; Humans; Immunocompromised Host; Immunoglobulin Light Chains; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Myeloma; Myeloma Proteins; Pneumonia, Aspiration; Pyrazines; Reflex, Abnormal; Transplantation, Homologous; Vincristine | 2005 |
Bortezomib-induced Sweet's syndrome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Administration Schedule; Erectile Dysfunction; Humans; Immunosuppressive Agents; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Prednisolone; Protease Inhibitors; Pyrazines; Recurrence; Sleep Initiation and Maintenance Disorders; Sweet Syndrome; Testicular Diseases | 2005 |
Skin lesions induced by bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cetirizine; Combined Modality Therapy; Dexamethasone; Drug Eruptions; Exanthema; Histamine H1 Antagonists, Non-Sedating; Humans; Immunocompromised Host; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prednisone; Pyrazines; Salvage Therapy | 2005 |
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Multiple Myeloma; Neoplasm Proteins; Plasma Cells; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Folding; Pyrazines; Signal Transduction | 2006 |
Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials as Topic; Deubiquitinating Enzyme CYLD; Humans; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tumor Suppressor Proteins; Ubiquitin; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2006 |
Bortezomib: an effective agent in extramedullary disease in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Soft Tissue Neoplasms; Treatment Outcome | 2006 |
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Thalidomide | 2005 |
[Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma].
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Humans; Interleukin-1beta; Interleukin-6; Mesenchymal Stem Cells; Multiple Myeloma; Protease Inhibitors; Pyrazines; Stem Cell Factor | 2006 |
Hematologic malignancies: from clinical science to clinical practice - 2nd European Congress.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Ki-1 Antigen; Molecular Structure; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Multiple Myeloma; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2006 |
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation.
Topics: Adult; Aged; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Graft Survival; Humans; Male; Multiple Myeloma; Protease Inhibitors; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2006 |
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; In Vitro Techniques; Indoles; Injections, Intravenous; Leupeptins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2006 |
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Disease Progression; Drug Approval; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; United States; United States Food and Drug Administration | 2006 |
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Topics: Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydrolases; Hydroxamic Acids; Indoles; Multiple Myeloma; Panobinostat; Poly(ADP-ribose) Polymerase Inhibitors; Protease Inhibitors; Pyrazines; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2006 |
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Melphalan; Multiple Myeloma; Panobinostat; Pyrazines | 2006 |
Life-threatening motor neurotoxicity in association with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Critical Illness; Female; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines | 2006 |
A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Pyrazines; Retrospective Studies; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous | 2006 |
Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Topics: Antineoplastic Agents; Boronic Acids; Clinical Trials as Topic; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines; Treatment Outcome | 2006 |
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
Topics: Antineoplastic Agents; Bone Marrow Neoplasms; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2006 |
Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Pyrazines; Remission Induction | 2006 |
Perspective on the current use of bortezomib in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2006 |
Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Quality of Life; Recurrence | 2006 |
The safety and efficacy of bortezomib in relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Pyrazines; Recurrence; Survival Rate; Treatment Outcome | 2006 |
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Pyrazines; Receptor, IGF Type 1; Structure-Activity Relationship; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome | 2006 |
Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Renal Insufficiency | 2006 |
Severe pulmonary complication after bortezomib treatment for multiple myeloma.
Topics: Aged; Boronic Acids; Bortezomib; Humans; Lung Diseases; Male; Multiple Myeloma; Pyrazines | 2006 |
Proteasome inhibitor drugs on the rise.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Ubiquitin; United States; United States Food and Drug Administration | 2006 |
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Lysis Syndrome | 2006 |
VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Doxorubicin; Etoposide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Protease Inhibitors; Pyrazines; Remission Induction | 2006 |
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Failure | 2007 |
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunohistochemistry; Liver Diseases; Male; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pyrazines; Tomography, X-Ray Computed | 2006 |
[Multiple myeloma cell line U266 apoptosis induced by velcade].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Messenger | 2006 |
Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Plasmacytoma; Pyrazines; Treatment Outcome | 2007 |
[A cure for multiple myeloma?].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
[Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Topics: Antineoplastic Agents; Bence Jones Protein; Biomarkers; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome | 2006 |
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carrier Proteins; CDC2-CDC28 Kinases; Chromosome Deletion; Cyclin-Dependent Kinases; Disease-Free Survival; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Pyrazines; Retrospective Studies; Risk Factors; Salvage Therapy; Survival Rate; Translocation, Genetic | 2007 |
Bortezomib-induced rhabdomyolysis in multiple myeloma.
Topics: Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Rhabdomyolysis; Salvage Therapy | 2006 |
Bortezomib-induced skin lesion.
Topics: Aged, 80 and over; Boronic Acids; Bortezomib; Drug Eruptions; Female; Humans; Multiple Myeloma; Pyrazines | 2006 |
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-X Protein; Biphenyl Compounds; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Division; Cell Survival; Humans; Multiple Myeloma; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Tumor Cells, Cultured | 2007 |
Bortezomib dosing in relapsed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Stem Cell Transplantation; Survival Rate | 2006 |
Multiple myeloma associated with porphyria cutanea tarda: a possible role of bortezomib?
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Porphyria Cutanea Tarda; Pyrazines | 2006 |
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Drug Eruptions; Drug Therapy, Combination; Erythema; Fever; Glucocorticoids; Histamine H1 Antagonists; Humans; Male; Medical Records; Middle Aged; Multiple Myeloma; Prednisone; Protease Inhibitors; Pyrazines; Skin; Skin Ulcer | 2006 |
Are the Scots getting a better deal on prescribed drugs than the English?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Delivery of Health Care; Drug Prescriptions; England; Humans; Multiple Myeloma; Pyrazines; Scotland; State Medicine | 2006 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Topics: Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytogenetic Analysis; Humans; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Survival Analysis | 2007 |
New drugs for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Design; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2006 |
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2006 |
Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure.
Topics: Aged; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Salvage Therapy; Treatment Outcome | 2006 |
Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Topics: Acyclovir; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Dexamethasone; Exanthema; Herpes Zoster; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin; Treatment Outcome | 2007 |
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chickenpox; Dexamethasone; Disease Susceptibility; Doxorubicin; Female; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Virus Activation | 2007 |
Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Pleural Effusion; Pyrazines; Respiratory Insufficiency; Vasculitis | 2007 |
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies | 2007 |
Management of toxicities associated with bortezomib.
Topics: Boronic Acids; Bortezomib; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Pyrazines; Treatment Outcome | 2006 |
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Multiple Myeloma; NF-kappa B; Proto-Oncogene Proteins c-akt; Pyrazines; Resveratrol; STAT3 Transcription Factor; Stilbenes; Syndecan-1; Thalidomide; Tumor Cells, Cultured | 2007 |
An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma.
Topics: Boronic Acids; Bortezomib; Chromosome Aberrations; Cytogenetic Analysis; Humans; Multiple Myeloma; Predictive Value of Tests; Prognosis; Pyrazines | 2007 |
Novel agents for multiple myeloma treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Design; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2006 |
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytotoxicity Tests, Immunologic; Dexamethasone; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Multiple Myeloma; Naphthalenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Signal Transduction; Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2007 |
[Follicular keratosis and multiple myeloma].
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Keratolytic Agents; Keratosis; Middle Aged; Multiple Myeloma; Pyrazines; Skin | 2006 |
Quantitative sensory findings in patients with bortezomib-induced pain.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Cold Temperature; Female; Hot Temperature; Humans; Lymphoma, B-Cell; Male; Middle Aged; Multiple Myeloma; Pain; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrazines; Sensation; Sensation Disorders; Thermosensing; Touch | 2007 |
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical h
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Boronic Acids; Bortezomib; Drug Approval; Female; Hematology; Humans; Japan; Lung Diseases; Lung Injury; Male; Multiple Myeloma; Pyrazines; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires | 2006 |
[Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Protease Inhibitors; Pyrazines; Salvage Therapy | 2006 |
Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Communication; Cell Line, Tumor; Colony-Forming Units Assay; Dendritic Cells; Flow Cytometry; Humans; Lymphoma; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2007 |
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Hematology; Humans; Japan; Lung Diseases; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Protease Inhibitors; Pyrazines; Recurrence; Risk Factors; Societies, Medical; Stem Cell Transplantation; Surveys and Questionnaires | 2006 |
Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Enterocolitis, Pseudomembranous; Female; Humans; Magnetic Resonance Imaging; Metronidazole; Multiple Myeloma; Pyrazines | 2007 |
Bortezomib-associated rash: a new recognizable and avoidable side-effect.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Exanthema; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2007 |
Medical management update: multiple myeloma.
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Care for Chronically Ill; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Jaw Diseases; Jaw Neoplasms; Multiple Myeloma; Oral Hemorrhage; Osteonecrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thalidomide | 2007 |
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Dendritic Cells; Gamma Rays; HSP90 Heat-Shock Proteins; Humans; Interferon-gamma; Lactams, Macrocyclic; Leukocytes, Mononuclear; Multiple Myeloma; Neoplasms; Proteasome Endopeptidase Complex; Pyrazines | 2007 |
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazines; Recurrence; Reproducibility of Results; Thalidomide | 2007 |
Community experience with bortezomib in patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Community Medicine; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Survival Rate | 2007 |
Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Middle Aged; Multiple Myeloma; Pulmonary Fibrosis; Pyrazines; Recurrence; Respiratory Insufficiency; Steroids; Treatment Failure | 2007 |
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation | 2007 |
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Topics: Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Immunoglobulin G; Immunoglobulin mu-Chains; Multiple Myeloma; NF-kappa B; Protease Inhibitors; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transcription Factor AP-1 | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Fatal Outcome; Humans; Male; Multiple Myeloma; Pyrazines; Respiratory Distress Syndrome | 2007 |
NICE: friend and foe.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Approval; Government Agencies; Multiple Myeloma; Public Opinion; Public Policy; Pyrazines; Quality-Adjusted Life Years; United Kingdom | 2007 |
[Bortezomib in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence | 2006 |
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; CCAAT-Binding Factor; Cell Differentiation; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Humans; Mesenchymal Stem Cells; Middle Aged; Multiple Myeloma; Osteoblasts; Protease Inhibitors; Pyrazines | 2007 |
Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Deletion; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunoglobulin A; Immunoglobulin Light Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Pyrazines; Retreatment; Transplantation Chimera; Transplantation, Homologous | 2007 |
Multiple myeloma therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; HSP90 Heat-Shock Proteins; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Melphalan; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Immune-modulatory effects of bortezomib in GVHD.
Topics: Antineoplastic Agents; Bone Marrow Cells; Boronic Acids; Bortezomib; Cytokines; Graft vs Host Disease; Humans; Immune System; Inflammation; Multiple Myeloma; NF-kappa B; Plasmacytoma; Pyrazines; Spleen; Stem Cell Transplantation; T-Lymphocytes; Transplantation, Homologous | 2007 |
Inhibition of chronic graft-vs-host disease with retention of anti-myeloma effects by the proteasome inhibitor bortezomib.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Boronic Acids; Bortezomib; Chronic Disease; gamma-Glutamyltransferase; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction | 2007 |
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Capsaicin; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Extracellular Signal-Regulated MAP Kinases; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Interleukin-6; Janus Kinase 1; Microtubule-Associated Proteins; Multiple Myeloma; Neoplasm Proteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; STAT3 Transcription Factor; Survivin; Thalidomide; Vascular Endothelial Growth Factor A | 2007 |
Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Fatal Outcome; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Pyrazines; Stevens-Johnson Syndrome; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Humans; I-kappa B Kinase; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Pyrimidines | 2007 |
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Humans; Membrane Proteins; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA Interference; RNA, Small Interfering; Up-Regulation | 2007 |
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Topics: Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Chi-Square Distribution; Clinical Trials as Topic; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Logistic Models; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Predictive Value of Tests; Pyrazines; Time Factors | 2007 |
Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Intestinal Pseudo-Obstruction; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Radiography | 2007 |
Unexpected cardiotoxicity in haematological bortezomib treated patients.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Female; Heart Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines | 2007 |
Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma.
Topics: Boronic Acids; Bortezomib; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunoglobulin Light Chains; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Treatment Outcome | 2007 |
Multiple myeloma involving the cavernous sinus: a report of 3 cases and response to bortezomib.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cavernous Sinus; Fatal Outcome; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Recurrence; Sensitivity and Specificity; Treatment Outcome | 2007 |
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Humans; Multiple Myeloma; Pyrazines | 2007 |
Bortezomib inhibits human osteoclastogenesis.
Topics: Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Cell Differentiation; Cell Lineage; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Male; Multiple Myeloma; NF-kappa B; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; RANK Ligand; Signal Transduction; Stem Cells; Transcription Factor AP-1; Vascular Endothelial Growth Factor A | 2007 |
Allografting or autografting for myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Pyrazines; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 2007 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Models, Biological; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Signal Transduction; Tumor Cells, Cultured; Ubiquitin | 2007 |
Bortezomib and lenalidomide effective in myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Thalidomide | 2007 |
Bortezomib plus doxorubicin combination slows progression of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Doxorubicin; Drug Therapy, Combination; Humans; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Looking beyond the headlines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Humans; Insurance Benefits; Multiple Myeloma; Pyrazines | 2007 |
Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Treatment Outcome | 2007 |
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; bcl-X Protein; Boronic Acids; Bortezomib; Burkitt Lymphoma; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Transformation, Viral; Herpesvirus 4, Human; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B p50 Subunit; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Transcription Factor RelA; Ubiquitin-Protein Ligases; Viral Matrix Proteins; Virus Latency; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2007 |
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome | 2007 |
Drug pricing: No cure, no cost.
Topics: Antineoplastic Agents; Behavioral Research; Boronic Acids; Bortezomib; Drug Costs; Drug Industry; Humans; Interprofessional Relations; Marketing; Multiple Myeloma; Pyrazines; Remission Induction; State Medicine; Treatment Failure; United Kingdom | 2007 |
Severe intestinal vasculitis in a patient under treatment with bortezomib.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Female; Gastrointestinal Hemorrhage; Hematopoietic Stem Cell Transplantation; Humans; Intestinal Diseases; Middle Aged; Multiple Myeloma; Postoperative Complications; Pyrazines; Salvage Therapy; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Evaluation; Female; Hematologic Diseases; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Nervous System Diseases; Protease Inhibitors; Pyrazines; Remission Induction; Retrospective Studies; Treatment Outcome | 2007 |
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Mice; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Up-Regulation | 2008 |
Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryptogenic Organizing Pneumonia; Glucocorticoids; Humans; Male; Methylprednisolone; Multiple Myeloma; Pyrazines; Tomography, X-Ray Computed | 2007 |
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Mice; Microtubule-Associated Proteins; Models, Animal; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylcholine; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; RNA, Small Interfering; Survivin; Transplantation, Heterologous | 2007 |
Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cytological Techniques; Diploidy; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Karyotyping; Mice; Mice, SCID; Models, Animal; Multiple Myeloma; Pyrazines | 2007 |
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.
Topics: Acute Kidney Injury; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2007 |
Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |
Managing patients with multiple myeloma and mantle cell lymphoma: where are we now?
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Multiple Myeloma; Nurse's Role; Nursing Assessment; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Multiple myeloma patient care: treatment options and nursing considerations.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasm Staging; Nurse's Role; Oncology Nursing; Pyrazines; Thalidomide | 2007 |
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Lysis Syndrome | 2008 |
Gene mutation revelation points to new target for myeloma treatment, studies say.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; I-kappa B Kinase; Multiple Myeloma; Mutation; NF-kappa B; Pyrazines; Signal Transduction; TNF Receptor-Associated Factor 3 | 2007 |
Deafness associated with the use of Bortezomib in multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Hearing Loss, Sensorineural; Humans; Immunoglobulin A; Multiple Myeloma; Pyrazines; Risk Factors | 2008 |
Neutrophilic dermatitis associated with bortezomib in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Eruptions; Humans; Male; Middle Aged; Multiple Myeloma; Neutrophil Infiltration; Pyrazines | 2007 |
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Multiple Myeloma; Neoplasm Proteins; Osteogenesis; Oxidative Stress; Proto-Oncogene Proteins; Pyrazines; Reactive Oxygen Species; Sulfonamides | 2007 |
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Topics: Boronic Acids; Bortezomib; Cell Membrane; Cell Survival; Down-Regulation; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Receptors, KIR; Sensitivity and Specificity; Tumor Cells, Cultured | 2008 |
Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Plasmacytoma; Pyrazines; Radiography; Remission Induction; Spinal Neoplasms; Thalidomide; Transplantation, Autologous | 2008 |
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; DNA Fragmentation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Immunotherapy; Interleukin-6; Multiple Myeloma; Pyrazines; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Syndecan-1 | 2007 |
Use of intrapleural bortezomib in myelomatous pleural effusion.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pleural Effusion; Pyrazines | 2007 |
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid | 2007 |
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Movement; Cell Survival; Endoplasmic Reticulum; Heat-Shock Proteins; Humans; Lactones; Mice; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Pyrroles; Xenograft Model Antitumor Assays | 2008 |
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Endothelial Cells; Enzyme Inhibitors; Humans; Macrophage Colony-Stimulating Factor; Mice; Mice, Nude; Multiple Myeloma; Neoplasms; NF-kappa B; Osteogenesis; Proteasome Inhibitors; Pyrazines; RANK Ligand; Threonine; Treatment Outcome; Ubiquitin; Xenograft Model Antitumor Assays | 2008 |
Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
Topics: Antigens, Neoplasm; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Isoquinolines; Multiple Myeloma; Protease Inhibitors; Pyrazines; Topoisomerase II Inhibitors | 2008 |
What is the correct philosophy for the treatment of multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Humans; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines | 2007 |
Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Nitrogen Mustard Compounds; Pyrazines; Salvage Therapy | 2007 |
Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Topics: Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Humans; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines | 2008 |
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
Topics: Animals; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Boronic Acids; Bortezomib; Clone Cells; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Mice; Mice, Inbred Strains; Multiple Myeloma; Neoplastic Stem Cells; Plasma Cells; Pyrazines; Syndecan-1; Thalidomide; Tumor Necrosis Factor Receptor Superfamily, Member 7; Tumor Stem Cell Assay | 2008 |
Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Topics: Aged; Angiogenic Proteins; Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Capillaries; Cytokines; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Prognosis; Pyrazines; Thalidomide | 2008 |
Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
Topics: Acetylcysteine; Apoptosis; B-Lymphocytes; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Endopeptidases; Drug Screening Assays, Antitumor; Humans; Interferon-gamma; Lymphoma; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein Subunits; Pyrazines | 2008 |
High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Multiple Myeloma; Neoplasm Proteins; Predictive Value of Tests; Pyrazines; Risk Factors; Time Factors | 2008 |
Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Colorimetry; Cyclin D3; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum; Estradiol; Estrogen Receptor Modulators; Flow Cytometry; G1 Phase; Humans; Immunoprecipitation; Mitochondria; Multiple Myeloma; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Selective Estrogen Receptor Modulators; Signal Transduction; Tumor Cells, Cultured | 2008 |
Concurrent radiation therapy and bortezomib in myeloma patient.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Radiotherapy Dosage | 2008 |
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cross-Priming; Dendritic Cells; Disease Progression; Histocompatibility Antigens Class I; Humans; Isoantibodies; Ligands; Multiple Myeloma; Prognosis; Pyrazines; Tumor Cells, Cultured | 2008 |
Bortezomib-induced skin eruption.
Topics: Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Skin | 2008 |
Bone building with bortezomib.
Topics: Animals; Antineoplastic Agents; Bone Diseases; Boronic Acids; Bortezomib; Cell Differentiation; Humans; Mesenchymal Stem Cells; Mice; Multiple Myeloma; Osteoblasts; Osteogenesis; Protease Inhibitors; Pyrazines | 2008 |
Unusual discordant responses in two multiple myeloma patients during bortezomib treatment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebellum; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Meninges; Multiple Myeloma; Neoplasm Invasiveness; Neoplasm Staging; Plasma Cells; Pyrazines; Skin | 2008 |
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Fatigue; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2008 |
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Protease Inhibitors; Pyrazines; Receptor, TIE-2; Salvage Therapy; Treatment Outcome | 2008 |
[Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Pyrazines; Tumor Cells, Cultured | 2008 |
Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
Topics: Acetylcysteine; Activating Transcription Factor 4; Antineoplastic Agents; Antioxidants; Boronic Acids; Bortezomib; Cell Death; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glutathione; Homeostasis; Humans; Multiple Myeloma; Neoplasm Proteins; Oxidation-Reduction; Protease Inhibitors; Pyrazines; Transcription Factor CHOP; Tumor Cells, Cultured | 2008 |
Controversies regarding the use of dexamethasone in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Doxorubicin; Glucocorticoids; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Vincristine | 2008 |
Multiple myeloma with testicular involvement.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Humans; Male; Multiple Myeloma; Prognosis; Protease Inhibitors; Pyrazines; Radiography; Skin Neoplasms; Testicular Neoplasms; Treatment Outcome | 2008 |
Treatment for elderly patients with multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Salvage Therapy; Survival Rate; Thalidomide | 2008 |
[Bortezomib in relapsed or refractory multiple myeloma: results in a cohort of 39 patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Recurrence | 2008 |
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Cell Nucleus; Cell Proliferation; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2008 |
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heat-Shock Proteins; Hematopoietic Stem Cells; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrazines; Pyridines; Tumor Cells, Cultured | 2008 |
[Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Kidney; Male; Middle Aged; Multiple Myeloma; Pyrazines | 2008 |
[Efficiency of bortezomib and dexamethasone in relapsed multiple myeloma treatment: retrospective study in consecutive cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Retrospective Studies; Survival Rate | 2008 |
Role of decorin in the antimyeloma effects of osteoblasts.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Coculture Techniques; Cyclin-Dependent Kinase Inhibitor p21; Decorin; Extracellular Matrix Proteins; Genetic Vectors; Humans; Lentivirus; Mesenchymal Stem Cells; Multiple Myeloma; Neovascularization, Pathologic; Osteoblasts; Plasma Cells; Proteoglycans; Pyrazines; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2008 |
Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Death; Cell Line; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Melphalan; Multiple Myeloma; Protein Isoforms; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Topics: Adult; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Humans; Male; Multiple Myeloma; Pyrazines; Renal Dialysis; Renal Insufficiency; Thalidomide | 2008 |
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; Growth Inhibitors; Humans; I-kappa B Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; NF-KappaB Inhibitor alpha; Protease Inhibitors; Pyrazines; Stromal Cells; Tumor Cells, Cultured | 2001 |
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Topics: Antigens, CD; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cysteine Endopeptidases; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha4; Intercellular Adhesion Molecule-1; Interleukin-6; Lymphocyte Function-Associated Antigen-1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Models, Biological; Mucin-1; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Stromal Cells; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2001 |
Cancer research. Taking garbage in, tossing cancer out?
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Endopeptidases; Humans; Multienzyme Complexes; Multiple Myeloma; Neoplasm Proteins; Neoplasms; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteins; Pyrazines | 2002 |
NF-kappa B as a therapeutic target in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Immunoblotting; Intercellular Adhesion Molecule-1; Models, Chemical; Multiple Myeloma; NF-kappa B; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2002 |